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Abstract 
 
The KEAP1/NRF2/ARE pathway is at the forefront of cellular defense. 
Induction of this pathway is protective against various conditions of stress such 
as oxidative stress and exposure to electrophiles. Conversely, failure to 
upregulate the pathway leads to increased disease susceptibility and 
accelerated pathogenesis. Under basal conditions, transcription factor nuclear 
factor erythroid 2 p45-related factor 2 (NRF2) is targeted for ubiquitination and 
proteasomal degradation by a repressor protein Kelch-like (ECH)-associated 
protein (KEAP1), a substrate adaptor for Cullin 3-based E3 ubiquitin ligase. 
Inducers of the pathway chemically modify specific cysteines within KEAP1, 
leading to loss of repressor function, NRF2 accumulation and enhanced 
transcription of genes encoding a large network of cytoprotective proteins.  
 
The cyanoenones are the most potent NRF2 activators known. 
Cyanoenones bind to KEAP1 covalently and reversibly, and are suitable for 
chronic in vivo administration. However, the cysteine sensor for these 
compounds is unknown. Among the cysteine sensors of KEAP1, C151 in the 
BTB domain and C273 and C288 in the intervening region, are best 
characterized. In this study using KEAP1-knockout mouse embryonic fibroblasts 
(MEFs) rescued with wild-type (WT) KEAP1 or cysteine mutants, we tested a 
series of cyanoenones for their ability to modify specific cysteine sensors in 
KEAP1. We discovered that remarkably, all compounds of this class specifically 
target C151 regardless of their molecular shape or size. In addition, primary 
peritoneal macrophages (PMφ) derived from KEAP1C151S/C151S knock-in mice 
generated using the CRISPR/Cas9 technology, had higher LPS-induced 
inflammatory responses than cells from WT animals. Furthermore, at nanomolar 
concentrations, the tricyclic cyanoenone TBE-31 strongly suppresses LPS-
induced inflammatory responses in primary PMφ cells, suggesting the potential 
for therapeutic use in inflammatory diseases.  
 
Another cytoprotective response is the heat shock response (HSR) which 
is activated when cells are exposed to stressors such as elevated temperatures, 
heavy metals and cytotoxic compounds. The HSR, mainly mediated by Heat 
Shock Factor 1 (HSF1), protects the integrity of the cellular proteome through 
the upregulation of a battery of genes involved in ameliorating proteotoxicity. 
Several small molecule activators of the KEAP1/NRF2/ARE pathway have been 
shown to activate HSR through the activation of HSF1. Work in this thesis 
focused on one such dual activator, the dietary agent phenethyl isothiocyanate 
(PEITC). We found that PEITC reacts with KEAP1 C151 to stabilize NRF2, and 
that it is able to activate the HSR by activating HSF1 through the inhibition of 
heat shock protein 90, the main negative regulator of HSF1. We further showed 
that PEITC activates p38 mitogen-activated protein kinases (MAPKs). In vitro, 
all members of the p38 MAPK family rapidly and stoichiometrically catalyze the 
phosphorylation of HSF1 on S326, a hallmark of HSF1 activation. The use of 
stable knockdown cell lines and inhibitors indicated that among the p38 MAPK, 
p38γ is the principal isoform responsible for the phosphorylation of HSF1 at 
S326 in cells. A protease-mass spectrometry approach confirmed S326 
phosphorylation, and unexpectedly, revealed that p38 MAPKs also catalyze the 
phosphorylation of HSF1 at S303/307, previously known repressive post-
translational modifications. Thus, we identified p38 MAPKs as highly efficient 
catalysts for the phosphorylation of HSF1. Furthermore, our findings suggest 
that the magnitude and persistence of activation of p38 MAPKs are important 
determinants of the extent and duration of the HSR.  
 
In order to investigate the physiological significance of HSF1 
phosphorylation at S326, we used immunofluorescence and western blotting 
techniques. We found that mitotic cells have high levels of HSF1 pS326 
compared to interphase cells. Interestingly, our studies revealed that 
phosphorylated HSF1 at S326 is concentrated at the midbody of telophase 
cells, suggesting a potential role for HSF1 during the late-stage of cell division. 
Further studies are needed to define the role(s) of the HSF1 pS326 during the 
cell cycle. 
	
Section 1: Introduction 
Chapter A 
NRF2, KEAP1 and their interaction 
 
1.A.1  Introduction 
 
Oxidation-reduction reactions, also known as redox reactions play a 
central role in numerous biological processes. Living organisms are constantly 
exposed to reactive oxygen species (ROS) (e.g. superoxide anion, peroxide, 
hydrogen peroxide, hydroxyl anion and singlet oxygen) or reactive nitrogen 
species (RNS) (e.g. nitroxyl anion, peroxyl nitrate, nitric oxide and nitrosyl cation) 
produced by both endogenous and exogenous sources. Oxidative stress is 
defined as the imbalance between the amount of oxidants and antioxidants, 
where the former is in excess, leading to the disturbance of the intracellular redox-
homeostasis and subsequent damage (Sies, 2015). Examples of exogenous 
oxidative stressors are electrophilic molecules, carcinogens such as DNA-
damaging agents, heavy metals and UV radiation. Endogenous stressors are 
usually produced by intracellular metabolic reactions during processes such as 
respiration and inflammation. Exposure to ROS/RNS or other chemically reactive 
species has been reported to damage cellular macromolecules such as DNA, 
proteins and cytoskeletal structures. As a consequence, chronic oxidative stress 
has been implicated in cancer (Mahalingaiah et al., 2015, Mehlman, 1992), 
diabetes (Ceriello, 2006, Bravi et al., 2006), neurodegenerative (Praprotnik et al., 
1996, Castellani et al., 1996), respiratory (Hector et al., 2014, Bast et al., 2010), 
cardiovascular (Bast et al., 2010, Costa et al., 2016) and inflammatory (Muntane 
et al., 1995) diseases as well as aging (Fukagawa, 1999, Joseph and Roth, 
1992). In order to protect themselves from such insults, eukaryotic cells have 
developed several complex mechanisms to restore cellular redox homeostasis. 
One such mechanism is by inducing the production of anti-oxidant and 
cytoprotective proteins. This cytoprotective response is orchestrated by the 
transcription factor nuclear factor erythroid 2 p45-related factor 2 (NRF2) (Fig. 
A1).  
 
1.A.2  The NRF2/KEAP1/ARE pathway 
 
At basal conditions, NRF2 is negatively regulated by interaction with 
Kelch-like (ECH)-associated protein (KEAP1) (Fig. A1) (Itoh et al., 1999), a 
substrate adaptor protein for Cullin 3–RING (really interesting new gene)-box 
protein (Rbx)1-based E3 ubiquitin ligase, which uses a cyclical mechanism to 
continuously target NRF2 for ubiquitination and proteasomal degradation (Fig. 
A2A) (Baird et al., 2013, Kensler et al., 2007, Suzuki et al., 2013, Hayes and 
Dinkova-Kostova, 2014). Small molecules which activate NRF2 (termed 
inducers) block this cycle by modifying reactive cysteine sensors of KEAP1 
(Dinkova-Kostova et al., 2002, McMahon et al., 2010) or disrupting the KEAP1 : 
NRF2 binding interface (Fig. A2B) (Hu et al., 2013, Marcotte et al., 2013). 
Consequently, NRF2 is not degraded and free KEAP1 is not regenerated. The 
newly synthesized NRF2 accumulates, translocates to the nucleus and binds (as 
a heterodimer with a small Maf protein) to antioxidant response elements (ARE, 
5’-TGACnnnGC-3’) in the upstream regulatory regions of its target genes (Suzuki 
et al., 2013, Kensler et al., 2007, Hayes and Dinkova-Kostova, 2014). In addition 
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Figure A1. Schematic diagram of NRF2 and KEAP1 domains A) Schematic
diagram of NRF2 domains. NRF2 has seven functional domains, termed NRF2-
ECH homology (Neh)1–7 domains. The low-affinity “DLG” and the high affinity
“ETGE” motifs that bind KEAP1-Kelch domain are shown. Neh4 and Neh5 are
transactivation domains that recruit cAMP response element-binding (CREB)-binding
protein (CBP) and/or receptor-associated coactivator (RAC)3. NRF2 is also
negatively regulated by binding to retinoid X receptor alpha (RXRα), through the
Neh7 domain of the transcription factor. The Neh6 domain mediates interaction with
another negative regulator, the β-transducin repeat-containing protein (β-TrCP1), a
substrate adaptor for the S-phase kinase-associated protein 1 (Skp1)–Cul1–Rbx1
ubiquitin ligase complex. The “DSGIS” and “DSAPGS” motifs that bind β-TrCP1 are
shown. Neh1 contains the heterodimerisation domain which is responsible for binding
with small musculoaponeurotic fibrosarcoma (Maf) proteins, and is the site of binding
to antioxidant/electrophile response element (ARE/EpRE) sequences in DNA. The C-
terminal Neh3 region of NRF2 is a transactivation domain that recruits chromo-
ATPase/helicase DNA-binding protein (CHD)6. B) Schematic diagram of KEAP1
domains. KEAP1 is a member of the BTB-Kelch family of proteins. Members of this
family are able to bind to Cullin 3 through their BTB domain. KEAP1 is a multidomain
homodimeric protein which has five distinct domains: N-terminal region (NTR) (amino
acids 1−60), broad complex, Tramtrack, Bric-á-brac (BTB) (amino acids 61−179),
intervening region (IVR) (amino acids 180−314), Kelch domain (KELCH) (amino
acids 315−598), and the C-terminal region (CTR) (amino acids 599−624). The black
bars represent cysteine residues present in each of the proteins.
A
B
Nrf2
Keap1
Cul3
Proteasome
Ubiquitin
Nucleus
Sulforaphane
FIGURE A2
A
B
Figure A2. The KEAP1/NRF2 pathway. (A) Monomeric NRF2 (purple) binds
sequentially to a free KEAP1 dimer (blue), a substrate adaptor protein for Cul3-based
E3 ubiquitin ligase (orange): first through the high-affinity “ETGE” motif (red sticks) to
form the open conformation of the KEAP1 : NRF2 protein complex, and then through
the low-affinity “DLG” motif (yellow sticks) to form the closed conformation of the
complex. In the closed conformation, NRF2 is targeted for ubiquitination and
degradation by the proteasome. Ubiquitinated NRF2 is released from KEAP1 and
degraded, free KEAP1 is regenerated and able to bind to newly-translated NRF2, and
the cycle of KEAP1-mediated degradation of NRF2 begins again. (B) Electrophiles
and oxidants (termed inducers and exemplified by the isothiocyanate sulforaphane)
activate NRF2 by reacting with cysteine sensors (green sticks) of KEAP1 and disrupt
the cycle by causing accumulation of the KEAP1 : NRF2 protein complex in the
“closed” conformation, without release of NRF2. Consequently, free KEAP1 is not
regenerated, and newly-synthesized NRF2 is stabilized. The transcription factor then
enters the nucleus, where it forms a heterodimer with a small Maf protein (green) to
drive transcription of downstream target genes [image drawn by Dr. Rumen Kostov
and taken from (Dayalan Naidu et al., 2015)].
to KEAP1, the activity of NRF2 is also negatively regulated through glycogen 
synthase kinase (GSK)3/ β-transducin repeat-containing protein (β-TrCP)1-
mediated degradation (Chowdhry et al., 2013) or by interaction with retinoid X 
receptor (RXR)α (Wang et al., 2013a).  
 
1.A.3  Cytoprotective response of the NRF2/KEAP1/ARE pathway 
 
NRF2-dependent genes encode a large network of cytoprotective 
proteins, including those that are involved in the metabolism and transport of a 
wide array of endo- and xenobiotics, proteins that have antioxidant functions, as 
well as those that participate in the synthesis, utilization, and regeneration of 
glutathione and NAD(P)H (Dayalan Naidu et al., 2015).  The number of genes 
that are under the transcriptional control of NRF2 is fascinatingly large: a recent 
study integrating chromatin-immunoprecipitation with parallel sequencing (ChIP-
Seq) and global transcription profiling identified 645 basal and 654 inducible 
direct targets of NRF2, with 244 genes at the intersection (Malhotra et al., 2010).  
Moreover, the functional diversity of the NRF2-dependent cytoprotective proteins 
is extraordinary and provides the cell with multiple layers of protection (Dayalan 
Naidu et al., 2015).  Examples of NRF2-dependent proteins include: (i) 
antioxidant enzymes (e.g., heme oxygenase 1 (HO-1), NAD(P)H:quinone 
oxidoreductase 1 (NQO1), thioredoxin reductase); (ii) conjugating enzymes (e.g. 
glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases); (iii) 
proteins that facilitate the export of xenobiotics and/or their metabolites (e.g., 
solute carrier- and ATP-binding cassette transporters); (iv) anti-inflammatory 
enzymes (e.g., leukotriene B4 dehydrogenase); (v) enzymes that participate in 
the synthesis and regeneration of glutathione (e.g., x-CT, the core subunit of the 
cystine/glutamate membrane transporter, Ɣ-glutamate cysteine ligase catalytic 
(GCLC) and modulatory (GCLM) subunits, glutathione reductase); (vi) enzymes 
that are responsible for the synthesis of reducing equivalents (e.g., glucose 6-
phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (PGD), 
malic enzyme (ME)1); (vii) proteins that protect against metal overload (e.g., 
ferritin and metallothioneins); and (viii) proteins that participate in the repair and 
removal of damaged proteins (e.g., subunits of the 26S proteasome) (Dayalan 
Naidu et al., 2015). 
 
NRF2 activity profoundly affects the levels of the main intracellular small 
molecule antioxidant, reduced glutathione (GSH). NRF2 controls the gene 
expression of the two subunits GCLC and GCLM, the enzyme catalyzing the rate-
limiting step in the GSH biosynthesis (Wild and Mulcahy, 2000) as well as of the 
cystine/glutamate antiporter (SLC7A11, system xc−) (Sasaki et al., 2002) that is 
responsible for the import of cystine, which in turn is converted to cysteine, a GSH 
precursor. Enhanced flux of glutamine into anabolic pathways under conditions 
of NRF2 activation (Mitsuishi et al., 2012) provides glutamate, the second GSH 
precursor; glutamate is also necessary for the import of cystine by system xc−. 
Provision of the third GSH precursor, glycine, is facilitated by the transporter 
SLC6A9, another NRF2-regulated gene (Hirotsu et al., 2012). In addition to the 
biosynthesis, NRF2 also regulates the regeneration of GSH.  The transcription 
factor controls the expression of glutathione peroxidase (GPX), which during 
detoxification of peroxides oxidizes GSH to oxidized glutathione (GSSG). 
Subsequently, glutathione reductase (GSR), another NRF2 target, regenerates 
GSH from GSSG using NADPH as a cofactor. The requirement for NADPH is 
provided by NRF2, which regulates the gene expression of the four principal 
NADPH-generating enzymes, i.e. G6PD, PGD, isocitrate dehydrogenase (IDH)1, 
and ME1 (Mitsuishi et al., 2012, Singh et al., 2013).  
 
1.A.4  KEAP1: The main negative NRF2 regulator 
 
In mammals, KEAP1 is a highly conserved 624-amino acid protein sharing 
approximately 90% sequence homology between species (Fig. A3). KEAP1 is 
mainly found in the cytoplasm as it is sequestered there due to its interaction with 
cytoskeletal actin filaments which prevent it from entering the nucleus (Kang et 
al., 2004). KEAP1 is also highly cysteine rich and the cysteines are highly 
conserved across the mammalian species. In humans there are 27 cysteine 
residues in KEAP1, whereas, in mouse there are 25 (Fig. A3), 9 of which (i.e., 
C23, C38, C151, C241, C273, C288, C297, C319, and C613) are flanked by basic 
amino acids.  The presence of neighboring basic amino acids is known to lower 
the pKa value of cysteine, favoring the formation of the thiolate anion at neutral 
pH, and thus increasing the cysteine reactivity (Snyder et al., 1981). Due to the 
presence of multiple cysteine residues, KEAP1 is able to function as an oxidative 
and electrophilic stress sensor and this is supported by experiments conducted 
by Dinkova-Kostova and colleagues where the authors discovered that several 
inducers of the KEAP1/NRF2/ARE pathway react with cysteine thiols in KEAP1 
to disrupt its binding to the Neh2 domain of NRF2 (Dinkova-Kostova et al., 2002).  
 
 
SP|Q14145|KEAP1_HUMAN  MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
SP|Q9Z2X8|KEAP1_MOUSE  MQPEPKLSGAPRSSQFLPLWSKCPEGAGDAVMYASTECKAEVTPSQDGNRTFSYTLEDHT 60
SP|P57790|KEAP1_RAT    MQPEPKPSGAPRSSQFLPLWSKCPEGAGDAVMYASTECKAEVTPSQDGNRTFSYTLEDHT 60
SP|Q684M4|KEAP1_PIG    MQPEPRPSGAGAHTQFLPLRSQRPEGAGDTVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
SP|Q5R774|KEAP1_PONAB  MQPDPRPSGAGACSRFLPLRSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
TR|H2QFB9|H2QFB9_PANTR MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
***:*: ***    :**** *: ******:****************.*************
SP|Q14145|KEAP1_HUMAN  KQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|Q9Z2X8|KEAP1_MOUSE  KQAFGVMNELRLSQQLCDVTLQVKYEDIPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|P57790|KEAP1_RAT    KQAFGIMNELRLSQQLCDVTLQVKYEDIPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|Q684M4|KEAP1_PIG    KQAFGIMNELRLSQQLCDVTLQVKYEDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|Q5R774|KEAP1_PONAB  KQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
TR|H2QFB9|H2QFB9_PANTR KQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
*****:*******************:* ********************************
SP|Q14145|KEAP1_HUMAN  EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|Q9Z2X8|KEAP1_MOUSE  EVVSIEGIHPKVMERLIEFAYTASISVGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|P57790|KEAP1_RAT    EVVSIEGIHPKVMERLIEFAYTASISVGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|Q684M4|KEAP1_PIG    EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|Q5R774|KEAP1_PONAB  EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
TR|H2QFB9|H2QFB9_PANTR EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
**************************:*********************************
SP|Q14145|KEAP1_HUMAN  PSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVR 240
SP|Q9Z2X8|KEAP1_MOUSE  PSNAIGIANFAEQIGCTELHQRAREYIYMHFGEVAKQEEFFNLSHCQLATLISRDDLNVR 240
SP|P57790|KEAP1_RAT    PSNAIGIANFAEQIGCTELHQRAREYIYMHFGEVAKQEEFFNLSHCQLATLISRDDLNVR 240
SP|Q684M4|KEAP1_PIG    PSNAIGIANFAEQIGCAELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVR 240
SP|Q5R774|KEAP1_PONAB  PSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVTKQEEFFNLSHCQLVTLISRDDLNVR 240
TR|H2QFB9|H2QFB9_PANTR PSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVR 240
****************.*****************:*************.***********
SP|Q14145|KEAP1_HUMAN  CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDY 300
SP|Q9Z2X8|KEAP1_MOUSE  CESEVFHACIDWVKYDCPQRRFYVQALLRAVRCHALTPRFLQTQLQKCEILQADARCKDY 300
SP|P57790|KEAP1_RAT    CESEVFHACIDWVKYDCPQRRFYVQALLRAVRCHALTPRFLQTQLQKCEILQADARCKDY 300
SP|Q684M4|KEAP1_PIG    CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPHFLQMQLQKCEILQSDSRCKDY 300
SP|Q5R774|KEAP1_PONAB  CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDY 300
TR|H2QFB9|H2QFB9_PANTR CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDY 300
**********:****** ****************:***.*** *********:*:*****
SP|Q14145|KEAP1_HUMAN  LVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
SP|Q9Z2X8|KEAP1_MOUSE  LVQIFQELTLHKPTQAVPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSNGSWLRLADLQV 360
SP|P57790|KEAP1_RAT    LVQIFQELTLHKPTQAVPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSNGSWLRLADLQV 360
SP|Q684M4|KEAP1_PIG    LVKIFQELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
SP|Q5R774|KEAP1_PONAB  LVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
TR|H2QFB9|H2QFB9_PANTR LVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
**:**:*********.:*******************************:*:*********
SP|Q14145|KEAP1_HUMAN  PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
SP|Q9Z2X8|KEAP1_MOUSE  PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCASMSVPRNRIGVGV 420
SP|P57790|KEAP1_RAT    PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCASLSVPRNRSGGGV 420
SP|Q684M4|KEAP1_PIG    PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
SP|Q5R774|KEAP1_PONAB  PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
TR|H2QFB9|H2QFB9_PANTR PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
*********************************************** :****** * **
SP|Q14145|KEAP1_HUMAN  IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|Q9Z2X8|KEAP1_MOUSE  IDGHIYAVGGSHGCIHHSSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|P57790|KEAP1_RAT    IDGHIYAVGGSHGCIHHSSVERYEPDRDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|Q684M4|KEAP1_PIG    IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|Q5R774|KEAP1_PONAB  IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
TR|H2QFB9|H2QFB9_PANTR IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
*****************.*******:**********************************
SP|Q14145|KEAP1_HUMAN  TNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
SP|Q9Z2X8|KEAP1_MOUSE  TNRLNSAECYYPERNEWRMITPMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
SP|P57790|KEAP1_RAT    TNRLNSAECYYPERNEWRMITPMNTIRSGAGVCVLHSCIYAAGGYDGQDQLNSVERYDVE 540
SP|Q684M4|KEAP1_PIG    TNRLNSAECYYPERNEWRMITPMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
SP|Q5R774|KEAP1_PONAB  TNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
TR|H2QFB9|H2QFB9_PANTR TNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
********************* **************.***********************
SP|Q14145|KEAP1_HUMAN  TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
SP|Q9Z2X8|KEAP1_MOUSE  TETWTFVAPMRHHRSALGITVHQGKIYVLGGYDGHTFLDSVECYDPDSDTWSEVTRMTSG 600
SP|P57790|KEAP1_RAT    TETWTFVASMKHRRSALGIAVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRLTSG 600
SP|Q684M4|KEAP1_PIG    TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
SP|Q5R774|KEAP1_PONAB  TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
TR|H2QFB9|H2QFB9_PANTR TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
******** *:*:******:****:**********************:********:***
SP|Q14145|KEAP1_HUMAN  RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|Q9Z2X8|KEAP1_MOUSE  RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|P57790|KEAP1_RAT    RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|Q684M4|KEAP1_PIG    RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|Q5R774|KEAP1_PONAB  RSGVGVAVTMEPCRKQIDQQNCTC 624
TR|H2QFB9|H2QFB9_PANTR RSGVGVAVTMEPCRKQIDQQNCTC 624
************************
Amino acid sequence alignment of mammalian Keap1 using Clustal Omega 
Program
FIGURE A3
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Figure A3. Amino acid sequence alignment of various mammalian KEAP1.
Alignment performed using the web-based Clustal Omega program found within
www.uniprot.org. The uniprot IDs are listed. Q14145 (Human), Q9Z2X8 (Mouse),
P57790 (Rat), Q684M4 (Pig), Q5R774 (Orangutan), H2QFB9 (Chimpanzee). The
highly conserved cysteine residues are highlighted in yellow.
1.A.4.1 KEAP1 structure and its cysteine sensors 
 
KEAP1 is a member of the BTB-Kelch family of proteins which are named 
Kelch-like 1 to 42 (KLHL1-42). All members of this family are able to bind to Cullin 
3 through their BTB domain. KEAP1 is a multidomain homodimeric protein which 
has five distinct domains (Fig. A1B): N-terminal region (NTR) (amino acids 
1−60), broad complex, Tramtrack, Bric-á-brac (BTB) (amino acids 61−179), 
intervening region (IVR) (amino acids 180−314), Kelch domain (KELCH) (amino 
acids 315−598), and the C-terminal region (CTR) (amino acids 599−624).  
 
The BTB domain is required for KEAP1 dimerisation, and it has been 
reported that mutation of S104 to an alanine residue prevents its 
homodimerisation and causes NRF2 accumulation in the nucleus (Zipper and 
Mulcahy, 2002). There are three cysteines present in the KEAP1 BTB domain, 
C77, C151 and C171. Single mutants of each of the cysteines in the BTB domain 
to a serine behave like the wild-type (WT) KEAP1 in terms of the ability to repress 
NRF2-dependent gene expression (Zhang and Hannink, 2003). The KEAP1 
C151 is the most well-characterised in the literature. The KEAP1 C151S mutant 
under basal conditions is also able to mediate the degradation of NRF2, similarly 
to the WT protein (McMahon et al., 2010, Zhang and Hannink, 2003, Saito et al., 
2015). Zhang et al. found that the BTB domain of KEAP1 protected KEAP1 from 
ubiquitin-mediated degradation (Zhang et al., 2005). Interestingly, it has been 
shown by several groups that under basal conditions, when subjected to SDS-
PAGE, WT KEAP1 migrates as two distinct species, one at approximately 65 kDa 
and the other at 130 kDa and that the slow migrating species does not appear 
with in the C151S mutant (Fourquet et al., 2010, Zhang and Hannink, 2003). 
Zhang and colleagues suggested that the slow migrating species of KEAP1 is 
due to the posttranslational modifications occurring on the protein, as the 
mutation of C151S prevents its occurrence. However, Fourquet et al. showed that 
the slower migrating KEAP1 species is non-inducible and redox insensitive and 
upon exposure to electrophiles, the intensity of the slower migrating species 
increased. The authors subsequently exposed induced samples to the reducing 
agent β-mercaptoethanol and observed a complete reduction in the intensified 
slower migrating species of KEAP1 hence suggesting that this species mainly 
comprises of the oxidized form of KEAP1 (Fourquet et al., 2010).  
 
Some of the well-known NRF2 inducers that modify C151 are the 
isothiocyanate sulforaphane (SFN), iodoacetamide (IAA), tert-butyl hydroquinone 
(tBHQ) and diethylmaleate (DEM) (McMahon et al., 2010, Takaya et al., 2012, 
Saito et al., 2015, Bryan et al., 2013). In 2010, using molecular modeling 
McMahon et al. postulated that the cysteine reactivity of C151 in KEAP1 was due 
to the presence of five proximate basic amino acid residues (His 129, Lys 131, 
Arg 135, Lys 150 and His 154) (McMahon et al., 2010), which have the ability to 
deprotonate the sulfhydryl group of C151 thus lowering its pKa. This results in the 
thiol group of C151 to exist as an anion under physiological pH conditions. 
Indeed, the authors discovered that KEAP1 bearing the triple mutations at 
K131M, R135M and K150M lost the ability to sense electrophiles that specifically 
targeted C151.  
 
The crystal structure of the BTB domain of KEAP1 with the triterpenoid 
CDDO was solved in 2014 and deposited in the Protein Database Bank (pdb.org) 
with the accession number 4CXI using the Pymol software (Fig.A4A) (Cleasby 
et al., 2014). We measured the distances of the 5 positively charged amino acids 
mentioned that were adjacent to C151 and found that R135 had the closest 
proximity to C151 with a distance of 3.6Å (Fig. A4B), which further supports the 
findings reported by McMahon and colleagues (McMahon et al., 2010). 
 
To date, there is no crystal structure of the IVR domain of KEAP1 (aa 180 
to 315). The KEAP1 IVR domain, flanked by the N-terminal BTB domain and the 
Kelch domain at the C-terminus, contains 8 cysteine residues (cysteines 196, 
226, 241, 249, 257, 273, 288 and 297), of which, C273 and C288 are the most 
well characterised. Exposure to electrophiles or alkylating agents targeting the 
cysteines within the IVR domain, predominantly C273 and C288, leads to the 
inactivation of KEAP1 and subsequent activation of NRF2 (Dinkova-Kostova et 
al., 2002, Kobayashi et al., 2004, Wu et al., 2010). Single or double mutations of 
C273 or C288 to serine or alanine render KEAP1 inactive with respect to its 
repression and degradation of NRF2 (McMahon et al., 2010, Zhang and Hannink, 
2003, Kobayashi et al., 2004, Levonen et al., 2004), Wakabayashi et al. 2004). 
Since these C273S/A and C288S/A mutants inactivated KEAP1, they presented 
a difficulty to study the electrophiles that could potentially target these cysteines. 
Recently, Saito and colleagues showed that single or double mutation of C273 
and C288 to tryptophan or glutamic acid did not impede the KEAP1-mediated 
repression and degradation of NRF2 hence allowing to precisely identify 
electrophiles that are sensed by either or both of these residues (Saito et al., 
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Figure A4. Structure of the human KEAP1 BTB domain. A) Cartoon
representation of the human KEAP1 BTB domain (grey). The basic amino acids
(His 129, Lys 131, Arg 135, Lys 150 and His 154) adjacent to the Cys 151
residue (green sticks) are represented with cyan coloured stick drawings.
Structure drawn using Pymol using the PDB accession 4CXI. B) The distances
calculated in angstroms (Å) between basic residues (His 129, Lys 131, Arg 135,
Lys 150 and His 154) and Cys 151.
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2015). In the report published by Saito et al. the authors showed that 15-deoxy-
Δ12,14-prostaglandin J2 (15d-PGJ2) is sensed specifically by C288. We performed 
molecular modeling of the amino acid residues comprising the IVR domain using 
the I-TASSER platform (Fig. A5), and found that it is comprised of 8 α-helices 
and that basic amino acids are found adjacent to C273 (i.e. R272 and H274) and 
C288 (i.e. K287), which could cause the deprotonation of the thiol groups, hence 
increasing their reactivity. 
 
The Kelch domain of KEAP1 is evolutionarily conserved and contains nine 
cysteine residues at amino acids 319, 368, 395, 406, 434, 489, 513, 518 and 583. 
The first crystal structure of the KEAP1 Kelch domain was solved at a resolution 
of 1.85Å in 2004 by Li and colleagues (Li et al., 2004). Several crystal structures 
of both the human and murine KEAP1 Kelch domains with different resolutions 
and in combination with compounds or short peptide sequences of the Neh2 
domain of NRF2 have since been reported (Lo et al., 2006, Tong et al., 2007, 
Komatsu et al., 2010, Fukutomi et al., 2014, Winkel et al., 2015, Davies et al., 
2016, Saito et al., 2016). The Kelch domain in KEAP1 contains six Kelch repeats 
that assembles into a six-bladed β-propeller structure (blades I-VI), where the C-
terminal residues form the first strand in the first blade. Four-stranded antiparallel 
β sheets (A-D) form one blade, where the shortest β sheet A is found at the 
central core (Canning et al., 2015, Li et al., 2004). The Kelch domain also 
contains double glycine repeats (DGR), which are located at the terminal end of 
the β sheets. In several reports within the literature, the Kelch domain and the 
CTR are collectively called the DGR.  
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Figure A5. Modelled structure of the human KEAP1 IVR domain. Cartoon
representation of the I-TASSER program modelled human KEAP1 IVR domain
displaying 8 α-helices, amino acids 180 to 315 (grey). The basic amino acids (Arg
272 and His 274, pink) found adjacent to the Cys 273 residue (green) as well as the
hydrophobic Lys 287 (pink) residue found adjacent to Cys 288 (green) are
represented with coloured stick drawings.
First discovered in 1999 by Itoh and colleagues, the N-terminal Neh2 
domain within NRF2 has been since reported by various groups to bind to the 
KEAP1 Kelch domain (Itoh et al., 1999). Using nuclear magnetic resonance 
spectroscopy, Tong et al. discovered that the Neh2 domain was intrinsically 
disordered (Tong et al., 2006). It was subsequently found that the evolutionarily 
conserved DLG (McMahon et al., 2004) and ETGE (Itoh et al., 1999) motifs within 
the NRF2-Neh2 domain (Fig. A1A) were responsible for binding to the KEAP1 
Kelch domains (McMahon et al., 2006, Tong et al., 2006). The DLG motif has a 
200-fold lower affinity binding constant to the Kelch domain of KEAP1 compared 
to the ETGE motif (Tong et al., 2007). When we compared the independently X-
ray crystallographically-resolved complexes of ETGE containing peptide-Kelch 
KEAP1 with the DLG containing peptide-Kelch KEAP1 by superimposing the two 
using the Pymol software, we discovered that that both the DLG and ETGE motifs 
occupy the Kelch domain pocket in a similar fashion (Fig.A6A and B). The most 
striking difference observed between the occupancy of the DLG containing 
peptide compared to the ETGE-containing peptide was that the N-terminus of the 
DLG peptide adopted an α-helical secondary structure (Fig. A6). The DLG and 
ETGE motifs flank a lysine-rich α-helix to allow for the conjugation of ubiquitin 
molecules by the activated E2-ubiquitin conjugating enzyme. To summarize, the 
dimer of KEAP1 binds to NRF2 through its Neh2 domain where one KEAP1 
monomer binds to the ETGE motif and the other binds to the DLG motif to serve 
as a substrate adaptor to mediate the proteasomal degradation of NRF2 through 
Cullin 3, a scaffolding protein for the E3 ubiquitin ligase complex.  
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Figure A6. Structure of the KEAP1 Kelch domain. Cartoon representation of
superimposed human KEAP1-Kelch domain (pale blue) complexed with the ETGE
(yellow) containing human NRF2 peptide sequence (amino acids 69 to 84) (blue)
(PDB ID: 2FLU) and the murine KEAP1-Kelch domain (pale pink) complexed with the
murine NRF2 peptide (amino acids 17-40) (pink) containing the DLG motif (green)
(PDB ID: 3WN7). A) shows the side view and B) shows the top view of the Kelch
domains of KEAP1.
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1.A.4.2 KEAP1-Cullin3 interaction 
 
The primary system for protein degradation in the cell is the ubiquitin-
proteasome system, where E3 ubiquitin ligases are essential components. 
Cullins are a family of hydrophobic proteins that confer substrate specificity by 
acting as scaffolds for E3 ubiquitin ligase complexes (Sarikas et al., 2011, 
Anderica-Romero et al., 2013). Thus far, in mammals, there have been seven 
Cullins (1, 2, 3, 4A, 4B, 5 and 7) identified. Cullin 3 is the only member of its family 
that is able to recognize BTB domains-containing proteins (Anderica-Romero et 
al., 2013). Since KEAP1 contains the BTB domain, in 2004, Kobayashi and 
colleagues hypothesized that under basal conditions, Cullin 3 could be mediating 
the degradation of NRF2 through binding of the substrate adaptor KEAP1 due to 
its ability to bind to proteins containing the BTB domain (Kobayashi et al., 2004). 
Indeed, they discovered that, in vivo, Cullin 3 was able to bind to KEAP1, 
however, it was surprising that the interaction between the two proteins was 
between the IVR domain of KEAP1 and the N-terminal domain of Cullin 3 instead 
of the BTB domain of KEAP1 (Kobayashi et al., 2004). Subsequently, at the 
beginning of 2005, in the same journal, Furukawa and Xiong, reported that 
KEAP1 and Cullin 3 binding occurs between the BTB-domain of the former and 
the N-terminal domain of the latter. Subsequently, it was discovered that Cullin 3 
homodimerisation requires the presence of its N-terminal domain and is 
dependent on its interaction with BTB domain containing substrates (i.e. KEAP1) 
which also are able to homodimerise at their BTB domains (Choo and Hagen, 
2012).  
 
Using a quantitative fluorescence recovery after photobleaching (FRAP)-
based approach, Baird and Dinkova-Kostova, found that NRF2 inducers such as 
the semisynthetic triterpernoid CDDO, the isothiocyante sulforaphane and 
hydrogen peroxide do not affect the binding between ectopically expressed 
fluorophore-tagged KEAP1-EGFP and mCherry-Cullin 3, and suggested that 
conformational changes could inactivate their repressive functions, ultimately 
leading to activation of NRF2 (Baird and Dinkova-Kostova, 2013). Under basal 
conditions, the KEAP1-E3 ubiquitin ligase complex binds to one NRF2 molecule. 
A small protein, Nedd8 is covalently attached to a highly conserved lysine residue 
at the C-terminus region of Cullin 3. This leads to the reconfiguration of the 
KEAP1-Cullin 3-E3 ubiquitinating complex and allows for the association E2 
enzymes to come into contact with NRF2, leading to its polyubiquitination and 
subsequent degradation by the proteasome (Canning et al., 2013, Duda et al., 
2008, Saha and Deshaies, 2008). It could be envisioned that when this complex 
is exposed to electrophiles or reactive oxygen species, the polyubiquitination of 
NRF2 ceases due to chemical modification of the reactive ‘sensor’ cysteine 
residues in KEAP1, which disables its NRF2-repressor function. 
 
1.A.5  Concluding remarks 
 
More than 20 years of research conducted on the KEAP1/NRF2 pathway 
by various independent groups have highlighted the exceptional importance of 
these two proteins. The extraordinary ability of KEAP1 to sense a multitude of 
inducers that vary in shape, size and order of reactivity has led to an intricately 
complex ‘cysteine code’, which guarantees a finely tuned and tightly regulated 
antioxidant response pathway. The induction of this pathway is the purpose of 
the small molecule NRF2 activators, which are currently in clinical trials. It is vital 
that further research is conducted to achieve a greater understanding of the 
detailed consequences of activating NRF2 by targeting of KEAP1 for the 
treatment and prevention of various diseases. 
 
	
Section 1: Introduction 
Chapter B 
The cytoprotective role of the mammalian heat shock factor 1 
1.B.1 Introduction 
In the early 1960s, the Italian researcher Ferruccio Rittosa was studying 
the type(s) of nucleic acid that was being transcribed at the puffs in the 
chromosomes of the Drosophila salivary glands (Ritossa and Vonborstel, 1964), 
where these chromosome puffs were found to be transcriptionally active regions. 
By accident, one of his colleagues had increased the temperature of the incubator 
where he had kept his Drosophila larvae and during this time (Ritossa, 1996), 
Ritossa noticed a unique puffing pattern in the Drosophila polytene chromosomes 
(Ritossa, 1964) when they were exposed to heat, sodium salicylate or di-
nitrophenol. Subsequently, independent groups observed this phenomenon in 
other Drosophila tissues, and this ultimately led to the discovery of the heat shock 
proteins when the researchers Tissieres and Mitchell found these proteins to be 
upregulated during the chromosomal puffing that occurred upon heat stress 
(Tissieres et al., 1974).  
In all living organisms known to man, the cellular response to elevated 
temperatures is universal, and is triggered by a temperature increase of just a 
few degrees above the optimal temperature. All organisms are adapted to a 
precise range of temperatures for optimal function. Cells within these organisms 
possess intricate mechanisms that allow for adaptation and survival during 
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elevated temperatures. In humans, the core body temperature is normally around 
37 degrees Celsius (oC). However, temperatures above 41 oC induce the heat 
shock response (HSR), which is characterized by the activation of transcription 
of heat shock protein (Hsp) genes orchestrated by a family of transcription 
factors, within which heat shock factor 1 (HSF1) is most prominent. The HSR 
causes the elevation of the Hsps such as Hsp24, Hsp40, Hsp70 and Hsp90 most 
of which are molecular chaperones that function to prevent protein misfolding and 
aggregation within the cell. The HSR is a cytoprotective mechanism that is also 
stimulated upon cellular stresses such as hypoxia (Benjamin et al., 1990), 
fluctuations in intracellular pH (Jolly and Morimoto, 2000), proteotoxicity and 
exposure to heavy metals (Lee et al., 2002a, Saydam et al., 2003). Critically, in 
addition to providing an adaptive response to thermal stress resulting in 
thermotolerance, the HSR orchestrated by HSF1 has protective effects in 
numerous pathophysiological conditions, including ageing and 
neurodegenerative diseases (Aridon et al., 2011, Hoshino et al., 2011, Anckar 
and Sistonen, 2011, Morley and Morimoto, 2004). 
1.B.2 HSF family members 
To date, there are four known members belonging to the HSF protein 
family, of which HSF1, HSF2 and HSF4 (Schuetz et al., 1991, Nakai et al., 1997) 
have been identified and characterized in mammals, and HSF3 was initially 
identified in the avian species (Nakai et al., 1995). In unstressed cells, HSF1 is a 
monomer and in contrast, HSF2 exists as a dimer. Upon stress, HSF2 can either 
form a homotrimer or it can heterotrimerize with HSF1 in the nucleus and induce 
27
the transcription of both the classical heat shock genes as well as non-classical 
heat shock genes such as the tandem satellite III DNA repeats (Sandqvist et al., 
2009, Ostling et al., 2007). A recent study has discovered that HSF1 and HSF2 
interact with each other through their coiled-coil domains adjacent to their DNA 
binding domains (Jaeger et al., 2016). Unlike HSF1, HSF2 expression is tissue- 
and cell-specific (Akerfelt et al., 2010). In the mouse, HSF2 plays a vital role in 
spermatogenesis, female fertility and early development (Wang et al., 2004a, 
Kallio et al., 2002). Kallio et al. discovered that HSF2-null (HSF2-/-) mice, 
although embryonically viable, display brain abnormalities, which are 
characterized by a reduced striatum and hippocampus; furthermore, HSF2-/- 
female mice produce eggs with meiotic defects (Kallio et al., 2002). Although 
much of the early research on HSF2 was focused on its role in development, a 
more recent study highlighted the link between HSF2 and neurodegeneration 
(Shinkawa et al., 2011). The researchers found that the loss of HSF2 in the R6/2 
Huntington’s disease mouse model exacerbates the aggregation of the 
polyglutamine protein leading to a decreased lifespan.  
HSF4 lacks the LZ4 domain that is required for the suppression of 
trimerization of HSF1, is localized mainly in the nucleus, and is ubiquitously 
expressed in cells. HSF4 plays an important role in development and its 
expression is increased during lens development (Fujimoto et al., 2004). Many 
studies have shown that HSF4 is crucial for the development and maintenance 
of the lens as mutations in HSF4 (Fujimoto et al., 2008), particularly in the DNA-
binding domain are correlated with the development of cataracts in humans (Ke 
et al., 2006, Forshew et al., 2005, Smaoui et al., 2004, Bu et al., 2002). One of 
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the isoforms of HSF4, HSF4a, has been shown to negatively regulate HSF2 by 
downregulating the expression and inhibiting the transcriptional activity of HSF2 
at the hsp70 promoter via directly binding to HSF2 (Kim et al., 2012b). Loss of 
the ATP-dependent chromatin remodelling enzyme Snf2h is vital for lens 
development in mice. Interestingly, depletion of Snf2h dramatically reduces HSF4 
transcript levels suggesting that the transcription factor is regulated by chromatin 
remodelling, and that the importance of Snf2h in lens development might be in 
part mediated by HSF4 (He et al., 2016). 
The mammalian HSF1 orthologue in avian cells is functionally redundant, 
however, in chickens, HSF3 is the major heat shock transcription factor 
(Kawazoe et al., 1999). Furthermore, human HSF1 is able to rescue the induction 
of the classical heat shock responsive genes in the absence of chicken HSF3, 
although chicken HSF1 confers cellular cytoprotection when cells are exposed to 
stressors such as UV irradiation (Inouye et al., 2003) and is able to do so without 
inducing the classical heat shock genes, suggesting that chicken HSF1 also plays 
a vital role in other pro-survival pathways. In the chicken, HSF3 exists as a dimer 
in unstressed cells and is able to form homotrimers upon heat shock(Nakai et al., 
1995, Nakai and Ishikawa, 2000). The mouse HSF3 discovered in 2010 by 
Fujimoto et al. (Fujimoto et al., 2010) can activate the transcription of non-
classical heat shock genes, and its isoform mHSF3a, has the ability of protect 
cells from heat shock and proteotoxicity. Of note, although HSF3 is considered 
to be the avian ortholog of the mammalian HSF1, a recent study suggests that its 
involvement in the regulation of a number of febrile response mediators, such as 
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the interleukins IL-6. IL-1β, and activating transcription factor 3 (ATF3), have 
evolutionally diverged in mammalian and avian species (Prakasam et al., 2013). 
1.B.3 HSF1: Structure, Function and Regulation 
HSF1 is the most well studied member of the HSF family. During 
unstressed conditions, the mammalian HSF1 exists as a monomer more 
abundantly in cytoplasm relative to the nucleus (Fig. B1). The DNA-binding and 
transcriptional capacity of the transcription factor is suppressed at both the 
intramolecular level as well as the intermolecular level, where in the latter, 
molecular chaperones such as Hsp70 (Shi et al., 1998) and Hsp90 (Ali et al., 
1998) interact with HSF1 to inhibit its activation. Upon cellular tress, HSF1 
undergoes several activating post-translational modifications and also forms a 
transcriptionally active trimer that accumulates in the nucleus and binds to heat 
shock elements (HSE) which contain the inverted repeats of the 
deoxyribonucleotides TTCnGAAnTTC that are found in the upstream regulatory 
regions of the hsp genes (Trinklein et al., 2004).  
Nuclear stress bodies (nSBs) are relatively large distinct structures (0.3 to 
3 μm in diameter) that are formed in the nucleus when the cell is exposed to 
stresses such as heat shock or heavy metals (Biamonti and Vourc'h, 2010). The 
formation of nSBs requires the transcriptionally active HSF1 to interact with 
pericentrometric tandem repeats of satellite III (sat II) sequences within the 9q12 
chromosomal locus leading to the transcription of non-coding single-stranded 
RNA molecules. Also, HSF1 binds to the histone acetyl transferase (HAT) CREB 
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Figure B1
Figure B1. The heat shock response. Various types of cellular stressors such as heat
and proteotoxicity can activate the heat shock response by causing the release of the
transcription factor HSF1 which is basally sequestered by the Hsp90 multi-chaperone
complex that also includes the co-chaperone Hsp70. In addition, the binding between the
leucine zipper (LZ) domains LZ1-3 and LZ4 is disrupted and the regulatory domain of
HSF1 becomes hyperphosphorylated at several serine residues within its regulatory
domain (RD), leading to HSF1 activation. The transcriptionally active HSF1 is then able
to enter the nucleus, homotrimerize and bind to the heat shock elements to induce the
transcription of its target genes. HSF1 that is basally present in the nucleus also
becomes activated upon stress and is able to homotrimerize to elicit the heat shock
response. In the attenuation phase of the heat shock response, nuclear Hsp70 binds to
the C-terminal transactivation domain (CTAD) of HSF1 to inhibit its function. During this
time HSF1 is also dephosphorylated and shuttles out of the nucleus, resumes its
inactivated form and is once again bound to the Hsp90- multichaperone complex.
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and causes the hyperacetylation of nucleosomes at the satellite III repeats, 
allowing RNA polymerase as well as several RNA-binding proteins to transcribe 
sat III mRNA transcripts. The mRNA and RNA-binding protein complexes 
generated are known as the perichromatin granules (PGs) and are generated in 
large clusters during stress forming mature distinct nSBs (Biamonti, 2004).  
Interestingly, at the nSBs, HSF1 and HSF2 form transcriptionally active 
heterocomplexes (Alastalo et al., 2003) and the formation of nSBs coincides with 
the nucleolar accumulation of Hsp70. Although, the function of the nSBs is 
currently quite unclear, it is interesting that upon stimulation, nSBs are formed as 
early as 5 minutes and they are able to last for several hours after the initial 
stimulation. During the heat shock response, Hsp70 levels are increased, and the 
HSF1 trimers that exit the nSBs are dissociated into inactive HSF1 monomers by 
the binding of Hsp70 (Biamonti, 2004).  
The generation of HSF1-knockout mice (HSF1-/-) provided new insights 
into the functional significance of HSF1(Yan et al., 2002). HSF1-/- mice have 
altered redox homeostasis in the cardiac cells, and their mitochondria are highly 
susceptible to oxidative damage. By use of mouse embryonic fibroblasts (MEFs), 
it was found that HSF1 is essential for induction of the classical heat shock genes, 
and HSF1-/- MEFs are more sensitive to apoptosis during heat stress compared 
to their wild-type counterparts (Yan et al., 2002) showing the importance of HSF1 
for cell survival. Female HSF1-/- mice display placental insufficiency, which 
contributes to the partial fetal lethality of the absence of the transcription factor. 
Male HSF1-/- mice are fertile, however the females with this genotype are sterile. 
HSF1 plays a vital role in oogenesis: HSF1 is highly abundant in the nucleus of 
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immature oocytes and plays an important role in the initial cleavage stages, 
hence explaining the infertility described in the HSF1-/- females (Christians et al., 
2000). 
HSF1 is constitutively expressed in most tissues and cell types and is 
regulated by multiple post-translational modifications (PTMs) such as 
sumoylation, acetylation and phosphorylation throughout its activation and 
attenuation cycle (Fig. B2). In an unstressed system, HSF1 is a monomeric 
phosphoprotein where it is phosphorylated on multiple serine residues (Sarge et 
al., 1993, Baler et al., 1993, Holmberg et al., 2001, Cotto et al., 1996), and is also 
negatively regulated at the intramolecular level due to the binding of the LZ1-3 
domain and the LZ4 domain. The LZ1-3 domain, or the oligomerization domain, 
due to its coiled-coil structure has the ability to form homotrimers (Rabindran et 
al., 1993, Farkas et al., 1998, Liu and Thiele, 1999). Upon stress, the 
intramolecular coiled-coil interaction is lost and an intermolecular coiled-coil 
interaction is established. The regulatory domain (RD) of HSF1 lies between the 
LZ1-3 and LZ4 domains. Its absence causes HSF1 to become transcriptionally 
active even in unstressed conditions, which highlights the role of the RD as a 
repressor of HSF1 activity and also as a stress sensor (Yoshima et al., 1998, 
Newton et al., 1996, Budzynski et al., 2015).  
During exposure to stress such as heat shock, HSF1 is 
hyperphosphorylated and this hyperphosphorylation of HSF1 increases the half-
life of the HSF1 trimers and prolongs its transactivating capabilities (Xia and 
Voellmy, 1997). The RD is subjected to many PTMs such as acetylation, 
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Figure B2. Schematic diagram of the structure and posttranslational
modifications of HSF1. HSF1 is posttranslationally modified by various
enzymes and these modifications can confer HSF1 to be either
transcriptionally active or inactive. The activating modifications (blue) are
phosphorylation (Ph) modifications on Ser residues 230, 326, and 419. The
repressive modifications (red) on HSF1 are acetylation (Ac) on Lys 80,
phosphorylation on Ser residues 121, 172, 303, 307 and 363 and sumoylation
(Su) on Lys 298. The enzymes that catalyze these modifications are listed
beside the respective residue modifications; DBD: N-terminal DNA-binding
domain, LZ: Leucine zippers LZ1-3 and LZ4, RD: Regulatory domain, and
CTAD: C-terminal transactivation domain. Trimerization of HSF1 occurs at the
LZ1-3 region, whereas at basal conditions, it is negatively regulated by LZ4.
Also, in unstressed systems the CTAD is negatively regulated by the RD.
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phosphorylation and sumoylation. In 2005, Guettouche and colleagues 
performed an extensive study on the phosphorylation sites on human HSF1 and 
identified that HSF1 was phosphorylated on at least 12 serine residues, and 
interestingly, they did not detect phosphorylation on threonine or tyrosine 
residues (Guettouche et al., 2005); however, other groups have identified 
phosphorylation events occurring on such residues (Soncin et al., 2003, Olsen et 
al., 2006). Although most of the phosphorylations that occur within the RD are 
inhibitory, phosphorylations on serine 230 (Holmberg et al., 2001) and serine 326 
(Guettouche et al., 2005, Boellmann et al., 2004) are activating. Thus, the 
calcium/calmodulin-dependent kinase CAMKII phosphorylates HSF1 at serine 
230 during stress conditions, and mutation of this residue reduces the 
transcriptional capacity of HSF1(Holmberg et al., 2001). The phosphorylation of 
serine 326 of HSF1 allows DAXX to bind to HSF1 to enhance its transcription 
(Boellmann et al., 2004), and mutations of serine 326 have been shown to reduce 
the transcriptional activity of HSF1 by more than 70% (Guettouche et al., 2005, 
Boellmann et al., 2004).  
The kinases that phosphorylate HSF1 at S326 were proposed to be MEK 
(Tang et al., 2015) and mTOR (Chou et al., 2012). Experiments described in this 
thesis showed that all members of the p38 MAPK family have the ability to 
phosphorylate HSF1 at S326 in vitro and in cells, p38Ɣ was identified to be the 
primary kinase that phosphorylates HSF1 at this site (Dayalan Naidu et al., 2016). 
In addition, phosphorylation on serine 303 that lies within the regulatory domain 
of HSF1 is required for sumoylation (conjugation of small ubiquitin modifiers 
(SUMO) 2/3) at lysine 298 (Hietakangas et al., 2003), and this mechanism was 
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first discovered in HSF1 where phosphorylation-dependent sumoylation motif 
(PDSM) characterized by the consensus sequence ΨKxExxSP (where Ψ is a 
branched hydrophobic amino acid and x is any amino acid) was identified 
(Hietakangas et al., 2006). Sumoylation at lysine 298 renders HSF1 
transcriptionally incompetent (Hilgarth et al., 2003). Brunet Simioni et al. found 
that the phosphorylation of serine 303 and 307 itself does not affect the 
transcriptional activity of HSF1; however, the phospho-S303-dependent 
sumoylation on lysine 298 blocks its transactivation capacity (Brunet Simioni et 
al., 2009).  
The DNA-binding domain (DBD) located at the N-terminal region of HSF1 
is highly conserved across species (Anckar and Sistonen, 2011) (Fig. B3). Within 
the HSF1 trimers, each of the DBD of the monomers recognizes the nGAAn 
sequence in the major groove (Cicero et al., 2001, Littlefield and Nelson, 1999). 
Phosphorylation of serine 121 by MAPK-activated protein kinase 2 (MAPKAPK2) 
at the DBD causes HSF1 to lose its transcriptional activity and promotes its 
binding to Hsp90, a negative regulator of HSF1 (Wang et al., 2006). In addition, 
acetylation on lysine 80 hinders the transcriptional capacity of HSF1, as 
mutagenesis studies in yeast have revealed a loss-of-function phenotype when 
lysine 80 was mutated (Hubl et al., 1994, Torres et al., 1995). Activation of the 
SIRT1 deacetylase prolonged the transcriptional competency of HSF1, whereas 
the decrease in SIRT1 accelerated the attenuation phase of HSF1. 
The available literature on the functional characterization of the HSF1 C-
terminal transactivation domain (CTAD) is limited compared to the other domains 
described above. The CTAD consists of two transactivation domains, TAD1 and 
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Figure B3. Structure of the DNA-binding domain (DBD) of human HSF1 (amino
acids 10-123). The domain is coloured according to the secondary structure of the
protein where the alpha helices and beta-sheets are represented by red and yellow
respectively. Amino acid residues Lysine 80 (K80) and Serine 121 (S121) are
represented as blue sticks. Figure drawn using Pymol using the PDB entry 2LDU.
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TAD2 (Newton et al., 1996). TAD1 (amino acids 401-420) is rich in hydrophobic 
amino acids and interacts with TATA-box binding protein associated factor TAF9 
in vitro, and mutations within the hydrophobic patch of TAD1 prevent HSF1 
transactivating capability (Choi et al., 2000). TAD2 contains both acidic and 
hydrophobic residues and is proline-rich. BRG1 belonging to chromatin 
remodeler SWI/SNF complex binds to HSF1 at the CTAD (Sullivan et al., 2001). 
It is likely that the CTAD could be the hub for interaction of transcriptional co-
factors and HSF1. Interestingly, Hsp70 binds to the CTAD of HSF1 (Abravaya et 
al., 1992), therefore, it could potentially negatively regulate HSF1 by disrupting 
the association of HSF1 with its transcriptional co-activators such as p300/CBP 
(Xu et al., 2008). Although it is clear from the literature that HSF1 and Hsp90 
interact (Zou et al., 1998, Ali et al., 1998, Shi et al., 1998), to our knowledge, the 
precise interaction site has not been mapped. 
1.B.4 Small molecule activators of HSF1 
1.B.4.1 Endogenous metabolites 
HSF1-mediated transcription can be induced by endogenously produced 
electrophilic oxidized and nitrated lipids as well as α,β-unsaturated aldehydes. 
Examples include 4-hydroxy-2-nonenal, acrolein, 10-nitro-octadecenoic acid 
(nitro-oleic acid), and 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) (Fig. B4). 
Nuclear accumulation of HSF1 and induction of Hsp70 and Hsp40, as well as of 
HSE-dependent luciferase reporter, have been observed when human colon 
cancer cells were exposed to 4-hydroxy-2-nonenal, and siRNA-mediated 
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Figure B4. Endogenous small-molecule activators of HSF1.
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silencing of HSF1 abolished this induction (Jacobs and Marnett, 2007). 
Treatment of human endothelial cells with 10-nitro-octadecenoic (nitro-oleic) 
acid, a nitrated product of oleic acid with cytoprotective activities, led to activation 
of the heat shock response (Kansanen et al., 2009). Induction of Hsp70 and 
Hsp40 also occurred when A549 human lung cancer cells were exposed to the 
electrophilic lipid peroxidation product acrolein (Thompson and Burcham, 2008). 
The DNA binding activity of HSF1 was increased and the expression of Hsp70 
was robustly upregulated by 15d-PGJ2 in the heart of male Wistar rats undergoing 
ischemia-reperfusion injury (Zingarelli et al., 2004). In addition, high 
concentrations of 17 β-estradiol have been shown to activate HSF1 and induce 
Hsp70 (Knowlton and Sun, 2001, Hamilton et al., 2004). Unlike the other 
endogenous HSF1 activators mentioned above, 17 β-estradiol is not electrophilic; 
however, it can be metabolically converted to the electrophilic quinone derivatives 
2-hydroxy- and 4-hydroxy-estradiol (Zhu and Conney, 1998), which might be the 
ultimate inducers. 
A striking common feature of these endogenous inducers is their 
electrophilicity. The role of this chemical property for inducer activity has been 
tested by use of structurally-related analogues. In contrast to the active 
electrophilic cyclopentenone 15d-PGJ2, which contain an α,β-unsaturated 
carbonyl moiety in its cyclopentane ring, other arachidonic acid metabolites which 
lack this electrophilic functional group, are inactive (Rossi et al., 1996, Elia et al., 
1999). Similarly, the non-electrophilic oleic acid is devoid of inducer activity, in 
sharp contrast to its electrophilic counterpart, nitro-oleic acid (Kansanen et al., 
2009). The importance of electrophilicity for inducer activity strongly suggests that 
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the primary protein targets contain reactive nucleophilic amino acids which act as 
sensors for inducers.  
As Hsp90 and Hsp70 are the major negative regulators of HSF1, it is 
possible that inducer binding to one or both of them interferes with their ability to 
form a complex with HSF1.  Indeed, covalent modification at cysteine 572 of 
Hsp90 by 4-hydroxy-2-nonenal has been detected in purified recombinant human 
Hsp90 (Carbone et al., 2005). Endogenous Hsp90 and Hsp70 were also modified 
upon exposure of cells to 4-hydroxy-2-nonenal (Jacobs and Marnett, 2007, 
Jacobs and Marnett, 2010), and to its azido- and alkynyl-tagged derivatives, as 
identified by click chemistry and ex vivo biotinylation (Vila et al., 2008). By use of 
noncovalent affinity capture with a biotinyl-geldanamycin probe, both Hsp90α and 
Hsp90β were isolated from human colorectal cancer cells, and histidine adducts 
that were endogenously formed by treatment with 4-hydroxy-2-nonenal were 
detected (Connor et al., 2011). Furthermore, modifications in Hsp90 and Hsp70 
by 4-hydroxy-2-nonenal have been reported to occur in rat liver in a model of 
alcoholic liver disease (Smathers et al., 2011). The same compound was also 
found to disrupt the interaction of ectopically expressed c-Myc-tagged Hsp70 with 
HSF1 and induce the HSR (Jacobs and Marnett, 2007). Interestingly, the yeast 
Hsp90 does not contain any cysteine residues, and C264 and C303 of the Hsp70 
chaperone Ssa1 serve as the sensors for electrophilic HSF1 activators, as 
demonstrated by mutagenesis analysis and click chemistry approach after 
treatment with an alkynyl-tagged derivative of 4-hydroxy-2-nonenal (Wang et al., 
2012). Together, these findings strongly suggest that modifications of the 
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negative regulators Hsp90 and/or Hsp70 may cause release of HSF1 and 
activation of HSF1-dependent transcription. 
In addition to endogenous electrophiles, the HSF1-mediated HSR is 
directly activated by the oxidant hydrogen peroxide (H2O2). Interestingly, in this 
case, HSF1 itself is the protein sensor as activation of murine HSF1 by H2O2 is 
dependent on cysteine 35 and cysteine 105, which form a disulfide bridge (Ahn 
and Thiele, 2003). The corresponding pair of cysteines (i.e., cysteine 36 and 
cysteine 103) in human HSF1 form an intermolecular disulfide bridge, promoting 
HSF1 trimerization and binding to the HSE (Lu et al., 2008). A subsequent study 
has shown that an intermolecular interaction between the aromatic residues 
tryptophan 37 and phenylalanine 104 supports the approach of cysteine 36 and 
cysteine 103 (Lu et al., 2009). In contrast, an intramolecular disulfide bridge 
formation (in which cysteine 153, cysteine 373 and cysteine 378 participate) 
inhibits trimerization and DNA binding of HSF1 (Lu et al., 2008). 
The signalling molecule nitric oxide has been reported to activate HSF1 
and induce Hsp70 in vascular smooth muscle cells (Xu et al., 1997). Interestingly, 
S-nitrosation at cysteine 597 of human Hsp90α inhibits the ATPase activity of the 
chaperone(Martinez-Ruiz et al., 2005), and substituting cysteine 597 with S-
nitrosation-mimicking residues, such as asparagine and aspartic acid, shifts the 
conformational equilibrium of the chaperone, decreasing its activity (Retzlaff et 
al., 2009). It is therefore possible that HSF1 activation by nitric oxide is due to 
inactivation of Hsp90. 
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Activation of HSF1 can also be stimulated by electrophilic and reactive 
oxygen species which are formed during physiological and pathophysiological 
processes. Thus, HSF1 is activated in atherosclerotic lesions, and cytokine 
stimulation and mechanical stretching of smooth muscle cells result in HSF1 
hyperphosphorylation, nuclear translocation, and enhanced Hsp70 expression 
(Metzler et al., 2003). In addition, HSF1 activation has been implicated in the 
production of plasminogen activator inhibitor-1 after stimulation by glycated low 
density lipoproteins as well as by oxidized very low density lipoproteins in cultured 
vascular endothelial cells (Zhao and Shen, 2007, Zhao et al., 2008). Subsequent 
studies have shown that in this case, activation of HSF1 is mediated by induction 
of NADPH oxidase (Zhao et al., 2009, Sangle et al., 2010, Zhao et al., 2011). 
1.B.4.2 Phytochemicals 
A screen of bioactive small molecules in the human HeLa cell line 
hsp70.1pr-luc (stably transfected with a luciferase-encoding construct under the 
transcriptional control of the hsp70 promoter) identified the phytochemical 
celastrol as inducer of the HSR (Westerheide et al., 2004b). Celastrol is a quinone 
methide triterpenoid (Fig. B5) found in the Chinese plant Tripterygium wilfordii. 
In addition to the cervical cancer HeLa reporter cell line, celastrol activates the 
hsp70 promoter reporter in the breast cancer cell lines MCF7 and BT474, the 
nonsmall cell lung carcinoma cell line H157, and the neuroblastoma cell line SH-
SY5Y), and importantly, the magnitude of activation is comparable to that induced 
by heat shock (42 °C) (Westerheide et al., 2004b). In agreement, exposure to 
celastrol is protective against lethal heat stress, and to a similar extent as a 42 
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°C heat shock. Treatment with celastrol leads to hyperphosphorylation of HSF1, 
enhanced binding of HSF1 to the HSE, and transcriptional activation of 
endogenous heat shock genes (Westerheide et al., 2004b). Transcriptional 
profiling and biochemical studies suggest that inhibition of Hsp90 by celastrol 
may be the initial event that triggers dissociation of HSF1 from the protein 
complex (Hieronymus et al., 2006, Zhang et al., 2008, Chadli et al., 2010, Matts 
et al., 2011). This possibility is further supported by mechanistic studies showing 
that celastrol reacts with Hsp90 and inhibits the ATPase activity of the chaperone 
without affecting ATP binding (Zhang et al., 2009b).  
The tetranortriterpenoid gedunin (Fig. B5) from the Indian neem tree 
Azadirachta indica is another activator of HSF1. Compared to celastrol, gedunin 
is less potent, but appears to use similar mechanisms by which it activates HSF1, 
i.e. inhibition of the function of the negative regulator Hsp90(Hieronymus et al., 
2006, Matts et al., 2011, Brandt et al., 2008). The use of a high content screening 
platform, an image-based, multiparametric assay which monitors the formation of 
HSF1/Hsp70 stress granules in heat-shocked HeLa cells (Au et al., 2008), 
identified four compounds closely related to gedunin, i.e., deoxygedunin, 
deacetoxy-7-oxogedunin, deacetylgedunin, and sappanone A, which were 
subsequently confirmed to activate HSF1 and induce Hsp70 in an HSF-
dependent manner(Zhang et al., 2009a).   
Withaferin A (Fig. B5), a withanolide found in the Indian plant Withania 
somnifera, was identified in a screen of a library of more than 80,000 natural and 
synthetic compounds using a reporter cell line which expresses enhanced green 
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fluorescent protein (EGFP) under the transcriptional control of a minimal 
consensus HSE-containing promoter(Santagata et al., 2012). Like celastrol and 
gedunin, withaferin A also inhibits the function of Hsp90, and this inhibition may 
be responsible for activation of HSF1 (Yu et al., 2010, Grover et al., 2011). The 
same high-throughput screen confirmed that celastrol, withaferin A, gedunin are 
all inducers of the HSR, and identified several other natural products, such as the 
limonoids anthothecol, cedrelone, and the gedunin derivative 7-desacetoxy-6,7-
dehydrogedunin, as well as a fungal product, the macrocyclic lactone 
dehydrocurvularin among the active compounds (Santagata et al., 2012). 
Notably, all of these compounds have an α,β-unsaturated carbonyl functional 
group, emphasizing the importance of electrophilicity for inducer activity. 
Curcumin [1,7-bis(4-hydroxy 3-methoxy phenyl)-1,6-heptadiene-3,5-
dione, diferuloylmethane, Fig. B5], a polyphenol from the East Indian plant 
Curcuma longa,  has been shown to induce heat shock proteins in numerous cell 
culture and animal models (Kato et al., 1998, Chen et al., 2004, Shen et al., 2007, 
Kanitkar and Bhonde, 2008, Khan and Heikkila, 2011). The observed disruption 
of the binding of the Hsp90-p23 complex to its client protein p210 BCR/ABL, and 
the consequent degradation of the kinase in chronic myelogenous leukemia cells 
upon exposure to curcumin (Wu et al., 2006) suggests that, for this compound 
too, induction of heat shock proteins could be a consequence of inhibition of 
Hsp90 function. Notably, curcumin has been present in the human diet for 
centuries, and there is a wealth of information regarding its safety and efficacy in 
both animals and humans (Surh and Chun, 2007, Hatcher et al., 2008, Lao et al., 
2006). To date, there have been 91 different clinical trials registered evaluating 
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this polyphenol in a number of conditions, including mild cognitive impairment, 
Alzheimer’s disease, multiple myeloma, pancreatic cancer, colorectal cancer, 
and myelodysplastic syndrome (www.clinicaltrials.gov). 
Sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane, Fig. B5] is an 
isothiocyante which is formed from a glucosinolate precursor (glucoraphanin) 
upon plant tissue injury. Cruciferous vegetables, such as broccoli (Brassica 
oleracea), are rich dietary sources of this phytochemical. Nuclear accumulation 
of HSF1 and induction of heat shock proteins by sulforaphane has been 
demonstrated in several cell culture models, including human cell lines, as well 
as in animals after a single oral dose of the isothiocyanate (Hu et al., 2006a, Gan 
et al., 2010, Sharma et al., 2010). Another isothiocyanate, phenethyl 
isothiocyanate which occurs in watercress, has also been shown to induce 
expression of heat shock proteins in cultured cells and animals(Hu et al., 2006b, 
Moon et al., 2011). Again, the available experimental evidence points to Hsp90 
as the target of sulforaphane which mediates HSF1 activation: (i) co-treatment 
with sulforaphane enhances the anti-tumor effect of the Hsp90 inhibitor 17-
allylamino 17-demethoxygeldanamycin (17-AAG); (ii) sulforaphane disrupts the 
interaction of Hsp90 with its co-chaperone Cdc37; (iii) synergistically with 17-
AAG, the isothiocyanate downregulates several Hsp90 client proteins, such as 
mutant p53, Raf-1, and Cdk4 (Li et al., 2011), (iv) Hsp90 is covalently modified 
by a sulfoxythiocarbamate derivative of sulforaphane both in vitro and in cells 
(Zhang et al., 2011, Zhang et al., 2014), and (v) the ability of sulforaphane to 
downregulate the activity of histone deacetylase (HDAC) (Myzak et al., 2004, 
Myzak et al., 2006b, Myzak et al., 2006a, Pledgie-Tracy et al., 2007, Gibbs et al., 
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2009) may further inhibit the activity of Hsp90 through altering acetylation of the 
chaperone. Indeed, inhibition or knock-down of HDAC6 leads to acetylation of 
Hsp90 and disruption of its chaperone function (Bali et al., 2005), and treatment 
with sulforaphane downregulates the activity of HDAC6, resulting in 
hyperacetylation of Hsp90 (Gibbs et al., 2009).  
In contrast to the electrophilic phytochemicals, the stilbene resveratrol 
(Fig. B5) appears to activate HSF1 by promoting the persistent DNA binding of 
the transcription factor and suppressing the attenuation phase of the HSR 
(Westerheide et al., 2009). In this case, the phytochemical functions by activating 
the predominantly nuclear NAD+-dependent deacetylase sirtuin-1 (SIRT1) and 
maintaining HSF1 in a deacetylated, DNA-binding competent state. Resveratrol 
directly activates SIRT1 through an allosteric mechanism resulting in the lowering 
of the Km for both the acetylated protein substrate and for the NAD+ cofactor 
(Howitz et al., 2003). Most small-molecule SIRT1 activators known to date are 
planar compounds comprised of multiple phenyl rings bearing hydroxyl groups 
(Howitz et al., 2003, Hubbard and Sinclair, 2014). Whether other phytochemicals 
which activate SIRT1, such as the flavonoid quercetin and the chalcone butein, 
have the same effect on HSF1 is presently unknown. 
1.B.4.3 Synthetic compounds 
The possibility of developing small molecule activators of the HSR as 
pharmacological agents for protection against human diseases, especially 
protein conformational diseases, has led to the development of several high-
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throughput screening strategies. Neef et al. reported the development of a 
humanized yeast-based high-throughput screen, which is insensitive to 
proteotoxic stress and Hsp90 inhibition, and identified two potent small-molecule 
activators of human HSF1 within a chemical library of over 10,000 compounds 
(Neef et al., 2010). These HSF1 activators (named HSF1A and HSF1C) are 
benzyl pyrazole derivatives (Fig. B6). The more potent compound, HSF1A, was 
then shown to activate HSF1 and induce Hsp70 in wild-type, but not HSF1-
deficient mouse embryonic fibroblast, as well as in HeLa cells. In contrast to the 
electrophilic HSF1 activators, pre-incubation with DTT had no effect on the 
inducer activity of HSF1A. HSF1A has been found to inhibit T-complex-protein-1 
(TCP1)-ring-complex/ chaperonin-containing TCP1 (TRiC/CCT)-HSF1-binding 
(Neef et al., 2014). 
Calamini et al. have developed a mammalian cell-based high-throughput 
screen (Calamini et al., 2012). It measures the activation of the HSR by cell-
permeable small molecules in HeLa cells stably transfected with a luciferase 
reporter gene under the transcriptional control of the proximal human HSP70.1 
promoter sequence. Approximately 900,000 compounds were screened, and 
~200 small molecule activators of the HSR were found. Electrophilicity is a 
common feature among many, although not all, active compounds. A 
cyclohexanone derivative (named compound A1) containing the electrophilic α,β-
unsaturated carbonyl groups is closely related to bis(benzylidene)acetone and 
bis(2-hydroxybenzylidene)acetone (Fig. B6), two structurally similar Hsp70 
inducers, which however differ substantially in inducer potency (Zhang et al., 
2011a). Inducer potency correlates with sulfhydryl reactivity: compared to the 
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hydroxylated analogue, bis(2-hydroxybenzylidene)acetone, the parent 
compound bis(benzylidene)acetone reacts more slowly with the sulfhydryl groups 
of glutathione and DTT (Dinkova-Kostova et al., 2001), and has lower potency in 
inducing Hsp70 (Zhang et al., 2011).  
The mildly-electrophilic sulfoxythiocarbamate analogues of the 
isothiocynate sulforaphane constitute another class of synthetic HSF1 activators. 
Sulfoxythiocarbamate alkyne (STCA) (Fig. B6), which forms stable adducts with 
sulfhydryl groups (Ahn et al., 2010), reacts with C412, C564, and C589/590 of 
recombinant Hsp90, and activates HSF1-mediated transcription of a luciferase 
reporter as well as of the endogenous Hsp70 in mammalian cells of many 
different types, including MEFs, HeLa, and MCF-7 cells (Zhang et al., 2011, 
Zhang et al., 2014). Pyrrolidinedithiocarbamate and 1,2-dithiole-3-thione are two 
other activators of HSF1-mediated induction of Hsp70 (Stuhlmeier, 2000, Kwak 
et al., 2004), which have the ability to react with sulfhydryl groups (Zhang et al., 
1996). Activation of HSF1 and induction of the HSR has also been reported to 
occur upon exposure of cells to pro-electrophilic oxidizable diphenols; in this 
case, the corresponding oxidized electrophilic metabolites are the ultimate 
inducers (Satoh et al., 2011). 
Notably, global transcriptional profiling and protein expression/proteomics 
analyses have consistently shown that, in addition to activating HSF1, most of 
the inducers discussed above, both naturally occurring as well as synthetic, also 
activate transcription factor nuclear factor-erythroid 2 p45-related factor 2 (NRF2) 
which controls the gene expression of numerous cytoprotective antioxidant, drug-
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metabolizing, anti-inflammatory, and metabolic proteins, providing an interface 
between redox and intermediary metabolism (Hayes and Dinkova-Kostova). In 
MEFs, induction of Hsp70 is dependent on HSF1, but independent of NRF2; 
conversely, transcriptional upregulation of the NRF2-dependnet enzyme NQO1 
occurs in the absence of HSF1, but requires functional NRF2 (Zhang et al., 2011). 
It is thus very likely that together, both HSF1- and NRF2-dependent responses 
mediate the overall cytoprotective effects (see below) of these compounds. 
1.B.5 HSF1 activates cytoprotective responses 
Transcriptional activation of HSF1 by heat shock results in enhanced 
expression of a large number of genes encoding proteins with versatile 
cytoprotective functions. Global transcriptional profiling, differential display, and 
proteomic approaches have revealed that, in different organisms, approximately 
50–200 genes are induced (Eisen et al, 1998, Hasch et al. 2000). These include 
the classical molecular chaperones that prevent unspecific aggregation of non-
native or partially misfolded proteins, proteolytic proteins that can eliminate or 
recycle irreversibly-damaged proteins which cannot be refolded by the 
chaperones, RNA- and DNA-modifying enzymes which participate in DNA 
damage repair, proteins involved in sustaining cellular structures such as the 
cytoskeleton and membranes, and proteins which participate in transport and 
detoxification. In addition, heat shock upregulates a number of metabolic 
enzymes ([e.g., ACAT2 (acetyl-CoA acetyltransferase), ALAS1 (aminolevulinate 
synthase), ChGn (chondroitin β-1,4-N-acetylgalactosaminyltransferase)] that are 
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needed to reorganize and maintain the energy supply of the cell. Induction of 
other transcription factors, kinases and phosphatases [e.g., RHOH (Ras 
homolog), PTPG1 (tyrosine phosphatase), RGS2 (regulator of G-protein 
signaling), IER5 (regulator of immediate early response)] also occurs following 
heat shock, and may further activate other stress response pathways, thus 
amplifying the initial signal. 
Notably, not all genes are induced at the same time and with the same 
duration: some, such as those responsible for the correct protein folding, are 
immediate responders (within minutes), whereas others, such as those involved 
in DNA damage repair and cell metabolism, are somewhat slower (within hours) 
(Richter et al., 2010). Overall, induction of the HSR provides broad protection 
against stress of various different types, including and extending beyond heat 
shock. Furthermore, a recent study in C. elegans has also shown that HSF1-
mediated activation of Hsp90 in response to an imbalance in proteostasis in one 
tissue functions in a non-autonomous fashion to initiate a protective response in 
adjacent tissues and to restore the balance within the whole organism (van 
Oosten-Hawle et al., 2013). 
1.B.6 Crosstalk between HSF1- and NRF2-regulated cytoprotective
responses 
A number of studies suggest the existence of crosstalk between NRF2- 
and HSF1-regulated cytoprotective responses (reviewed in Dayalan Naidu et al., 
2015). The participation of both transcription factors has been implicated in the 
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regulation of gene expression of the rodent heme oxygenase 1 (HO-1, also 
known as Hsp32) (Prestera et al., 1995, Maines and Ewing, 1996), the murine 
and zebrafish Hsp70 (Almeida et al., 2010), and in the autophagy cargo protein 
sequestosome 1 (p62/SQSTM1) (Komatsu et al., 2010, Jain et al., 2010, Lau et 
al., 2010, Copple et al., 2010, Zhang et al., 2008). HSF1-mediated induction of 
p62 may activate NRF2 as p62, especially upon phosphorylation, can displace 
NRF2 from KEAP1 and activate it (Komatsu et al., 2010, Ichimura et al., 2013), 
leading to NRF2-dependent upregulation of p62 expression. In addition, both 
HSF1 and NRF2 regulate the expression of activating transcription factor 3 
(ATF3), a member of the mammalian activation transcription factor/cAMP 
responsive element-binding (CREB) protein family of transcription factors (Takii 
et al., 2010, Kim et al., 2010), and thus HSF1 and NRF2 have the ability to 
modulate gene expression indirectly. Finally, HSF1 and NRF2 affect the redox 
balance of the cell, promoting a more reduced environment. NRF2 controls the 
gene expression of both subunits (GCLC and GCLM) of Ɣ-glutamylcysteine 
ligase, the enzyme that catalyzes the rate-limiting step in the biosynthesis of 
glutathione (Wild and Mulcahy, 2000). In addition, the levels of glucose-6-
phosphate dehydrogenase (G6PDH), the rate-limiting enzyme in the pentose 
phosphate pathway, which is involved in the regeneration of NADPH that in turn 
is used by glutathione reductase to reduce oxidised glutathione (GSSG) to 
reduced glutathione (GSH), are increased by both activation of NRF2 (Mitsuishi 
et al., 2012, Lu and Wan, 2008) and upregulation of Hsp25/27 (Rajasekaran et 
al., 2007). Conversely, the enzyme activity of G6PDH and the GSH : GSSG ratio 
are decreased in the heart of HSF1-deficient mice compared to their wild-type 
counterparts (Yan et al., 2002). 
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Interestingly, methionine deprivation in HEK293 cells was recently shown 
to increase the expression of Hsp70 in an NRF2-dependent manner, but 
independently of HSF1 (Hensen et al., 2013a). Remarkably, in cells expressing 
an HSF1 mutant in which lysine 80 in the DNA binding domain is substituted with 
glutamine (HSF1 K80Q), thus impairing DNA binding, heat shock caused a 
delayed upregulation of Hsp70 and HO-1 at 24 h, when the primary 
transcriptional response to the heat shock in HSF1 wild-type expressing cells was 
largely attenuated; this delayed secondary response was found to be mediated 
by NRF2 (Hensen et al., 2013b), suggesting the possibility that upregulation of 
the NRF2-dependent antioxidant response may be partially compensating for 
HSF1 dysfunction. In agreement, the basal levels of HO-1 are higher (Zhang et 
al., 2011) and its induction is dramatically enhanced, from 12- to 130-fold 
(Calamini et al., 2012), in HSF1-knockout cells compared to their wild-type 
counterparts.  
1.B.7 HSF1 and neurodegenerative diseases 
Imbalances in protein homeostasis (termed proteostasis), oxidative stress 
and chronic inflammation are common features of many neurodegenerative 
diseases. Attenuation of HSF1 during ageing has been proposed to be an 
"upstream" event in the series of processes leading to synaptic dysfunction and 
cognitive impairment (Perez et al., 2014). Prominent among the protein 
conformational diseases are those which arise as a result of accumulation of 
misfolded polyglutamine expansion-containing proteins, such as the androgen 
receptor (AR), huntingtin (HTT), tau, α-synuclein, and Cu/Zn superoxide 
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dismutase (SOD1). These proteins adopt alternate folded states that have the 
propensity to self-associate and aggregate, leading to cytotoxicity. 
Genetic or pharmacological induction of the HSR is an attractive strategy 
for restoring the cellular proteostasis as it results in enhanced expression of 
chaperones that are involved in ensuring the correct folding of proteins and in 
facilitating the degradation of abnormal proteins. Indeed, induction of the HSR, 
and especially Hsp70, is protective in numerous cell culture and animals models 
of protein conformational diseases (Morimoto, 2011). A recent study has reported 
an association between the expression levels of HSF1 and the accumulation of 
the pathogenic form of the AR in a mouse model of spinal and bulbar muscular 
atrophy, an adult-onset motor neuron disease caused by the expansion of a 
polyglutamine repeat in the AR (Kondo et al., 2013). In comparison with HSF1 
wild-type animals expressing the human AR with 97 polyglutamine repeats (AR-
97Q), their heterozygous HSF1-knockout counterparts accumulate high AR 
levels in both neuronal and non-neuronal tissues, and display exacerbated 
neuromuscular phenotype. Importantly, lentiviral-mediated delivery of HSF1 into 
the brain increases HSF1 expression and lowers the pathogenic AR 
accumulation and neuronal brain atrophy. 
In Drosophila models of Huntington's and other polyglutamine protein 
conformational diseases, polyglutamine toxicity is synergistically suppressed by 
co-expression of Hsp70 and Hsp40 (Warrick et al., 1999, Kazemi-Esfarjani and 
Benzer, 2000, Chan et al., 2000). Protection can be also achieved by 
pharmacological induction of the HSR. Thus, in cells ectopically expressing a 
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fusion protein of polyglutamine and the yellow fluorescent protein (Q57-YFP), 
treatment with the HSF1 activator celastrol prevented the aggregation of the 
fusion protein and the associated cytotoxicity (Zhang and Sarge, 2007). Similarly, 
in a yeast model, curcumin inhibited the formation of Q72-GFP protein 
aggregates, and furthermore, this polyphenol was able to disrupt pre-formed 
Q72-GFP aggregates (Verma et al., 2012). Deoxygedunin, deacetoxy-7-
oxogedunin, and deacetylgedunin, were all shown to activate HSF1, induce 
Hsp70, and improve cell survival in HeLa cells transiently transfected with a 
polyglutamine-expanded toxic isoform (Q103) of huntingtin as well as in an MG-
132-induced protein misfolding neuronal cell culture model (Zhang et al., 2009a). 
The synthetic cyclohexanone derivative compound A1 and a barbituric 
acid scaffold-containing compound, named ML346 (Fig. B5) (Calamini et al., 
2010) were shown to be protective in two models of Huntington’s disease. Thus, 
in PC12 cells conditionally expressing human huntingtin exon 1 containing an 
expansion of 74 glutamines fused to green fluorescent protein (HTTQ74-GFP), 
compound A1 and ML346 reduced the formation of HTTQ74-GFP protein 
aggregates, without altering the amounts of HTTQ74-GFP protein. Furthermore, 
in C. elegans expressing expanded polyglutamines (35 glutamines fused to 
yellow fluorescent protein, or polyQ35-YFP), the same compounds suppressed 
polyQ35-YFP aggregation and prevented polyQ35-mediated toxicity, almost 
completely restoring motility to that of wild-type animals. Similarly, the benzyl 
pyrazole HSF1A induced Hsp70 and reduced protein aggregation and 
cytotoxicity in HTTQ74-GFP expressing PC12 cells (Neef et al., 2010). 
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Using two mouse models of Huntington’s disease, R6/2 exon 1 transgenic 
(Mangiarini et al., 1996) and HdhQ150-knockin (Lin et al., 2001, Woodman et al., 
2007) mice, Labbadia et al. (Labbadia et al., 2011) reported that pharmacological 
activation of HSF1 with a brain-permeable Hsp90 inhibitor was beneficial and led 
to a significant phenotypic improvement. However the beneficial effects are 
transient, because alterations in chromatin architecture during disease 
progression leads to reduced binding of HSF1 to DNA, and impairing the HSR. It 
is tempting to speculate that similar chromatin alterations could be responsible, 
at least in part, for the observed decline in the HSR with ageing. 
Curiously, a recent study has shown that although the HSR is triggered by 
genetic (overexpression) or pharmacological HSF1 activation, this results in a 
decrease, and not an increase, in the concentration threshold leading to protein 
aggregation of mutant polyglutamine-expanded fragments of the huntingtin 
protein (Bersuker et al., 2013). This finding suggests that rather than promoting 
refolding of the mutant protein, activation of the HSR may mediate its degradation 
or clearance, resulting in decreased aggregate formation or increased aggregate 
turnover. Whether this is indeed the case for mutant huntingtin (and possibly 
other polyglutamine-expanded mutant proteins) remains to be established. 
In rodent models of Alzheimer's disease, genetic or pharmacological (by 
using the inducers celastrol or curcumin) upregulation of HSF1 is protective 
against the amyloid-β-associated pathologies, improving memory, learning, and 
psychomotor activity (Allison et al., 2001, Paris et al., 2010, Pierce et al., 2013). 
By inhibiting Hsp90, 17-(allylamino)geldanamycin (17-AAG) activates HSF1, 
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inducing transcription of heat shock and synaptic proteins in primary neurons, 
and attenuates amyloid-β-mediated synaptic toxicity as well as memory loss in 
mice (Chen et al., 2014). In a mouse model of Parkinson’s disease, celastrol 
protected against the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP); the same study also found protection by celastrol 
against 3-nitropropionic acid-mediated neurotoxicity (Cleren et al., 2005). The 
protective effects of curcumin have been demonstrated in numerous models of 
both Alzheimer's disease and Parkinson’s disease, and these, along with the 
limitations in translating the findings to human populations, have been extensively 
reviewed (Darvesh et al., 2012, Chin et al., 2013, Lee et al., 2013). The 
experimental evidence is further supported by epidemiological studies, such as 
the Indo-US Cross National Dementia Study, which have linked high curcumin 
consumption with lower prevalence of Alzheimer's disease and other types of 
dementia (Chandra et al., 1998). Although curcumin is able to cross the blood-
brain barrier, it has low bioavailability; to overcome this limitation 
nanotechnology-based delivery systems are being developed. Thus, curcumin-
encapsulated nanoparticles have recently been generated and shown to reverse 
learning and memory impairments in an amyloid-β-induced rat model of 
Alzheimer's disease (Tiwari et al., 2014). 
Mutations in the Cu/Zn superoxide dismutase gene (SOD1) are 
responsible for 20% of the familial forms of amyotrophic lateral sclerosis (ALS). 
In vitro, the small heat shock proteins αB-crystallin and Hsp27 suppress SOD1 
aggregation (Yerbury et al., 2013). In the G93A SOD1 transgenic mouse model 
of ALS, neuronal cell death, weight loss, and motor performance were all 
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improved by celastrol, and furthermore, disease onset was delayed (Kiaei et al., 
2005). In the same mouse model, resveratrol decreased the acetylation of HSF1 
and increased the levels of Hsp25 and Hsp70 in the spinal cord, and delayed the 
onset of disease and extended survival (Han et al., 2012). In the SOD1 
H46R/H48Q transgenic ALS mice expressing mutant SOD1, over-expression of 
human HSF1 upregulated the expression of Hsp70 and αB-crystallin in spinal 
cord, and increased the solubility of mutant SOD1 (Lin et al., 2013). Furthermore, 
HSF1 over-expression was protective against weight loss, and led to a delay in 
disease onset and increased survival. 
Of note, it was recently reported that HSF1 is a critical factor for neuronal 
cell survival and, furthermore, protects neurons against degeneration caused by 
non-proteotoxic as well as proteotoxic stress independently of its ability to 
trimerize and induce transcription of genes encoding heat shock proteins (Verma 
et al., 2014). Whilst the detailed mechanism remains to be established, it is 
interesting that the broad-spectrum HDAC inhibitor trichostatin A abolishes 
HSF1-mediated protection, whereas knockdown of HSF1 abrogates 
neuroptotection by SIRT1, suggesting that HSF1 and SIRT1 cooperate in 
neuronal protection. Another recent study has uncovered a role for HSF1 in 
increasing fetal cortical tolerance to prenatal environmental stressors, such as 
alcohol, maternal seizure, and methylmercury, and thus protecting against 
neuropsychiatric diseases (Hashimoto-Torii et al., 2014). 
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1.B.8 HSF1 and cardiovascular disease 
The role of HSF1 in cardiovascular disease is both duration- and context-
dependent. Whereas transient activation of HSF1 is beneficial in ischemic heart 
disease, constitutive excessive production of heat shock proteins, especially 
small heat shock proteins, and the associated redox imbalance may also be a 
causative factor for certain heart conditions, such as cardiomyopathy. HSF1-
mediated induction of the HSR has been implicated in the protective effects of 
17β-estradiol against ischemia/reperfusion injury (Knowlton and Korzick, 2014). 
Activation of HSF1 is observed after ischemia/reperfusion (Nishizawa et al., 
1996). This activation, and the subsequent induction of Hsp70 and Hsp90, is 
mediated by reactive oxygen species (Nishizawa et al., 1999). Elevated heat 
shock protein levels in the heart are associated with reduction in infarct size and 
enhanced recovery after ischemia (Currie et al., 1988, Currie and Karmazyn, 
1990, Currie et al., 1993, Donnelly et al., 1992, Karmazyn et al., 1990, Hutter et 
al., 1994, Locke et al., 1995). Part of the protective effect of HSF1 involves 
activation of Akt and inactivation of Jun N-terminal kinase and caspase 3 (Zou et 
al., 2003). Hsp70 itself has cardioprotective effects against myocardial 
dysfunction after ischemia/reperfusion by improving the mitochondrial function 
and preventing apoptosis (Marber et al., 1995, Trost et al., 1998, Suzuki et al., 
2002). Cardiomyocyte apoptosis triggered by ischemia/reperfusion is also 
suppressed by overexpression of Ca2+/calmodulin-dependent protein kinase 
(CaMK)II-deltaB which leads to phosphorylation of HSF1 and induction of Hsp70 
(Peng et al., 2010). HSF1 and heat shock proteins are important for stabilization 
of the restored sinus rhythm after mitral valve surgery (Cao et al., 2011). The 
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cardioprotective effects of HSF1 are not solely due to induction of heat shock 
proteins, and HSF1 also protects the heart against ischemia as well as pressure 
overload by its ability to promote angiogenesis (Zou et al., 2011, Kubo et al., 
2012). Overexpression of HSF1 attenuates cardiomyocyte cell death via 
inhibiting TNFα-mediated NFκB activation (Wu et al., 2013). Interestingly, 
transplantation of stem cells which had been subjected to heat shock was 
recently shown to have beneficial effects after myocardial infarction, attenuating 
cell death and fibrosis in the ischemic heart (Feng et al., 2014).  
It is well established that the ability to mount the HSR decreases with age 
(Liu et al., 1989, Choi et al., 1990, Fargnoli et al., 1990, Blake et al., 1991, Heydari 
et al., 1993, Nitta et al., 1994). In comparison with hearts from adult mice, HSF1 
activation and Hsp70 expression are reduced following heat stress in hearts from 
aged animals, even though the myocardial levels of the HSF1 protein are similar 
between aged and adult animals (Locke and Tanguay, 1996). A recent study has 
challenged these findings, and has shown that, compared to young mice, the 
protein levels of HSF1 in heart, but not in any other tissues, are dramatically 
reduced in old animals, although the HSF1 mRNA levels do not differ (Carnemolla 
et al. 2014). This is accompanied by lower levels of heat shock proteins, 
suggesting that if this is also the case in humans, the compromised expression 
of heat shock proteins in the heart may be a contributing factor for the cardiac 
amyloid deposits that are frequently observed in humans over 80 years old 
(Carnemolla et al., 2014, Dungu et al. 2012). Curiously, whereas the HSR 
decreased with age in hepatocytes from F344/Jcl rats, increased HSR was 
reported to occur in rats of the F344/DuCrj strain (Takahashi et al., 2002b), and 
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it is of interest that compared to F344/Jcl rats, F344/DuCrj animals have lower 
blood glucose levels and enhanced insulin secretion in an oral glucose tolerance 
test (Nagakura et al., 2001), suggesting a link between the HSR and glucose 
metabolism. Interestingly, following myocardial infarction, the induction of Hsp70 
by heat stress is impaired in the failing heart, and it was found that the nuclear 
translocation of HSF1 was attenuated, whereas phosphorylation at Ser303 
(Marunouchi et al., 2013b) and the amount of HSF1 bound to the Hsp90 
chaperone complex were increased (Marunouchi et al., 2013a). Treatment with 
the Hsp90 inhibitor 17-AAG led to dissociation of HSF1 from Hsp90, induction of 
Hsp70, and preservation of cardiac function (Marunouchi et al., 2013a), 
suggesting the possibility of using Hsp90 inhibitors as therapeutic agents for 
heart failure following myocardial infarction. 
The HSR also plays an important role in vascular health. In vascular 
smooth muscle cells, nitric oxide activates HSF1 and induces the expression of 
Hsp70 (Xu et al., 1997). In addition to heat shock proteins, exposure of 
endothelial cells to heat shock increases the expression of thrombomodulin 
(Conway et al., 1994). Thrombomodulin is expressed on the luminal surface of 
endothelial cells and forms a complex with thrombin, modifying its function to 
activate the anticoagulant protein C. Curiously, statins cause nitric oxide-
dependent dissociation of HSF1 from Hsp90, nuclear translocation of HSF1, and 
binding to heat shock elements in the promoter of thrombomodulin (Fu et al., 
2008, Uchiyama et al., 2007). These findings implicate HSF1 in the protective 
effects of statins in the vascular endothelium, beyond their cholesterol-lowering 
activity. 
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However, HSF1 activation and small heat shock protein induction can also 
have deleterious consequences for the cardiovascular system (Mehlen et al., 
1995, Brewer et al., 2013). Paradoxically, the double knockout of αB-crystallin 
and Hsp25 is protective against acute heart ischemia/reperfusion injury 
(Benjamin et al., 2007). Accumulation of Hsp27, but not Hsp70 or Hsp90, in the 
heart has been reported in humans with dilated cardiomyopathy and end-stage 
heart failure (Knowlton et al., 1998). An increase in the levels of Hsp27 also 
occurs during ischemic heart failure in rats (Tanonaka et al., 2003). In mice, 
overexpression of Hsp25 has been implicated in the cardiomyopathy and 
congestive heart failure caused by the chemotherapeutic agent doxorubicin: it 
was shown that doxorubicin treatment causes oxidative stress, activation of 
HSF1 and induction of Hsp25, followed by p53 activation and increase in the 
levels of the pro-apoptotic protein Bax, ultimately contributing to the death of 
cardiomyocytes in the failing heart (Vedam et al., 2010). 
Transgenic mice overexpressing cardiac-specific loss-of-function mutant 
human αB-crystallin (hR120GCryAB) (Bova et al., 1999, Perng et al., 1999) have 
increased activity of glucose 6-phosphate dehydrogenase (G6PDH) and altered 
glutathione metabolism, and develop cardiomyopathy (Rajasekaran et al., 2007, 
Rajasekaran et al., 2008). Overexpression of R120G αB-crystallin triggers the 
HSR, inducing Hsp25 and antioxidant responses, including increased activity of 
G6PDH. In turn, the G6PDH-generated NADPH is used by glutathione reductase 
to reduce oxidised glutathione (GSSG), leading to increased levels of reduced 
glutathione (GSH). This is in agreement with earlier studies showing that the 
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levels of reactive oxygen species were decreased and GSH was elevated upon 
expression of the human and Drosophila Hsp27, and human αB-crystallin in 
murine fibroblasts (Mehlen et al., 1996), and that the presence of large 
aggregates of Hsp27 caused increase in the levels of G6PDH (Mehlen et al., 
1997). Conversely, HSF1-knockout mice, which have lower cardiac expression 
of Hsp25 and αB-crystallin, have decreased GSH : GSSG ratio (Yan et al., 2002). 
The demonstration that G6PDH deficiency rescues the cardiomyopathic 
phenotype of the hR120GCryAB transgenic mouse established the central role 
of this enzyme in the disease pathogenesis (Rajasekaran et al., 2007). The 
development of a model of R120G αB-crystallin expression in Drosophila further 
revealed, that similar to G6PDH, mutants or RNAi-mediated knockdown of 6-
phosphogluconate dehydrogenase, isocitrate dehydrogenase, and malic 
enzyme, the other major NADPH-generating enzymes, decreased the ratio of 
reduced to oxidized glutathione (GSH : GSSG) and suppressed the R120G αB-
crystallin-mediated pathology, confirming the link with NADPH and glutathione 
metabolism (Xie et al., 2013).  
Critically, increased NRF2 activity upregulates the gene expression of all 
of the four NADPH-generating enzymes (Thimmulappa et al., 2002, Lee et al., 
2003, Wu et al., 2011, Mitsuishi et al., 2012, Lu and Wan, 2008) as well as of Ɣ-
glutamylcysteine ligase and glutathione reductase, the enzymes involved in the 
biosynthesis and regeneration of GSH (Wild and Mulcahy, 2000). Curiously, 
stable transfection of human Hsp27 in murine fibroblasts lowers the levels of iron 
(Arrigo et al., 2005). Although the underlying reasons for this are not understood 
at present, it is of interest that a microarray analysis of cardiac tissue of transgenic 
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mice overexpressing the human R120G αB-crystallin has revealed upregulation 
of expression of the iron-storage protein ferritin (Rajasekaran et al., 2008), 
another NRF2-dependent protein (Thimmulappa et al., 2002, Pietsch et al., 
2003). It has been also shown that R120G αB-crystallin overexpression promotes 
formation of reactive oxygen species and sequesters KEAP1 in protein 
aggregates, thereby activating NRF2 (Rajasekaran et al., 2011). It is thus highly 
likely that activated NRF2 is ultimately responsible for the increased levels of 
NADPH and GSH. Together, these findings establish a tight connection between 
the HSR and the redox state of the cell, whereby increased expression of small 
heat shock proteins activates NRF2 and tilts the balance towards a more reduced 
state (i.e., increased GSH : GSSG ratio), a condition termed reductive stress 
(Rajasekaran et al., 2011, Brewer et al., 2013).  
1.B.9 HSF1 and cancer 
The HSR elicited by HSF1 in normal cells is a cytoprotective mechanism 
to ensure cell adaptation and survival during stressful conditions. On the other 
hand, in cancer, the HSF1 promotes malignant phenotypes as cells become 
addicted to the cytoprotective mechanisms it provides. Interestingly, using a 
chemical skin carcinogenesis mouse model, Dai and colleagues (Dai et al., 2007) 
found that HSF1-/- mice had a significantly lower tumour burden at 24 weeks 
compared to their wild-type counterparts; in addition, mice lacking HSF1 survived 
for a longer time. They also found that the lack of HSF1 in mice carrying the 
mutant p53 R172H allele were resistant to the tumourigenic effect of mutant p53 
and survived much longer compared to the HSF1+/+ mice with the similar p53 
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background (Dai et al., 2007). When subjected to a variety of stresses, including 
the exposure to inhibitors of Hsp90, the activation of the heat shock response by 
HSF1 causes the elevation of the molecular chaperones such as Hsp27 
(Schepers et al., 2005, Gorman et al., 2005) Hsp70 (Mosser et al., 2000, Garrido 
et al., 2003) which confer cytoprotection through their anti-apoptotic roles. On the 
other hand, small molecules that directly inhibit Hsp90 at its N-terminal ATP-
binding pocket (Lesko et al., 2007, Nimmanapalli et al., 2001) (e.g. geldanamycin, 
17-AAG, 17-DMAG) or possess the ability to modify its cysteine residues (Zhang 
et al., 2014)  (e.g. the isothiocyanate analogue, sulfoxythiocarbamate alkyne) 
have been shown to cause apoptosis in cancer cells. 
Inhibition of Hsp90 results in: 1) destabilisation and degradation of its 
oncogenic client proteins such as HER2 (Peng et al., 2005) and RAF1 (Schulte 
et al., 1995), 2) release of HSF1 from the Hsp90 protein complex, and 3) 
transcriptional activation of heat shock genes, and the subsequent elevation of 
the respective proteins. Cancer cells are intrinsically stressed, hence the 
requirement for the elevated expression and activation of HSF1 to provide them 
with anti-apoptotic proteins which are also molecular chaperones that help aid 
the stability of the mutated and aberrantly expressed oncogenic proteins within 
the cell that facilitates its survival. Many tumours have elevated expression of 
HSF1 and express high levels of Hsp90. As Hsp90 functions as a molecular 
chaperone to prevent protein misfolding and aggregation, cancer cells use the 
chaperone to stabilize multiple oncoproteins and prevent them from being 
degraded. Hence the elevation of Hsp90 by HSF1-mediated HSR allows for 
oncoprotein addiction. Thus, Hsp90, in recent years is actively being pursued as 
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a drug target in cancer. However, inhibition of Hsp90 often increases the stability 
of the HSF1 trimers and hence allows the heat shock response to continue. HSF1 
is also a crucial transcriptional regulator of numerous genes that are essential for 
cell survival during conditions of stress by helping to coordinate fundamental 
cellular pathways such as glucose metabolism. 
Recent research has allowed scientists to use HSF1 as a prognostic 
marker for breast cancer (Santagata et al., 2011). Increased nuclear HSF1 levels 
correlate with a poor prognosis in breast, colon and lung cancer (Mendillo et al., 
2012, Dai et al., 2012). Furthermore, it is becoming increasingly clear that HSF1 
is able to support malignant human cancers by orchestrating a transcriptional 
program beyond the HSR (Mendillo et al., 2012). It can be said that, HSF1, in 
cancer cells, is an essential promoter and regulator of oncogenesis. Hence, in 
addition to targeting Hsp90, inhibiting HSF1 could, in theory, improve the 
effectiveness of Hsp90 inhibitors. Several studies and clinical trials have shown 
synergistic effects when Hsp90 inhibitors are used in concert with conventional 
chemotherapeutic compounds that inhibit the transcriptional activation of HSF1. 
In a Phase I clinical trial, 17-AAG was given in combination with cisplatin and 
gemcitabine to patients with solid refractory tumours, and anti-tumour activity was 
observed (Hubbard et al., 2011). 
Santagata and colleagues discovered that inhibition of protein translation 
in malignant cells reduced the activation of HSF1 (Santagata et al., 2013) 
providing an insight that a close relationship exists between the translational 
machinery and the transcriptional programme orchestrated by HSF1. The group 
68
screened more than 300,000 compounds in search for HSF1 inhibitors, and 
successfully identified one compound, the naturally occurring rocaglamide A 
(Santagata et al., 2013). A series of natural and synthetic derivatives of 
rocaglamide A were then tested, and a very potent inhibitor of HSF1 was 
identified and named Rohinitib, which has an IC50 value of approximately 20 nM 
(Santagata et al., 2013). Recently, it was discovered that EP300/CREB, a histone 
acetyl transferase, was responsible for stabilization of HSF1 though acetylation 
of several of its lysine residues; knockdown of this enzyme by RNAi resulted in 
destabilisation of HSF1 (Raychaudhuri et al., 2014). This finding raises the 
possibility of targeting HSF1 by inhibiting the cellular processes that lead to 
stabilisation of HSF1 in cancer.  
1.B.9.1 HSF1 and chemoresistance 
Of late it has emerged that HSF1 plays a major role in maintaining 
chemoresistance. Desai et al. (Desai et al., 2013) found that when breast cancer 
cells were treated with the clinically approved chemotherapeutic drug carboplatin, 
which induces autophagy and inhibits cell proliferation, the administration of the 
drug was able to significantly increase these processes when HSF1 was knocked 
down. Autophagy is a cytoprotective process in response to stress such as 
starvation, hypoxia as well as exposure to chemotherapeutic agents. It is also a 
catabolic process by which cellular material such as organelles and several 
proteins are sequestered and degraded intracellularly within double-membrane 
structures known as autophagolysosomes to provide building blocks for protein 
synthesis and energy in the form of ATP. This process is orchestrated mainly by 
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the autophagy related genes (ATGs). Samples from breast cancer patients 
showed that higher expression levels of ATG7 correlated with poor prognosis. 
ATG7 is instrumental in autophagosome formation (Komatsu et al., 2005). HSF1 
was found to be activated upon carboplatin exposure and to induce the 
transcription of ATG7 and furthermore, the knockdown of HSF1 prevented the 
induction of ATG7, suggesting a role of HSF1 in regulating cytoprotective 
autophagy which promotes cancer cell survival (Desai et al., 2013).  
Local hyperthermia combined with administration of cisplatin has been 
used to treat patients with cervical cancer with positive outcomes (de Wit et al., 
1999, Wust et al., 2002, Takahashi et al., 2002a).  A study by Rossi et al. (Rossi 
et al., 2006) showed that loss of HSF1 in the human cervical cancer derived cells 
increased the sensitivity of cell death by apoptosis during a combined exposure 
to heat shock and cisplatin. These authors also found that when they co-
expressed Hsp27, Hsp70 and Hsp90 in cells lacking HSF1, under similar 
conditions of combined exposure to heat shock and cisplatin, apoptosis was 
partially inhibited. Hence, this study further solidifies the role of HSF1 as a 
promoter of chemoresistance in cancer cells. 
1.B.10 HSF1 and cell division 
One of the most evolutionarily conserved processes is the cell division 
cycle. The cell cycle is characterised by four main phases: 1) cell growth, 2) DNA 
duplication 3) separation of duplicated DNA to the daughter cells, and 4) cell 
division. The cell division cycle itself can be divided into four main phases: Gap1 
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Figure B7. Control of cell cycle progression by cyclin-CDK complexes. The activation
of these cyclin-CDK complexes are required during these stages of the cell cycle in order
to act as a checkpoint and promote transition into the next stage.
71
(G1), Synthesis (S), Gap2 (G2) and Mitosis (M) (Fig. B7). It is during the G1 
phase that cells commit to enter M phase, where the cell grows in size and is 
highly metabolically active, however, at this stage the DNA is not duplicated. 
During S phase, the DNA is replicated. The S phase is followed by the G2 phase 
where the cell continues to grow and prepare itself for transition into the M phase. 
The M phase is divided into four main stages, prophase, metaphase, anaphase 
and telophase, and it is followed by cytokinesis where two daughter cells are 
produced with identical genetic information (Fig. B8).  
The cell cycle is tightly controlled. Cyclin-dependent kinases are serine-
threonine kinases that exist as monomers, but form heterocomplexes with cyclins 
in order to be activated. CDK inhibitors (CDKi) are proteins that inhibit the function 
of the CDKs and are also essential regulators of the cell cycle. The activity of the 
CDKs fluctuate depending on the stages of the cell cycle. Cyclin-CDK complexes 
govern various stages of the cell cycle and function as important checkpoints to 
maintain the integrity of the cell division cycle (Fig. B7). Cancer cells differ greatly 
from normal cells in numerous ways (Hanahan and Weinberg, 2011), and one of 
the hallmarks of cancer is the presence of imbalanced chromosomes, known as 
aneuploidy. Overexpression of HSF1 inhibits mitotic exit, where cells are arrested 
in the G2/M phase due to the dysregulation of the metaphase-anaphase 
transition, ultimately increasing the chances of chromosomal abnormalities (Lee 
et al., 2008b). The authors show that the regulatory domain of HSF1 (amino acids 
212-380) binds directly to Cdc20 and inhibits the anaphase-promoting complex 
(APC). HSF1 overexpression also caused increases in aneuploidy and 
multinucleation of mouse tumour (RIF) cells (Lee et al., 2008b). In support of this 
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Figure B8
Figure B8. Different phases during mitosis. (Taken from the website
http://www2.le.ac.uk/departments/genetics/vgec/schoolscolleges/topics/cellcycle-
mitosis-meiosis. Accession date: 1st August 2016)
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finding, overexpression of a dominant negative HSF1 (DN-HSF1), where LZ-4 of 
the C-terminal transactivation of HSF1 had been deleted, inhibits aneuploidy in 
prostate cancer (PC-3) cells. Overexpression of WT-HSF1 in PC-3 cells has been 
shown to regulate the degradation of Cyclin B1, where Cyclin B1/CDK1 complex 
promotes and regulates entry into mitosis (Wang et al., 2004b). DN-HSF1 
overexpression prevents cyclin B1 degradation in cells undergoing mitosis, hence 
inhibiting mitotic exit, and could be one of the reasons why aneuploidy is 
decreased in cells overexpressing DN-HSF1 (Wang et al., 2004b).  
HSF1 also plays a major role in gametogenesis (Le Masson et al., 2011, 
Nakai et al., 2000, Metchat et al., 2009, Wang et al., 2004a). Nakai and 
colleagues found that male mice expressing an active form of HSF1 in the testis 
were infertile due to the meiotic cells being arrested at the pachytene stage which 
ultimately resulted in apoptosis of the germ-line cells  (Nakai et al., 2000). Le 
Masson and colleagues showed that oocytes from HSF1-deficient mice displayed 
chromosomal abnormalities. They also performed a comparative transcriptomic 
analysis on WT, HSF1-/- and HSF2-/- oocytes and identified that HSF1 and HSF2 
regulated 1665 and 959 genes, respectively. Of these genes, 262 were regulated 
by both HSF1 and HSF2 suggesting their overlapping function or their roles as 
co-activators or co-repressors of these genes (Le Masson et al., 2011). Further 
analysis also showed that unlike HSF2, HSF1 was involved in the regulation of 
75 genes that were involved in the cell cycle and the authors discovered that 
HSF1 regulated several meiotic genes (Le Masson et al., 2011). Intriguingly, in 
normally cycling cells exposed to heat stress, HSF1 was found to be bound to 
1207 loci, however in mitotic cells exposed to heat stress, HSF1 was only able to 
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bind to 35 loci which mainly consisted of promoters of chaperones and proteins 
involved in mRNA translation (Vihervaara et al., 2013). Collectively, these data 
suggest that HSF1 plays a vital role in cell division, however it could have 
divergent roles in mitosis and meiosis. 
Loss of HSF1 blocked meiosis, and it was shown that this was due to the 
persistent activation of the spindle assembly checkpoint (SAC) (Le Masson et al., 
2011). The SAC is vital for monitoring the integrity of chromosomal segregation 
during mitosis or meiosis, where it controls the onset of anaphase until all the 
kinetochores on the chromosomes have been attached to the spindle fibres 
(Lara-Gonzalez et al., 2012). The effect of HSF1 on cell division has not only 
been observed in mammalian cells but also in yeast where it was discovered that 
the temperature sensitive HSF1 mutant displayed defects in spindle pole body 
duplication causing defects in cell division (Zarzov et al., 1997). Another study 
found that during mitosis, HSF1 was localised to the centrosome and also to the 
spindle poles during metaphase (Lee et al., 2008a), and the authors identified 
PLK1 as the kinase that mediated the phosphorylation of serine 216 at the 
DSGXXS motif of HSF1 during mitosis. This phosphorylated motif is recognised 
by the ubiquitin ligase complex SKP1-CUL1-F-BOX protein (SCF) bound to the 
E3 ubiquitin ligase β-TrCP (SCFβ-TrCP), which targets S216-phosphorylated HSF1 
for degradation during mitosis. Interaction of HSF1 with Cdc20 prevents the 
recruitment of SCFβ-TrCP and as a result, inhibits the transcription factor’s 
degradation. 
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1.B.11 HSF1 turnover: Stability and degradation 
Proteotoxic insults destabilise the cellular protein homeostasis by causing 
the misfolding and aggregation of proteins which deteriorates the overall health 
of the cell. Upon exposure to proteotoxic stress, HSF1 potentiates the 
transcription of a battery of molecular chaperone genes that aid in ameliorating 
the overall protein health and hence allowing the cells to adapt to the stress. The 
regulation of HSF1 with respect to its post-translational modifications has been 
well-studied in the field, however there is relatively less research done to uncover 
the mechanisms that govern the turnover of HSF1. The endogenous HSF1 
protein has a relatively long half-life spanning from 13.6 h to 20 h (Kourtis et al., 
2015, Yang et al., 2008, Seo et al., 2006). Unlike the long half-life of the protein, 
the half-life of HSF1 mRNA is approximately 100 mins (Kim et al., 2012a). It is 
highly likely that the reason for HSF1 being such a long-lived protein is to be 
readily available in the event of exposure to cytotoxic stress so that it is able to 
exert its cytoprotective effects immediately. The histone acetyltransferase E1A 
Binding Protein P300 (EP300) promotes the stability of endogenously expressed 
HSF1 through acetylation on several of its lysine residues (i.e., K208 and K298) 
hence preventing it from being targeted for proteasomal degradation 
(Raychaudhuri et al., 2014). Also, EP300 maintains HSF1 stability irrespective of 
its phosphorylation status (Raychaudhuri et al., 2014). One of the first insights 
regarding HSF1 turnover was provided by a study published in 2001 by Bonelli 
and colleagues who found that only under heat shock conditions, serum-starved 
late passage human fibroblast (HF) cells displayed reduced HSF1 levels 
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compared to early passage serum-starved HF cells (Bonelli et al., 2001). This 
finding is further supported by a recent publication showing that HSF1 
degradation increases dramatically post-heat shock and furthermore, RNAi-
mediated depletion of the proteasomal subunit PSMA7, prolonged the Hsp70 
mRNA production by approximately 5 h under conditions of heat shock 
suggesting that the HSR is attenuated by the proteasome (Raychaudhuri et al., 
2014). Interestingly, Riluzole which is the only FDA-approved drug for the 
treatment of the neurodegenerative disease Amyotropic Lateral Sclerosis (ALS), 
is able to dramatically increase the protein half-life of endogenous HSF1 from 
13.6 h to 69.3 h (Yang et al., 2008), allowing greater activation of the HSR in 
cancer and neuronal cells (Yang et al., 2008, Liu et al., 2011). Furthermore, 
silencing LAMP2A using RNAi, curbed the turnover HSF1 in the presence of 
Riluzole which suggests that the compound could potentially block the clearance 
of HSF1 through chaperone-mediated autophagy (CMA) as LAMP2A is an 
essential potentiator of this process (Yang et al., 2008).  
Until recently, not much was known about the mechanisms by which HSF1 
is degraded, however, studies have emerged implicating several proteins that 
mediate the degradation of HSF1, namely, filamin interacting protein 1-like 
(FILIP-1L) and the E3 ligases, SCFβ-TrCP, F-Box and WD Repeat Domain 
Containing 7 (FBXW7) and neural precursor cell-expressed developmentally 
downregulated gene 4 (NEDD4). FILIP-1L was identified as a binding partner of 
HSF1 through a yeast-two-hybrid screen (Hu and Mivechi, 2011). The 
downregulation of FILIP-1L has been implicated in various human tumours and 
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has also been linked with hypermethylation at the FILIP-1L promoter and also 
global DNA methylation (Burton et al., 2011, Lu and Hallstrom, 2012). Hu and 
Mivechi discovered that overexpression of FILIP-1L leads to the decrease in 
HSF1 levels and as a consequence inhibits the transcription of HSF1 target 
genes. Also, they found that FILIP-1L acts as an adaptor protein for HSF1 to allow 
for binding to hHR23A, an ubiquitin receptor protein that functions to transfer 
ubiquitinated proteins to the 19S proteasomal subunit (Hu and Mivechi, 2011).  
As described in the previous section, phosphorylation of HSF1 at S216 
targets the protein for degradation by the E3 ubiquitin ligase SCF β-TrCP during 
mitosis, and mutation of this residue to arginine, dramatically increases its half-
life (Lee et al., 2008a). FBXW7 is the substrate recognition component of the SCF 
ubiquitin ligase complex and in humans it functions as a tumour suppressor as it 
mediates the degradation of many proto-oncogenes such as MYC, NOTCH and 
JUN  (Welcker and Clurman, 2008). FBXW7 binds to its substrates via their 
phosphodegron motifs which are called Cdc4 phosphodegrons (CPDs) where 
phosphorylation within the phosphodegrons has to occur in order for binding to 
take place (Welcker and Clurman, 2008). In most cases, FBXW7 substrates such 
as the ones mentioned above are phosphorylated by GSK3 within the 
phosphodegron. Interestingly, a recent article has linked the protein stability of 
HSF1 to FBXW7α; the authors reported that the SCFFBXW7 complex targets the 
degradation of HSF1 through direct binding at the phosphodegron motif spanning 
S303 and S307, where GSK3 and ERK1 phosphorylate these sites respectively 
(Kourtis et al., 2015). The phosphorylation of serine 303 and serine 307 is 
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required for the binding of FBXW7α to HSF1, and loss of FBXW7α causes 
persistent nuclear accumulation and activation of HSF1. In human melanoma 
cells, FBXW7α is downregulated, and Kourtis and colleagues showed that HSF1 
accumulation and activation drives the metastatic potential (Kourtis et al., 2015). 
GSK3 is activated under low-serum or serum-starved conditions (Sutherland, 
2011, Hetman et al., 2000, Sato et al., 2009). Taken together, the observations 
by Bonelli et al. and Kourtis et al. suggest that during serum-starvation heat shock 
could cause the activation of GSK3 and subsequent phosphorylation of HSF1 at 
the S303 and S307 phosphodegron to allow for SCFFBXW7-mediated degradation 
of the transcription factor (Bonelli et al., 2001, Kourtis et al., 2015).  
In contrast to cancer cell models, there have been numerous reports 
linking the loss of HSF1 to the promotion of neurodegenerative diseases (Jiang 
et al., 2013, Kondo et al., 2013). α-Synucleinopathies represent progressive 
neurodegenerative diseases such as Parkinson’s Disease (PD), multiple system 
atrophy (MSA) and dementia with Lewy bodies (DLB) (Fellner and Stefanova, 
2013, McCann et al., 2014) where there is accumulation of α-synuclein in the 
cytoplasm of a subset of neuronal and glial cells. A53T α-synuclein is able to form 
aggregates more readily that WT α-synuclein. In a recent study, Lim et al. found 
that overexpression of the mutant A53T α-synuclein in neuronal cells caused a 
decrease in HSF1 protein levels of more than 70% compared to WT α-synuclein 
whilst not affecting the HSF1 mRNA levels (Kim et al., 2016). WT α-synuclein 
caused the decrease of HSF levels in the nucleus unlike the mutant A53T α-
synuclein which decreased HSF1 levels in both the nucleus and cytoplasm (Kim 
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et al., 2016). A53T α-synuclein overexpression increased the amount of 
ubiquitinated HSF1, the authors had previously identified the E3 ligase NEDD4 
levels to be elevated in brains from PD patients (Kwak et al., 2012), leading them 
to overexpress NEDD4 in neuronal cells where they observed a prominent 
decrease in HSF1 protein levels (Kim et al., 2016). The authors also found that 
loss of NEDD4 or the overexpression of HSF1 led to the display of a 
neuroprotective phenotype against α-synucleinophathy (Kim et al., 2016).  
1.B.12 Concluding remarks 
HSF1 orchestrates a comprehensive transcriptional program that includes 
genes encoding chaperones which prevent protein misfolding and aggregation to 
maintain cellular proteostasis, as well as proteins which take part in the repair 
and clearance of damaged macromolecules and maintain cellular metabolism. 
Together with transcription factor NRF2, activation of HSF1 allows adaptation 
and survival under conditions of electrophilic, oxidative, inflammatory, and 
thermal stress due to the extraordinary functional diversity of their downstream 
target genes. Small molecule activators of HSF1 and/or NRF2 have shown 
protective effects in numerous animal models of chronic disease, including 
neurodegenerative disease, cardiovascular disease, and cancer. However, 
although the functions of both HSF1 and NRF2 are undoubtedly broadly 
cytoprotective, the consequences of their activation are both context- and 
duration-dependent and may have not only beneficial, but also negative effects 
for the organism, such as promoting cardiomyopathy or accelerating tumour 
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growth. This dichotomy should be very carefully considered when these 
transcription factors are being targeted for disease prevention or treatment. 
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Section 1: Introduction 
Chapter C 
p38 mitogen-activated protein kinases 
1.C.1 Introduction 
Eukaryotic cells have evolved ways to be able to respond quickly to 
external or internal stimuli by being able to sense, transmit the signals and 
coordinate the appropriate responses. Examples of these stimuli are in the form 
of growth factors, nutrients, cytokines, toxins, and physical changes such as 
osmolarity and oxygen levels. The signal transduction occurs through a subset of 
proteins known as kinases, which control the functional properties of their 
substrates by catalysing phosphorylation reactions. In the human genome, there 
are more than 600 putative kinase genes (Cheng et al., 2014). To date, 518 
human kinases have been described, and of these, only approximately 50% have 
been studied (Johnson and Hunter, 2005, Jacoby et al., 2015). Kinases belonging 
to the mitogen-activated protein kinase (MAPK) family are among the most well-
studied protein kinases. MAPK signalling pathways play major roles in various 
cellular processes such as immunity, inflammation, development, cell 
differentiation and cancer. MAPKs operate through a three-tiered signalling 
cascade, where the top tier is comprised of a MAPK kinase kinase (MAP3K) 
which when activated by phosphorylation, usually by autophosphorylation, 
phosphorylates and activates the middle tier MAPK kinase (MAP2K) which 
ultimately phosphorylates the MAPK belonging to the final tier. Subsequently, the 
phosphorylation activated MAPK is then able to phosphorylate its substrate(s). 
There are four main subfamilies belonging to the MAPK superfamily and they are 
c-JUN NH2-terminal kinases or stress-activated protein kinases (JNK/SAPK), 
extracellular signal regulated kinases (ERKs), ERK5/big MAP kinase 1(BMK1) 
and p38 MAPKs (Zarubin and Han, 2005, Manna and Stocco, 2011). 
 
1.C.2  p38 MAPKs 
 
To date, in mammalian cells, four main isoforms of p38 MAPKs encoded 
by different genes have been identified: p38α, p38β, p38Ɣ and p38δ (Fig. C1A). 
p38α and p38 β are more closely related to each other sharing 75% of amino acid 
sequence identity, whereas p38Ɣ and p38δ share 64% amino acid sequence 
homology. All four isoforms share approximately 45% amino acid sequence 
identity and their relative amino acid sequence identity is listed in Fig. C1B. p38α 
was the first out of the four isoforms to be isolated and most of the literature on 
the p38 MAPKs focuses on this particular isoform. p38α was initially isolated as 
a 38-kDa protein that was phosphorylated on its tyrosine residue when cells were 
exposed to lipopolysaccharide (LPS) or hyperosmolarity (Han et al., 1994). Also, 
in the same year, p38α was identified as a protein that was bound to pyridinyl 
imidazole class of compounds that were found to inhibit the production of the 
cytokines, interleukin 1 (IL-1) and tumour necrosis factor (TNF) in various cell 
types when exposed to inflammatory stimuli (Lee et al., 1994). This finding paved 
the way in the drug development field in search of p38αinhibitors for the treatment 
of inflammatory diseases, with SB203580, a compound belonging to the pyridinyl 
imidazole class, being one of the most widely studied p38α inhibitors (Lee et 
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Figure C1. p38 MAPK isoforms. 1A) Characteristic properties of the p38
isoforms. B) Table showing the sequence homology between the different
p38 MAPK isoforms, the percentages shown are derived from aligning the
p38 isoform sequences in the uniprot.org website.
al.,1994). Structural and crystallographic studies have identified that pyridinyl 
imidazole compounds competitively bind the ATP-binding pocket of p38α.  
Several years after the isolation of p38α, the other three isoforms were 
characterised. Due to the central role of p38 MAPKs in transducing inflammatory 
responses, there has been extensive research performed on them. Furthermore, 
since its discovery, efforts were made to develop and identify selective and potent 
p38 inhibitors. However, since it was discovered that p38 MAPKs have more than 
100 substrates (Trempolec et al., 2013) which are involved in cellular pathways 
other than inflammation, it has become clear that inhibiting p38 inadvertently 
causes unwanted side effects, hence restricting the clinical application of this 
approach (Gurgis et al., 2014). 
 
1.C.3  Structure of p38 MAPKs 
 
The structures of human p38α (ter Haar et al., 2007), β (Roy et al., 2015) 
and δ (Patel et al., 2009) have been solved by X-ray crystallography. All isoforms 
of p38 contain a glycine-rich phosphate-anchoring domain containing the 
consensus sequence Gly-X-Gly-X-X-Gly at the N-terminus (aa 31-36) which is 
followed by the ATP-binding region (aa 42-52). The phosphorylation or activation 
lip of the protein contains the amino acids 170-185 (Wilson et al., 1996, 
Badrinarayan and Sastry, 2011). Within the activation lip, p38 is activated upon 
phosphorylation at T180 and Y182 at the highly conserved amino acid sequence 
Thr180-Gly181-Tyr182 (Wilson et al., 1996, Badrinarayan and Sastry, 2011). The 
linker consisting of the amino acids Asp168-Phe169-Gly170 also known as the DFG 
loop adopts two different conformations: 1) ‘DFG-in’ and 2) ‘DFG-out’. When p38 
assumes the ‘DFG-in’ conformation, the ATP-binding pocket is exposed and 
phosphotransfer can be catalysed, whereas, when p38 adopts the ‘DFG-out’ 
conformation, the hydrophobic pocket that was previously occupied by Phe169 is 
revealed, rendering the kinase inactive (Young, 2013, Badrinarayan and Sastry, 
2011) (Fig. C2). Unlike ATP-competitive inhibitors such as the pyridinyl imidazole 
class of inhibitors like SB202190, a compound belonging to the diaryl urea class, 
BIRB796, allosterically binds to and inhibits the function of all isoforms of p38 as 
it forces p38 to adopt the ‘DFG-out’ conformation (Cuenda and Rousseau, 2007, 
Cuadrado and Nebreda, 2010).  
 
Interestingly, p38Ɣ is the only isoform that at the end of its C-terminus 
contains a 5 amino acid sequence KETPL which is a PDZ (PSD-95, discs large, 
zona occludens 1) binding domain where the consensus sequence for this 
domain is KETXL where X can be any amino acid (Hasegawa et al., 1999). The 
PDZ binding domain on p38Ɣ allows it to bind to substrates containing the PDZ 
domain and strikingly many of the p38Ɣ-specific substrates such as α 1-
syntrophin, myogenic differentiation 1 (MyoD1) and disks large homolog 1 
(DLG1) contain the PDZ domain (Escos et al., 2016). 
 
1.C.4  p38 MAPK signalling 
 
The expression pattern of the p38 isoforms differs greatly in terms of tissue 
distribution. Although, p38α and p38β are ubiquitously expressed in most tissues, 
p38β has been found to be highly expressed in the brain (Lawson et al., 2013), 
whereas, p38Ɣ is expressed mainly in skeletal muscle tissues and p38δ is mainly 
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Figure C2. Schematic diagram of the p38α structure. The phosphate anchor (yellow), ATP-binding site (orange), flanking kinase domain (green) and
the activation lip (blue) are labelled with the corresponding amino acid numbering.
expressed in the testis, pancreas, kidney and small intestine (Fig. C1A). The 
activation of the p38 signalling pathway through environmental stimuli has been 
observed in various species such as the budding yeast Sacchromyces cerevisiae 
(Hog1) (Posas et al., 1996), the round worm Caenorhabditis elegans (pmk1, 
pmk2 and pmk3) (Berman et al., 2001), the fruit fly Drosophila melanogaster 
(p38a, p38b and p38c) (Stronach and Perrimon, 1999) and in the African clawed 
frog Xenopus laevi (p38) (Keren and Bengal, 2010). In the yeast, HOG1 is a 
crucial regulator of adaptation and survival upon exposure to osmotic stress (Kim 
and Shah, 2007). Deletion of HOG1 in yeast exposed to high osmolarity confers 
lethality (Lee et al., 2002b). Also HOG1 is activated upon exposure to 
environmental stressors such as heat shock (Winkler et al., 2002). In mammalian 
systems, p38 has been found to be activated by osmotic shock, heat stress, 
ultraviolet (UV) radiation and exposure to endotoxins (e.g. LPS) as well as 
inflammatory cytokines (IL-1 and TNF-α) and growth factors (e.g. NGF and GM-
CSF) (Lee and Young, 1996, ten Hove et al., 2007, Zhang et al., 2001, Seo et al., 
2002, Xing et al., 1998, Winkler et al., 2002, Lee et al., 1994, Han et al., 1994). 
The ability of p38 MAPK pathway to sense and be activated by numerous forms 
of stimuli demonstrates that this pathway is highly sensitive and complex. The 
four p38 MAPK isoforms are differentially activated by their upstream kinases 
MAP2Ks which themselves are activated by their upstream kinases, the MAP3Ks 
(Fig. C3). 
 
 
 
 
FIGURE C3
Figure C3. p38 MAPK signalling cascade showing the substrate specificities for the individual isoforms. Diagram taken from Escos et al. 2016.
1.C.4.1 p38 MAPK signalling cascade 
 
The MAP3Ks bring about specificity for a stimulus-dependent triggering of 
the MAP2K-MAPK signalling cascade as well as have a role in determining cell 
fate (Craig et al., 2008, Escos et al., 2016). The main MAP3Ks that play a vital 
role in MKK3/4/6-p38 MAPK activation are Thousand-and-one amino acid kinase 
1 and 2 (TAO1 and TAO 2), Apoptosis signal-regulating kinase 1 (MEKK5/ASK1), 
Mixed-lineage kinases 2 and 3 (MLK2 and MLK3), TGF-β activated kinase 1 
(TAK1) and MAPK/ERK kinase kinases (MEKK) (Escos et al., 2016) (Fig. C3). 
All the MAP2Ks or MAP kinase kinases (MKKs) upstream of p38 MAPKs 
phosphorylate p38 at the TGY motif found within the activation loop. MKKs 
contain a D-domain docking site for binding to various MAPKs such as JNK family 
and p38 MAPKs (Sharrocks et al., 2000). All isoforms of the p38 MAPKs have 
been reported to be activated by MKK3 and MKK6 in vitro and in vivo, however, 
the p38 isoforms are differentially activated by MKK3 and MKK6 in response to 
different stress stimuli (Brancho et al., 2003, Remy et al., 2010). Interestingly, 
MKK4 is able to activate all three isoforms of the JNK family of MAPKs as well as 
two isoforms of p38 MAPKs (α and β) (Deacon and Blank, 1997, Whitmarsh and 
Davis, 2007). These findings suggest that the MKKs are differentially regulated 
in order to provide an organised and synchronised p38 MAPK signalling cascade. 
 
The scale and extent of p38 activation is vital in determining its effects on 
the cell. Within a few minutes upon stimulation, p38 MAPKs are rapidly activated, 
and depending on the cell type and stimulus, this activation could be transient or 
persistent, suggesting that p38 activation is tightly controlled under basal 
conditions. p38 isoforms have various substrates that play an important role in 
cellular processes such as apoptosis, transcription, cell growth, cell division, 
protein transport and secretion, protein chaperoning, cytoskeletal organisation, 
protein degradation. The p38 MAPK isoforms have overlapping substrates as 
well as unique substrates (Fig. C3). 
 
One of the first p38 MAPK substrates to be identified was MAPK-activated 
protein kinase 2 (MAPKAPK2 or MK2). MK2 when activated by p38, as able to 
activate various signals through the modulation of its substrates. MK2 is involved 
in cellular processes such as the inflammatory response, apoptosis and cell 
division. As mentioned earlier, since p38 inhibitors have failed in the clinical 
setting due to the presentation of high liver toxicity and unwarranted side-effects 
in patients, inhibitors targeting its downstream substrates are highly sought after. 
Activated MK2 is essential for the production of the pro-inflammatory cytokines 
TNFα, IL-1α, IL-1β, IL-6 (Castillo et al., 2016). MK2-/- mice have reduced 
production of pro-inflammatory cytokines and macrophages compared to their 
wild-type counterparts and are protected from developing neoplasms in a 
colorectal cancer model. MK2 phosphorylation by p38 allows for phosphorylation 
of heat shock protein 27 (Hsp27) which is found complexed to protein kinase B 
(AKT). Upon phosphorylation by MK2, Hsp27 dissociates from AKT. Hsp27 is 
known to be able to protect cells against oxidative damage caused by reactive 
oxygen species (ROS) which could be produced by environmental stimuli such 
as cytokines, heat stress and hypoxia (Zheng et al., 2006). Hsp27 decreases 
ROS levels by increasing intracellular glutathione levels and decreasing 
intracellular iron levels (Arrigo et al., 2005). Tristetrapolin (TTP), a protein that 
functions to destabilise mRNA stability has been found to be inactivated through 
phosphorylation of the p38-MK2 signalling cascade suggesting a role in for the 
p38 MAPKs in mRNA processing. Other p38 MAPK substrates include 
transcription factors such as activating transcription factor 2 (ATF2), proto-
oncogene c-Fos (FOS), transcription factor MafA (MafA) which are involved in 
pathways regulating DNA-damage response, cell proliferation and insulin 
regulation, respectively (Trempolec et al., 2013). Other substrates of the p38 
MAPK pathway include the cell cycle regulator Cyclin D3 (Casanovas et al., 
2004), the structural proteins Stathmin (Parker et al., 1998, Mizumura et al., 2006) 
and tau (Zhu et al., 2000, Reynolds et al., 1997) and RNA splicing factor 45 
(SPF45) (Al-Ayoubi et al., 2012).  
 
1.C.5 Some of the pathophysiological impacts of p38 MAPK 
signalling 
 
1.C.5.1 Specific roles and functional redundancies 
 
Each of the p38 isoforms have their unique substrates, and their substrate 
specificities are also cell and context dependent. However, the p38 isoforms 
share many substrates which suggests functional redundancies due to their high 
sequence homologies. In vivo knockout models have shed light on the functional 
redundancies of the p38 MAPKs. Thus far, only p38β, p38Ɣ and p38δ-knockout 
mouse models have been generated and they all exhibit a normal phenotype. On 
the contrary, p38α-knockout mice display embryonic lethality at midgestation due 
to placental defects, suggesting a role for p38α in embryonic development. These 
placental defects could not be rescued by a knock-in allele of p38β under the 
control of the p38α promoter, implying that these isoforms are not completely 
functionally redundant. Interestingly, tissue-specific p38α knockouts in mice have 
implicated the kinase in cardiomyocyte proliferation (Engel et al., 2005), liver 
gluconeogenesis (Jing et al., 2015) and hepatocyte proliferation (Tormos et al., 
2013). Although, p38β-knockout mice are viable, several studies have emerged 
implicating the requirement of this isoform for bone mineralisation. Micro CT 
scans have shown that bones of four-week old p38β-knockout mice present with 
osteopenia (Greenblatt et al., 2010). Interestingly, p38β deficiency in osteoblasts 
showed defects in late stage of differentiation, whereas, p38α deficiency in the 
same system exhibits defects in both early and late stages of osteoblast 
differentiation (Greenblatt et al., 2010, Rodriguez-Carballo et al., 2016). Murine 
embryos deficient in both p38α and β displayed spina bifida, exencephaly and 
heart defects, and these phenotype were not observed in the single knockout 
embryos of either isoforms (del Barco Barrantes et al., 2011), suggesting that 
during embryonic development, p38α and β are functionally redundant. 
 
The generation of single and double p38Ɣ or/and p38δ knockout mice has 
provided answers regarding the functional roles and redundancies of these 
isoforms. It has been reported that p38Ɣ/δ -double knockout mice-derived 
macrophage and dendritic cells have an impaired innate immune response when 
challenged with endotoxins such as LPS (Escos et al., 2016). In addition, the 
p38Ɣ/δ-double knockout mouse displays cardiac hypertrophy (Gonzalez-Teran 
et al., 2016a). Since p38Ɣ is mainly and highly expressed in skeletal tissues, and 
is induced during muscle differentiation, it is not surprising that the double 
knockout of Ɣ and δ isoforms display heart defects. Indeed, p38Ɣ is an important 
factor for adult muscle differentiation and regeneration (Lassar, 2009). Studies 
conducted in p38δ-deficient mice have shown that this isoform, which is highly 
expressed in the lungs, is important for recruitment of neutrophils to sites of 
inflammation in the lung (Ittner et al., 2012).  
 
There are publications showing that loss of p38Ɣ or/and p38δ confers 
protection in several disease models. Sumara et. al. showed that the loss of p38δ 
promotes insulin secretion in pancreatic β cells and enhances glucose tolerance 
(Sumara et al., 2009). The authors found that pancreatic β cells from p38δ-null 
mice contain profoundly activated protein kinase D (PKD) which promotes insulin 
exocytosis in these cells (Sumara et al., 2009). Furthermore, mice lacking both 
p38Ɣ and δ in their myeloid cells are resistant to the development of non-alcoholic 
fatty liver disease (NAFLD), glucose intolerance and triglyceride accumulation in 
the liver (Gonzalez-Teran et al., 2016b). The authors show that this protection is 
mediated by impaired recruitment of neutrophils to the liver, which as a 
consequence prevents inflammation and the development of liver steatosis 
(Gonzalez-Teran et al., 2016b). Using the two-stage 7,12-
dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate 
(TPA) skin carcinogenesis protocol, it was found that both p38δ-knockout and 
p38Ɣ/δ-double knockout mice have a reduced susceptibility to tumour formation 
which could be due to defects in mounting inflammatory and proliferative 
responses (Schindler et al., 2009, Zur et al., 2015). Recently, Yin and colleagues 
showed that intestinal epithelial cell specific knockout of p38Ɣ leads to inhibition 
of inflammation and tumouriginesis in a colitis-associated colon cancer model 
(Yin et al., 2016). Global knockdown of both p38Ɣ and p38δ is also protective in 
this model (Del Reino et al., 2014). 
 
1.C.6  Conclusions 
 
There have been a plethora of reports implicating the importance of p38 
MAPKs in cellular pathways such as proliferation, differentiation, apoptosis, cell 
survival, development, senescence, inflammation and aging (Fig. C4). Notably, 
the p38 inhibitors that have been used in clinical trials primarily target the α and 
β isoforms, and such inhibitors have failed due to toxicities and importance of 
these pathways. Inhibiting their substrates such as MK2 as mentioned earlier 
seems to be a better option as it provides a more linear approach. Also, it is 
important to note that targeting p38Ɣ and δ could be another possibility since in 
the last decade there has been significant progress in the understanding of the 
roles of these two isoforms. p38Ɣ and δ have been shown to be vital regulators 
of inflammation, and the development of drugs that specifically target them might 
ameliorate inflammatory disease pathogenesis. Interestingly, it was recently 
found that the use of relatively specific p38δ inhibitors reduced the amount of 
mucus production in human bronchial epithelial cells (Escos et al., 2016). It will 
be fascinating to understand more about the mechanism behind how the Ɣ and 
δ p38 MAPK isoforms govern innate immunity. This will ultimately lead to the 
search for highly selective inhibitors which could be of therapeutic use for the 
treatment of inflammatory diseases. 
	
FIGURE C4
Figure C4. The physiological roles and pathological implications of p38 MAPKs. Diagram taken from Cuenda and Rousseau, 2007.
Section 2: Materials and Methods 
 
2.1  Materials 
All general chemicals and reagents were of analytical grade and obtained from 
either Sigma-Aldrich (Dorset, United Kingdom) or MERCK Millipore 
(Massachusetts, USA). PEITC was prepared as a stock solution in acetonitrile 
and diluted 1:1,000 in the cell culture medium before treatment. The 
concentration of the solvent was maintained at 0.1% (v/v) in all wells. The p38α/β 
MAPK inhibitor SB202190 was purchased from SYNkinase (Parkville, Australia). 
The pan p38 inhibitor BIRB0796 was purchased from Axon Medchem 
(Groningen, Netherlands). The JNK inhibitor JNK-In-8 was a kind gift from Dario 
Alessi (University of Dundee). The GST-tagged recombinant NRF2 NEH6+ 
protein was a kind gift from Professor. John D. Hayes. 
 
2.2   Cell culture 
MDA-MB-231 cells were from ATCC. HeLa-HSE-luc cells (Calamini et al., 2012) 
were a generous gift from Richard I. Morimoto (Northwestern University, USA). 
MCF7 cells were a kind gift from Dr. Mark Saville (University of Dundee, UK). 
HeLa cells were a generous gift from Dr. Sonia Rocha (University of Dundee, 
UK). Mouse embryonic fibroblasts (MEF) from wild-type or HSF1-knockout mice 
were isolated as described previously (Xiao et al., 1999). The human epidermoid 
cancer cell line A431 and the production and transduction of lentivirus short 
hairpin RNA to generate stable clones, which do not express p38Ɣ or p38δ, have 
been described (Zur et al., 2015). All cell lines were maintained at 5% CO2 in air 
at 37°C and were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
(Invitrogen) supplemented with 10% (v/v) heat-inactivated FBS (Invitrogen) 
unless specified. The medium in which HeLa-HSE-luc cells were grown also 
contained 100 µg/mL G418 (Invitrogen), whereas the medium for MEF cells was 
additionally supplemented with non-essential amino acids (Invitrogen) and 50 
U/ml penicillin/streptomycin (Invitrogen). 
 
2.3   Western blotting sample preparation 
Cells grown in 6-well plates were washed twice with phosphate buffered saline 
(PBS) and lysed in 150 μl of either RIPA buffer [50 mM Tris-Cl pH 7.5, 150 mM 
NaCl, 0.5% (w/v) sodium deoxycholate, 1% IGEPAL (v/v), 0.1% SDS (w/v) and 1 
mM EDTA), containing 1 protease inhibitor cocktail tablet (Roche) per 10 ml of 
buffer] or SDS-lysis buffer [50 mM Tris-Cl pH 6.8, 2% (w/v) SDS, 10% (v/v) 
glycerol and 0.005% bromophenol blue). The lysates derived from RIPA buffer 
were transferred into 1.5-ml Eppendorf tubes which were placed on a rotator at 
4°C for 30 min. The cell debris was then removed by centrifugation at 16,300 x g 
for 10 min at 4°C, and the supernatant was transferred to a new tube. The lysates 
derived from the SDS-lysis buffer were subjected to sonication at 20% amplitude 
for 20 sec. The BCA assay (Thermo) was used to determine protein 
concentrations.  
 
2.4   Western Blot Analysis 
2.4.1   SDS-PAGE gel electrophoresis 
For this technique, unless specified, equal amounts of sample lysates (5 μg – 20 
μg protein) were incubated with sodium dioecyl sulphate (SDS) lysis buffer (13.3 
mM Tris HCL pH 6.8, 6% (v/v) Glycerol, 1% (w/v) SDS, 1.2% (v/v) β-
Mercaptoethanol and 0.1% w/v Bromophenol Blue). The samples, along with a 
prestained standard protein marker (Invitrogen), were loaded onto SDS-
polyacrylamide (ProtoGel 30%, National Diagnostics) gels prepared in the 
laboratory, and separated by electrophoresis (SDS-PAGE) using 80V for 30 
minutes and 120V for 1 hour. The gel was run using the gel running buffer (25 
mM Tris, 192 mM Glycine, 0.1% (w/v) SDS) and the system used was purchased 
from the manufacturer Biorad. 
 
2.4.2  NuPAGE gel electrophoresis 
For this technique, unless specified, equal amounts of sample lysates (5 μg – 20 
μg protein) were incubated with SDS-lysis buffer. The samples along with a 
prestained standard protein marker (Pageruler, Invitrogen) were loaded onto 
precast 4-12% gradient or 10% NuPAGE gels and separated by electrophoresis 
using 80V for 15 minutes and 150V for 1 hour. The gel was run using the gel 
running buffer (1 X MOPS buffer, Invitrogen) and the gel-running system used 
was purchased from the manufacturer Invitrogen. 
 
2.4.3  Wet transfer 
The proteins from the gel were transferred onto 0.45 μm nitrocellulose membrane 
(NC) (Amersham Biosciences) using the wet transfer system following the 
manufactuer’s instructions (Critereon, Biorad). The transfer buffer (25 mM Tris, 
192 mM glycine and 20% (v/v) methanol) was used to transfer the proteins from 
the gel to the NC membrane at 100V for 30 or 45 minutes for 0.75 mm or 1.00 
mm thick gels respectively. Once the proteins were transferred from the gel to 
the NC membrane, the latter was blocked using 10% w/v milk (Marvel) prepared 
in 0.1% PBS containing 0.1% Tween 20 (PBS-T) for 30 min at a constant agitation 
of 70 rpm on a shaker (SSM1, Stuart). 
 
 
2.4.4  Immunoblotting 
All the antibodies were prepared in 10% (w/v) milk (Marvel) dissolved in PBS-T 
(0.1% (v/v) Tween 20 dissolved in PBS) and contained within a 50 ml centrifuge 
tubes. Next, the NC membrane was added to the preferred primary antibody 
contained in the falcon tube. The 50 m tubes containing the primary antibody and 
the NC membrane were placed on a rotator (SRT6, Stuart) for an overnight 
incubation (16-24 h) at 4oC or 2 h at room temperature (RT).  
 
After the incubation with the primary antibodies, the membrane was washed 
thrice every 15 minutes in PBS-T. The NC membrane is incubated with its 
respective secondary antibody (Section 2.3) for 45 minutes at RT.  Next, the 
membrane was washed with PBS-T for three times every 15 minutes. Enhanced 
chemiluminescence (ECL) stock A (2.5 mM Luminol (Fluka), 100 mM Tris HCL 
pH 8.5, 0.4 mM p-coumaric acid) and B (0.0192% H2O2 and 100 mM Tris HCL 
pH 8.5) are mixed at a 1:1 ratio. 1 ml of ECL (A+B) was required for one 
membrane. The ECL solution was spread onto the NC membrane evenly. A 
developing cassette containing a transparent plastic film was used for the 
membranes to be placed beneath it. In the dark room, the membranes were 
exposed to an X-ray film, which were developed using the machine (Compact X4, 
Xograph). 
 
2.5   Primary antibodies 
Table displaying the specifications of the primary antibodies used. 
 
Antibody dilution solutions are as follows: 
PBST: 0.1% (v/v) Tween 20 dissolved in PBS 
PBST-milk: 5% milk (Marvel) (w/v) dissolved in PBST   
PBST-BSA: 1% bovine serum albumin (BSA) dissolved in PBST 
PBS-NGS: 2.5% (v/v) normal goat serum (NGS) in PBS 
TBST: 0.1% (v/v) Tween 20 dissolved in TBS 
PBST-milk: 5% milk (Marvel) (w/v) dissolved in TBST   
 
2.6    Nuclear-cytoplasmic separation 
MDA-MB-231 cells (106 per dish) were plated in 6-cm dishes and treated for the 
indicated periods of time with 0.1% (v/v) acetonitrile or PEITC. The REAP method 
described by Suzuki et al. was used to obtain separate cytoplasmic and nuclear 
fractions (Suzuki et al., 2010). In short, cells were washed twice with ice-cold 
phosphate buffered saline (PBS, pH 7.5), collected in 500 μl of ice-cold PBS, 
Antibody Name Species Type Dilution Diluted in Company Country APPLICATIONS
Hsp70 Mouse Monoclonal 1:1,000 PBST-MILK StressMarq York, UK WB
Hsp90 Mouse Monoclonal 1:5,000 PBST-MILK BD Biosciences New Jersey, USA WB
HER2 Rabbit Polyclonal 1:500 PBST-MILK Millipore California, USA WB
RAF1 Rabbit Polyclonal 1:200 PBST-MILK Santa Cruz California, USA WB
HSF1 Rabbit Polyclonal 1:1,000 PBST-BSA Enzo Life Sciences Exeter, UK WB
HSF1 Mouse Monoclonal 1:1,000 PBST-BSA Santa Cruz California, USA WB, IP, IF
HSF1 pS326 Rabbit Monoclonal 1:10,000 PBST-BSA Abcam Cambridge, UK WB
p38 MAPK Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
pp38 MAPK Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
p38α MAPK Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
p38β MAPK Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
p38Ɣ MAPK Rabbit Polyclonal 1:1,000 PBST-BSA DSTT Dundee, UK WB
p38δ MAPK Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
MK2 pT334 Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
S6 pS235/236 Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
ERK1/2 Rabbit Monoclonal 1:800 PBS-NGS Cell Signaling Massachusetts, USA IF
JNK1/2 Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
pJNK1/2 Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
pERK1/2 Rabbit Polyclonal 1:1,000 PBST-BSA Cell Signaling Massachusetts, USA WB
GAPDH Rabbit Polyclonal 1:5,000 PBST-MILK Sigma Dorset, UK WB
β-actin Mouse Monoclonal 1:10,000 PBST-MILK Sigma Dorset, UK WB
HRP-β-actin Mouse Monoclonal 1:40,000 PBST-MILK Sigma Dorset, UK WB
α-tubulin Mouse Monoclonal 1:5,000 TBST-MILK Cell Signaling Massachusetts, USA WB, IF
NRF2 Rat Monoclonal 1:100 TBST Yamamoto Lab Sendai, Japan WB
KEAP1 Rat Monoclonal 1:100 TBST-MILK Yamamoto Lab Sendai, Japan WB
HA Rat Monoclonal 1:1,000 TBST-MILK Roche California, USA WB
transferred to Eppendorf tubes, and subjected to centrifugation at 10,000 x g for 
30 sec at room temperature. Next, the supernatant was discarded and the pellet 
was resuspended in 450 μl of ice-cold 0.1% IGEPAL (v/v) in PBS. The lysates 
were then subjected to a further centrifugation at 10,000 x g for 30 sec at room 
temperature. The supernatant was collected as the cytoplasmic fraction. One 
volume of 5X sample SDS loading buffer [250 mM Tris-Cl pH 6.8, 10% (v/v) 
sodium dodecyl sulphate, 50% (v/v) glycerol and 0.025% (w/v) bromophenol 
blue] was added to four volumes of the cytoplasmic fraction and the samples 
were heated for 5 min at 100oC and subjected to SDS/PAGE. The remaining 
pellet containing the nuclear fraction was washed twice with ice cold 0.1% 
IGEPAL (v/v) in PBS and dissolved in 1X sample loading buffer [50 mM Tris-Cl 
pH 6.8, 2% (v/v) sodium dodecyl sulphate, 10% (v/v) glycerol and 0.005% (w/v) 
bromophenol blue] and heated for 5 min at 100oC. The nuclear fractions were 
sonicated before subjecting them to SDS-PAGE. 
 
2.7    Quantitative real-time PCR  
The primers and probes for quantifying the levels of the mRNA species were from 
Applied Biosystems (hspa1a: Mm01159846_s1; HER2: HS01001580_m1 and 
RAF1: HS00234119_m1). Cells (2 x 105 per well) were seeded in 6-well plates. 
After 24 h, the cells were exposed to vehicle (0.1% acetonitrile) or PEITC for a 
further 8 (MEFs) or 16 h (MEFs and MDA-MB-231 cells).  After cell lysis, total 
RNA was extracted using RNeasy Kit (Qiagen Ltd.), and 500 ng total RNA was 
reverse transcribed into cDNA with Omniscript Reverse Transcription Kit (Qiagen 
Ltd.). Real-time PCR was performed on Applied Biosystems 7900HT Fast Real-
Time PCR System. The data were normalized using β-actin (mouse ACTB, 
Applied Biosystems, Mm00607939_s1) as an internal control. Real-time PCR 
experiments shown in Section 3, Chapter 1 were performed in Professor 
Masayuki Yamamoto’s Lab in Sendai, Japan. 
 
2.8   Luciferase assay 
HeLa-HSE-luc cells (105 per well) were seeded in each well of a 24-well plate, 
and 24 h later treated with PEITC or 0.1% (v/v) acetonitrile vehicle for 8-, 16-, 24-
, or 48 h. Cells were washed twice with 0.1% PBS, and 100 µl of 1X reporter lysis 
buffer (Promega) was added to each well. The plate was placed at -20°C for a 
minimum for 2 h, and then transferred to thaw on a shaker at room temperature 
for 30 min. Cell lysates were collected into Eppendorf tubes and subjected to 
centrifugation at 15,000 x g for 2 min at 4°C. Luciferase activity was measured in 
10 µl of cell lysate in opaque 96-well plates (Corning) using a microplate-reader 
based luminometer (Orion II, Berthold), and normalized for protein concentration 
determined by the Bradford’s assay (BioRad). 
 
2.9    ATP-binding assay 
MDA-MB-231 cells (0.5 x 106 per dish) were seeded in 6-cm dishes. After 24 h, 
the cells were treated for a further 24 h with 0.1% acetonitrile as the vehicle 
control for sulfoxythiocarbamate alkyne (STCA, 75 µM) and PEITC (20 µM) 
treatments, or with 0.1% DMSO as the vehicle control for the geldanamycin (GA, 
1 µM) and celastrol (CL, 0.8 µM) treatments. Cells were harvested by scraping 
into 300 µl of lysis buffer [10 mM Tris pH 7.5, 150 mM NaCl, 0.25% IGEPAL, with 
one protease inhibitor tablet (Roche) per 10.0 ml of buffer], frozen, thawed, and 
lysed for 30 min at 4°C. ATP-agarose beads (Jena Bioscience) were washed with 
the incubation buffer (10 mM Tris pH 7.5, 150 mM NaCl, 20 mM MgCl2, 0.05% 
IGEPAL, 1 mM DTT). Cell lysates (200 µg total protein) were added to a 
suspension of 30 µl of beads in 1.25 ml of buffer, and the samples were incubated 
rotating overnight at 4°C. The beads were collected by centrifugation and washed 
three times with the incubation buffer. 5 X SDS loading buffer (10 µl) and 
incubation buffer (40 µl) were added to the beads, and the samples were 
incubated for 5 min at 100°C. The beads were pelleted by centrifugation, and the 
supernatants were collected and subjected to western blot analysis. 
 
2.10   Detection of HSF1 trimerization 
MDA-MB-231 (2 x 106 per dish) cells were grown on 10-cm dishes for 24 h and 
treated with 0.1% acetonitrile or 20 μM PEITC for a further 3 h. Cells were then 
washed twice with PBS. 10 ml of 0.4% paraformaldehyde (w/v) in PBS (0.4% 
PFA-PBS) was added to the dishes over 10 min, where fresh 0.4% PFA-PBS was 
added every 5 min. Next, the PFA-PBS was removed and the reaction was 
quenched with the addition of 3 ml of ice-cold 1.25 M Glycine-PBS. After washing 
twice with PBS, nuclear and cytoplasmic fractions were obtained. Cells were 
lysed in buffer A [10 mM KCl, 5 mM MgCl2, 50 mM Tris-Cl pH 7.5, 0.5% (v/v) 
IGEPAL, 1 mM DTT, one EDTA-free complete mini protease inhibitor cocktail 
tablet (Roche) and one phos-STOP tablet (Roche) per 10 ml of buffer]. The 
lysates were subjected to centrifugation at 1,000 x g for 5 min at 4oC. The 
supernatant containing the cytoplasmic fraction was transferred to a fresh 
Eppendorf tube where one volume of 5X SDS sample loading buffer was added 
to four volumes of the cytoplasmic fraction. The pellet containing the nuclear 
fraction was washed three times with the buffer A before dissolving it in 1X 
sample loading buffer [50 mM Tris-Cl pH 7.4, 2% (w/v) SDS, 10% (v/v) glycerol, 
and 0.005% (w/v) bromophenol blue]. The nuclear fractions were subjected to 
sonication. Both the cytoplasmic and the nuclear fractions were subjected to 
SDS-PAGE before immunoblotting. 
 
2.11   Co-immunoprecipitation 
MDA-MB-231 cells (4 x 106 per dish) were grown on 10-cm dishes for 24 h, and 
the treated with 0.1% DMSO or 20 μM PEITC for 45 min. The dishes with cells 
were placed on ice and washed twice with ice-cold PBS. Protein G Dynabeads 
(30 μl slurry, from Invitrogen) were washed twice for 5 min with PBS and 
incubated with 1 μg of mouse monoclonal HSF1 antibody (Santa Cruz) for 1 h at 
room temperature, after which the beads were washed three times every 10 min 
with PBS. Cells were lysed with 1.0 ml ice-cold CO-IP buffer (150 mM NaCl, 50 
mM Tris-Cl, pH 7.4, 1 mM EDTA, 1% IGEPAL, 0.1% w/v sodium deoxycholate) 
supplemented with one EDTA-free protease cocktail inhibitor tablet (Roche) and 
one phosphatase inhibitor tablet (PhoSTOP Roche). Cell lysates were passed 
through a 23-gauge needle 10 times before they were clarified by centrifugation 
at 4°C for 30 min at 16,000 x g. Fifty μl of the clarified lysate (IP sample) was 
transferred to a fresh Eppendorf tube to serve as an input sample. To pre-clear 
the IP sample, 30 μl of Protein G Dynabeads slurry was washed twice for 5 min 
with PBS, and the beads were added to each of the IP sample (containing 0.8-
1.0 mg protein), and incubated for 1 h at 4°C on a tube rotator. Subsequently, the 
Protein G Dynabead-antibody conjugate was added to the pre-cleared IP sample 
and incubated for 16 h at 4°C on a tube rotator. The immunoprecipitated 
complexes were washed three times with ice-cold CO-IP buffer every 10 min, and 
were eluted from the beads by adding 70 μl of 1X LDS buffer (Invitrogen) and 
heating the sample at 70°C for 10 min. After cooling, 7 μl of sample reducing 
agent (SRA, Invitrogen) was added to the sample, and incubated for 15 min at 
room temperature. Immuproprecipitated proteins (35 μl) were resolved by 
electrophoresis. Antibodies against Hsp90 (monoclonal, BD Biosciences) and 
HSF1 (rabbit polyclonal, Enzo Life Sciences) were used for detection of the 
respective proteins. 
 
2.12  Generation of p38δ and p38Ɣ stable knockdown cell lines 
p38δ and p38Ɣ expression was reduced by RNA interference using Mission 
shRNA constructs (Sigma; plasmid clone IDs TRCN0000006145 and 
TRCN0000006147 for p38Ɣ and TRCN0000000827 and TRCN0000009979 for 
p38δ. A lentivirus containing the control pLKO.1 or the shRNA plasmids was used 
to infect MDA-MB-231 cells. To produce the virus, HEK293T cells were 
transfected using Lipofectamine 2000 (Invitrogen) with empty pLKO.1-puro 
vector or the shRNA constructs against p38Ɣ or p38δ together with the packaging 
vectors (psPAX2 and pMD2.G) in serum-reduced medium. On the following day, 
the medium was replaced with complete DMEM, and after 24 h, the lentivirus-
containing supernatant was collected, filtered, and used to transduce MDA-MB-
231 cells. Cells containing the shRNA plasmid were selected, expanded and 
maintained with supplementation of puromycin (2 mg/ml) for approximately three 
weeks, during which time cell lysates were collected every three to four days to 
ensure the respective p38 expression levels were reduced throughout the 
selection period. 
 
2.13  Expression and purification of recombinant  
   hexahistidine-tagged HSF1 
Full-length HSF1 cDNA was amplified by PCR from a plasmid obtained from 
Addgene (Plasmid ID: #32537, in which the cDNA sequence was found to have 
a nucleotide substitution at position 1343 from a C to T, leading to a change from 
P to L at position 448 in the protein sequence) and subcloned into the bacterial 
expression vector pet15b using Nde1 and Xho1. Following transformation into 
E.coli (BL21(DE3)pLysS), the cells were grown to an optical density at 600 nm of 
0.6, and induced for a further 3.5 h at 37°C with 400 mM isopropyl-β-D-
thiogalactopyranoside (IPTG). The induced cells were harvested by 
centrifugation and resuspended in extraction buffer [20 mM Tris-Cl pH 7.9, 150 
mM NaCl, 5 mM imidazole and 0.01% (v/v) IGEPAL CA-630]. After freezing and 
thawing, the cells were disrupted by sonication for 5 min on ice. Cell debris were 
then cleared by centrifugation at 10,000 x g for 15 min at 4oC. The resultant 
supernatant was left on ice for 30 min before applying to nickel agarose resin 
(His-TrapTMHP, GE Healthcare). The resin was washed with 20 mM Tris-Cl pH 
7.9, 150 mM NaCl, 5 mM imidazole. The supernatant (20 ml) was then incubated 
for 1 h at 4°C with 1 ml resin. After three washes with buffer, the protein was 
eluted with 2 ml of 20 mM Tris-Cl pH 7.9, 150 mM NaCl, 250 mM imidazole. To 
remove the imidazole, the preparation was dialyzed in 50 mM Tris-Cl pH 7.4, 150 
mM NaCl. Mutant S326A HSF1 was generated by site-directed mutagenesis of 
the plasmid vector pet15b containing the HSF1 cDNA by using the primers 5’-
GTGGACACCCTCTTGGCCCCGACCGCCCTCATTG-3’ and 
5’CAATGAGGGCGGTCGGGGCCAAGAGGGTGTCCAC-3’ and the 
QuikChange® II Mutagenesis kit (Stratagene). The hexahistidine-tagged mutant 
S326A HSF1 recombinant protein was generated using the method described 
above. 
 
2.14   High content microscopy and analysis 
HSF1-knockout MEFs were seeded in black-walled 96-well plates (Corning 
Costar 3904) at 4 x 103 cells/well and transfected with 50ng/well GFP-tagged 
wild-type or S326A or S326E mutants of HSF1 using Lipofectamine LTX reagent 
(Invitrogen), using 8 replicate wells per condition. Twenty-four hours after 
transfection, cells were fixed using 4% paraformaldehyde in PBS for 10 min at 
room temperature, and permeabilised using methanol at -20°C for 5 min. Cells 
were blocked using 2.5% normal goat serum in PBS/0.1% sodium azide, and 
counterstained using rabbit anti-ERK1/2 mAb (clone 137F5, Cell Signaling 
Technology) and Alexa 546 labelled highly cross adsorbed goat anti-rabbit 
secondary antibody (Invitrogen). DNA was labelled with 300 nM DAPI (Sigma) in 
PBS and images were acquired using an IN Cell Analyzer 2000 robotic 
fluorescence microscope (GE Healthcare) using a 20x lens to capture 4 fields per 
well for each fluorophore (DAPI, GFP and Alexa 546) using 2x2 pixel binning to 
maximise signal/noise. Images were analyzed using a custom algorithm 
constructed within IN Cell Developer software (GE Healthcare), using DAPI and 
ERK1/2 images to identify nuclear and cytoplasmic regions, respectively, in order 
to assess fluorescence distribution within the GFP channel. 
 
2.15   Kinase assays 
The incubation mixtures contained purified recombinant kinase (at a specific 
activity of either 6 mU/μl or 0.06 mU/μl), recombinant HSF1 (1 μg) substrate, 10 
mM MgCl2, 0.1 mM [Ɣ-32P]-ATP (approximately 0.5 x 106 cpm/nmol), and kinase 
buffer [50 mM Tris-Cl, 0.03% (v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol] in a 
total volume of 50 μl. The kinase assays were performed at 30°C. At the times 
indicated, a 15-μl aliquot of each incubation mixture was removed, the reaction 
was terminated by the addition of SDS gel loading buffer, the sample was loaded 
on SDS-PAGE, and the excess [Ɣ-32P]-ATP was removed by electrophoresis. 
The gels were dried and subjected to autoradiography. Protein-containing gel 
pieces (visualized by staining with Coomassie Brilliant Blue) were then excised, 
and phosphate incorporation into HSF1 was quantified by scintillation counting. 
Cold assays were performed in an analogous manner using purified recombinant 
kinase (at a specific activity of 0.06 mU/μl), recombinant HSF1 (1 μg) substrate, 
MgCl2 (10 mM), and ATP (0.1 mM) instead of [Ɣ-32P]-ATP. For identification of 
the phosphorylated sites, the gel bands were excised, reduced with DTT (10 mM), 
alkylated with iodoacetamide (50 mM), and digested overnight (16 h) with trypsin 
(Modified Sequencing Grade, Roche) at 30°C. The resulting peptides were 
extracted from the gel, dried in a SpeedVac concentrator (Thermo Scientific), 
resuspended in 10 µl 5% formic acid, and diluted five times. Any residual particles 
were removed by centrifugation, the samples were then transferred to HPLC 
vials, and analyzed by LC/MS/MS on Ultimate3000 RSLCnano System (Thermo 
Scientific) coupled to a LTQ OrbiTrap VelosPro (Thermo Scientific) with 
EasySpray source. The data files were analyzed with Proteome Discoverer (Ver. 
1.4.1) using Mascot (Ver. 2.4.1) as the search engine using Protein specific 
database (HisTag-HSF1) and IPI-Human (ipi.HUMAN.v3.87) database. 
 
 
2.16   Generation of HSF1-knockout HeLa cell line 
The CRISPR/Cas 9 technology was used in order to knockout endogenous HSF1 
in the HeLa cells. The cells were transfected with the either the plasmid 
pLentiCRISPRv2, which contains sequences coding for Cas9, puromycin 
resistance or the pLentiCRISPRv2_HSF1, which contains sequences coding for 
Cas9, puromycin resistance, as well as the guideRNA (gRNA) sequence 5’-
GTCCGGGTCGCTCACGA-3’, which targets the region within the 1st exon at the 
32nd amino acid region (at the translation level). The primers that were used to 
insert the HSF1 exon1 targeting gRNA into the pLentiCRISPRv2 plasmid were 
5’-CCT ATT CCC TCC TTG CTC GAG ATG G-3’ (forward) and 5’-CCG ATG TCC 
TCT GGG GCA TAG-3’ (reverse).  
HeLa cells (2 x 105) were plated in each well of a 6-well plate as transfected with 
1.5 μg of plasmid and 4 μl of Lipofectamine 2000 complex. Twenty-four h after 
transfection, cells containing the pLentiCRISPRv2 or pLentiCRISPRv2_HSF1 
were treated with 1 μg/ml of puromycin for a further 48 h. WT HeLa cells 
comprises of the pooled population of the surviving cells transfected with 
pLentiCRISPRv2 and treated with puromycin. The surviving cells containing the 
plasmid pLentiCRISPRv2_HSF1 that were puromycin resistant were replated into 
96-well plates using the concentration of 1 cell/well that was achieved using serial 
dilution. The 96-well plates containing the single clones in each well were left to 
incubate in the 37oC humidified incubator supplemented with 5% CO2 for a further 
2-3 weeks and were checked frequently.  
The wells containing only one distinct colony were selected for expansion. Six 
colonies were selected to be expanded and were subsequently validated by 
western blotting to ensure that HSF1 was knocked out in these isogenic cell lines. 
Five out of these six colonies were positive for HSF1 knockout. Subsequently, 
the genomic DNA from each isogenic cell line was extracted. Restriction digestion 
PCR was also conducted to test whether the clones were positive for HSF1 
knockout using the forward primer 5’- CAC CGG GTG TCC GGG TCG CTC ACG 
A-3’ and the reverse primer 5’- AAA CTC GTG AGC GAC CCG GAC ACC C-3’. 
A PCR was conducted in each of the lysates to expand the gRNA targeting 
region, gRNA was designed where it targeted a site within Exon1 of HSF1 that 
has a unique restriction digest site, Bst2BI, giving rise to two short (300 bp) 
fragments. In the event the restriction site was lost, the PCR product would not 
be able to be cut by this enzyme, further confirming that the 
pLentiCRISPRv2_HSF1 transfection led to the editing of the endogenous HSF1 
DNA sequence to produce a HSF1 mRNA that is unable to be translated into the 
HSF1 protein. Unfortunately, human HSF1 exon1 region is highly GC-rich, hence, 
we were not able to amplify this region even though we used different methods 
and conditions to optimise the PCR. 
 
2.17   Cell viability assay 
Wild-type HeLa and HSF1-KO HeLa cells were seeded at a cell density of 5 x 103 
cells per well of a clear and flat-bottomed 96-well plate (Corning). The cells were 
treated with 0.1% ACN (vehicle control) and varying concentrations of PEITC for 
48 h. Four h before the 48 h treatments, the alamar blue dye (AbdSerotec) was 
added to the wells. The amount of alamar blue dye that was added is 10% of the 
total volume of mediawithin each well (100 µl). Therefore, in this experiment, 10 
µl of alamar blue (AB) was added to each well. In the same plate, 100 µl of media 
was added to six empty wells (wells that do not contain any cells); these wells 
served as the blank for the experiment. Ten µl of AB was added to each of the 
blank wells, and the plates are then returned to the humidified 37oC incubator 
and kept for a further 4 hours after which. The plates were collected from the 
incubator and read using the plate reader (SpectraMax M2, Molecular Deivces) 
where the fluorescence in each well of the 96-well plate was measured with 
excitation wavelength of 560nm and emission of 590nm. The relative 
fluorescence units (RFU). The RFU values obtained for each of the treatments 
were averaged and subtracted for RFUbackground values and plotted. The values 
obtained were directly proportional to the number of viable cells and were 
represented as a percentage relative to the vehicle- treated cells, which served 
as the control. 
 
2.18   Mitotic wash-off 
U20S or HeLa cells were grown to a confluency of 70-80% in three 15 cm dishes 
where they were treated with 1.46 or 0.73 μM taxol, respectively. Following 14-
16 h (for U2OS cells) or 12 h (for HeLa cells) of taxol treatment, the dishes were 
visualized under the microscope to ensure that the taxol treatment caused cells 
undergoing mitosis to be arrested. Mitotic cells appear rounded and are relatively 
less attached to the dishes compared to interphase cells exposed to taxol. The 
mitotic cells were “washed-off’ the dish by gentle pipetting with the media 
containing the taxol which they were growing in, and were transferred to a 50 ml 
tube. This step was repeated once more with PBS, and the remaining mitotic cells 
are washed off and transferred to the same 50 ml tube. The tubes containing the 
mitotic cells were subjected to centrifugation at 1000 rpm for 5 mins. The pellet 
obtained was resuspended in PBS and centrifuged once more. Subsequently, 
the supernatant was removed and the cells were lysed with the SDS-lysis buffer. 
The remaining cells on the 15 cm dish represent interphase cells which had been 
exposed to taxol and were washed twice with PBS and subjected to lysis using 
SDS-lysis buffer. The protein concentrations are measured in the lysates, which 
were used for western blotting. 
 
2.19   Immunofluorescence 
2.5x105 U2OS cells (2.5x105) were seeded on 18mm by 18mm glass coverslips 
with a 1.5 thickness (VWR) placed in each well of a 6-well plate. Twenty to 24 h 
later the cells were washed thrice with 37oC pre-warmed PBS and fixed with pre-
warmed 3.7% paraformaldehyde in PBS at 37oC for 15 min in order to preserve 
the cytoskeletal structure of the cells. The cells were permeabilised by washing 
them with 0.1% Triton X-100 in PBS (PBS-Tx) for a further 15 min. During all the 
fixation steps extra caution was taken so as so prevent the mitotic cells from being 
dislodged. Next, the cells were placed in blocking solution (3% normal donkey 
serum in PBS-Tx) for 30 min at room temperature (RT) after which they were 
incubated with mouse anti-total HSF1 (1:200) (E-4, Santa Cruz) or mouse anti-a-
tubulin (1:10000) (DM1A, CST) and rabbit anti-HSF1 pS326 (1:200) (abcam, 
EP1713Y) antibodies diluted in the blocking solution for 1 – 1.5 h at RT. The cells 
were subjected to three washes every 5 min using PBS-Tx. Next, the cells were 
incubated with Alexa Flour 594 nM fluorophore-conjugated anti-rabbit (1:400) and 
Alexa Fluor 680 nM fluorophore-conjugated anti-mouse (1:400) secondary 
antibodies (Jackson Immunoresearch) diluted in the blocking solution for 1 h at 
kept protected from light. Next, the cells were washed three times every 5 min 
using PBS-Tx and were washed for a further 5 min with PBS. The cells were 
incubated with DAPI dissolved in PBS at a final concentration of 2.5 µg/ml for 5 
min at RT in the dark. The cells were quickly washed thrice with PBS and were 
subsequently mounted onto frosted glass slides (VWR) using 30 µl of ProLong 
gold anti-fade mounting medium (Invitrogen) and let to cure overnight at RT. The 
following day the samples were analysed and imaged using the confocal 
microscope (Zeiss LSM 710) (as a single optical section) or the widefield 
microscope (Deltavision Elite, GE Healthcare) (maximum intensity projection of 
25 optical sections obtained with 0.2 µm thickness per section). 
 
2.20   Generation of stable Keap1-knockout Keap1-rescued cell lines 
Immortalized KEAP1-knockout (KKO) mouse embryonic fibroblasts (MEFs) were 
grown in with DMEM (Wako Chemical) with 9% fetal bovine serum (FBS). The 
PiggyBac transposon system was purchased from System Biosciences Inc. 
(California, USA) was utilized in KKO MEFs to generate stable cell lines 
expressing HA-tagged mouse Keap1 (HA-Keap1) by incorporating the cDNA 
encoding its protein sequence. KKO- MEFs were co-transfected with the 
PiggyBac expression vector and the plasmid encoding the transposase using 
electroporation pulsed with 100V for 30 ms. Fourty eight hours to 72 h post-
transfection, the KKO-MEFs were selected with 2 mg/ml of puromycin for 1 week 
up to 10 days. The red fluorescent protein (RFP) expression was used as a 
marker for HA-KEAP cDNA incorporation and single colonies were isolated. The 
single colonies that were isolated were expanded and determined for the relative 
protein expression of endogenous NRF2 as well as HA-KEAP1 levels by western 
blotting. The generation of individual stable KKO-MEFs cell lines expressing HA-
KEAP1 (wild-type, single mutant C151S, double mutant C273W/C288E or triple 
mutant C151S/C273W/C288E) was performed by Dr. Ryota Saito in Professor 
Masayuki Yamamoto’s lab at the University of Tohoku in Sendai, Japan. 
 
2.21   Generation of Keap1 knock-in mice 
The KEAP1C151S/C151S knock-in mice were generated in Professor Masayuki 
Yamamoto’s lab at the University of Tohoku in Sendai, Japan following the 
detailed protocol described in the publication by Wang and colleagues (Wang et 
al., 2013b) and is also briefly explained in Saito et. al (Saito et al., 2015). In short, 
KEAP1C151S/C151S knock-in mice were generated using the CRISPR/Cas9 
technology where B6D2F1 (C57B6 x DBA2) superovulating female mice were 
mated with B6D2F1 stud males and fertilized embryos were collected. A cocktail 
of Guide RNA (gRNA), Cas9 mRNA and the donor oligonucleotide were injected 
into the cytoplasm of fertilized embryos were injected into the pronuclei stage 
zygotes which were maintained with KSOM mouse embryo media placed in a 
37oC humidified incubator with 5% CO2 in the air until they reached the blastocyst 
stage which occurred at 3 and a half days. Subsequently, 15 to 25 blastocysts 
were implanted into pseudopregnant B6D2F1 female mice. The mice containing 
the mutations on both alleles were crossed with wild-type C57B6 mice to produce 
heterozygote mice. Mice which were confirmed heterozygotes, were crossed to 
produce the homozygote KEAP1C151S/C151S mice. The KEAP C151S/C151S mice used 
at the time of the experiments were maintained for at most two generations by 
crossing with the wild-type C57B6 mice.  Genotyping of mice were performed 
using real-time PCR (Taqman) to determine whether the mice carried the 
mutations. The oligos and gRNA sequences are provided upon request. The wild-
type mice used in all the experiments were of C57B6 background. 
2.22   Peritoneal macrophage isolation 
Wild-type or KEAP C151S/C151S mice were injected with 3 ml of 4% thioglycolate 
solution into their intraperitoneal cavity. 4 days after injection, the peritoneal 
macrophages (PMφ) were extracted by carefully injecting to the peritoneal cavity 
and extracting the fluid containing the PMφ. The PMφ were immediately kept on 
ice and suspended in ice-cold PBS and RPMI without serum and centrifuged 
twice for 3 min at 1000 rpm. Next, the PMφ cells were resuspended in RPMI 1640 
medium supplemented with 10 % FBS, counted, plated in 6-well plates with 1x106 
cells per well and placed in a 37oC humidified incubator with 5% CO2 in air. Within 
4 h, the PMφ adheres to the plates and cells were washed twice with PBS before 
proceeding with further experiments. This procedure is also briefly explained in 
Saito et. al (Saito et. al, 2015). 
 
2.23  In-cell western (ICW) 
MCF7 cells (1 x 104) were seeded in each well of a 96-well plate, and 16 h after 
seeding, the cells were pre-treated with either the vehicle (0.1% DMSO) or the 
kinase inhibitors (Aloisine, BIRB796, CDK9I, SB202190 or ZM336372) dissolved 
in conditioned media for 1 h. Subsequently, the cells were treated with either the 
vehicle or 20 μM PEITC dissolved in conditioned media for a further 3 h, after 
which the cells were briefly washed thrice with PBS and fixed with ice-cold (-
20oC) methanol for 10 mins in -20oC. Following methanol fixation, the fixed cells 
were washed three times every 5 mins in PBS, where the last wash was 
performed with PBS-T [0.1% (v/v) Tween 20 in PBS]. Next, the cells were blocked 
with 5% PBST-milk [0.1% (v/v) Tween 20, 5% (w/v) milk in PBS] for 1 h at RT. 
Next, the fixed cells were incubated with HSF1 pS326 primary antibody diluted 
1:500 in PBST-milk for 2 h at RT. Following primary antibody incubation, the cells 
were washed thrice every 10 mins with PBST and were incubated with secondary 
goat anti-rabbit IRDye 680 nm (LiCOR) antibody diluted 1:800 in PBST-milk for 1 
h at RT in the dark. The secondary antibody was removed by washing three times 
with 10 min intervals. Subsequently, the 96-well plate was scanned and 
quantified using the LI-COR® Odyssey® Infrared Imaging system. The 
background values were obtained from wells which contained cells that were not 
incubated with primary antibody, but were only incubated with the secondary 
antibody. Background values were subtracted for the quantification of the signal. 
 
2.24   Statistical analysis 
Values are means ± 1 SD. The differences between groups were determined by 
Student’s t-test and one-way ANOVA and the analyses were performed using 
Excel (Microsoft Corp.) and GraphPad Prism 7. 
Section 3: Results, Discussion and Conclusions 
Chapter 1 
Cyanoenone class of compounds are sensed by a specific 
cysteine residue in KEAP1 
 
3.1.1  Introduction 
 
As, described in Chapter A of Section 1, the KEAP1/NRF2/ARE pathway 
is at the forefront of cellular defense. Induction of this pathway is protective 
against various conditions of stress.  Conversely, failure to upregulate the 
pathway leads to increased susceptibility and accelerated disease pathogenesis. 
Under basal conditions, transcription factor NRF2 is targeted for ubiquitination 
and proteasomal degradation by a repressor protein KEAP1, a substrate adaptor 
for Cullin 3-based E3 ubiquitin ligase (CUL3) (Fig. A2). Inducers of the pathway 
chemically modify specific cysteines within KEAP1, leading to loss of repressor 
function, NRF2 accumulation and enhanced transcription of genes encoding a 
large network of cytoprotective proteins. 
 
Plant triterpenoids are secondary metabolites that are synthesized by the 
cyclization of 2,3-oxidosqualene and the mevalonate pathway. Oleanolic acid 
(3b-hydroxyolean-12-en-28-oic acid) (OA), a pentacyclic triterpenoid found in 
various plant species, is enriched in the Oleaceae family, especially the olive 
plant (Olea europaea) which it was named after (Castellano et al., 2013, Liu, 
1995). Exciting ROS-scavenging (Wang et al., 2010), NRF2-activating (Feng et 
al., 2011, Reisman et al., 2009, Wang et al., 2010), anti-inflammatory 
(Dharmappa et al., 2009, Singh et al., 1992, Cordova et al., 2014, Kim et al., 
2014), anti-diabetic (Mukundwa et al., 2016, Wang et al., 2015), chemoprotective 
(George et al., 2012, Janakiram et al., 2008), hepatoprotective (Kim et al., 2004, 
Liu et al., 2013, Lu et al., 2014, Liu et al., 1995), neuroprotective (Sarkar et al., 
2014, Mabandla et al., 2015, Caltana et al., 2014) as well as microbicidal (Jesus 
et al., 2015, Jimenez-Arellanes et al., 2013) properties of OA have emerged 
making it a promising compound for therapeutic use. On the other hand, poor 
water solubility and high metabolic clearance of OA limits its bioavailability in the 
body.  
 
Although efforts have been made to improve the bioavailibity of OA, it was 
the chemical synthesis and biological analyses of its semi-synthetic derivatives 
that led to major leaps towards its potential use in clinical medicine. In particular, 
introduction of a cyanoenone group within the structure of the semi-synthetic 
pentacyclic OA derivative CDDO (2-cyano-3,12-dioxooleana-1, 9(11)-dien-28-oic 
acid) conferred potent NRF2-antioxidant response inducing and anti-
inflammatory activities at low nanomolar concentrations, and the methyl ester 
analog of CDDO (CDDO-Me, also known as Bardoxolone methyl) significantly 
improved the estimated glomerular filtration rate of type II diabetic patients 
(T2DB) with severe chronic kidney disease (CKD) in Phase 2B placebo-
controlled clinical trials (Clinicaltrials.gov). CDDO-Me progressed to Phase 3 
clinical trials (BEACON study) to treat stage 4 CKD patients with T2DB, however, 
the trial was terminated one year later due to the escalation in the number of 
heart-related adverse events such as cardiovascular-related hospitalizations and 
deaths in the drug-treated group (Clinicaltrials.gov). To find an explanation for the 
possible reasons for adverse cardiovascular events, further analyses on the 
primary outcome of this trial showed that CDDO-Me affected the endothelin 
pathway, increased sodium and fluid retention and elevated blood pressure (Chin 
et al., 2014). Apart from the adverse effects of CDDO-Me reported from these 
studies, one should appreciate the progress made towards the implementation 
of CDDO-Me in clinical medicine, which also highlights the need for synthesizing 
and testing new derivative compounds of oleanolic acid to improve the safety 
profile of the drug whilst retaining its powerful medicinal properties.  
 
The cyanoenones, such as CDDO-Me, are the most potent NRF2 
activators known. Cyanoenones bind to KEAP1 covalently and reversibly, and 
are suitable for chronic in vivo administration. However, the cysteine sensor for 
these compounds has not been established. Among the cysteine sensors of 
KEAP1, C151 in the BTB domain and C273 and C288 in the intervening region, 
are best characterized. In this study using KEAP1-knockout mouse embryonic 
fibroblasts (MEFs) rescued with wild-type (WT) or cysteine mutants of KEAP1, 
we tested a series of cyanoenones, and identified C151 as their main cysteine 
sensor. 
 
  
3.1.2  RTA-408 
 
The pentacyclic cyanoenone RTA-408 [N-(11-cyano-2,2,6a,6b,9,9,12a-
heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-
hexadecahydro-2H-picen-4a-yl)-2-2-difluoro-propionamide, omaveloxolone] 
(Fig. 1.1A) is a semi-synthetic oleanane triterpenoid produced by Reata 
Pharmaceuticals (Irving, TX) (Reisman et al., 2014). The nonenolizable 
cyanonoenone in ring A of RTA-408 is a Michael acceptor which reacts readily 
with the sulfhydryl groups of cysteine moieties on proteins, particularly the 
substrate adaptor protein KEAP1, causing loss of its function and activation of 
transcription factor NRF2. RTA-408 is a potent NRF2 activator with a CD value 
(Concentration that Doubles the specific enzyme activity of the NRF2-target 
NQO1) of 2.5 nM in murine Hepa1c1c7 cells (Maureen Higgins, unpublished). 
 
Topical application of RTA-408 has been found to protect mice from 
dermatitis caused by exposure to ionizing radiation by activating the NRF2-
mediated antioxidant response and also by inhibiting the pro-inflammatory 
transcription factor nuclear factor-kappa b (NF-κB) mediated pathways (Reisman 
et al., 2014). In this study by Reisman and colleagues, RTA-408 lotion (at doses 
of 0.01%, 0.1% or 1%) was topically applied once daily on the skin of irradiated 
mice for 35 days, and at the end of the study, the researchers saw striking 
improvements in the appearance of the skin, which occurred in a dose-dependent 
manner. They also found that the group of mice treated with the highest 
concentration of RTA-408 did not present with dermal necrosis and had 
completely healed skin ulcers and hair regrowth (Reisman et al., 2014).  
RTA-408 has also been shown to confer cytoprotection in the small 
intestine of mice exposed to lethal doses of radiation by promoting the survival of 
crypt cells (Alexeev et al., 2014). Additionally, in the same study, the authors 
found that RTA-408 selectively inhibited the growth of prostate cancer xenografts 
in mice whilst leaving the growth and survival of normal tissues unaffected 
(Alexeev et al., 2014) highlighting the potential for use in chemoradiation 
therapies.  
 
Oxidative stress-induced injury in retinal pigment epithelial (RPE) cells has 
been implicated in the disease pathogenesis of age-related macular 
degeneration (AMD) (Lu et al., 2006). Liu et al. have shown that pre-treatment of 
RPE cells with RTA-408 protected them from hydrogen peroxide (H2O2)-induced 
oxidative stress through the activation of NRF2-antioxidant response pathway 
(Liu et al., 2015).  
 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease which affects 1-2% of the human population (Pickrell and Youle, 2015). 
There is no known cure for PD and the only available treatment options provide 
symptomatic relief with no amelioration of the disease progression. Mitochondrial 
dysfunction has been associated with PD pathogenesis and mitochondrial quality 
control is vital for disease progression. Mutations in the mitochondrial 
serine/threonine PTEN-induced putative kinase 1 (PINK1) have been implicated 
in hereditary juvenile PD. PINK1 accumulates on the outer membrane of 
dysfunctional mitochondria and activates Parkin, an E3 ubiquitin ligase, by 
phosphorylating it. PINK1-activated Parkin ubiquitinates the damaged 
mitochondria and targets them for mitophagy (Geisler et al., 2010, Narendra et 
al., 2008). In PD, mutations in PINK1, prevents the recruitment of Parkin to the 
damaged mitochondria, hence, the cell is unable to degrade the dysfunctional 
mitochondria. In primary co-cultures of midbrain neurons and astrocytes of PINK1 
knockout mice or NRF2 knockout mice which usually exhibit mitochondrial 
dysfunction, Dinkova-Kostova et al. showed that RTA-408 treatment reinstated 
the mitochondrial membrane potential (Dinkova-Kostova et al., 2015). They also 
showed that NRF2 activation by RTA-408 ameliorated dopamine-induced 
neurotoxicity in the primary co-cultures (Dinkova-Kostova et al., 2015). This study 
highlights the potential of RTA-408 as a drug that could be used to treat patients 
with PD to prevent disease progression.  
 
More recently, in a Phase 1 clinical trial (https://clinicaltrials.gov/ct2/show/ 
NCT02029716), in one group, RTA-408 lotion (0.5%, 1% and 3%) was applied 
twice daily on healthy human volunteers (male and female) aged 18-65 years old 
(Reisman et al., 2015) for two weeks on 4 cm2 sites. In another group, 3% RTA-
408 lotion was applied twice daily to 100 cm2 sites or 500 cm2 sites for two weeks 
and four weeks respectively (Reisman et al., 2015). At the end of the human 
study, it was established that application of RTA-408 lotion was well-tolerated at 
the highest concentration with the highest surface area and longest duration and 
that skin biopsies from these healthy volunteers showed upregulation of NQO1, 
a prototypical marker of NRF2 activation (Reisman et al., 2015).  
 
Thus far, RTA-408 has been investigated in five Phase I clinical trials 
(Clinicaltrials.gov), including patients with advanced solid tumours, ocular 
inflammation and pain, and risk of radiation-induced dermatitis. Currently, three 
new clinical trials involving treatment with RTA-408 capsules are recruiting 
patients with either advanced melanoma, mitochondrial myophathy or Friedrich’s 
Ataxia (Clinicaltrials.gov). 
 
3.1.2.1 KEAP1 cysteine 151 is a sensor for RTA-408 in vitro and ex 
vivo 
 
As mentioned earlier, there is a growing pool of evidence that RTA-408 is 
a well-tolerated drug in animals and human that has beneficial effects in various 
disease models such as cancer, neurodegeneration and inflammation through its 
potent NRF2-activating capability and anti-inflammatory properties. The cysteine 
sensor(s) of KEAP1 which is modified by RTA-408 to activate NRF2, to our 
knowledge, is unknown. Since RTA-408 is being used in several clinical trials, it 
is vital to understand the underlying molecular mechanism by which it 
upregulates NRF2. Therefore, we sought to identify the cysteine residue(s) of 
KEAP1 that is the sensor of RTA-408 to allow for accumulation of NRF2 by using 
KEAP1 knockout (KKO) mouse embryonic fibroblast (MEF) cells rescued with N-
terminally HA tagged mouse WT KEAP1 or cysteine mutants (C151S, 
C273E/C288W and C151S/C273W/C288W) of KEAP1. Fig. 1.1B clearly shows 
that upon a 3-h exposure to 25 or 50 nM RTA-408, NRF2 is stabilized in the WT 
and in the double mutant C273W/C288E KEAP1-rescued KKO MEFs (WT-KKO 
MEFs and C273W/C288E-KKO MEFs respectively). Contrastingly, in the single 
mutant C151S KEAP1-rescued KKO MEFs (C151S-KKO MEFs) and the triple 
mutant C151S/C273W/C288W KEAP1-rescued KKO MEFs 
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Figure 1.1. KEAP1 C151 is the primary sensor for RTA-408. A) The chemical structure of RTA-408. B)
Western blot analyses of total cell lysates of KEAP1-knockout MEFs rescued with either wild-type (WT), single
cysteine mutant C151S, double cysteine mutant C273W/C288E or triple cysteine mutant C151S/C273W/C288E
of mouse N-terminally tagged HA-KEAP1. Cells were exposed to vehicle (0.1% DMSO) or varying concentrations
of RTA-408 for 3 h after which the cells were lysed. Immunoblotting was performed on cell lysates using NRF2,
HA and α-tubulin antibodies. C) Western blot analysis performed on total cell lysates of primary (WT) or
KeapC151S/C151S mouse peritoneal macrophages that were treated with vehicle (0.1% DMSO) or varying
concentrations of RTA-408 for 3 h. NRF2, KEAP1 and alpha-α-tubulin antibodies were used for detection. The
data in this figure are representative of two independent experiments.
(C151S/C273W/C288W-KKO MEFs), these concentrations of RTA-408 are 
unable to cause the accumulation of NRF2 (Fig. 1.1B). Exposure to 15 or 30 nM 
RTA-408 of primary peritoneal macrophage (PMφ) cells isolated from wild-type 
C57B or from C57B/BDF1 KEAP1C151S/C151S knock-in mice generated using the 
CRISPR/Cas9 technology (Fig. 1.1C) also shows that NRF2 upregulation, at 
these concentrations, only occurs in the WT PMφ cells, but not in the 
KEAP1C151S/C151S PMφ cells. Taken together, these results establish that KEAP1 
C151 is the primary sensor for RTA-408. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.3  TBE-31 
 
The acetylinic tricyclic bis(cyanoenone) (±)-(4bS,8aR,10aS)-10a-ethynyl-
4b,8,8-trimethyl-3,7-dioxo-3.4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-
dicarbonitrile (TBE-31, Fig. 1.2A) is known to be one of the most potent inducers 
of the KEAP1/NRF2/ARE pathway (Kostov et al., 2015, Honda et al., 2011, Liby 
et al., 2008), with a CD value of 0.9 nM in the murine hepatoma Hepa1c1c7 cells 
(Zheng et al., 2012). TBE-31 is highly reactive with sulfhydryl groups as it 
contains two activated Michael acceptors found within the rings A and C (Fig. 
1.2A) rendering it relatively more potent than most of the compounds in the 
cyanoenone group. Like RTA-408, TBE-31 has been shown to target KEAP1, 
hence allowing for activation of the NRF2-mediated antioxidant response. In vitro, 
TBE-31 binds reversibly to KEAP1 cysteines (Dinkova-Kostova et al. 2010) 
(Kostov et al., 2015). In various cellular systems and in mice, at low nanomolar 
concentrations, TBE-31 is able to activate the NRF2-mediated antioxidant 
response as well as inhibit pro-inflammatory pathways (Liby et al. 2008; Dinkova-
Kostova et al. 2010; Kostov et al. 2015; Knatko et al. 2015). It has been reported 
that 1 nM of TBE-31 is sufficient to suppress nitric oxide (NO) production induced 
by exposure to interferon gamma (IFNƔ) in RAW 264.7 cells (Zheng et al., 2012). 
In 2008, Liby and colleagues showed that exposure of TBE-31 in leukemia 
cells prevents cell proliferation and causes apoptotic cell death (Liby et al., 2008). 
They also found that oral administration of TBE-31 in rats protected them from 
aflatoxin-induced hepatocarcinogenesis by reducing the formation of DNA-
aflatoxin adducts as well as the size and number of preneoplastic hepatocellular 
lesions (Liby et al., 2008) and suggested that this effect was mediated through 
the activation of the transcription factor NRF2 and the inhibition of pro-
inflammatory pathways. Importantly, it was this study that introduced the potential 
use of TBE-31 in cancer treatment as a chemotherapeutic and chemopreventive 
agent. 
Solid organ transplant patients have a 65-250 times higher risk of 
developing cutaneous squamous cell carcinoma (cSCC) compared to the normal 
healthy population (Jensen et al., 2000, Hartevelt et al., 1990) mainly due to the 
treatment with immunosuppressive agents (Jiyad et al., 2016).  Azathioprine, a 
purine antimetabolite, is a strong immunosuppressant and is often part of chronic 
life-long treatment of patients who have undergone solid organ transplant. 
Azathioprine increases skin photosensitivity to ultraviolet radiation and causes 
the incorporation of 6-thioguanine (6-TG) nucleotide in DNA of skin cells; upon 
exposure to ultraviolet radiation, 6-TG incorporated in DNA causes the production 
of reactive oxygen species (ROS), leading to oxidative stress and subsequent 
damage to DNA and DNA repair proteins, ultimately increasing the risk of 
developing cSCC (Zhang et al., 2007, Karran, 2006, Kalra et al., 2012). Since 
TBE-31 is a potent inducer of the KEAP1/NRF2/ARE pathway and a robust 
inhibitor of pro-inflammatory responses, in our lab, Kalra et al. investigated the 
effect of using TBE-31 to prevent the abovementioned effects of azathioprine 
treatment. It was found that at low nanomolar concentrations, TBE-31 protected 
cells containing 6-TG in their DNA against UVA-induced oxidative stress (Kalra 
et al., 2012). They also found that topical daily treatment of TBE-31 to the skin 
reduced the incorporation of 6-TG in mice treated with azathioprine. In a follow-
up study, our lab found that compared to WT SKH-1 hairless mice, the incidence, 
multiplicity and tumour burden of cutaneous tumors formed after chronic 
exposure to solar-simulated UV radiation was much lower in KEAP1-knockdown 
mice where the basal levels of NRF2 are higher and the latter is also constitutively 
activated (Knatko et al., 2015). Also, a study recently conducted and completed 
in our lab (Knatko et al. 2016) has shown that in NRF2 knockout / KEAP1 
knockdown SKH-1 mice, the tumour incidence, multiplicity and burden after 
exposure to solar-simulated UV radiation were comparable to their WT 
counterparts, strongly signifying that NRF2 activation is the primary factor for 
maintaining a chemopreventive phenotype. Our lab has also found that genetic 
or TBE-31-mediated activation of NRF2 reduced the pro-inflammatory responses 
in the skin of mice irradiated with UV. In addition, TBE-31 treatment was well 
tolerated by the mice in both studies. Furthermore, recently, it was discovered 
that at concentrations in the sub-micromolar range, TBE-31 inhibits non-small cell 
lung cancer (NSCLC) cell migration and epithelial mesenchymal transition (EMT) 
by inhibiting TGF-β dependent actin stress fiber formation and also directly 
binding to actin, inhibiting its polymerization (Chan et al., 2016), highlighting the 
potential use of TBE-31 in metastatic cancers.  
Taken together, these findings raise the potential for TBE-31 to be used 
for the treatment of patients suffering from cancer, chronic inflammatory and 
immunosuppresion-related diseases. Like RTA-408, although TBE-31 has been 
well-studied in the past eight years, the cysteine sensor in KEAP1 for TBE-31 
has not been characterized. Discovering the mechanism by which TBE-31 
activates NRF2 through chemical modification of KEAP1 would allow scientists 
to understand the molecular basis of its cytoprotective effects and potentially 
advance the use of TBE-31 in human studies. 
3.A.3.1 KEAP1 cysteine 151 is the primary sensor for TBE-31 in vitro 
and ex vivo 
 
KKO MEF cells stably expressing WT KEAP1 or several cysteine mutants 
were exposed to low nanomolar concentrations of TBE-31 for 3 h. In the WT-
KKO and in the double cysteine mutant C273W/C288E-KKO MEFs, NRF2 
accumulated upon treatment with 10 or 50 nM of TBE-31; however, under the 
same conditions, NRF2 did not accumulate in KKO MEFS harboring the single 
KEAP1 mutant C151S or the triple mutant C151S/C273W/C288E (Fig 1.2B and 
1.2C). These results suggest that KEAP1 C151 is the primary sensor for TBE-
31-mediated NRF2 upregulation. We also exposed primary WT PMφ and 
KEAP1C151S/C151S PMφ cells to 15, 30, 60 and 120 nM of TBE-31 for 3 h (Fig. 
1.2D). In the primary WT PMφ cells, NRF2 accumulation was observed at all of 
the tested concentrations of TBE-31, whereas, in the primary KEAP1C151S/C151S 
PMφ cells NRF2 was unable to accumulate when exposed to lower 
concentrations (15, 30 or 60 nM) of TBE-31 (Fig. 1.2D). However, 120 nM TBE-
31 (the highest concentration used) was able to cause upregulation of NRF2 in 
both the primary WT and KEAP1C151S/C151S PMφ cells. This could be due to the 
fact that the basal levels of KEAP1 proteins in the cells are kept very low, and 
increasing the concentration of a highly sulfhydryl reactive electrophile like TBE-
31 would have saturated the modifications at KEAP1 C151 and the remaining 
freely available TBE-31 is allowed to target other reactive cysteines within 
KEAP1. Collectively, the results from Fig. 1.2B-D indicate that KEAP1 C151 is 
the primary sensor for TBE-31. 
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Figure 1.2. KEAP1 C151 is the primary sensor for TBE-31. A) The chemical structure of TBE-31 and its reaction
with sulfhydryl groups. B and C) Western blot analyses of total cell lysates of KEAP1-knockout MEFs rescued with
either wild-type (WT), single cysteine mutant C151S, double cysteine mutant C273W/C288E or triple cysteine mutant
C151S/C273W/C288E of mouse N-terminally tagged HA-KEAP1. Cells were exposed to vehicle (0.1% DMSO) or
varying concentrations of TBE-31 for 3 h after which the cells were lysed. Immunoblotting was performed on cell
lysates using NRF2, HA and α-tubulin antibodies. D) Western blot analysis performed on total cell lysates of primary
(WT) or KeapC151S/C151S mouse peritoneal macrophages that were treated with vehicle (0.1% DMSO) or varying
concentrations of TBE-31 for 3 h. NRF2, KEAP1 and α-tubulin antibodies were used for detection. The data in this
figure are representative of three independent experiments.
3.A.3.2  TBE-31 is a potent anti-inflammatory agent 
 
Lipopolysaccharide (LPS) is a major component of the outer membrane of 
Gram-negative bacteria. Exposure of macrophages to LPS initiates toll-like 
receptor 4 (TLR4), CD14 and myeloid differentiation protein-2 (MD-2) to activate 
a battery of pro-inflammatory responses which results in the production of 
inflammatory cytokines such as tumour necrosis factor alpha (TNFα) (Fang et al., 
2004, Fujihara et al., 2003). To investigate whether TBE-31, like other 
compounds in the cyanoenone class such as CDDO-Me and RTA-408, has the 
ability to repress inflammatory responses, we pretreated primary murine PMφ 
cells with 10 nM TBE-31 for 24 h, exposed the cells to LPS for a further 4 h, and 
used real-time PCR to evaluate the effect of TBE-31 on LPS-induced pro-
inflammatory genes (Fig. 1.3B-F). First, we analyzed the transcript levels of the 
prototypic NRF2 target gene NQO1 to assess the degree of activation of NRF2 
by TBE-31. From Fig. 1.3A, it is evident that there was a significant induction of 
NQO1 (14-17 fold) in the primary WT PMφ cells that were exposed to 10 nM TBE-
31 for 24 h compared to the vehicle-treated cells. LPS treatment in the vehicle-
treated primary PMφ cells resulted in the gene expression of the cytokines 
interleukin1-β (IL-1β), interleukin-6 (IL-6), TNFα as well as cyclooxygenase 2 
(COX2) and inducible nitric oxide synthase (iNOS). The LPS-induced 
inflammatory gene expression levels of IL-1 β, IL-6, TNFα and iNOS were 
significantly reduced by 30-60 % with pretreatment of TBE-31 for 24 hours 
indicating that TBE-31 acts as a powerful anti-inflammatory agent (Fig. 1.3B-D 
and 1.3F). 
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FIGURE 1.3
Figure 1.3. TBE-31 suppresses LPS-induced inflammation in WT mouse peritoneal macrophage cells.
WT mouse peritoneal macrophages were treated with vehicle (0.1% DMSO) or 10 nM TBE-31 for 24 h and
subsequently stimulated with 10 ng/ml of LPS for 4 h. A-F) Quantitative real-time PCR analyses showing
relative mRNA levels of the NRF2 target gene NQO1 (A) and a panel of pro-inflammatory mediators and
cytokines, namely, IL-1β (B), IL-6 (C), TNF-α (D), COX-2 (E) and iNOS (F). Statistical analyses were
performed using one-way ANOVA with the Tukey-Kramer post-test; *, ** and *** represent p values lower than
0.05, 0.001 and 0.0001, respectively for triplicate wells. This experiment was conducted once..
3.A.3.3 TBE-31-mediated suppression of inflammation is potentially 
dependent on KEAP1 C151 
 
To investigate whether TBE-31-mediated suppression of inflammation 
was dependent on KEAP1 C151, we obtained primary PMφ cells from WT and 
KEAP1C151S/C151S mice and treated them for 6 h with: (i) vehicle, (ii) vehicle + LPS, 
(iii) 50 nM TBE-31, and (iv) 50 nM TBE-31 + LPS. We used real-time PCR to 
measure the changes in gene expression of a panel of pro-inflammatory gene 
markers as well as the prototypic NRF2 target gene NQO1. In the primary WT 
PMφ cells NQO1 is robustly upregulated (~10 fold) with the treatment of TBE-31, 
compared to a modest two-fold induction in the primary KEAP1C151S/C151S PMφ 
cells (Fig. 4A). In this preliminary experiment, since the cells were co-treated with 
TBE-31 and LPS for 6 h, a robust anti-inflammatory effect by TBE-31 was not 
observed when evaluating the expression at the pro-inflammatory genes (Fig. 
1.4C and 1.4D). However, some of the genes such as IL-1β and TNFα 
displayed reduced expression, by 20-30% in the WT PMφ cells co-treated with 
LPS and TBE-31 compared to WT PMφ cells treated with only LPS. Interestingly, 
when comparing the same conditions in the KEAP1C151S/C151S PMφ cells, there 
was no reduction in expression levels of these genes (Fig. 1.4B and 1.4E). These 
preliminary data suggest that the TBE-31-mediated suppression of inflammation 
is dependent on KEAP1 C151. Due to time-constraints faced in Japan, I was not 
able to repeat this experiment. However, this experiment described in Fig. 1.4 will 
have to be conducted in the PMφ cells derived from both the WT and 
KEAP1C151S/C151S knock-in mice, where a pre-treatment of TBE-31 for 24 hours 
before exposure to LPS will be essential to allow the cells to show a clear effect 
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FIGURE 1.4
Figure 1.4. NRF2 activation of TBE-31 in mouse peritoneal macrophage cells is primarily through
KEAP1 C151. WT or KEAP1C151S/C151S mouse peritoneal macrophages were treated with vehicle (0.1%
DMSO) or 50 nM TBE-31 in combination with the presence or absence of 10 ng/ml of LPS for 6 h. A-E)
Quantitative real-time PCR analyses showing relative mRNA levels of the NRF2 target gene NQO1 (A)
and a panel of pro-inflammatory mediators and cytokines, namely, IL-1β (B), IL-6 (C), TNF-α (D), COX-2
(E). Statistical analyses were performed using one-way ANOVA with the Tukey-Kramer post-test; *, **
and *** represent p values lower than 0.05, 0.001 and 0.0001, respectively for triplicate wells. This
experiment was conducted once.
of TBE-31 as an anti-inflammatory agent and be able to conclude whether this 
protective response observed can be attributed to the presence of C151 on 
KEAP1. 
 
3.1.3.4 KEAP1C151S/C151S knock-in mice are more susceptible to LPS-
induced inflammation than KEAP1 wild-type animals 
 
In the presence of LPS, the gene expression levels of IL-1β, IL-6, TNFα, 
COX2  and iNOS are greatly induced in both genotypes. Interestingly, WT and 
KEAP1C151S/C151S PMφ cells differ greatly in the magnitude of induction of LPS-
induced inflammatory genes compared to their respective vehicle treatments, 
where the relative induction in the KEAP1C151S/C151S is 1.5- to 5-fold greater than 
that of the WT PMφ cells (Fig. 1.5A-E). Although the genetic background of the 
mice are slightly different, as explained in the Methods section, this finding raises 
the interesting possibility that the KEAP1C151S/C151S mice are more susceptible to 
inflammatory responses, and more importantly, that C151 of KEAP1 is mediating 
an anti-inflammatory response through activation of NRF2 thus acting as a 
central endogenous sensor during pro-inflammatory insults.  
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FIGURE 1.5
Figure 1.5. KEAP1C151S/C151S mouse peritoneal macrophages are much more sensitive to LPS-
induced inflammation than their WT counterparts. WT or KEAP1C151S/C151S mouse peritoneal
macrophages were treated with vehicle (0.1% DMSO) or 50 nM TBE-31 in the presence or absence of
10 ng/ml of LPS for 6 h. A-E) Quantitative real-time PCR analyses showing relative mRNA levels of a
panel of pro-inflammatory mediators and cytokines, namely, IL-1β (A), IL-6 (B), COX-2 (C), TNF-α (D),
iNOS (E). This figure is representative of two independent experiments.
3.1.4  MCE-23 
 
The cyanoenone MCE-23 [9a-ethynyl-3-oxo-9,9a-dihydro-3H-fluorene-2-
carbonitrile] (Fig. 6A) is a tricyclic compound similar to TBE-31 (Fig. 1.2A); 
however, the carbonyl and cyanoenone groups are absent from ring A making 
MCE-23 comparatively much less reactive and less potent as an NRF2-inducer 
(CD = 41 nM in Hepa1c1c7 cells). Recently, by use of the crystalline-sponge 
method Duplan et al. have reported the structure of the Michael adduct of MCE-
23 with a small molecule thiol (Duplan et al. 2016). 
 
3.1.4.1 KEAP1 cysteine 151 is the primary sensor for MCE-23 
To determine the cysteine sensor(s) of KEAP1 for MCE-23, KEAP1 KO 
MEFs rescued with either WT or cysteine mutants of KEAP1 were treated with 
150 nM or 300 nM of MCE-23 for 3 hours (Fig. 1.6B). In the WT-KKO and double 
mutant C273/C288-KKO MEFs, NRF2 accumulated in a dose-dependent 
manner. On the other hand, treatment of the single mutant C151S-KKO or the 
triple mutant C151S/C273W/C288E-KKO MEFs, with 150 nM or 300 nM of MCE-
23 failed to upregulate NRF2, indicating that C151 is the primary sensor in KEAP1 
for this compound. Since, MCE-23 contains only one active reactive center, on 
ring C, and is sensed by C151 in KEAP1, this result suggests that ring C in TBE-
31 is most important for its specificity and reactivity with KEAP1 C151. 
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Figure 1.6. KEAP1 C151 is the primary sensor for MCE-23. A) The chemical structure of MCE-23. B)
Western blot analyses of total cell lysates of KEAP1-knockout MEFs rescued with either wild-type (WT),
single cysteine mutant C151S, double cysteine mutant C273W/C288E or triple cysteine mutant
C151S/C273W/C288E of mouse N-terminally tagged HA-KEAP1. Cells were exposed to vehicle (0.1%
DMSO) or varying concentrations of MCE-23 for 3 h after which the cells were lysed. Immunoblotting was
performed on cell lysates using NRF2, HA and α-tubulin antibodies. The data in this figure are
representative of two independent experiments.
3.1.5  MCE-1 
 
The monocyclic cyanoenone MCE-1 (3-ethynyl-3-methyl-6-oxocyclohexa-
1,4-dienecarbonitrile) (Fig. 1.7A) was derived from ring C of TBE-31 (Fig. 1.2A 
and 1.2B). It has been established that MCE-1 is a highly reactive Michael 
acceptor and that its addition to thiols is reversible (Dinkova-Kostova et al. 2010; 
Zheng et al., 2012). Like the other cyanoenones described, MCE-1 is a potent 
NRF2 inducer with a CD value of 22 nM in Hepa1c1c7 cells (Dinkova-Kostova et 
al. 2010), and has a strong anti-inflammatory effect in RAW 264.7 cells and 
primary murine PMφ cells (Zheng et al., 2012). Also, in their studies, Zheng et al. 
found that 5.8 nM of MCE-1 was sufficient to suppress NO production induced by 
exposure to IFNƔ in RAW 264.7 cells. 
 
3.1.5.1 KEAP1 cysteine 151 is the primary sensor for MCE-1 in vitro 
and ex vivo 
 
KKO-MEFs rescued with WT or cysteine mutants of KEAP1 were treated 
with 50 or 150 nM of MCE-1 for 3 h. The treatment of MCE-1 in the WT-KKO-
MEFs as well as in the double mutant C273W/C288E-KKO MEFs caused 
upregulation of NRF2, whereas, this effect was not observed in the single mutant 
C151S-KKO MEFs or in the triple mutant C151S/C273W/C288E-KKO MEFs 
(Fig. 1.7C). Moreover, a 3-h exposure to 12.5 or 25 nM of MCE-1 in WT PMφ 
caused NRF2 accumulation, whilst this effect was not observed in the PMφ 
KEAP1C151S/C151S cells (Fig. 1.7C). These findings confirm that the mechanism of 
NRF2 activation by MCE-1 is mediated through the sensing by KEAP1 C151S. 
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Figure 1.7. KEAP1 C151 is the primary sensor for MCE-1. A) The chemical structure of MCE-1. B) Synthesis
of CDDO (Image taken from http://www.stonybrook.edu/commcms/chemistry/faculty/honda.tadashi.html.)
C) Western blot analyses of total cell lysates of KEAP1-knockout MEFs rescued with either wild-type (WT), single
cysteine mutant C151S, double cysteine mutant C273W/C288E or triple cysteine mutant C151S/C273W/C288E
of mouse N-terminally tagged HA-KEAP1. Cells were exposed to vehicle (0.1% DMSO) or varying concentrations
of MCE-1 for 3 h after which the cells were lysed. Immunoblotting was performed on cell lysates using NRF2, HA
and α-tubulin antibodies. D) Western blot analysis performed on total cell lysates of primary (WT) or
KeapC151S/C151S mouse peritoneal macrophages that were treated with vehicle (0.1% DMSO) or varying
concentrations of MCE-1 for 3 h. NRF2, KEAP1 and α-tubulin antibodies were used for detection. The data in this
figure are representative of two independent experiments.
3.1.6  Conclusions 
 
Activation of the NRF2/KEAP1/ARE pathway is critical for cytoprotection. 
Although this pathway has been studied extensively, there is still much to 
discover. In our study, we have shown that all of the cyanonenone compounds 
tested are able to upregulate NRF2 at low nanomolar concentrations, and are 
specifically sensed by KEAP1 C151. We have also found that TBE-31 has potent 
NRF2-inducing and strong anti-inflammatory properties and these properties 
should be explored further. Another exciting revelation of this study is that 
KEAP1C151/C151S mice peritoneal macrophages are more sensitive to LPS-
induced inflammation, suggesting that C151 is an important endogenous stress 
sensor, and that the absence of this cysteine may be detrimental to the organism 
in the face of infections. 
It is extraordinary that a 5-ringed molecule like RTA-408 can be reduced 
in size to a 3-ringed molecule like TBE-31 or MCE-23, which can be further 
reduced to a single-ringed molecule like MCE-1, and still maintain specificity for 
the same cysteine sensor in KEAP1, C151. This finding implies that preserving 
the reactive cyanoenone center is sufficient to confer specificity, and that 
chemical reactivity (rather than shape or size) is the most important feature of the 
cyanoenone inducers. Recently, Saito and colleagues reported that the 
pentacyclic semisynthetic triterpenoid CDDO-Im (1-[2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oyl]imidazole) (Fig. 1.8A), an imidazolide derivative of CDDO, is 
sensed by KEAP1 C151 (Saito et al., 2015). Strikingly, to further support the 
findings from this and our study, the recently crystallized structure of the human 
KEAP1 BTB domain in complex with CDDO has shown that the reactive 
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Figure 1.8. Structure of CDDO and its complex with KEAP1 BTB domain. A) The chemical structure of
CDDO and its derivatives, CDDO-Me and CDDO-Im B) The crystal structure of human KEAP1 BTB domain
bound to CDDO C) Crystal structure showing C151 of human KEAP1 BTB domain covalently binding to the
CDDO compound. Structure drawn using PyMol using PBD entry 4XCT.
cyanoenone center of CDDO (in Ring A) is the only part of the molecule that binds 
covalently to KEAP1, and that this binding occurs with the C151 residue (Caltana 
et al., 2014).  
 
 
 
 
 
 
 
	
Section 3: Results, Discussion and Conclusions 
Chapter 2 
Heat Shock Factor 1 is a substrate for p38 MAPKs 
 
3.2.1  Phenethyl isothiocyanate (PEITC) 
 
The naturally occurring isothiocyanates are a class of dietary compounds 
which are secondary metabolites found enriched in plants mostly belonging to 
the Cruciferae (also called Brassicaceae) family (e.g. Brussels sprouts, broccoli, 
watercress). In humans, diets rich in cruciferous vegetables are known to be 
protective against neurodegenerative, cardiovascular and cancer-related 
diseases. Numerous reports have indicated that these cruciferous vegetables 
belonging to the Brassica genus have many chemopreventive attributes. 
Nasturtium officinale or watercress, a vegetable that belongs to the Cruciferae 
family, contains a glucosinolate precursor, gluconasturtiin. Phenethyl 
isothiocyanate (PEITC) is an isothiocyanate (ITC) that is derived from the 
modification of gluconasturtiin through the participation of myrosinase (a beta-
thioglucosidase) during plant tissue injury (Fahey et al., 2001). PEITC has been 
shown to have promising anticancer properties where it has been shown to 
prevent human glioblastoma GBM 8401 cell migration and inhibition (Chou et al., 
2015). PEITC inhibited tumourigenesis in Apcmin/+ mice (Khor et al., 2008) and 
also lowered the tumour incidence in azoxymethane-initiated colon cancer in 
mice (Cheung et al., 2010). Interestingly, in a very recent case study, a 53-year-
old man with end-stage B-cell prolymphocytic leukemia (B-LL), a rare and 
aggressive disease which is chemoresistant and has a median survival of three 
years, was treated concurrently with PEITC for 8 weeks with 6 cycles of R-CHOP 
(Rituximab, Cyclophosphamide, Hydroxydaunorubicin [doxorubicin 
hydrochloride], Oncovin [vincristine sulfate], Prednisolone) chemotherapy 
presented with normal white blood cell count and disease stabilization, allowing 
the patient to qualify for allogenic peripheral blood stem cell transplant. During 
the time of publication, 43 months after initial diagnosis and treatment, the patient 
was reported to be doing well with no occurrence of CD20+ small B-cell. The 
authors suggested that PEITC sensitized B-LL cells to chemotherapeutic drugs 
and proposed that PEITC should be used in synergy with other drugs for future 
treatments (Nachat et al., 2016). 
 
One of the potential mechanisms by which PEITC exerts its anti-tumour 
effect is possibly through its well-established ability to upregulate the transcription 
factor Nrf2 by activating the KEAP1/NRF2/ARE pathway. The gluthathione-S-
transferases (GSTs), which are well-established transcriptional targets of Nrf2, 
play vital role in benzene metabolism. A recent publication by Yuan et. al. shows 
that in PEITC administration in smokers null for GSTM1 and GSTT1 exhibited a 
strong protective effect by enhancing benzene detoxification (Yuan et al., 2016). 
Another potential mechanism by which PEITC could mediate cytoprotective 
effects could be due to the upregulation of heat shock proteins. Although there 
have been many publications demonstrating that PEITC, like many 
isothiocyanates, is able to activate the KEAP1/NRF2/ARE pathway, the exact 
mechanism by which it does so is not clear. It has been suggested that PEITC 
and other isothiocyanates cause Nrf2 stabilisation by modifying cysteine residues 
in Keap1 to inactivate its function. PEITC is highly cysteine reactive due to the 
presence of the electron withdrawing isothiocyanate (N=C=S) group (Fig. 2.1A). 
Therefore, we wanted to identify the cysteine residue(s) in Keap1 that sense(s) 
PEITC. 
 
3.2.2 PEITC causes stabilisation of NRF2 through reacting with 
cysteine 151 of KEAP1 
 
We used KEAP1-knockout mouse embryonic fibroblasts (KKO MEFs) rescued 
with either the wild-type (WT) or the KEAP1 mutants C151S, C273W/C288E and 
C151S/ C273W/C288E. Exposure to 2.5 and 7.5 μM PEITC caused the 
stabilisation of Nrf2 in all genotypes regardless of the mutation status of KEAP1 
(Fig 2.1B). This result suggests that the intracellular concentration of PEITC is 
much higher than the amount of KEAP1, hence it is able to react with multiple 
cysteines in Keap1 in order to stabilise NRF2. The same experiment was 
repeated using lower concentrations of PEITC, and this time it was clear that 2 
μM PEITC was sufficient to cause upregulation of NRF2 in the KKO MEFS 
rescued with either the WT or the double mutant C273W/C288E KEAP1. In 
contrast, this dose of PEITC was not able to upregulate NRF2 in the KKO MEFs 
rescued with the single mutant C151S or triple mutant C151S/C273W/C288E 
KEAP1, indicating that C151 is the main sensor for PEITC (Fig. 2.1C). 
Interestingly, the results from Fig. 1B and C suggest that there is a very narrow 
window of stabilisation of NRF2 by PEITC through KEAP1 C151 between the 
range of 0.5 μM to 2 μM.  
 
In another experiment, primary peritoneally derived macrophage (PMO) cells 
from either the WT or KEAP1C151S/C151S mice exposed to concentrations ranging 
from 0.94 to 7.5 μM of PEITC caused the stabilisation of NRF2 in both genotypes 
(Fig. 2.1D). Primary cells could be more sensitive to PEITC than the immortalised 
KKO MEFs, hence, lower concentrations should be used in the future to elucidate 
whether Keap1 C151 is the main sensor for PEITC in the primary PMO cells. 
Collectively, the results from Fig 2.1B, C and D raise the possibility of other 
Keap1 cysteine(s) potentially sensing PEITC. It is interesting to note that the 
highest concentration of PEITC (7.5 μM) used causes a significant reduction in 
the protein levels of tubulin (Fig. 2.1D). It has been reported that the 
isothiocyanates BITC, PEITC and SF covalently modify α-tubulin in cells by 
reacting with its cysteine residues and as a consequence preventing its 
polymerisation (Xiao et al., 2012). PEITC has also been reported to cause the 
degradation of both α and β-tubulin in prostate cancer cells PC3 and that the 
degradation could be rescued by co-incubation of the antioxidant N-acetyl-L-
cysteine (NAC) (Yin et al., 2009). Together, these results confirm that cysteine 
reactivity underlies the multiple biological activities of PEITC. 
 
We have previously reported that structurally diverse NRF2 activators, all 
of which react with sulfhydryl groups, induce the heat shock response, and 
demonstrated the essential requirement for HSF1 (Zhang et al., 2011b). The 
isothiocyanates represent a prominent class of NRF2 activators, which have 
shown chemoprotective effects in numerous animal models of chronic disease; 
some have been and/or currently are in clinical trials (Dinkova-Kostova and 
Kostov, 2012, Dinkova-Kostova, 2013, Kensler et al., 2012). We therefore 
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Figure 2.1. KEAP1 C151 is the primary sensor for PEITC. A) The chemical structure of PEITC.
B and C) Western blot analyses of KEAP1-knockout MEFs rescued with either wild-type (WT),
single mutant C151S, double mutant C273W/C288E or triple mutant C151S/C273W/C288E of
mouse N-terminally tagged HA-KEAP1 which were exposed to vehicle (0.1% DMSO) or varying
concentrations of PEITC for 3 h. Immunoblotting was performed on cell lysates using NRF2, HA
and α-tubulin antibodies for detection. D) Western blot analysis performed on primary (WT) or
KeapC151S/C151S mouse peritoneal macrophages that were treated with vehicle (0.1% DMSO) or
varying concentrations of PEITC for 3 h. NRF2, KEAP1 and alpha-tubulin antibodies were used for
detection. The data are representative of two independent experiments.
examined the potential heat shock response-inducer activity of three 
representative isothiocyanates: allyl- (AITC), benzyl- (BITC), and phenethyl 
isothiocyanate (PEITC) (Fig. 2.2A) in the human breast cancer cell line MDA-
MB-231, using Hsp70 as a prototypic heat shock protein. 
 
 
3.2.3  Cysteine-reactive PEITC induces the heat shock response 
 
When cells were exposed for 24 h to the aromatic isothiocyanates BITC 
or PEITC at a concentration of 10 μM, the levels of Hsp70 increased by ~12- and 
~10-fold, respectively, whereas the levels of Hsp70 remained unchanged upon 
exposure to 10 μM of the aliphatic isothiocyanate AITC (Fig. 2.2B). PEITC is in 
clinical trials for prevention of lung cancer and for depletion of oral cells 
expressing mutant p53 (ClinicalTrials.gov). We therefore focused our subsequent 
studies on this isothiocyanate.  
 
We wanted to find out whether the upregulation of Hsp70 by PEITC was 
mediated by HSF1, therefore we exposed cells which were HSF1-deficient and 
their wild-type counterparts to PEITC and observed the levels of Hsp70 in these 
cells. 
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FIGURE 2.2
Figure 2.2. PEITC is a robust inducer of the heat shock response. (A) Chemical structures of allyl
isothiocyanate (AITC), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate (PEITC). (B) MDA-MB-
231 cells (2.5 x 105 per well) growing in 6-well plates were exposed to vehicle (0.1% acetonitrile), AITC,
BITC, or PEITC for 16 h. Cells were lysed in RIPA buffer, proteins were resolved by SDS/PAGE,
transferred to immobilon-P membranes, and probed with an antibody against Hsp70. The levels of β-actin
served as loading control.
3.2.4  PEITC requires HSF1 for the induction of Hsp70 
 
Western blot analysis of human cervical cancer HeLa cells with either WT HSF1 
(HSF1 WT HeLa) or HSF1 knocked-out (HSF1-KO HeLa) generated using the 
CRISPR/Cas9 technology confirmed the requirement of HSF1 for the induction 
of Hsp70 by PEITC. In the HSF1 WT HeLa cells, exposure to 7.5 μM or 15 μM 
PEITC caused an induction of Hsp70 by ~1.1 and ~1.5-fold respectively (Fig 
2.3A), whereas in the HSF1-KO HeLa cells exposed to the same concentrations 
showed no induction of Hsp70. Importantly, the basal levels of Hsp70 were 
reduced by 60% in the HSF1-KO HeLa cells compared to their wild-type 
counterparts, suggesting the partial requirement of the presence of HSF1 under 
homeostatic conditions. Further validation of the requirement of HSF1 for Hsp70 
induction was observed in experiments conducted in mouse embryonic 
fibroblasts (MEFs). In wild-type MEFs, exposure to 7.5- or 10 μM PEITC for 24 h 
caused an upregulation of Hsp70 by ~2- and ~3.2-fold, respectively, whereas the 
levels of this heat shock protein remained unchanged in their HSF1-deficient 
counterparts (Fig. 2.3B).  
 
We wanted to find out whether the loss of HSF1 would affect the efficacy 
of PEITC, therefore we conducted a cytotoxicity assay using the cell permeable 
reagent known as reazurin (blue), which is weakly fluorescent and an oxidation-
reduction indicator, that undergoes colourimetric and flourometric changes in 
response to cellular metabolic changes. When reazurin is reduced, it forms 
resofurin (bright pink) which is highly fluorescent and the intensity of the 
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Figure 2.3. PEITC requires HSF1 for the induction of Hsp70. (A) HSF1 WT or HSF1-KO HeLa
cells (3.5 x 105 per well) (B) or mouse embryonic fibroblasts (MEF, 2 x 105 per well) growing in 6-well
plates were exposed to vehicle (0.1% acetonitrile) or PEITC for 24 h. Experimental data from panel B
was obtained by Dr. Ying Zhang. Cells were lysed in SDS lysis buffer, proteins were resolved by
SDS/PAGE, transferred to immobilon-P membranes, and probed with an antibody against Hsp70.
The levels of β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading
control.
fluorescence has been found to be directly proportional to the number of respiring 
cells. 
 
3.2.5  Loss of HSF1 enhances the cytotoxicity of PEITC 
 
The dose of PEITC required to cause 50 % cell death (IC50 value) in HSF1 
WT HeLa cells is 16 μM, whereas it is 12 μM in the HSF1-KO HeLa cells (Fig. 
2.4). This result suggests that loss of HSF1 renders the cells more sensitive to 
PEITC, probably due to inability to mount the pro-survival heat shock response 
where upregulation of heat shock proteins have been shown to promote cell 
survival. However, the difference between the two cell lines is relatively modest, 
indicating that other transcription factors (such as NRF2) may compensate for 
the absence of HSF1. 
 
Under unstressed conditions, HSF1 is mostly cytoplasmic and is found to 
be in complex with its negative regulators Hsp70 and Hsp90. Upon exposure to 
stress, HSF1 is released from this complex, and translocates into the nucleus. It 
is clear from the literature that during exposure to heat stress, HSF1 forms a 
homotrimer within 15 min and the HSF1 trimer binds to heat shock elements 
(HSE) (Guettouche et al., 2005, Ahn et al., 2005). To our knowledge, it is not 
known whether the trimerization of HSF1 precedes its nuclear translocation 
during stress conditions. We decided to answer this question by performing a 
nuclear and cytoplasmic separation after cells were exposed to either the solvent 
control [0.1% (v/v) acetonitrile] or PEITC. Before performing the subcellular 
fractionation, we fixed the cells with 0.4% paraformaldehyde to ensure that the 
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Figure 2.4. Loss of HSF1 enhances cytotoxicity of PEITC. HSF1 WT or HSF1-KO HeLa cells (5 x 103 per
well) in 96-well plates were exposed to vehicle (0.1% acetonitrile) or various concentrations of PEITC for 48 h.
AlamarBlue reagent was added to all the wells 4 h before the 48 h time point. The fluorescence was measured
(ex. 560 nm/em. 590 nm) 4 h after AlamarBlue addition and the fluorescence values obtained were corrected
for blank and normalised as a percentage against the wells treated with the vehicle.
monomeric, dimeric and trimeric forms of HSF1 would be preserved and 
ultimately be able to be detected by western blotting. 
 
3.2.6 PEITC causes nuclear accumulation of HSF1 and its 
trimerization 
 
Nuclear-cytoplasmic separation experiments conducted in MDA-MB-231 
cells showed that PEITC caused nuclear translocation of HSF1 (Fig. 2.5). Thus, 
in vehicle-treated cells, HSF1 was present in both the cytoplasmic and nuclear 
fractions. In sharp contrast, in the cytoplasmic fraction of cells treated with PEITC 
for 3 h, there was no detectable HSF1, and essentially all HSF1 was in the 
nuclear fraction. Furthermore, the presence of monomeric, dimeric and trimeric 
HSF1 species was readily detectable in the nuclear fraction of PEITC-treated 
cells. Notably, the gel electrophoretic mobility of monomeric HSF1 in the nuclear 
fraction of PEITC-treated cells was slower than in their vehicle-treated 
counterparts (Fig. 2.5), indicative of occurrence of post-translational 
modifications. This experiment shows that upon PEITC treatment, HSF1 
undergoes nuclear translocation and trimerization. 
 
Trimerization is required for the transcriptional activity of HSF1 (Sorger 
and Nelson, 1989, Perisic et al., 1989, Peteranderl and Nelson, 1992, Rabindran 
et al., 1993). To test whether the HSF1 trimers that form upon treatment with 
PEITC are able to enhance transcription through heat shock elements (HSEs), 
we used the cervical cancer HeLa HSE-luciferase reporter cell line (HeLa-HSE-
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Figure 2.5. PEITC causes nuclear accumulation of HSF1 and its trimerization. MDA-MB-231
cells (2.5 x 105 per well) growing in 6-well plates were exposed to vehicle (0.1% acetonitrile) or
20 μM PEITC for 3 h. Cells were then fixed with 0.8% (w/v) paraformaldehyde. Cell lysates were
subjected to nuclear (N) and cytoplasmic (C) separation, proteins were resolved by SDS/PAGE
(10% gel), transferred to immobilon-P membranes, and probed with an antibody against HSF1.
The levels of lamin B2 and GAPDH served as fraction purity indicators and as loading controls.
luc) stably transfected with the HSP70.1 promoter fused to the luciferase gene 
(Calamini et al., 2012). 
 
3.2.7 PEITC causes an increase in Hsp70.1 promoter activity as well 
as Hsp70 mRNA levels  
 
Remarkably, PEITC led to a dramatic dose- and time-dependent induction 
of the reporter, with a maximal increase of more than 1000-fold (Fig. 2.6A). 
Consistent with the increase in the protein levels of Hsp70 (Fig. 2.3B), the mRNA 
levels for hspa1a were upregulated by 4.1- and 3.5-fold after exposure of wild-
type MEF cells to 10 μM PEITC for 8- or 16 h, respectively (Fig. 2.6B). Together, 
these results demonstrate that PEITC is a potent and robust inducer of the heat 
shock response. 
 
Activation of HSF1 requires release from its negative regulators; indeed, 
inhibition of Hsp90, the main negative regulator of HSF1, often leads to induction 
of the heat shock response (Jhaveri et al., 2012). To test whether PEITC inhibits 
the function of Hsp90, we evaluated the stability of two well-established Hsp90 
client oncoproteins, the tyrosine kinase HER2 and the serine/threonine kinase 
RAF1, both of which bind strongly to Hsp90 (Taipale et al., 2012). 
 
3.2.8  PEITC inhibits Hsp90 
 
Following treatment with PEITC, the levels of HER2 and RAF1 were 
decreased by ~60- and ~35%, respectively, consistent with Hsp90 inhibition (Fig. 
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Figure 2.6 PEITC causes an increase in Hsp70.1 promoter activity as well as Hsp70 mRNA
levels. (A) HeLa-HSE-luc cells (1.3 x 105 per well) stably transfected with the luciferase gene under
the control of the HSP70.1 promoter, were grown in 12-well plates and exposed to vehicle (0.1%
acetonitrile) or PEITC. Luciferase activity was determined in cell lysates. The relative luminescence
units (RLU) were quantified and normalized with respect to the vehicle control treatment. (B) Wild-
type MEF cells (2 x 105 per well) in 6-well plates were exposed to vehicle (0.1% acetonitrile) or PEITC
for 8 or 16 h. Cells were lysed, total RNA was extracted, and reverse transcribed into cDNA. The
mRNA levels for hspa1a were quantified using real-time PCR. The data were normalized using β-
actin as an internal control. Data represent means ± SD and are expressed as ratio of the relative
transcripts in treated over control samples. These experiments were performed by Dr. Ying Zhang.
2.7A). Treatment with 10 μM PEITC did not lead to any changes in the 
transcription of either of these genes, as quantified by real-time PCR. 
Interestingly however, the 20- μM PEITC treatment led to a significant (p = 0.002, 
n = 3) 45% decrease in the mRNA levels for HER2, although the mRNA levels 
for RAF1 were not affected (not shown). The reason for this decrease in HER2 
expression, and its potential contribution to the decreased HER2 protein levels at 
the high concentration of PEITC is presently unknown. In contrast to 
geldanamycin (GA), an Hsp90 inhibitor that competes with ATP, but similarly to 
celastrol (CL) and sulfoxythiocarbamate alkyne (STCA), which inhibit Hsp90 by 
modifying its cysteine residues without interfering with ATP binding (Zhang et al., 
2014), PEITC did not prevent the ability of the chaperone to bind ATP (Fig. 2.7B). 
These results support the notion that PEITC, by virtue of its cysteine reactivity 
inhibits Hsp90, and further suggest that, by inhibiting Hsp90, the isothiocyanate 
may trigger the release of HSF1. Indeed, immunoprecipitation experiments 
showed that the amount of HSF1 bound to Hsp90 is greatly reduced upon 
exposure to PEITC (Fig. 2.7C). 
 
3.2.9  PEITC causes phosphorylation of HSF1 at S326 
 
In addition to release from Hsp90, full transcriptional activation of HSF1 
requires its phosphorylation at S326 (Guettouche et al., 2005, Chou et al., 2012). 
The shift in gel electrophoretic mobility of the monomeric form of HSF1 in nuclear 
fractions of PEITC-treated cells (Fig. 2.5, 2.8A) indicated the occurrence of post-
translational modifications. Given the dramatic activation of the HSE-luciferase 
reporter by PEITC (Fig. 2.6A), we tested the possibility that exposure to PEITC 
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Figure 2.7. PEITC inhibits Hsp90. (A) MDA-MB-231 cells (2.5 x 105 per well) in 6-well plates were
treated with vehicle (0.1% acetonitrile) or PEITC for 24 h. The levels of HER2 and RAF1 were detected
by western blot analysis. The levels of β-actin served as loading control. (B) MDA-MB-231 cells (0.5 x
106 per dish) were grown in 6-cm dishes. After 24 h, the cells were treated for a further 24 h with 0.1%
acetonitrile (ACN) as the vehicle control for sulfoxythiocarbamate alkyne (STCA) and PEITC treatments,
or with 0.1% DMSO as the vehicle control for the geldanamycin (GA) and celastrol (CL) treatments.
Cells were lysed and subjected to ATP pulldown using ATP-agarose beads. For the ATP pull-down and
input samples, Hsp90 or GAPDH were detected by western blot analyses. This experiment was
performed with Dr. Ying Zhang. (C) MDA-MB-231 cells (1 x 106 per well) were grown in 6-cm dishes and
treated with vehicle (0.1% acetonitrile) or PEITC for 45 min. cells were lysed and subjected to
immunoprecipitation with an anti-HSF1 antibody, and then immunoblotted with an anti-Hsp90 antibody.
An aliquot of total lysate was subjected to immunoblot analysis with anti-Hsp90 and anti-HSF1
antibodies.
was causing HSF1 phosphorylation at S326. The use of a pS326-
phosphospecific antibody revealed a time- and dose-dependent increase in 
pS326 HSF1 and an upregulation of Hsp70 upon exposure to PEITC (Fig. 2.8A). 
Notably and in full agreement with the shift in electrophoretic mobility of HSF1 in 
nuclear fractions of PEITC-treated cells (Fig. 2.5) as well as in the 
immunoprecipitation experiment (Fig. 2.7C), in this experiment the migration of 
HSF1 was slower in lysates from cells treated with 20 μM PEITC than from 
vehicle- or 10 μM PEITC-treated cells (Fig. 2.8A). Surprisingly however, although 
HSF1 S326 phosphorylation was more extensive upon treatment with the higher 
concentration (20 μM) of PEITC, induction of Hsp70 appeared to be greater at 
the lower concentration (10 μM) of the isothiocyanate. Nuclear-cytoplasmic 
separation further confirmed the accumulation of pS326 HSF1 in both 
cytoplasmic and nuclear fractions (Fig. 2.8B). The results from this shorter time-
course experiment also indicated that HSF1 phosphorylation occurred in the 
cytoplasm and preceded the nuclear translocation of the transcription factor. 
Also, the phosphorylated HSF1 at S326 in the 20 μM PEITC treatment enters the 
nucleus within 15 min, indicating a rapid activation of the transcriptional response 
by the isothiocyanate. 
 
Only a stringent subset of kinases, known as CMGC kinases are able to 
phosphorylate proline-directed sites (Ubersax and Ferrell, 2007). There are 14 
proline-directed phosphorylation sites on HSF1 (Fig. 2.9) many of which have 
been reported to play a role in either activating or repressing the transcriptional 
capability of HSF1. S326 of HSF1 represents a proline-directed phosphorylation 
site. Phosphorylation of S326 of HSF1 has been implicated in increasing the 
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Figure 2.8. PEITC causes phosphorylation of HSF1 at S326. MDA-MB-231 cells (2.5 x 105
per well) in 6-well plates were treated with vehicle (0.1% acetonitrile) or PEITC for either 24 h
(A) or for the indicated periods of time (B). In (A), the levels of pS326 HSF1, total HSF1, and
Hsp70 were detected by western blot analysis in cell lysates, and the levels of β-actin served as
loading control. In (B), the levels of pS326 HSF1 were detected by western blot analysis in
cytoplasm and nucleus following nuclear-cytoplasmic separation. The levels of lamin A and
GAPDH served as fraction purity indicators and as loading controls.
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Figure 2.9. Predicted proline-directed phosphorylation sites on HSF1. The human HSF1
protein sequence was obtained from the protein database www.uniprot.org using the unique
entry ID Q00613. There are 14 proline-directed sites, either SP or TP, on HSF1.
transcriptional capability of the transcription factor. Several studies have reported 
that mutation of the S326 to an alanine decreases the transcriptional capability of 
HSF1 (Chou et al., 2012, Guettouche et al., 2005, Tang et al., 2015). There have 
been reports that the kinases that phosphorylates this site could be either 
mTORC1 (Chou et al., 2012) or MEK (Tang et al., 2015). However, none of them 
are proline-directed kinases, which makes them unlikely to be the kinases that 
phosphorylate this proline-directed S326 site. In addition, these experiments 
have used near stoichiometric amounts of each kinase and HSF1 in vitro, which, 
in our opinion ‘forces’ the interaction between the two. Furthermore, in these 
experiments the researchers used kinase inhibitors for 24 h in order to see a 
decrease in phosphorylation of S326 of HSF1. Usually 30-60 min incubation with 
a kinase inhibitor is sufficient to inhibit a kinase, hence, a 24 h incubation with an 
inhibitor could ultimately produce off-target effects.  
 
Given these caveats, we conducted a small screen using several CMGC 
kinase inhibitors. We first developed a high-throughput cell-based assay for the 
detection of HSF1 S326 phosphorylation by taking advantage of a technique 
known as the ‘In-Cell Western” (ICW). In short, ICW is a procedure that is usually 
conducted in a 96-well or 384-well format, where cells are plated in the wells are 
fixed and subjected to immunostaining, where the secondary antibody used is 
conjugated to infrared-excitable flourophores for quantitative detection by the 
Oddessey Scanner (Licor). We seeded MCF7 cells in 96-well plates and treated 
them with varying concentrations of kinase inhibitors for 1 h. After treatment with 
the inhibitors, either vehicle (0.1% DMSO) or 20 μM PEITC was added for 4 h, 
after which the cells were subjected to the ICW procedure for quantification of the 
HSF1 pS326 levels in each of the wells. From this screen we found that inhibition 
of p38 mitogen-activated protein kinases (MAPK) led to a decrease in basal 
phosphorylation of HSF1 at S326 by the p38 MAPK inhibitor ZM33673 
(Appendix Fig. 5.1C). Also, as PEITC has been reported to activate p38 MAPK 
(Cheung et al., 2008), we next examined their status in MDA-MB-231 cells. 
 
3.2.10  PEITC activates p38 MAPK 
  
A dose-dependent phosphorylation of p38 MAPK was readily detectable, 
and increased by ~30- and ~90-fold, after treatment with 10- and 20 μM of PEITC, 
respectively (Fig. 2.10A). Importantly, the levels of p38 MAPK were unchanged, 
showing that PEITC did not cause any alterations in protein expression or stability 
of the kinases. In contrast to the activation of p38 MAPK, exposure to PEITC 
decreased the phosphorylation of the ribosomal subunit S6 at S235/236 (Fig. 
2.10B), indicating inhibition of the mechanistic target of rapamycin (mTOR), a 
kinase that had been previously implicated in the phosphorylation of HSF1 at 
S326 (Chou et al., 2012). Moreover, the dose-dependent PEITC-mediated 
phosphorylation of p38 MAPK correlates well with the extent of phosphorylation 
of HSF1 at S326, which increased by 30- and 55-fold, after treatment with 10- 
and 20 μM PEITC, respectively (Fig. 2.10A).  
 
Recently, it was reported that HSF1 physically interacts and is 
phosphorylated at S326 by MAPKK (also known as MEK) (Tang et al., 2015). We 
therefore next examined the effect of inhibiting MEK on HSF1 S326 
phosphorylation using the highly selective MEK1/2 inhibitor 1,4-diamino-2,3-
GAPDH
GAPDH
pp38
p38
HSF1 pS326
Hsp70
HSF1 pS326
p-S6 
(S235/236)
b-Actin
B
A
PEITC (μM): 0 10 20
PEITC (μM): 0 10 20
41 kDa
70 kDa
100 kDa
36 kDa
MDA-MB-231
MDA-MB-231
FIGURE 2.10
Figure 2.10. PEITC activates p38 MAPK. PEITC activates p38 and inhibits mTOR.
MDA-MB-231 cells (2.5 x 105 per well) growing in 6-well plates were treated with vehicle
(0.1% acetonitrile) or PEITC for either 24 h (A), 3 h (B) or for the indicated periods of time
(D). The levels of HSF1, pS326 HSF1, pS235/6 S6, Hsp70, phosphorylated p38 (pp38),
p3, were detected by western blot analysis.
dicyano-1, 4-bis[2-aminophenylthio]butadiene (U0126) (Favata et al., 1998). In 
agreement with the published report (Tang et al., 2015), we were able to detect 
reduced levels of phosphorylation of HSF1 at S326 in lysates of heat-shocked 
cells that had been pre-treated for 24 h with U0126 (Fig. 2.11A). However, the 
MEK inhibitor had no effect on the phosphorylation of HSF1 at S326 in heat-
shocked cells that had been pre-treated with U0126 for 1 h (Fig. 2.11B). Overall, 
these findings raise the possibility that p38 MAPK could represent one group of 
the long-sought catalysts for the phosphorylation of this key residue. 
 
3.2.11  p38 MAPK phosphorylate HSF1 at S326 in vitro 
 
Next, we used recombinant HSF1 to test the ability of purified recombinant 
p38 MAPK isoforms to phosphorylate HSF1 in vitro. HSF1 was expressed as a 
His-tagged fusion protein in Escherichia coli. Purified His-HSF1 migrated as a 
major band during NuPAGE® at the expected molecular weight, and showed a 
tendency to form spontaneously dimeric and trimeric species (Fig. 2.12A). The 
four p38 MAPK isoforms (α, β, Ɣ and δ) were expressed individually in 
Escherichia coli from human cDNAs as inactive GST-fusion proteins, and purified 
by affinity chromatography on glutathione-Sepharose. Recombinant MKK6 was 
then used to activate the p38 proteins, and subsequently removed by passage 
through amylose resin. The enzyme activity of each p38 isoform was quantified 
by the phosphorylation of a standard substrate, myelin basic protein. Each kinase 
was used at an equivalent specific enzyme activity in reactions with HSF1 as a 
substrate.  
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Figure 2.11. The MEK inhibitor U0126 reduces the levels of heat-shock induced
phosphorylation of HSF1 at S326 after a 24 h pre-treatment, but 1 h pre-treatment has
no effect. MDA-MB-231 cells (2.5 x 105 per well) in 6-well plates were pre-treated with
U0126 for either 24 h (A) or 1 h (B), and subsequently subjected to heat shock (HS). The
levels of HSF1 and pS326 HSF1 were detected by western blot analysis. The levels of β-actin
served as loading control.
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Figure 2.12. p38 MAPK phosphorylate HSF1 in vitro. (A) Electrophoretic mobility (NuPAGE NoVex Bis-Tris
4-12% gradient gel) of recombinant hexahistidine-tagged HSF1 wild-type (WT) and S326A mutant. (B-D)
Purified activated recombinant p38 MAPK isoforms (0.06 mU/μl) were incubated with recombinant wild-type
(WT), S326A mutant HSF1, or (all 0.1 μg/μl at 30°C for 15 min in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP. Identical reactions were carried out in the presence of increasing concentrations of the p38α/β
inhibitor SB202190 or BIRB0796, which inhibits all p38 isoforms. The reactions were terminated by addition of
SDS gel loading buffer, the samples were loaded on SDS/PAGE, and the excess [Ɣ-32P]-ATP was removed by
electrophoresis. The gels were dried and subjected to autoradiography (C). After staining with Coomassie
Brilliant Blue, the protein bands were excised and the incorporated radioactivity (B) was determined by
scintillation counting. *, p < 0.05. (D) Purified activated recombinant p38α (0.06 mU/μl) was incubated with
recombinant wild-type (WT) or S326A mutant HSF1 (0.1 μg/μl) at 30°C for 15 min in the presence of 10 mM
MgCl2 and 0.1 mM ATP. The reactions were terminated by addition of SDS gel loading buffer, the samples
were loaded on SDS/PAGE, and the phosphorylation of HSF1 at S326 and the levels of total HSF1 were
detected by western blotting. These experiments were performed in collaboration with Dr. Calum D.
Sutherland.
All p38 isoforms were able to rapidly phosphorylate HSF1 (Fig. 2.12B, 
black bars). Quantitative analysis of incubation reactions of HSF1 with either 
p38α, p38β, p38Ɣ or p38δ and Mg-[γ32P]-ATP revealed that p38δ phosphorylated 
HSF1 at a higher rate and stoichiometry than did p38α, p38β or p38Ɣ, indicating 
that HSF1 is a better substrate for p38δ than for any of the other p38 isoforms 
(Fig. 2.12B, black bars and Fig. 2.12C). Parallel reactions in the absence of 
HSF1 showed that, under these experimental conditions, there was no detectable 
autophosphorylation of any of the kinases (not shown), and the radioactivity in 
these samples (as quantified by scintillation counting) was identical to that of the 
buffer blank. Western blot analysis using the S326-phosphospecific antibody 
confirmed this conclusion and clearly demonstrated that S326 was one of the 
phosphorylation sites (Fig. 2.12D).  
 
The extent of phosphorylation of HSF1 was dependent on the kinase 
concentration as well as the incubation time. Thus, with 6 mU/μl of enzyme and 
60 min incubation (when phosphate incorporation had reached or was 
approaching a plateau), the stoichiometry of the reaction was 2, 1.3, 0.8, and 2.2 
mol/mol for the α, β, Ɣ and δ isoforms, respectively, suggesting that, under these 
experimental conditions, p38α, p38β and p38δ were able to phosphorylate at 
least two sites on HSF1. With 0.06 mU/μl of enzyme and 15 min incubation, the 
stoichiometry of the reaction for HSF1 was 0.04, 0.03, 0.03, and 0.28 mol/mol for 
p38α, p38β, p38Ɣ and p38δ, respectively (Fig. 2.12B, black bars), indicating that 
p38δ was the most efficient catalyst among the isoforms. The p38δ-mediated 
phosphorylation of HSF1 was inhibited by BIRB0796 (Fig. 2.13A), which inhibits 
all p38 MAPK isoforms (Kuma et al., 2005). In contrast to wild-type (WT) HSF1, 
AC
p38a p38d
SB202190 (µM) SB202190 (µM)
HSF1 MK2 MBP
p38d (WT) p38d (D168A)
+
-
+
-
-
+
-
+
+
+
+
+
p38d: 
Coomassie
Hot assay
Cold assay
HSF1 
pS326
HSF1
IB:
HSF1: 
Autorad
+
-
+
-
-
+
-
+
+
+
+
+
HSF1 MK2 MBP
p38d
510.1 0.50BIRB0796
(µM):
0
HSF1
MBP
B
FIGURE 2.13
Figure 2.13. p38 MAPK phosphorylate HSF1 in vitro. (A-C) Purified activated
recombinant p38 MAPK isoforms (0.06 mU/μl) were incubated with recombinant wild-type
(WT), S326A mutant HSF1, MK2, or myelin basic protein (MBP) (all at 0.1 μg/μl) at 30C
for 15 min in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-32P]-ATP. Identical reactions
were carried out in the presence of increasing concentrations of the p38α/β inhibitor
SB202190 or BIRB0796, which inhibits all p38 isoforms. The reactions were terminated by
addition of SDS gel loading buffer, the samples were loaded on SDS/PAGE, and the excess
[Ɣ-32P]-ATP was removed by electrophoresis. The gels were dried and subjected to
autoradiography. (B-C) Purified activated recombinant p38α (0.06 mU/μl) was incubated
with recombinant wild-type (WT) or S326A mutant HSF1 (0.1 μg/μl) at 30C for 15 min in
the presence of 10 mM MgCl2 and 0.1 mM ATP. The reactions were terminated by addition
of SDS gel loading buffer, the samples were loaded on SDS/PAGE, and the phosphorylation
of HSF1 at S326 and the levels of total HSF1 were detected by western blotting. These
experiments were performed in collaboration with Dr. Calum D. Sutherland.
under the same experimental conditions, the stoichiometry of the reaction for 
mutant HSF1, in which S326 was replaced with alanine (S326A) was 0.02, 0.02, 
0.01 and 0.14 mol/mol for the p38α, β, Ɣ and δ isoforms, respectively (Fig. 2.12B, 
grey bars and Fig. 2.12C), implicating S326 as one of the phosphorylation sites, 
and confirming the existence of additional site(s) within HSF1 which are also 
phosphorylated by p38 MAPK. Interestingly, this experiment also showed that, 
although not as robust as p38δ, p38Ɣ was the most selective isoform in 
phosphorylating S326. 
 
To confirm the unusually high substrate preference of p38δ for HSF1 
relative to the more widely studied p38α and β isoforms, we carried out analogous 
reactions with MK2 as a substrate. In comparison with p38δ, the initial rates of 
activation of this physiological substrate are ~20 times faster for the α or β 
isoforms (Goedert et al., 1997). Indeed, p38δ was far less effective in 
phosphorylating MK2 than was p38α (Fig. 2.13B). In sharp contrast, p38δ was 
more than 20-fold more efficient than p38α in catalyzing the phosphorylation of 
HSF1. As expected, the p38α-, but not p38δ-mediated phosphorylation of all 
three substrates was dose-dependently inhibited by the p38α/β inhibitor 
SB202190.  
 
As mentioned above, we employed MBP-MKK6 to obtain active bacterially 
produced human p38 MAPK. To make absolutely certain that the phosphorylation 
of HSF1 was not due to any residual MKK6, a new preparation of p38δ was made 
in parallel with a preparation of a kinase-dead mutant (D168A) version of the 
enzyme under identical conditions. After incubation and removal of the activating 
kinase, each protein was used at an equivalent concentration in a reaction with 
HSF1 as a substrate. Phosphorylation of HSF1 only occurred with the active, but 
not kinase-dead p38δ, as revealed by autoradiography and western blot analysis 
(Fig. 2.13C), establishing the p38δ enzyme as the only HSF1 kinase activity in 
the preparation. 
 
Together, these data demonstrate that HSF1 can be phosphorylated in 
vitro by all p38 MAPK isoforms at S326, and that p38δ is the most efficient 
catalyst among the isoforms, whereas p38Ɣ is the most specific. However, it is 
important to note that S326 is not the only site of phosphorylation by these 
kinases as the S326A mutant HSF1 was also phosphorylated, albeit with the 
expected reduction in stoichiometry. To identify the phosphorylation sites 
precisely, we employed a protease-mass spectrometric approach. Recombinant 
HSF1 was incubated with recombinant p38α or p38δ and, after electrophoretic 
separation and in-gel proteolytic digestion, the resulting tryptic peptides were 
analyzed by mass spectrometry. Under these conditions, the sequence coverage 
was ~50%. We found that the two p38 isoforms phosphorylated identical sites 
(Table 2.1), suggesting that the increased phosphate incorporation with p38δ 
was due to a faster rate of phosphorylation of the same sites that were 
phosphorylated by p38α and not due to phosphorylation of additional site(s). 
Three phosphorylated peptides were identified in each sample. The 
corresponding mass (m/z 2902.4659 for p38α and m/z 2902.4683 for p38δ) of 
the longest peptide was in precise agreement with the calculated molecular 
weight of a peptide containing phosphorylated S326 (m/z 2902.4689, 
R.VEEASPGRPSSVDTLLS326PTALIDSILR.E). The mass of the shorter peptides 
p38 MAPKα + HSF1
Peptide sequence Phospho-S M (calc.) M (expt.)
K.EEPPS303PPQS307PR.V 
R.VKEEPPS303PPQS307PR.V
R.VEEASPGRPSSVDTLLS326PTALIDSILR.E
S303/307
S303/307
S326
1299.5496
1526.7130
2902.4689
1299.5487
1526.7121
2902.4659
p38 MAPKδ + HSF1
Peptide sequence Phospho-S M (calc.) M (expt.)
K.EEPPS303PPQS307PR.V 
R.VKEEPPS303PPQS307PR.V
R.VEEASPGRPSSVDTLLS326PTALIDSILR.E
S303/307
S303/307
S326
1299.5496
1526.7130
2902.4689
1299.5493
1526.7121
2902.4683
Table 2.1
Table 2.1. Phosphopeptides identified by liquid chromatography tandem mass spectrometry after
60-min incubation of recombinant human HSF1 (1.0 μg) with p38 MAPKα or p38 MAPKδ (0.06
mU/μl), followed by SDS/PAGE separation, and in-gel tryptic digestion.
(m/z 1299.5487 and 1526.7121 for p38α and m/z 1299.5493 and 1526.7121 for 
p38δ) corresponded exactly to the molecular weight of peptides 
K.EEPPSPPQS307PR.V (m/z 1299.5496) and R.VKEEPPS303PPQS307PR.V (m/z 
1526.7130), in which both S303 and S307 were phosphorylated. Notably, S303 
was found in both phosphorylated as well as unphosphorylated forms. The 
phosphorylation of HSF1 at S303/307 by the same kinase which phosphorylates 
the transcription factor at S326 was at first glance surprising, because in contrast 
to the activating S326 phosphorylation, phosphorylation at S303/307 is inhibitory 
(Kline and Morimoto, 1997, Chu et al., 1998, Xavier et al., 2000). However, this 
finding provides a possible explanation for the observation that although PEITC 
treatment causes a concentration-dependent increase in HSF1 phosphorylation 
(Fig. 2.8A and 2.10A), induction of Hsp70 is lower at the higher PEITC 
concentration (Fig. 2.2B, 2.8A and 2.10A). Immunoblotting performed by our 
collaborators at the Centro Nacional de Biotechnologia/CSIC in Madrid (Dr. Ana 
Cuenda and colleagues) with isoform-specific antibodies showed that p38α, p38γ 
and p38δ are well expressed in MDA-MB-231 cells, and confirmed that the levels 
of these kinases did not change upon exposure to PEITC (Appendix 5.2C).  
 
We established that PEITC causes the phosphorylation of the p38 MAPKs 
the MDA-MB-231 cells and showed that all isoforms for the p38 MAPKs are able 
to phosphorylate HSF1 in vitro. We also determined in vitro that amongst the p38 
MAPK isoforms, p38γ was the isoform that showed the highest specificity to 
HSF1 in terms of mediating its phosphorylation at S326. On the other hand, from 
our in vitro studies p38δ was the isoform that had a 10-fold greater efficiency in 
phosphorylating HSF1. 
3.2.12  Deletion or inhibition of p38γ decreases the phosphorylation 
of HSF1 at S326 in cells 
  
To address whether p38γ and p38δ play a role in the phosphorylation of 
HSF1 at S326 in cells, we first used the human epidermoid cancer cell line A431, 
in which both p38γ and p38δ are expressed, along with its derivatives in which 
p38γ or p38δ had been stably knocked down by more than 90%, using selective 
short hairpin RNA (shRNA) (Fig. 2.14A) (Zur et al., 2015). In comparison to the 
parental cells or cells deficient in p38δ, the heat shock-mediated phosphorylation 
of HSF1 at S326 was reduced by 60% in cells lacking p38γ (Fig. 2.14B), in close 
agreement with the high selectivity of this isoform for the S326 phosphorylation 
in vitro (Fig. 2.12B-D). Treatment with the p38α/β-specific inhibitor SB202190 
had no further effect, indicating that p38α and p38β do not contribute significantly 
to the phosphorylation of S326 in these cells (Fig. 2.14B).  
 
Similar results were obtained in MDA-MB-231 cells: shRNA-mediated 
knockdown (by more than 90%) of p38γ led to a substantial reduction (by ~50%) 
in the phosphorylation of HSF1 at S326 at basal cell culture conditions, whereas 
the knockdown of p38δ did not have this effect (Fig. 2.15). The knockdown of 
p38γ led a corresponding decrease in the levels of Hsp70 (Fig. 2.15). 
Interestingly, the levels of Hsp70 were also reduced upon p38δ knockdown, even 
though the phosphorylation of HSF1 at S326 was not affected. These data 
suggest that p38δ might be involved in catalyzing the phosphorylation of other 
(than S326) sites, which activate HSF1, consistent with the highest stoichiometry 
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Figure 2.14. Deletion or inhibition of p38Ɣ MAPK reduces the levels of pS326 HSF1 in cells. (A)
Immunoblotting for p38 Ɣ and δ in A431 cells, which either express both p38Ɣ and p38δ (WT), or in
which p38Ɣ or p38δ had been stably knocked down using selective shRNA. (B) A431 cells (5 x 105 per
well, WT or p38Ɣ- or p38δ-deficient) were pre-incubated for 1 h with vehicle (0.1% acetonitrile) or
SB202190, and exposed to heat shock (42 °C) for a further 1 h. The levels of HSF1 phosphorylated at
S326 was detected by western blot analysis. The levels of α-tubulin (A) or β-actin (B) served as loading
controls.
HSF1 pS326  
(high exposure)
HSF1 pS326
HSF1 (total)
p38 (total)
p38d
p38g
b-Actin
1 0.5 0.51 0.6 0.5
Hsp70
p38 ɣ + +
p38 δ + +
CTL + +
shRNA:
41 kDa
38 kDa
38 kDa
38 kDa
70 kDa
70 kDa
70 kDa
70 kDa
100 kDa
100 kDa
MDA-MB-231
FIGURE 2.15
Figure 2.15. Deletion or inhibition of p38Ɣ MAPK reduces the levels of pS326 HSF1 in
cells. p38Ɣ or p38δ was stably knocked down in MDA-MB-231 cells using selective shRNA.
The levels of total HSF1, HSF1 phosphorylated at S326, total p38, p38Ɣ, and p38δ, and
Hsp70 were detected by western blot analysis.
of the reaction of this p38 isoform in vitro with both WT and S326A mutant HSF1 
(Fig. 2.12B and C); the identity of these potential sites is presently unknown.  
 
The conclusion that p38α and p38β do not contribute significantly to the 
phosphorylation of S326 in A431 cells was further supported by studies in PEITC-
treated MDA-MB-231 cells, where SB202190 either had no effect (at the high 
concentration of PEITC) or even enhanced by 2.5-fold (at the low concentration 
of PEITC) the levels of pS326 HSF1 after exposure to the isothiocyanate (Fig. 
2.16A). The activation of p38α/β by PEITC and the efficacy of SB202190 were 
confirmed by monitoring the levels of phosphorylated (at T334) MK2 (Fig. 2.16A). 
Finally, we used BIRB0796, which inhibits all four p38 MAPK isoforms (Kuma et 
al., 2005). Pre-treatment with BIRB0796 for 1 h reduced the phosphorylation of 
S326 in PEITC-treated MDA-MB-231 cells (Fig. 2.16B). Together, these findings 
strongly suggest that p38γ is the principal p38 MAPK isoform responsible for the 
phosphorylation of HSF1 at S326 in cells. 
 
Phosphorylation at S326, but not at any of the other serine residues 
identified by Guettouche et al., has been shown to affect the heat shock-induced 
transcriptional activity of HSF1 without affecting the trimerization of nuclear 
translocation of the transcription factor. In agreement, we found that both purified 
recombinant wild-type and S326A mutant HSF1 have the propensity to form 
dimers and trimers spontaneously (Fig. 2.12A). In collaboration with Jim Caunt 
(University of Bath), we used quantitative high content imaging to examine the 
nuclear and cytoplasmic distribution of wild-type, S326A or S326E mutant GFP-
HSF1 fusion proteins after their ectopic expression in HSF1 knockout (HSF1-KO) 
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BIRB0796 (µM):
HSF1 
pS326
b-Actin
1 µM SB202190Vehicle
HSF1 pS326
MK2 pT334
1 111 0.4 180.4 17 13 12 1113
A
0 0 10 10 20 20 0 0 10 10 20 20PEITC (μM):
0 0 1 1 10 10 0 0 1 1 10 10
70 kDa
41 kDa
100 kDa
70 kDa
41 kDa
100 kDa
55 kDa
40 kDa
MDA-MB-231
MDA-MB-231
FIGURE 2.16
Figure 2.16. Deletion or inhibition of p38Ɣ MAPK reduces the levels of pS326 HSF1 in cells.
MDA-MB-231 cells (5 x 105 per well) grown in 6-well plates were pre-treated with vehicle (0.1%
acetonitrile), SB202190 (A) or BIRB0796 (B) for 1 h, and subsequently either treated with vehicle
(0.1% acetonitrile) or PEITC for a further 1.5 h. (A,B) HSF1 phosphorylated at S326 and MK2
phosphorylated at T334 were detected by western blot analysis. β-actin served as a loading control.
MEFs, and did not observe any significant differences among the genotypes (Fig. 
2.17). Notably however, these results should be interpreted with caution: it is well 
documented that in C. elegans, ectopic expression of HSF1 produces a gain-of-
function phenotype (Morley and Morimoto, 2004, Chiang et al., 2012), indicating 
that any level of overexpression of HSF1 may not accurately reflect the 
physiological properties of the endogenous protein.  
 
As mentioned earlier, several reports have emerged showing that when 
the S326 is mutated to an alanine (A), the transcriptional activity of HSF1 is 
compromised (Tang et al., 2015, Chou et al., 2012, Guettouche et al., 2005). We 
wanted to find out whether performing similar experiments in our system would 
also allow us to reproduce the effect that these authors have observed.   
 
3.2.13 HSF1 S326A, S326D and S326E mutants do not affect the 
binding at the Hsp70.1 promoter under basal conditions  
 
To investigate whether the phosphorylation of S326 could affect the 
transcriptional activity of HSF1, we generated the phospho-deficient alanine 
mutant S326A and the phospho-mimetic aspartic acid and glutamic acid mutants 
S326D and S326E. We overexpressed either the WT, S326A, S326D or S326E 
FLAG-HSF1 constructs in the HeLa-HSE-luc cells stably expressing the Hsp70.1 
promoter fused upstream of the luciferase gene and measured the luciferase 
activity in these cells (Fig. 2.18A). We normalized the luciferase activity to the 
protein expression levels of the individual constructs that were transfected. There 
were no differences between the WT and mutant HSF1, indicating that the 
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Figure 2.17. S326A/E mutation does not influence the nucleo-cytoplasmic distribution of
ectopically expressed HSF1-GFP. HSF1-knockout MEFs were transfected with GFP-tagged wild-type or
S326A/E mutants of HSF1 prior to counter staining with anti-ERK1/2 antibodies and DAPI. Four fields of
view per well of eight replicate wells per condition were imaged using a robotic high content microscope.
Automated and systematic analysis of images was performed using a custom algorithm. (A) A single
representative field of view is shown from one well. DAPI and ERK1/2 images were used to define
nuclear and cytoplasmic regions, respectively, and GFP fluorescence was recorded from each region (as
indicated in the inset screengrab showing automated cell definition), accepting >70 AFU per cell as
positively transfected. (B) Plots of single cell data show a frequency histogram of nuclear : cytoplasmic
GFP fluorescence (left panel) indicating a bimodal distribution of HSF1, which is unaffected by S326A/E
mutation. The right hand panel shows a comparison of whole cell GFP fluorescence in the same cell
populations versus nucleo-cytoplasmic distribution, indicating that the bimodal distribution is apparent
across a 10-fold difference in HSF1-GFP levels, and is again unaffected by S326A/E substitution. This
experiment was conducted by Dr. Jim Caunt at the University of Bath.
phosphorylation at this site was not crucial for activating the transcriptional 
capability of HSF1 (Fig. 2.18A).  Furthermore, we conducted a similar experiment 
in HSF1-KO MEFs, where we co-transfected the Hsp70.1 promoter luciferase, 
renilla luciferase and HSF1 WT or mutants, and measured the luciferase activity 
in these cells, however, we were unable to obtain conclusive data as the RLU 
levels were too low to be detectable. One of the shortcomings of the experiments 
of this nature is that the protein expression levels of the mutants vary greatly 
which could be due to differences in their turnover. 
 
Since we have established that the p38 MAPKs, specifically, p38Ɣ is the 
main kinase that phosphorylates HSF1 at S326 in A431 and MDA-MB-231 cells, 
we wanted to uncover the mechanism by which PEITC activates the p38 MAPK. 
It has been well-documented that the p38 MAPKs are activated by the upstream 
kinase, apoptosis signal-regulating kinase 1 (ASK1) (Dorion et al., 2002, Hsieh 
et al., 2010, Ichijo et al., 1997, Tobiume et al., 2001). Also, during basal 
conditions, the reduced form of thioredoxin (TXN1) has been shown to inhibit the 
function of ASK1 by directly binding to the N-terminal domain of the latter (Saitoh 
et al., 1998). When intracellular ROS levels increase, TXN1 is oxidized, and is 
unable to bind to and inhibit ASK1. When ASK1 fully dissociates from TXN1, it 
undergoes autophosphorylation at T845(murine)/T838(human) which is located 
within its kinase domain, which is followed by its subsequent oligomerization 
through its N-terminal coiled-coiled domain (NCC) which leads to its activation 
(Soga et al., 2012, Zhang and Zhang, 2002, Bunkoczi et al., 2007). Interestingly, 
exposure to PEITC increases intracellular ROS levels (Xiao et al., 2010, Hong et 
al., 2015, Jutooru et al., 2014) and the levels of oxidised TXN1, and 
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Figure 2.18. HSF1 S326A, S326D and S326E mutants do not affect the Hsp70.1 promoter activity
under basal conditions. (A) HeLa-HSE-luc cells (1.3 x 105 per well) of a 12-well plate, stably expressing
the luciferase gene under the control of the HSP70.1 promoter, were transfected with either FLAG-WT HSF1
or the mutants FLAG-S326A, FLAG-S326D and FLAG-S326E constructs for 24 h after which they were
exposed to vehicle (0.1% acetonitrile) or PEITC. Luciferase activity was determined in cell lysates. The
relative luminescence units (RLU) were quantified and normalized with respect to the vehicle control
treatment. (B) MDA-MB-231 cells (1 x 106 per well) were grown in 6-cm dishes and transfected with either
FLAG-WT HSF1 or the mutants FLAG-S326A, FLAG-S326D and FLAG-S326E constructs for 24 h. Cells
were lysed and subjected to immunoprecipitation with an anti-HSF1 antibody, and then immunoblotted with
an anti-Hsp90 antibody. An aliquot of total lysate was subjected to immunoblot analysis with anti-Hsp90 and
anti-HSF1 antibodies.
correspondingly decreases the levels of reduced TXN1 (Zhang et al., 2012). 
Therefore, we conducted a preliminary study to perform the knockdown of ASK1 
using siRNA. We initially performed the knockdown experiments in the HeLa-
HSE-luc cells as they were highly transfectable cells and would give us 
information on the efficiency of the knockdown. 
 
3.2.14 siRNA-mediated knockdown of ASK1 in HeLa-HSE-luc cells 
greatly reduces the basal and PEITC-mediated 
phosphorylation of HSF1 at S326 
 
The mRNA levels of ASK1 at 24 and 48 h after siRNA transfection were 
greatly reduced by 10, 20 and 40 nM of the siRNA compared to the non-targeting 
negative control siRNA (siCONTROL). Relative to siCONTROL knockdown 
treatment, when comparing the ASK1 transcript levels, knockdown of ASK1 at 48 
h post-transfection was three times more efficient when compared to 24 h post-
transfection. Hence, for all future experiments associated with siRNA-mediated 
ASK1 KD, we analysed and conducted experiments on cells 48 h post-
transfection. Next, we treated HeLa-HSE-luc cells which we knocked down with 
the siCONTROL or siASK1 for 48 h and exposed the cells to vehicle, 10 μM or 
20 μM PEITC for 5 h. The siASK1 knockdown cells showed greatly reduced levels 
of HSF1 pS326 in all treatments compared to the mock transfected cells. 
Excitingly, PEITC was unable to cause the phosphorylation of HSF1 at S326 in 
the ASK1 knockdown cells (Fig. 2.19) indicating that PEITC-mediated 
phosphorylation of HSF1 at S326 was mediated through the ASK1-p38 MAPK 
signaling cascade. We spent our efforts finding for an antibody that recognized 
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FIGURE 2.19
Figure 2.19. Knockdown of ASK1 in HSE-HeLa-luc cells greatly reduces the
phosphorylation of HSF1 at S326. HSE-HeLa-luc cells (2.5 x 105 per well) growing in 6-well
plates were transfected with either the negative control siRNA (siCONTROL) or ASK1 siRNA
(siASK) for 48 h after which the cells were treated with vehicle (0.1% acetonitrile) or PEITC for
a further 5 h. The levels of pS326 HSF1 and Hsp70 and β-actin were detected by western blot
analysis, where β-actin served as a loading control.
the endogenous form of ASK1, therefore, we purchased 7 different commercially 
available ASK1 antibodies, however, we were unable to blot for ASK1. 
Interestingly, we observed a slight reduction in Hsp70 levels in the ASK1 
knockdown cells compared to the mock transfected cells. Hsp70 is a prototypic 
marker of transcriptional activation of HSF1, it is likely that reduction of HSF1 
pS326 levels could indicate that HSF1 is not as transcriptionally active compared 
to when it is phosphorylated at this particular site in these cells.  
 
Since we observed that ASK1 knockdown profoundly decreases the HSF1 
pS326 levels and slightly decrease Hsp70 protein levels in the HeLa-HSE-luc 
cells, we wanted to find out whether this effect would decrease the Hsp70.1 
promoter activity basally or when stimulated with PEITC in these cells. 
 
3.2.15 siRNA-mediated knockdown of ASK1 in HeLa-HSE-luc cells 
increases the Hsp70.1 promoter activity during PEITC-
mediated heat shock response activation 
 
We found that knockdown of ASK1, did not affect the basal Hsp70.1 promoter-
driven luciferase activity. However, surprisingly, compared to the mock 
transfected cells under the same conditions of PEITC treatment, knockdown of 
ASK1 caused an increase in Hsp70.1 promoter activity by ~2 and 2.5-fold with 
10 μM and 20 μM PEITC, respectively (Fig. 2.20). Together, these results 
suggest that, contrary to published work, phosphorylation of HSF1 at S326 is not 
always necessary for increasing the transcriptional activity of HSF1. 
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Figure 2.20. siRNA-mediated knockdown of ASK1 in HSE-HeLa-luc cells increases the
Hsp70.1 promoter activity during PEITC-mediated heat shock response activation.
HSE-HeLa-luc cells (1.3 x 105 per well) of a 12-well plate stably expressing the luciferase
gene under the control of the HSP70.1 promoter were transfected with either the negative
control siRNA (siCONTROL) or ASK1 siRNA (siASK) for 48 h after which the cells were
treated with vehicle (0.1% acetonitrile) or PEITC for a further 16 h. Luciferase activity was
determined in cell lysates. The relative luminescence units (RLU) were quantified and
normalized with respect to the vehicle siCONTROL treatment.
3.2.16 siRNA-mediated knockdown of ASK1 and exposure to the 
ASK1 inhibitor (NDQI-1) in MDA-MB-231 cells does not affect 
phosphorylation of HSF1 at S326. 
 
Since we observed a reduction of HSF1 pS326 in ASK1 knockdown HeLa-HSE-
luc cells, we wanted to investigate whether we would be able to observe a similar 
effect in the MDA-MB-231 cells. Therefore, we conducted a similar experiment 
where we treated MDA-MB-231 cells with either the siCONTROL or siASK1 for 
48 h and exposed them to vehicle, 10 μM or 20 μM PEITC for 5 h post-
transfection. Unlike the HeLa-HSE-luc cells, in the MDA-MB-231 cells, the levels 
of HSF1 pS326 remained unchanged despite the reduction of ASK1 levels (Fig. 
2.21A). The efficiency of the siRNA knockdown was validated by analyzing the 
transcript levels of ASK1 using real-time PCR (Fig. 2.22). In another experiment, 
we pretreated MDA-MB-231 cells with the commercially available ASK1 inhibitor 
2,7-Dihydro-2,7-dioxo-3H-naphtho[1,2,3-de]quinoline-1-carboxylic acid ethyl 
ester (NDQI-1) for 1 h, exposed these cells to PEITC for a further 2 h, analyzed 
the levels of phosphorylated HSF1 S326 by western blotting (Fig 2.21B), and 
found no reproducible reduction in pS326 HSF1. The combination of NDQI-1 and 
PEITC led to increased cytotoxicity, hence, the HSF1 S326 phosphorylated levels 
were difficult to interpret. 
 
Taken together, these results indicate that the phosphorylation of HSF1 at S326 
might not be critical for its transcriptional activation, contrary to what has been 
published in the literature thus far (Fig. 2.21, 2.22). However, it is important to 
note that phosphorylation of HSF1 at S326 is a prominent marker for activation 
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Figure 2.21 Knockdown of ASK1 and exposure to the ASK1 inhibitor (NDQI-1) in MDA-MB-231 cells
does not affect phosphorylation of HSF1 at S326. (A) MDA-MB-231 cells (3 x 105 per well) transfected
with either the negative control siRNA (siCONTROL) or ASK1 siRNA (siASK) for 48 h after which the cells
were treated with vehicle (0.1% acetonitrile) or PEITC for a further 3 h. (B)MDA-MB-231 cells (5 x 105 per
well) grown in 6-well plates were pre-treated with vehicle (0.1% acetonitrile) or NDQI-1 for 1 h, and
subsequently either treated with vehicle (0.1% acetonitrile) or PEITC for a further 3 h. (A,B) HSF1
phosphorylated at S326 was detected by western blot analysis. β-actin served as a loading control.
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Figure 2.22 siRNA for ASK1 efficiently reduces ASK1 mRNA levels. (A) MDA-MB-231 cells (3
x 105 per well) transfected with either the negative control siRNA (siCONTROL) or ASK1 siRNA
(siASK) for 24 (A) or 48 h (B). Cells were lysed, total RNA was extracted, and reverse transcribed
into cDNA. The mRNA levels for ASK1 were quantified using real-time PCR. The data were
normalized using 18S as an internal control. Data represent means ± SD and are expressed as
ratio of the relative transcripts in treated over control samples. *** is when p < 0.01.
of the heat shock response as it occurs rapidly upon exposure to heat stress or 
electrophiles such as PEITC. These results beg the question as to why this site, 
S326, is rapidly phosphorylated during the activation of the heat shock response. 
As described earlier, during homeostatic conditions, monomeric HSF1 is bound 
to the Hsp90 multichaperone complex in the cytoplasm. Upon exposure to stress, 
HSF1 is released from the Hsp90 multichaperone complex and undergoes 
posttranslational modifications, mainly phosphorylation events, and is then able 
to translocate to the nucleus where it assumes its transcriptionally active trimeric 
form. Perhaps the phosphorylation of HSF1 at S326 during stress, prevents its 
binding to its negative regulator Hsp90, and hence allows it to function as a 
transcription factor. We tested this possibility in the next set of experiments. 
 
3.2.17 HSF1 S326E phospho-mimetic mutant is unable to bind to 
Hsp90 
 
We transfected constructs encoding the FLAG-tagged WT HSF1 and its 
mutants S326A, S326D and S326E into HeLa-HSE-luc cells and performed a co-
immunoprecipitation experiment 24 h later. We pulled down HSF1 using a total 
HSF1 antibody and immunoblotted for endogenous Hsp90. We found that the 
phosphomimetic mutant HSF1 S326E was unable to bind to endogenous Hsp90 
(Fig. 2.18B). This result suggests that phosphorylation of HSF1 S326 may 
dissociate the transcription factor from its negative regulator Hsp90, perhaps 
facilitating its translocation into the nucleus to trimerize and bind to heat shock 
elements. 
 
3.2.18  Discussion 
 
By use of mass spectrometry and protein sequencing, Guettouche et al. 
(Guettouche et al., 2005) found that in cells subjected to heat shock, human 
HSF1 is phosphorylated at 12 serine residues: S121, S230, S292, S303, S307, 
S314, S319, S326, S344, S363, S419, and S444. More recently, using mass 
spectrometry-based proteomics, Xu et al. (Xu et al., 2012) reported the 
phosphorylation at five additional serine residues (S127, S195, S216, S320, and 
S368), and at four threonine residues (T142, T323, T367, and T369). The 
functional significance of most threonine phosphorylations is unknown, except for 
T142, the phosphorylation of which by casein kinase 2 (CK2) has been reported 
to increase the transcriptional activity of HSF1 (Soncin et al., 2003). It is well 
established that phosphorylations at S303/307, S121 and S363 inhibit the 
function of the transcription factor and are involved in the attenuation phase of 
the heat shock response (Kline and Morimoto, 1997, Chu et al., 1998, Xavier et 
al., 2000, Wang et al., 2006), whereas phosphorylation at S216 by Polo-like 
kinase 1 (PLK1) promotes the ubiquitination and degradation of HSF1 during 
mitosis (Lee et al., 2008a). Curiously, PLK1 also phosphorylates HSF1 at S419, 
but in contrast to the inhibitory S216 phosphorylation, phosphorylation at S419 is 
activating and promotes the nuclear translocation of the transcription factor (Kim 
et al., 2005). Phosphorylation at S320 by protein kinase A (PKA) also activates 
HSF1 (Murshid et al., 2010). Another activating phosphorylation occurs at S230; 
it is catalyzed by calcium/calmodulin-dependent protein kinase II (CaMKII) and 
enhances the magnitude of the response upon heat stress (Holmberg et al., 
2001). Although the DNA-binding ability of the S230A mutant of HSF is retained, 
its transcriptional activity is reduced by ~50% in comparison with wild-type HSF1.  
 
Phosphorylation at S326 is a hallmark for HSF1 activation, and several 
studies have attempted to identify the kinase(s) phosphorylating this site. It was 
reported that the mechanistic target of rapamycin (mTOR) is able to catalyze the 
phosphorylation of HSF1 at S326 (20). However, PEITC inhibits mTOR (Cavell 
et al., 2012). In full agreement, we also found that the mTOR pathway was 
inhibited by PEITC, as evidenced by the decreased phosphorylation of the 
ribosomal subunit S6 at S235/236 (Fig. 2.10B). Overall, our data presented in 
this contribution imply that mTOR is not the primary kinase responsible for the 
phosphorylation of S326 on HSF1 in response to treatment with PEITC, and 
further implicate the family of proline-directed p38 MAPK as highly efficient 
catalysts, which phosphorylate HSF1 rapidly and stoichiometrically. Notably 
however, neither pharmacological inhibition of p38 MAPK by small molecule 
inhibitors or genetic downregulation of p38γ or p38δ eliminated completely the 
phosphorylation of HSF1 at S326 (Fig. 2.16B). These results imply that although 
p38γ is the principal isoform within the p38 MAPK family that phosphorylates this 
site, inactivation of p38γ allows for compensation by other kinases. One such 
candidate is JNK1/2, which is also activated by PEITC, albeit at a later time point 
in comparison with p38 MAPK. It has been reported that p38 MAPK engage in 
feedback control loops that suppress the activities of upstream MAP kinase 
kinase kinases (MAP3Ks), which participate in the activation JNK, and by 
disrupting these feedback control loops, inhibition of p38 leads to hyperactivation 
of JNK (Cohen, 2009). The possibility that JNK1/2 could phosphorylate HSF1 at 
S326 requires a further study. 
 
Interestingly and unexpectedly, we found that in addition to S326, p38 
MAPK can also catalyze the phosphorylation of HSF1 at S303/307 (Table 2.1). 
In contrast to the activating function of the S326 phosphorylation, phosphorylation 
at S303/307 inhibits the function of HSF1 (14-16). Although surprising, the fact 
that the same kinase can catalyze phosphorylation of two distinct sites on HSF1 
with opposing functional consequences is not unprecedented. As mentioned 
above, phosphorylation at S216 by PLK1 inhibits HSF1, whereas phosphorylation 
at S419 by the same kinase activates the transcription factor (Kim et al., 2005, 
Lee et al., 2008a). Our results imply that either p38 MAPK phosphorylate S326 
at a faster rate than at S303/307, thus giving a “window” of HSF1 activation due 
to S326 phosphorylation before the repressive effect of S303/307 
phosphorylation takes place, or alternatively, that there is a threshold of MAPK 
p38 activation below which S326 is the principal target, and above which the 
S303/307 phosphorylation becomes dominant. The second possibility is 
supported by the fact that induction of Hsp70 is lower upon treatment with the 
higher (20 μM) compared to the lower (10 μM) concentration of PEITC, whereas 
the extent of HSF1 phosphorylation is dependent on the dose of PEITC. In 
addition, the identity of the phosphatases involved may also influence the relative 
turnover rates of phosphorylation at each site. Dissecting these possibilities 
requires better tools for quantitation of relative stoichiometry of phosphorylation 
at S303/307 vs. S326 in different cell compartments.  
 
Previous investigations have suggested the possible involvement of 
MAPK signaling in the activation of HSF1. Thus, loss of the tumor suppressor 
neurofibromatosis type 1 (NF1) leads to activation of MAPK signaling and HSF1 
(Dai et al., 2012). Chronic exposure of rodent fibroblast cells to heat stress 
causes phosphorylation of p38 MAPK and induction of Hsp70 (Banerjee Mustafi 
et al., 2009). In addition, the anti-inflammatory agent sodium salicylate, has been 
reported to activate p38 MAPK, promote HSF1 DNA binding and transcriptional 
activity, and induce Hsp70 expression (Seo et al., 2005). Most recently, it was 
reported that HSF1 physically interacts and is phosphorylated by MEK (Tang et 
al., 2015). However, to our knowledge, there are no prior publications linking 
HSF1 phosphorylation at S326 directly with p38 MAPK activation. In our study, 
the identification of p38 MAPK as one family of kinases, which phosphorylate 
HSF1 at S326 was greatly facilitated by the observation that PEITC is an 
exceptionally robust activator of HSE-dependent transcription (Fig. 2.6A). PEITC 
shares the ability to induce the heat shock response with celastrol (Dayalan 
Naidu et al., 2015, Trott et al., 2008, Westerheide et al., 2004a), another natural 
product which like PEITC, has a characteristic chemical signature, reactivity with 
sulfhydryl groups (Trott et al., 2008). Notably, in a screen comprising ~900 000 
small molecules, Calamini et al. (Calamini et al., 2012) discovered new classes 
of HSF1 activators, all of which, although structurally diverse, bear the same 
chemical signature. We propose that this chemical property underlies the ability 
of PEITC to both inhibit Hsp90 as well as activate p38 MAPK. The role of 
phosphorylation in the activation of NRF2 is not well-established, and it a subject 
of investigation by multiple groups. Although PEITC causes NRF2 stabilisation 
through cysteine modifications of KEAP1, we also considered the possibility that 
by activating p38 MAPK, PEITC might further contribute to NRF2 activation. In a 
preliminary experiment, we conducted an in vitro kinase assay by incubating the 
recombinant human NRF2 Neh6 fragment with the p38 β, Ɣ and δ isoforms and 
found that they were all able to phosphorylate NRF2. Interestingly, p38 β and Ɣ 
selectively phosphorylate NRF2 at the S324 site, whereas the δ isoform’s 
preferred phosphorylation site was S347 (Fig. 2.23). As discussed in the 
Introduction of Section 1, Chapter B, NRF2 and HSF1-regulated cytoprotective 
pathways and target genes at times overlap depending on the stressors, and this 
data presents the idea that these two transcription factors could be regulated by 
the same, if not, similar subset of proteins such as the p38 MAPKs. 
 
3.2.18  Conclusions 
 
Pharmacological targeting of p38γ and p38δ has been recently proposed 
for the treatment of autoimmune and inflammatory diseases, as well as cancer 
(Escos et al., 2016). As HSF1 activation supports malignant transformation 
(Santagata et al., 2011, Mendillo et al., 2012), this approach holds promise for 
targeting HSF1 for cancer treatment. Also, we have discovered that the upstream 
kinase ASK1, is responsible for mediating phosphorylation of HSF1 at S326 (Fig. 
2.19), possibly through activation of p38 MAPKs, however, this effect is only 
observed in the HeLa-HSE-luc cells and not in the MDA-MB-231 cells (Fig. 2.21). 
It is possible that there are different upstream kinases activated by PEITC, which 
in turn activate the p38 MAPK signaling cascade in different cell lines, hence, 
uncovering these pathways will be vital for our understanding of activation of the 
heat shock response. Interestingly, dual-specificity phosphatase 26 (DUSP26) 
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Figure 2.23. p38 MAPKs are able to phosphorylate the Neh6 domain of NRF2. Purified activated
recombinant DYRK2, p38 β, Ɣ and δ (0.06 mU/μl) was incubated with recombinant wild-type GST-tagged
NEH6 domain of NRF2 (0.1 μg/μl) at 30C for 15 min in the presence of 10 mM MgCl2 and 0.1 mM ATP. The
reactions were terminated by addition of SDS gel loading buffer, the samples were loaded on SDS/PAGE, and
the phosphorylation of NRF2 at S342 and S347 and the levels of total GST were detected by western blotting.
directly dephosphorylates p38 MAPK and represses its downstream kinase 
activity; mutation of cysteine 151 in its active site to a serine, inactivates the 
phosphatase (Vasudevan et al., 2005). It is possible that PEITC is able to 
inactivate DUSP26 by targeting C151, hence allowing for continued p38 
phosphorylation resulting in the sustained phosphorylation of HSF1 at S326. 
Further studies need to be conducted to test this hypothesis.  
 
	
Section 3: Results, Discussion and Conclusions 
Chapter 3 
Physiological significance of HSF1 phosphorylation at S326 
 
3.3.1  Introduction 
 
As described in Chapter 2 of Section 3, we have found that all four p38 
MAPK isoforms are able to catalyse the phosphorylation of HSF1 at S326 in vitro 
(Dayalan Naidu et al., 2016). We further identified p38Ɣ as the main isoform that 
phosphorylates HSF1 at S326 in cells (Dayalan Naidu et al., 2016). We have also 
shown evidence that phosphorylation of HSF1 at S326 does not affect its 
transcriptional activity of HSF1, in contrast to previous reports (Guettouche et al., 
2005, Chou et al., 2012). Nevertheless, it is clear from the work from our lab and 
other groups that phosphorylation of HSF1 at S326 is a marker of activation of 
the HSR (Dai et al., 2012). Upon exposure to the Hsp90 inhibitor and the HSR 
activator PEITC, phosphorylation of HSF1 at S326 occurs within 15 min in the 
cytoplasm, and subsequently the phosphorylated HSF1 S326 accumulates in the 
nucleus (Dayalan Naidu et al., 2016). Under basal conditions, HSF1 pS326 levels 
are significantly lower than when the HSR is activated. Apart from the two 
observations that phosphorylated HSF1 at S326 levels dramatically increase 
upon HSR activation and that increase of these levels correlates with poor cancer 
prognosis (Yih et al., 2012, Li et al., 2014, Chou et al., 2012), the question of the 
physiological significance of this phosphorylation still remains.  
 
We first wanted to compare the sub-cellular localisation of HSF1 pS326 to 
that of the total HSF1. To address this question, we performed 
immunofluorescence experiments using the osteosarcoma cell line U2OS as 
these cells have a well-functioning HSR and express HSF1 pS326 basally. 
Unsynchronised U2OS cells were fixed using 37oC pre-warmed 3.7% 
paraformaldehyde to preserve most of the cellular structures including 
cytoskeletal filaments and DNA orientation, and co-stained with antibodies 
against total HSF1 and HSF1 pS326. We also used DAPI (4',6-diamidino-2-
phenylindole), a fluorescent nucleic acid stain, to allow for identification of the 
localisation of the chromosomes. 
 
3.3.2  HSF1 pS326 and HSF1 differ in their sub-cellular localisation 
 
In U2OS interphase cells, HSF1 is mainly localised in the cytoplasm and 
is mostly concentrated at the periphery of the nucleus (Fig. 3.1 and 3.2); its 
staining pattern is reminiscent of that of proteins found in the Golgi apparatus 
such as GOLGB1 (Asante et al., 2013) and GOLM1 (Byrne et al., 2015). Although 
not as intense, it is evident that the total HSF1 antibody recognises HSF1 pS326 
as it stains the regions where HSF1 pS326 is present. In contrast to the total 
HSF1, the HSF1 pS326 staining shows that the phosphorylated protein is 
localised predominantly in the cytoplasm. In the cytoplasm, HSF1 pS326 seems 
to be localised to a particular cytoskeletal structure within the cell (Fig. 3.1 and 
3.2). Overall, it is striking that the localisation of HSF1 phosphorylated at S326 in 
interphase cells is almost mutually exclusive to the total HSF1 localisation (Fig. 
3.1 and 3.2).  
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Figure 3.1. Localisation of HSF1 phosphorylated at S326 in interphase or
resting cells is almost mutually exclusive to total HSF1 localisation.
Representative image of unsynchronised U2OS cells stained with antibodies against
total HSF1 (left top panel, red on overlay), HSF1 pS326 (right top panel, green on
overlay) and with DAPI (left bottom panel, blue on overlay). The bottom right image
is a merged image of all three channels. The image was obtained and deconvolved
using the DeltavisionTM Elite (GE Healthcare) microscope and imaging system.
Maximum intensity of 25 optical sections is shown. The scale bar represents 25 μm.
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FIGURE 3.2
Figure 3.2. Localisation of HSF1 phosphorylated at S326 in interphase or
resting cells is almost mutually exclusive to total HSF1 localisation.
Representative image of unsynchronised U2OS cells stained with antibodies against
total HSF1 (left top panel, red on overlay), HSF1 pS326 (right top panel, green on
overlay) and with DAPI (left bottom panel, blue on overlay). The bottom right image is
a merged image of all three channels. The individual channels are displayed without
colour. The bottom right image is a merged image of all three channels. The image
was obtained using the Zeiss LSM 710 (Zeiss) microscope and imaging system. A
single optical section is shown. The white scale bar represents 10 μm.
 3.3.3           The levels of HSF1 pS326 are significantly higher in mitotic 
cells compared to interphase cells 
 
Interestingly, we noticed that a small number of fixed cells stained with 
HSF1 pS326 had exceptionally high staining intensity compared to the other cells 
(Fig. 3.1). Upon examination of DAPI staining, we discovered that these cells 
were at various stages of mitosis. Fig. 3.3 and 3.4 show representative images 
of such cells from over three independent experiments. In Fig. 3.3, the cell 
indicated by an arrow,  is likely to be at the late prometaphase, as apparent from 
the image of compacted chromosomes in the DAPI channel (bottom left panel). 
The cell indicated by arrowhead is in metaphase, with the chromosomes (DAPI 
channel, bottom left image)  aligned at the metaphase plate. Both cells display 
strongly elevated levels of HSF1 (top left panel) and HSF1 pS326 (top right 
panel), compared to the surrounding cells in this field of view. In Fig. 3.4, the two 
cells with the highest intensity of total HSF1 (top left) and HSF1 pS326 (top right) 
are both undergoing different stages of mitosis: telophase (arrow) and metaphase 
(arrowhead). Thus, it appears that mitotic cells have higher levels of HSF1 and/or 
HSF1 pS326, compared to the neighbouring interphase cells. At this point, it is 
precarious to assume that total HSF1 levels are increased during mitosis, as the 
total HSF1 antibody is also able to recognise the HSF1 pS326, and since HSF1 
pS326 levels are increased in mitotic cells, the total antibody will be able to bind 
it as well. A western blot analysis comparing total and pS326 HSF1 levels in 
interphase versus mitotic cells would solve the question of whether total HSF1 
levels are increased during mitosis. We have addressed this later in this section. 
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Figure 3.3. Phosphorylation of HSF1 at S326 is significantly higher in mitotic
cells compared to interphase cells. Representative confocal
immunofluorescence image of unsynchronised U2OS cells stained with antibodies
against total HSF1 (red), HSF1 pS326 (green) and the DNA stain, 4′,6-Diamidino-2-
phenylindole dihydrochloride (DAPI) (blue). The individual channels are displayed
without colour. The bottom right image is a merged image of all three channels.
There are two mitotic cells in this figure, where they are at the following stages of
mitosis: 1) prometaphase (top, arrow) and 2) metaphase (bottom, arrowhead). The
image was obtained using the Zeiss LSM 710 (Zeiss) microscope and imaging
system. A single optical section is shown. The white scale bar represents 10 μm.
DAPI
HSF1 pS326Total HSF1
MERGED
FIGURE 3.4
Figure 3.4. Phosphorylation of HSF1 at S326 is significantly higher in mitotic
cells compared to interphase cells and colocalises with total HSF1.
Representative confocal immunofluorescence image of unsynchronised U2OS cells
stained with antibodies against total HSF1 (red), HSF1 pS326 (green) and the DNA
stain, 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (blue). The individual
channels are displayed without colour. The bottom right image is a merged image
of all three channels. There are two mitotic cells in this figure, where they are at the
following stages of mitosis: 1) telophase (left, arrow) and 2) metaphase (right,
arrowhead). The image was obtained using the Zeiss LSM 710 (Zeiss) microscope
and imaging system. A single optical section is shown. The white scale bar
represents 10 μm.
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FIGURE 3.5
Figure 3.5. Total HSF1 and HSF1 pS326 co-localise in an U2OS cell
undergoing prophase. Representative confocal immunofluorescence image of
unsynchronised U2OS cells stained with antibodies against total HSF1 (left top
panel, red on overlay), HSF1 pS326 (right top panel, green on overlay) and with
DAPI (left bottom panel, blue on overlay). The bottom right image is a merged image
of all three channels. The individual channels are displayed without colour. The
bottom right image is a merged image of all three channels. The image was
obtained using the Zeiss LSM 710 (Zeiss) microscope and imaging system. A single
optical section is shown. The white scale bar represents 10 μm.
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FIGURE 3.6
Figure 3.6. Total HSF1 and HSF1 pS326 co-localise in an U2OS cell
undergoing telophase. Representative confocal immunofluorescence image of
unsynchronised U2OS cells stained with antibodies against total HSF1 (left top
panel, red on overlay), HSF1 pS326 (right top panel, green on overlay) and with
DAPI (left bottom panel, blue on overlay). The bottom right image is a merged
image of all three channels. The individual channels are displayed without colour.
The bottom right image is a merged image of all three channels. The image was
obtained using the Zeiss LSM 710 (Zeiss) microscope and imaging system. A
single optical section is shown. The white scale bar represents 10 μm.
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FIGURE 3.7
Figure 3.7. Total HSF1 and HSF1 pS326 co-localise in an U2OS cell
undergoing telophase and are present at the midbody. Representative
confocal immunofluorescence image of unsynchronised U2OS cells stained with
antibodies against total HSF1 (left top panel, red on overlay), HSF1 pS326 (right
top panel, green on overlay) and with DAPI (left bottom panel, blue on overlay).
The bottom right image is a merged image of all three channels. The individual
channels are displayed without colour. The bottom right image is a merged image
of all three channels. The image was obtained using the Zeiss LSM 710 (Zeiss)
microscope and imaging system. A single optical section is shown. The white scale
bar represents 10 μm.
 3.3.4 The localisation of HSF1 pS326 and α-tubulin are mutually 
exclusive in interphase cells 
 
Since we observed the staining of HSF1 pS326 to be localised to 
cytoskeletal structures, we wondered whether HSF1 could be bound to α-tubulin, 
a major cytoskeletal structure found in most cells. An α-tubulin/β-tubulin 
heterodimer is the basic subunit of microtubules (Nogales et al., 1998). 
Microtubules are essential for intracellular structure and transport, and are the 
primary component of the spindle fibres required for mitosis to occur (Tuszynski 
et al., 2006).  
 
However, co-staining of HSF1 pS326-stained U2OS cells with α-tubulin-
specific antibody ruled out the microtubular localisation of phosphorylated HSF1. 
Representative images of interphase cells in Fig. 3.8 and 3.9 show that the 
localisation of HSF1 pS326 and α-tubulin are mutually exclusive. The α-tubulin 
staining (top left) shows that the microtubules have a more curved and stringy 
fibrous appearance in contrast to HSF1 pS326 staining (top right) that is fibrous 
in appearance but localises in relatively straight and angular lines. Interestingly, 
HSF1 pS326 staining shows a rhomboidal-like pattern (Fig. 3.9). The data from 
this experiment suggests that HSF1 pS326 bind to other cytoskeletal elements 
other than microtubules (Fig. 3.8 and 3.9). For example, it is possible that HSF1 
pS326 binds to β-actin or other intermediate filaments. 
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Figure 3.8. HSF1 pS326 shows a filamentous localisation that does not co-
localise with in an U2OS cell in interphase. Representative confocal
immunofluorescence image of unsynchronised U2OS cells stained with antibodies
against α-tubulin (left top panel, red on overlay), HSF1 pS326 (right top panel,
green on overlay) and with DAPI (left bottom panel, blue on overlay). The bottom
right image is a merged image of all three channels. The individual channels are
displayed without colour. The bottom right image is a merged image of all three
channels. The image was obtained using the Zeiss LSM 710 (Zeiss) microscope
and imaging system. A single optical section is shown. The white scale bar
represents 10 μm.
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Figure 3.9. HSF1 pS326 shows a filamentous localisation that does not co-
localise with in an U2OS cell in interphase. Representative confocal
immunofluorescence image of unsynchronised U2OS cells stained with antibodies
against α-tubulin (left top panel, red on overlay), HSF1 pS326 (right top panel,
green on overlay) and with DAPI (left bottom panel, blue on overlay). The bottom
right image is a merged image of all three channels. The individual channels are
displayed without colour. The bottom right image is a merged image of all three
channels. The image was obtained using the Zeiss LSM 710 (Zeiss) microscope
and imaging system. A single optical section is shown. The white scale bar
represents 10 μm.
3.3.5 HSF1 pS326 localisation is diffused throughout the mitotic cell 
and is not present at the chromosomes 
 
The staining pattern of HSF1 pS326 in interphase U2OS cells contrasts 
greatly with that in mitotic cells (Fig. 3.1-3.9). In interphase cells, it has a 
structured filamentous appearance (Fig. 3.1, 3.2, 3.8 and 3.9), whereas in most 
mitotic cells, the staining pattern of HSF1 pS326 is unstructured and diffused 
throughout the cell (Fig. 3.5-3.7 and 3.10-3.13). This could be due to the 
disassembly or absence of the cytoskeletal structure that HSF1 pS326 binds to 
during interphase.  
 
3.3.6  HSF1 pS326 concentrates at the midbody during telophase 
 
To date, not much is known about the function of the midbody. 
Cytoskeletal elements have been found to be concentrated within the midbody. 
The midbody comprises of three main molecular machineries: 1) the 
chromosomal passenger complex containing Aurora B kinase, 2) Protein 
regulator of cytokinesis 1 (PRC1), a microtubule cross-linking protein and 3) the 
centralspindlin complex containing mitotic kinesin-like protein (MKLP1) (Green et 
al., 2013, Hu et al., 2012). Polo-like kinase 1 (PLK1) has been found to be a major 
regulator for midbody assembly (Hu et al., 2012). 
 
Interestingly and strikingly, U2OS cells undergoing telophase, exhibit 
HSF1 pS326 concentrated at their midbodies (Fig 3.4, 3.7, 3.14-16). HSF1 
pS326 is also diffused throughout the cells, however the staining intensity at the 
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Figure 3.10. HSF1 pS326 is ubiquitously expressed in an U2OS cell
undergoing mitosis with lower expression at the chromosomes. Representative
confocal immunofluorescence image of U2OS cells stained with antibodies against
α-tubulin (left top panel, red on overlay), HSF1 pS326 (right top panel, green on
overlay) and with DAPI (left bottom panel, blue on overlay). The bottom right image
is a merged image of all three channels. The individual channels are displayed
without colour. The bottom right image is a merged image of all three channels. The
image was obtained using the Zeiss LSM 710 (Zeiss) microscope and imaging
system. A single optical section is shown. The white scale bar represents 10 μm.
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FIGURE 3.11
Figure 3.11. HSF1 pS326 is ubiquitously expressed in an U2OS cell
undergoing at metaphase with lower expression at the chromosomes.
Representative confocal immunofluorescence image of unsynchronised U2OS cells
stained with antibodies against α-tubulin (left top panel, red on overlay), HSF1
pS326 (right top panel, green on overlay) and with DAPI (left bottom panel, blue on
overlay). The bottom right image is a merged image of all three channels. The
individual channels are displayed without colour. The bottom right image is a
merged image of all three channels. The image was obtained using the Zeiss LSM
710 (Zeiss) microscope and imaging system. A single optical section is shown. The
white scale bar represents 10 μm.
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Figure 3.12. HSF1 pS326 is ubiquitously expressed in an U2OS cell in late
anaphase with lower expression at the chromosomes. U2OS cells stained with
antibodies against α-tubulin (left top panel, red on overlay), HSF1 pS326 (right top
panel, green on overlay) and with DAPI (left bottom panel, blue on overlay). The
bottom right image is a merged image of all three channels. The individual channels
are displayed without colour. The bottom right image is a merged image of all three
channels. The image was obtained using the DeltavisionTM Elite (GE Healthcare)
microscope and imaging system. Maximum intensity of 25 optical sections is shown.
The white scale bar represents 10 μm.
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FIGURE 3.13
Figure 3.13. HSF1 pS326 is ubiquitously expressed in an U2OS cell in late
anaphase with lower expression at the chromosomes. U2OS cells stained with
antibodies against α-tubulin (left top panel, red on overlay), HSF1 pS326 (right top
panel, green on overlay) and with DAPI (left bottom panel, blue on overlay). The
bottom right image is a merged image of all three channels. The individual channels
are displayed without colour. The bottom right image is a merged image of all three
channels. The image was obtained using the Zeiss LSM 710 (Zeiss) microscope and
imaging system. A single optical section is shown. The white scale bar represents
10 μm.
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FIGURE 3.14
Figure 3.14. HSF1 pS326 is highly expressed at the midbody of an U2OS cell
undergoing telophase. U2OS cells stained with antibodies against α-tubulin (left top
panel, red on overlay), HSF1 pS326 (right top panel, green on overlay) and with DAPI
(left bottom panel, blue on overlay). The bottom right image is a merged image of all
three channels. The bottom right image is a merged image of all three channels. The
image was obtained using the Zeiss LSM 710 (Zeiss) microscope and imaging
system. A single optical section is shown. The white scale bar represents 10 μm.
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FIGURE 3.15
Figure 3.15. HSF1 pS326 is highly expressed at the midbody of an U2OS cell
undergoing telophase. U2OS cells stained with antibodies against α-tubulin (left top
panel, red on overlay), HSF1 pS326 (right top panel, green on overlay) and with DAPI
(left bottom panel, blue on overlay). The bottom right image is a merged image of all
three channels. The bottom right image is a merged image of all three channels. The
image was obtained using the Zeiss LSM 710 (Zeiss) microscope and imaging
system. A single optical section is shown. The white scale bar represents 10 μm.
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FIGURE 3.16
Figure 3.16. HSF1 pS326 is highly expressed at the midbody of an U2OS cell
undergoing telophase. Representative confocal immunofluorescence image of
unsynchronised U2OS cells stained with antibodies against α-tubulin (left top panel,
red on overlay), HSF1 pS326 (right top panel, green on overlay) and with DAPI (left
bottom panel, blue on overlay). The bottom right image is a merged image of all three
channels. The individual channels are displayed without colour. The bottom right
image is a merged image of all three channels. The image was obtained using the
Zeiss LSM 710 (Zeiss) microscope and imaging system. A single optical section is
shown. The white scale bar represents 10 μm.
MERGED
midbody is significantly higher than the staining intensity in other compartments 
of the cell. It is plausible that HSF1 could play other roles in the cell apart from 
being a transcription factor. 
 
In order to further validate the data obtained using immunofluorescence, 
where we discovered that mitotic U2OS cells highly express HSF1 pS326 
compared to interphase cells (Fig. 3.3 and 3.4), we performed a western blot 
analysis comparing the levels of HSF1 pS326 and total HSF1 levels in taxol-
arrested mitotic U2OS cells and interphase U2OS cells. To control for possible 
effects of drug treatment, we used interphase cells that were exposed to the same 
concentration of the taxol as the mitotically-arrested cells as a control population.  
We used the microtubule toxin, taxol, which stabilises microtubules and arrests 
cells in mitosis (Gascoigne and Taylor, 2009), possibly via preventing spindle 
checkpoint satisfaction or by delaying stable kinetochore attachments. We 
collected the taxol-arrested mitotic cells by selectively detouching them from the 
dish using the “mitotic shake-off” method (explained in detail in the Methods 
Section 2.18). The cells remaining on the dish after mitotic cells were collected 
were further vigorously washed and collected for taxol-treated interphase-cell 
control. The total population of asynchronous U2OS were used as an additional 
control. 
 
 
 
 
 
3.3.7 The HSF1 pS326 levels are significantly higher in taxol-
arrested mitotic cells compared to interphase cells 
 
Various amounts of U2OS cell lysate from each experimental group were 
loaded as follows: 1) Unsynchronised cells, 2) taxol-treated interphase cells and, 
3) taxol-arrested mitotic cells (Fig. 3.17). Western blot analysis of these samples 
shows that in U2OS cells, there are minimal differences in the levels of HSF1 
pS326 between untreated unsynchronised cells and taxol-treated interphase 
cells (Fig. 3.18). However, in comparison with interphase cells treated with taxol, 
HSF1 pS326 is more highly expressed in taxol-arrested mitotic cells (Fig. 3.18). 
The same phenomenon is observed in a similar experiment conducted in HeLa 
cells (Fig. 3.19). These results further support our previous observations using 
immunofluorescence (Fig. 3.3 and 3.4).  
 
Interestingly, in both U2OS and HeLa cells, two distinct bands are 
observed in the HSF1 pS326 immunoblot: ~70 kDa and ~130 kDa. However, in 
the U2OS cells, the 130 kDa band is expressed more highly than the 70 kDa 
band (Fig. 3.18), whereas in the HeLa cells, it is the opposite: the 70 kDa band 
is expressed more highly than the 130 kDa (Fig. 3.19). Since the actual molecular 
weight of HSF1 is ~65 kDa, the upper band could represent a homodimeric 
species. Alternatively, the upper band could be a conjugation of HSF1 with 
multiple SUMO proteins as HSF1 has been previously reported to be SUMO-
modified (Hong et al., 2001, Hilgarth et al., 2003, Hietakangas et al., 2003, 
Goodson et al., 2001). Also interestingly, in both HeLa and U2OS cells, only in 
the taxol-arrested mitotic cells, HSF1 pS326 appears as a smear, suggesting 
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FIGURE 3.17
Figure 3.17. Ponceau S staining of a western blot membrane. U2OS
cells were exposed to 1.46 μM taxol for 14 h in order to arrest cells in
mitosis. Mitotic cells were collected by mitotic wash-off and lysed
immediately with SDS-lysis buffer. The remaining cells consisted of non-
mitotic (interphase) cells exposed to taxol were lysed directly using the
same buffer. Increasing amounts of protein (μg) from each group were
loaded and resolved using the NuPAGE system. The proteins from the gels
were immobilised onto 0.2 μm nitrocellulose (NC) membranes. The NC
membranes were stained using a water-soluble and reversible protein stain
Ponceau S to ensure an even protein transfer and loading.
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FIGURE 3.18
Figure 3.18. HSF1 pS326 levels are significantly higher in taxol-arrested mitotic cells
compared to interphase cells. U2OS cells were exposed to 1.46 μM taxol for 14 h in
order to arrest cells in mitosi or left without treatment (unsynchronised). Mitotic cells were
collected from the taxol-treated dish and lysed immediately with SDS-lysis buffer. The
remaining attached (interphase) cells that were exposed to the same Taxol treatment were
lysed directly using the same buffer. Unsynchronised cells were trypsinised and lysed in
SDS-lysis buffer without separation. Increasing amounts of protein (mg) from each group
were loaded and resolved using the NuPAGE system. The proteins from the gels were
immobilised onto 0.2 μm nitrocellulose (NC) membranes. The western blot membranes
were probed with antibodies against total HSF1, HSF1 pS326, Histone H3, Histone H3
pS10 and β-actin. Histone H3 pS10 was used as a mitotic marker and to ensure the purity
of the separation. β-actin and Histone H3 served as loading controls. This experiment was
performed with Dr. Dina Dikovskaya.
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FIGURE 3.19
Figure 3.19. Total HSF1 is degraded, whereas, HSF1 pS326 levels are
significantly higher in taxol-arrested mitotic cells than in interphase
cells. HeLa cells were exposed to 0.73 μM taxol for 12 h in order to arrest
cells in mitosi or left without treatment (unsynchronised). Mitotic cells were
collected from the taxol-treated dish and lysed immediately with SDS-lysis
buffer. The remaining attached (interphase) cells that were exposed to the
same Taxol treatment were lysed directly using the same buffer.
Unsynchronised cells were trypsinised and lysed in SDS-lysis buffer without
separation. Increasing amounts of protein (mg) from each group were
loaded and resolved using the NuPAGE system. The proteins from the gels
were immobilised onto 0.2 μm nitrocellulose (NC) membranes. The western
blot membranes were probed with antibodies against total HSF1, HSF1
pS326, Histone H3, Histone H3 pS10 and β-actin. Histone H3 pS10 was
used as a mitotic marker and to ensure the purity of the separation. β-actin
and Histone H3 served as loading controls. This experiment was performed
with Dr. Dina Dikovskaya.
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potential ubiquitination of the protein (Fig. 3.18 and Fig. 3.19). Furthermore, in 
these cells, the HSF1 pS326 migrates more slowly than in the taxol-exposed 
interphase cells, suggesting that there could be other post-translation 
modification(s) occurring on the phosphorylated HSF1 S326 species. The 
additional post-translation modification(s) could include PLK1-catalysed 
phosphorylation of HSF1 at S216 that has been reported to occur during mitosis 
(Lee et al., 2008a).  
 
3.3.8 The total HSF1 levels decrease in taxol-arrested mitotic cells 
and interphase cells 
 
In U2OS cells, the total HSF1 levels are slightly lower in taxol-arrested 
mitotic cells compared to taxol-exposed interphase cells (Fig. 3.18). A more 
dramatic decrease in total HSF1 levels is observed in mitotic HeLa cells arrested 
with taxol compared to the interphase cells treated with taxol (Fig. 3.19). These 
results clarify the immunofluorescence data (Fig. 3.3 and 3.4) where total HSF1 
levels seemed to be higher in mitotic cells compared to interphase cells. It is now 
obvious that in the immunofluorescence data using the total HSF1 antibody, the 
apparent increased intensity observed in mitosis is not a reflection of the total 
HSF1 levels, but more likely of the HSF1 pS326 that is increased during mitosis. 
 
We wanted to find out if there were any other phosphorylation events 
occurring on HSF1 during mitosis as we observed that HSF1 undergoes a further 
posttranslational event(s) during this cell cycle phase (Fig. 3.18 and 3.19). Using 
the available antibodies, we probed for HSF1 pS303 and HSF1 pS121, both of 
which have been reported to repress the transcriptional activity of HSF1. 
 
3.3.9 HSF1 pS303 and pS121 levels are decreased in U2OS cells 
arrested in mitosis with taxol compared to interphase cells 
 
In Fig. 3.20, HSF1 pS303 and pS121 levels are decreased in U2OS cells 
arrested in mitosis with taxol compared to interphase cells exposed to taxol. It is 
interesting that phosphorylation of these sites, which inhibits HSF1 transcriptional 
activity (Wang et al., 2006, Hietakangas et al., 2003), is downregulated in mitosis, 
suggesting that perhaps HSF1 has to be active and able to bind to the HSEs 
during mitosis as reported by Vihervaara et. al. (Vihervaara et al., 2013). 
However, the decrease in the levels of HSF1 pS303 and pS121 that we observed 
could also be due to the total HSF1 protein decrease during mitosis (Fig. 3.18 
and Fig. 3.19). Notably, we found that these “phosphospecific” antibodies are 
able to recognise unphosphorylated recombinant HSF1 (data not shown), hence 
the specificities of these antibodies are highly questionable and the detected 
species could represent a mixed population of total HSF1 as well as the 
phosphorylated residues on HSF1 it is supposed to recognise. Interestingly, in 
contrast to the levels of HSF1 p326, the levels of transcription factor NRF2 are 
decreased in taxol-arrested mitotic U2OS cells (Fig. 3.20). 
 
Because we discovered that all members of the p38 MAPK family are able 
to efficiently catalyse the phosphorylation of HSF1 at S326 (Dayalan Naidu et al., 
2016), we next wanted to find out if these kinases were mediating the increase in 
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Figure 3.20. HSF1 pS303 and HSF1 pS121 levels are lower in taxol-arrested
mitotic cells compared to interphase cells. U2OS cells were exposed to 1.46
μM taxol for 14 h in order to arrest cells in mitosi or left without treatment
(unsynchronised). Mitotic cells were collected from the taxol-treated dish and
lysed immediately with SDS-lysis buffer. The remaining attached (interphase)
cells that were exposed to the same Taxol treatment were lysed directly using the
same buffer. Unsynchronised cells were trypsinised and lysed in SDS-lysis buffer
without separation. Increasing amounts of protein (mg) from each group were
loaded and resolved using the NuPAGE system. The proteins from the gels were
immobilised onto 0.2 μm nitrocellulose (NC) membranes. The western blot
membranes were probed with antibodies against HSF1 pS121, HSF1 pS303,
Nrf2, Histone H3 pS10 and β-actin. Histone H3 pS10 was used as a mitotic
marker and to ensure the purity of the separation. β-actin served as a loading
control. These lysates belong to the experiment described in Figure 3.17. This
experiment was performed with Dr. Dina Dikovskaya.
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HSF1 pS326 levels in taxol-arrested mitotic cells. We therefore determined the 
levels of all p38 isoforms as well as the phosphorylated (i.e. active) total p38 in 
the U2OS cell lysates described in Fig. 3.18.  
 
3.3.10 p38α and p38β are active in interphase cells whereas, p38β is 
predominantly active in taxol -arrested mitotic cells 
 
The levels of all of the individual p38 isoforms are very similar when 
comparing taxol-arrested mitotic U2OS cells and taxol-exposed interphase cells 
(Fig. 3.21). The phosphospecific p38 antibody recognises all four isoforms of 
p38, and it can be seen in Fig. 3.21 that p38α and p38β are phosphorylated in 
taxol-exposed interphase cells, whereas p38β is predominantly phosphorylated 
in taxol-arrested mitotic cells. It is thus possible that in mitotic cells, p38β 
mediates the phosphorylation of HSF1 at S326 observed in Fig. 3.18. 
 
3.3.10  Discussion 
 
Here we have shown that the basal sub-cellular localisation of HSF1 
pS326 is very different compared to the overall HSF1. In resting cells, HSF1 
pS326, although also present in the nucleus, is mainly localised to cytoskeletal 
filaments and appears as straight and angular lines (Fig. 3.1 and 3.2). Basally, 
most of the HSF1 has a more globular appearance and is mainly localised at 
structures resembling the Golgi bodies.  
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Figure 3.21. Different p38 isoforms are phosphorylated during taxol-
arrested mitosis compared to interphase cells. U2OS cells were exposed to
1.46 μM taxol for 14 h in order to arrest cells in mitosi or left without treatment
(unsynchronised). Mitotic cells were collected from the taxol-treated dish and
lysed immediately with SDS-lysis buffer. The remaining attached (interphase)
cells that were exposed to the same Taxol treatment were lysed directly using
the same buffer. Unsynchronised cells were trypsinised and lysed in SDS-lysis
buffer without separation. Increasing amounts of protein (mg) from each group
were loaded and resolved using the NuPAGE system. The proteins from the
gels were immobilised onto 0.2 μm nitrocellulose (NC) membranes. The
western blot membranes were probed with antibodies against total p38, p38α,
p38β, p38Ɣ, p38δ, phospho p38, Histone H3 pS10 and β-actin. Histone H3
pS10 was used as a mitotic marker and to ensure the purity of the separation.
β-actin served as a loading control. These lysates belong to the experiment
described in Figure 3.17. This experiment was performed with Dr. Dina
Dikovskaya.
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We have shown by immunofluorescence and western blotting that HSF1 
pS326 levels are significantly higher in taxol-arrested mitotic cells compared to 
interphase cells (Fig. 3.3, 3.4, 3.18 and 3.21). HSF1 pS326 is highly expressed 
at all stages of mitosis. We also found that HSF1 pS326 localises and 
concentrates at the midbody of cells undergoing telophase and cytokinesis (Fig. 
3.4, 3.7 and 3.14-3.16). It is interesting that HSF1 pS326 adopts this localisation 
pattern during cell division. Since the midbody is a hub for cytoskeletal filaments, 
such as actin and myosin filaments (Green et al., 2013), it is possible that HSF1 
phosporylated at S326 has a high affinity to a particular protein, possibly a 
cytoskeletal protein, that is concentrated at the midbody. This finding exposes 
the intriguing possibility that HSF1 could have a role beyond its function as a 
transcription factor. The kinase that phosphorylates and maintains the 
phosphorylation of HSF1 at S326 could potentially be p38β (Fig 3.21). On the 
other hand, as observed in Chapter 2, Fig. 2.16A, treatment of cells with the p38a 
and p38b inhibitor SB202190 did not reduce HSF1 pS326 levels, however these 
data were obtained in unsynchronised cells and do not represent the mitotic cell 
population.  
 
Preliminary western blot analysis of cells pre-treated with the CDK9 
inhibitor (CDK9I) showed a decrease in HSF1 pS326 levels (Fig. 3.22) CDK9 
could potentially be the kinase involved in the phosphorylation of HSF1 at S326 
during mitosis. Another obvious candidate is CDK1, a kinase that is activated in 
late G2 and throughout mitosis. Notably, in yeast, a heat-sensitive mutant HSF1 
has been linked with a defect in spindle pole body (the equivalent to the 
centrosome in mammalian cells) duplication (Zarzov et al., 1997). The spindle 
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Figure 3.22. CDK9 Inhibitor reduces HSF1 pS326 in MCF7 cells. 5 x 105
MCF7 cells per well of a 6 well plated were seeded. 20 h after seeding the
MCF7 cells were pretreated with either 10 μM Aloisine, 1 μM BIRB0796 or 1 μM
CDK9 Inhibitor for 1 h. Subsequently the cells were exposed to vehicle (0.1%
DMSO) or 10 or 20 μM PEITC for a further 3 h afterwhich cells were lysed
immediately with SDS-lysis buffer. Cell lysates (10 μg) were loaded and
resolved using the SDS-PAGE system. The proteins from the gels were
immobilised onto 0.45 μm nitrocellulose (NC) membranes. The western blot
membranes were probed with antibodies against HSF1 pS326 and GAPDH
were used, where the latter served as a loading control.
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pole body organises the microtubule cytoskeleton. Importantly, this particular 
mutant was isolated as a co-lethal allele with cdc28-109 (the yeast equivalent of 
the mammalian CDK1). This observation agrees with the staining pattern of HSF1 
pS326 in the cells, and indicates that CDK1 could be a potential kinase that 
mediates the phosphorylation of this site. Like p38 MAPK, the CDKs belong to 
the CMGC family of proline-directed kinases known for their promiscuity and 
functional redundancies. It is entirely plausible that HSF1 is phosphorylated by 
one or more of these kinases during mitosis. Also, since the overall HSF1 total 
protein levels drop during mitosis (Fig. 3.18 and 3.19), it could be that 
phosphorylation of HSF1 at S326 promotes the acetylation of HSF1 at key lysine 
residues such as K208, which has been reported to promote its protein stability 
by preventing it from ubiqutination and degradation by the proteasome 
(Raychaudhuri et al., 2014).  
 
3.3.11             Future Perspectives 
 
This study presented in Chapter 3 has raised many important and interesting 
questions regarding the physiological significance of HSF1 phosphorylation at 
S326 during mitosis: 1) Is this phosphorylation a prerequisite for entering into 
mitosis? 2) Is this phosphorylation a consequence of high CDK activity during 
mitosis? 3) How is the dephosphorylation of this site mediated when exiting 
mitosis and does this occur through the midbody expulsion, or are phosphatases 
involved? 4) Why is HSF1 pS326 sequestered to cytoskeletal elements in 
interphase cells? Further experiments need to be conducted to address all of 
these questions. 
Concluding Remarks 
 
HSF1 and NRF2 orchestrate comprehensive transcriptional programs that 
include genes encoding antioxidant and drug-metabolizing enzymes, chaperones 
which prevent protein misfolding and aggregation, as well as proteins which take part 
in the repair and clearance of damaged macromolecules, thus maintaining the cellular 
redox and intermediary metabolism. These programs provide powerful means for 
adaptation and survival under conditions of electrophilic, oxidative, inflammatory, and 
thermal stress due to the extraordinary functional diversity of their downstream target 
genes. However, although the functions of both HSF1 and NRF2 are undoubtedly 
broadly cytoprotective, the consequences of their activation are both context- and 
duration-dependent and may have not only beneficial, but also negative effects for the 
organism, such as promoting cardiomyopathy, facilitating tumor growth, and may even 
reduce longevity. This dichotomy should be very carefully considered when these 
transcription factors are targeted for disease prevention or treatment. 
 
Although HSF1 and NRF2 are currently considered as drug targets, and both 
inducers and inhibitors are being developed for use as pharmacological agents, many 
questions still need to be answered before such agents can enter clinical practice. The 
initial signal that triggers release of HSF1 from its main negative regulators is still 
unclear. The primary cellular sensor for electrophilic small-molecule activators of 
HSF1 in the mammalian cell has not been established, although based on the ability 
of these compounds to react with sulfhydryl groups, it could be speculated that this 
sensor is a protein(s) equipped with reactive cysteine(s). It is also not clear whether 
small-molecule dual activators of HSF1 and NRF2 activate both pathways sequentially 
or simultaneously. The requirement for higher inducer concentrations for HSF1 than 
for NRF2 activation suggests that the Keap1/NRF2 pathway is activated first, and the 
heat shock response follows. It would be important to establish, whether, in addition 
to HSF1, heat shock can also activate (or repress) NRF2 function, and if so, whether 
this requires HSF1, and whether there might be a physical interaction between the two 
transcription factors. Although both NRF2 and HSF1 affect mitochondrial function, how 
this occurs is not known at present. It is possible that genes encoding critical 
mitochondrial proteins are direct transcriptional targets of HSF1 and/or NRF2. 
Alternatively, by compromising the cellular proteostasis and redox balance, the 
absence of HSF1 and/or NRF2 may affect the catalytic function of thermodynamically 
unstable and/or redox-sensitive mitochondrial proteins indirectly. Finally, it would be 
very interesting to generate HSF1/NRF2-double knockout mice and, if they are viable, 
to examine their responses to stress of different types and performance in various 
models of human disease. 
 
 
  
 
 
 
 
 
 
 
Section 4: References 
  
ABRAVAYA, K., MYERS, M. P., MURPHY, S. P. & MORIMOTO, R. I. 1992. The human heat shock 
protein hsp70 interacts with HSF, the transcription factor that regulates heat shock gene 
expression. Genes Dev, 6, 1153-64. 
AHN, S. G., KIM, S. A., YOON, J. H. & VACRATSIS, P. 2005. Heat-shock cognate 70 is required for 
the activation of heat-shock factor 1 in mammalian cells. Biochem J, 392, 145-52. 
AHN, S. G. & THIELE, D. J. 2003. Redox regulation of mammalian heat shock factor 1 is essential for 
Hsp gene activation and protection from stress. Genes Dev, 17, 516-28. 
AHN, Y. H., HWANG, Y., LIU, H., WANG, X. J., ZHANG, Y., STEPHENSON, K. K., BORONINA, T. N., 
COLE, R. N., DINKOVA-KOSTOVA, A. T., TALALAY, P. & COLE, P. A. 2010. Electrophilic 
tuning of the chemoprotective natural product sulforaphane. Proc Natl Acad Sci U S A, 107, 
9590-5. 
AKERFELT, M., MORIMOTO, R. I. & SISTONEN, L. 2010. Heat shock factors: integrators of cell stress, 
development and lifespan. Nat Rev Mol Cell Biol, 11, 545-55. 
AL-AYOUBI, A. M., ZHENG, H., LIU, Y., BAI, T. & EBLEN, S. T. 2012. Mitogen-activated protein kinase 
phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site 
utilization, proliferation, and cell adhesion. Mol Cell Biol, 32, 2880-93. 
ALASTALO, T. P., HELLESUO, M., SANDQVIST, A., HIETAKANGAS, V., KALLIO, M. & SISTONEN, 
L. 2003. Formation of nuclear stress granules involves HSF2 and coincides with the nucleolar 
localization of Hsp70. J Cell Sci, 116, 3557-70. 
ALBENA T. DINKOVA-KOSTOVA , Y. Z., SHARADHA DAYALAN NAIDU, RUMEN V. KOSTOV, 
ASHLEY PHEELY, VITTORIO CALABRESE 2013. Sulfhydryl-Reactive Phytochemicals as 
Dual Activators of Transcription Factors NRF2 and HSF1. In: GANG, D. (ed.) 50 Years of 
Phytochemistry Research. 1 ed.: Springer International Publishing. 
ALEXEEV, V., LASH, E., AGUILLARD, A., CORSINI, L., BITTERMAN, A., WARD, K., DICKER, A. P., 
LINNENBACH, A. & RODECK, U. 2014. Radiation protection of the gastrointestinal tract and 
growth inhibition of prostate cancer xenografts by a single compound. Mol Cancer Ther, 13, 
2968-77. 
ALI, A., BHARADWAJ, S., O'CARROLL, R. & OVSENEK, N. 1998. HSP90 interacts with and regulates 
the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol, 18, 4949-60. 
ALLISON, A. C., CACABELOS, R., LOMBARDI, V. R., ALVAREZ, X. A. & VIGO, C. 2001. Celastrol, a 
potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. 
Prog Neuropsychopharmacol Biol Psychiatry, 25, 1341-57. 
ALMEIDA, D. V., NORNBERG, B. F., GERACITANO, L. A., BARROS, D. M., MONSERRAT, J. M. & 
MARINS, L. F. 2010. Induction of phase II enzymes and hsp70 genes by copper sulfate through 
the electrophile-responsive element (EpRE): insights obtained from a transgenic zebrafish 
model carrying an orthologous EpRE sequence of mammalian origin. Fish physiology and 
biochemistry, 36, 347-53. 
ANCKAR, J. & SISTONEN, L. 2011. Regulation of HSF1 function in the heat stress response: 
implications in aging and disease. Annu Rev Biochem, 80, 1089-115. 
ANDERICA-ROMERO, A. C., GONZALEZ-HERRERA, I. G., SANTAMARIA, A. & PEDRAZA-
CHAVERRI, J. 2013. Cullin 3 as a novel target in diverse pathologies. Redox Biol, 1, 366-72. 
ARIDON, P., GERACI, F., TURTURICI, G., D'AMELIO, M., SAVETTIERI, G. & SCONZO, G. 2011. 
Protective role of heat shock proteins in Parkinson's disease. Neurodegener Dis, 8, 155-68. 
ARRIGO, A. P., VIROT, S., CHAUFOUR, S., FIRDAUS, W., KRETZ-REMY, C. & DIAZ-LATOUD, C. 
2005. Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its 
reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal, 7, 414-22. 
ASANTE, D., MACCARTHY-MORROGH, L., TOWNLEY, A. K., WEISS, M. A., KATAYAMA, K., 
PALMER, K. J., SUZUKI, H., WESTLAKE, C. J. & STEPHENS, D. J. 2013. A role for the Golgi 
matrix protein giantin in ciliogenesis through control of the localization of dynein-2. J Cell Sci, 
126, 5189-97. 
AU, Q., KANCHANASTIT, P., BARBER, J. R., NG, S. C. & ZHANG, B. 2008. High-content image-based 
screening for small-molecule chaperone amplifiers in heat shock. J Biomol Screen, 13, 953-9. 
BADRINARAYAN, P. & SASTRY, G. N. 2011. Sequence, structure, and active site analyses of p38 
MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads. J Chem 
Inf Model, 51, 115-29. 
BAIRD, L. & DINKOVA-KOSTOVA, A. T. 2013. Diffusion dynamics of the Keap1-Cullin3 interaction in 
single live cells. Biochem Biophys Res Commun, 433, 58-65. 
BAIRD, L., LLERES, D., SWIFT, S. & DINKOVA-KOSTOVA, A. T. 2013. Regulatory flexibility in the 
Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein 
complex. Proc Natl Acad Sci U S A, 110, 15259-64. 
BALER, R., DAHL, G. & VOELLMY, R. 1993. Activation of human heat shock genes is accompanied 
by oligomerization, modification, and rapid translocation of heat shock transcription factor 
HSF1. Mol Cell Biol, 13, 2486-96. 
BALI, P., PRANPAT, M., BRADNER, J., BALASIS, M., FISKUS, W., GUO, F., ROCHA, K., 
KUMARASWAMY, S., BOYAPALLE, S., ATADJA, P., SETO, E. & BHALLA, K. 2005. Inhibition 
of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 
90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem, 280, 
26729-34. 
BANERJEE MUSTAFI, S., CHAKRABORTY, P. K., DEY, R. S. & RAHA, S. 2009. Heat stress 
upregulates chaperone heat shock protein 70 and antioxidant manganese superoxide 
dismutase through reactive oxygen species (ROS), p38MAPK, and Akt. Cell Stress 
Chaperones, 14, 579-89. 
BAST, A., WESELER, A. R., HAENEN, G. R. & DEN HARTOG, G. J. 2010. Oxidative stress and 
antioxidants in interstitial lung disease. Curr Opin Pulm Med, 16, 516-20. 
BENJAMIN, I. J., GUO, Y., SRINIVASAN, S., BOUDINA, S., TAYLOR, R. P., RAJASEKARAN, N. S., 
GOTTLIEB, R., WAWROUSEK, E. F., ABEL, E. D. & BOLLI, R. 2007. CRYAB and HSPB2 
deficiency alters cardiac metabolism and paradoxically confers protection against myocardial 
ischemia in aging mice. Am J Physiol Heart Circ Physiol, 293, H3201-9. 
BENJAMIN, I. J., KROGER, B. & WILLIAMS, R. S. 1990. Activation of the heat shock transcription 
factor by hypoxia in mammalian cells. Proc Natl Acad Sci U S A, 87, 6263-7. 
BERMAN, K., MCKAY, J., AVERY, L. & COBB, M. 2001. Isolation and characterization of pmk-(1-3): 
three p38 homologs in Caenorhabditis elegans. Mol Cell Biol Res Commun, 4, 337-44. 
BERSUKER, K., HIPP, M. S., CALAMINI, B., MORIMOTO, R. I. & KOPITO, R. R. 2013. Heat shock 
response activation exacerbates inclusion body formation in a cellular model of Huntington 
disease. J Biol Chem, 288, 23633-8. 
BIAMONTI, G. 2004. Nuclear stress bodies: a heterochromatin affair? Nat Rev Mol Cell Biol, 5, 493-8. 
BIAMONTI, G. & VOURC'H, C. 2010. Nuclear stress bodies. Cold Spring Harb Perspect Biol, 2, 
a000695. 
BLAKE, M. J., FARGNOLI, J., GERSHON, D. & HOLBROOK, N. J. 1991. Concomitant decline in heat-
induced hyperthermia and HSP70 mRNA expression in aged rats. Am J Physiol, 260, R663-7. 
BOELLMANN, F., GUETTOUCHE, T., GUO, Y., FENNA, M., MNAYER, L. & VOELLMY, R. 2004. DAXX 
interacts with heat shock factor 1 during stress activation and enhances its transcriptional 
activity. Proc Natl Acad Sci U S A, 101, 4100-5. 
BONELLI, M. A., ALFIERI, R. R., POLI, M., PETRONINI, P. G. & BORGHETTI, A. F. 2001. Heat-
induced proteasomic degradation of HSF1 in serum-starved human fibroblasts aging in vitro. 
Exp Cell Res, 267, 165-72. 
BOVA, M. P., YARON, O., HUANG, Q., DING, L., HALEY, D. A., STEWART, P. L. & HORWITZ, J. 
1999. Mutation R120G in alphaB-crystallin, which is linked to a desmin-related myopathy, 
results in an irregular structure and defective chaperone-like function. Proc Natl Acad Sci U S 
A, 96, 6137-42. 
BRANCHO, D., TANAKA, N., JAESCHKE, A., VENTURA, J. J., KELKAR, N., TANAKA, Y., KYUUMA, 
M., TAKESHITA, T., FLAVELL, R. A. & DAVIS, R. J. 2003. Mechanism of p38 MAP kinase 
activation in vivo. Genes Dev, 17, 1969-78. 
BRANDT, G. E., SCHMIDT, M. D., PRISINZANO, T. E. & BLAGG, B. S. 2008. Gedunin, a novel hsp90 
inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med 
Chem, 51, 6495-502. 
BRAVI, M. C., ARMIENTO, A., LAURENTI, O., CASSONE-FALDETTA, M., DE LUCA, O., MORETTI, 
A. & DE MATTIA, G. 2006. Insulin decreases intracellular oxidative stress in patients with type 
2 diabetes mellitus. Metabolism, 55, 691-5. 
BREWER, A. C., MUSTAFI, S. B., MURRAY, T. V., RAJASEKARAN, N. S. & BENJAMIN, I. J. 2013. 
Reductive stress linked to small HSPs, G6PD, and Nrf2 pathways in heart disease. Antioxid 
Redox Signal, 18, 1114-27. 
BRUNET SIMIONI, M., DE THONEL, A., HAMMANN, A., JOLY, A. L., BOSSIS, G., FOURMAUX, E., 
BOUCHOT, A., LANDRY, J., PIECHACZYK, M. & GARRIDO, C. 2009. Heat shock protein 27 
is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the 
transcription factor activity. Oncogene, 28, 3332-44. 
BRYAN, H. K., OLAYANJU, A., GOLDRING, C. E. & PARK, B. K. 2013. The Nrf2 cell defence pathway: 
Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol, 85, 705-
17. 
BU, L., JIN, Y., SHI, Y., CHU, R., BAN, A., EIBERG, H., ANDRES, L., JIANG, H., ZHENG, G., QIAN, 
M., CUI, B., XIA, Y., LIU, J., HU, L., ZHAO, G., HAYDEN, M. R. & KONG, X. 2002. Mutant 
DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner 
cataract. Nat Genet, 31, 276-8. 
BUDZYNSKI, M. A., PUUSTINEN, M. C., JOUTSEN, J. & SISTONEN, L. 2015. Uncoupling Stress-
Inducible Phosphorylation of Heat Shock Factor 1 from Its Activation. Mol Cell Biol, 35, 2530-
40. 
BUNKOCZI, G., SALAH, E., FILIPPAKOPOULOS, P., FEDOROV, O., MULLER, S., SOBOTT, F., 
PARKER, S. A., ZHANG, H., MIN, W., TURK, B. E. & KNAPP, S. 2007. Structural and functional 
characterization of the human protein kinase ASK1. Structure, 15, 1215-26. 
BURTON, E. R., GAFFAR, A., LEE, S. J., ADESHUKO, F., WHITNEY, K. D., CHUNG, J. Y., HEWITT, 
S. M., HUANG, G. S., GOLDBERG, G. L., LIBUTTI, S. K. & KWON, M. 2011. Downregulation 
of Filamin A interacting protein 1-like is associated with promoter methylation and induces an 
invasive phenotype in ovarian cancer. Mol Cancer Res, 9, 1126-38. 
BYRNE, A. M., BEKIARIS, S., DUGGAN, G., PRICHARD, D., KIRCA, M., FINN, S., REYNOLDS, J. V., 
KELLEHER, D. & LONG, A. 2015. Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-
responsive modulator of oesophageal cell migration and invasion. Br J Cancer, 113, 1332-42. 
CALAMINI, B., SILVA, M. C., MADOUX, F., HUTT, D. M., KHANNA, S., CHALFANT, M. A., ALLAIS, 
C., OUIZEM, S., SALDANHA, S. A., FERGUSON, J., MERCER, B. A., MICHAEL, C., TAIT, B. 
D., GARZA, D., BALCH, W. E., ROUSH, W. R., MORIMOTO, R. I. & HODDER, P. 2010. 
ML346: A Novel Modulator of Proteostasis for Protein Conformational Diseases. Probe Reports 
from the NIH Molecular Libraries Program. Bethesda (MD). 
CALAMINI, B., SILVA, M. C., MADOUX, F., HUTT, D. M., KHANNA, S., CHALFANT, M. A., 
SALDANHA, S. A., HODDER, P., TAIT, B. D., GARZA, D., BALCH, W. E. & MORIMOTO, R. I. 
2012. Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem 
Biol, 8, 185-96. 
CALTANA, L., RUTOLO, D., NIETO, M. L. & BRUSCO, A. 2014. Further evidence for the 
neuroprotective role of oleanolic acid in a model of focal brain hypoxia in rats. Neurochem Int, 
79, 79-87. 
CANNING, P., COOPER, C. D., KROJER, T., MURRAY, J. W., PIKE, A. C., CHAIKUAD, A., KEATES, 
T., THANGARATNARAJAH, C., HOJZAN, V., AYINAMPUDI, V., MARSDEN, B. D., GILEADI, 
O., KNAPP, S., VON DELFT, F. & BULLOCK, A. N. 2013. Structural basis for Cul3 protein 
assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem, 288, 7803-14. 
CANNING, P., SORRELL, F. J. & BULLOCK, A. N. 2015. Structural basis of Keap1 interactions with 
Nrf2. Free Radic Biol Med, 88, 101-7. 
CAO, H., XUE, L., XU, X., WU, Y., ZHU, J., CHEN, L., CHEN, D. & CHEN, Y. 2011. Heat shock proteins 
in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients 
after mitral valve surgery. Cell Stress Chaperones, 16, 517-28. 
CARBONE, D. L., DOORN, J. A., KIEBLER, Z., ICKES, B. R. & PETERSEN, D. R. 2005. Modification 
of heat shock protein 90 by 4-hydroxynonenal in a rat model of chronic alcoholic liver disease. 
J Pharmacol Exp Ther, 315, 8-15. 
CARNEMOLLA, A., LABBADIA, J. P., LAZELL, H., NEUEDER, A., MOUSSAOUI, S. & BATES, G. P. 
2014. Contesting the dogma of an age-related heat shock response impairment: implications 
for cardiac-specific age-related disorders. Hum Mol Genet. 
CASANOVAS, O., JAUMOT, M., PAULES, A. B., AGELL, N. & BACHS, O. 2004. P38SAPK2 
phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation. Oncogene, 23, 
7537-44. 
CASTELLANI, R., SMITH, M. A., RICHEY, P. L. & PERRY, G. 1996. Glycoxidation and oxidative stress 
in Parkinson disease and diffuse Lewy body disease. Brain Res, 737, 195-200. 
CASTELLANO, J. M., GUINDA, A., DELGADO, T., RADA, M. & CAYUELA, J. A. 2013. Biochemical 
basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes. Diabetes, 
62, 1791-9. 
CASTILLO, E. F., RAY, A. L. & BESWICK, E. J. 2016. MK2: an unrecognized regulator of tumor 
promoting macrophages in colorectal cancer? Macrophage (Houst), 3. 
CAVELL, B. E., SYED ALWI, S. S., DONLEVY, A. M., PROUD, C. G. & PACKHAM, G. 2012. Natural 
product-derived antitumor compound phenethyl isothiocyanate inhibits mTORC1 activity via 
TSC2. J Nat Prod, 75, 1051-7. 
CERIELLO, A. 2006. Oxidative stress and diabetes-associated complications. Endocr Pract, 12 Suppl 
1, 60-2. 
CHADLI, A., FELTS, S. J., WANG, Q., SULLIVAN, W. P., BOTUYAN, M. V., FAUQ, A., RAMIREZ-
ALVARADO, M. & MER, G. 2010. Celastrol inhibits Hsp90 chaperoning of steroid receptors by 
inducing fibrillization of the Co-chaperone p23. J Biol Chem, 285, 4224-31. 
CHAN, E., SAITO, A., HONDA, T. & DI GUGLIELMO, G. M. 2016. The acetylenic tricyclic bis(cyano 
enone), TBE-31, targets microtubule dynamics and cell polarity in migrating cells. Biochim 
Biophys Acta, 1863, 638-49. 
CHAN, H. Y., WARRICK, J. M., GRAY-BOARD, G. L., PAULSON, H. L. & BONINI, N. M. 2000. 
Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and 
modulation of protein solubility in Drosophila. Hum Mol Genet, 9, 2811-20. 
CHANDRA, V., GANGULI, M., RATCLIFF, G., PANDAV, R., SHARMA, S., BELLE, S., RYAN, C., 
BAKER, C., DEKOSKY, S. & NATH, L. 1998. Practical issues in cognitive screening of elderly 
illiterate populations in developing countries. The Indo-US Cross-National Dementia 
Epidemiology Study. Aging (Milano), 10, 349-57. 
CHEN, H. W., YU, S. L., CHEN, J. J., LI, H. N., LIN, Y. C., YAO, P. L., CHOU, H. Y., CHIEN, C. T., 
CHEN, W. J., LEE, Y. T. & YANG, P. C. 2004. Anti-invasive gene expression profile of curcumin 
in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol, 65, 
99-110. 
CHEN, Y., WANG, B., LIU, D., LI, J. J., XUE, Y., SAKATA, K., ZHU, L. Q., HELDT, S. A., XU, H. & 
LIAO, F. F. 2014. Hsp90 chaperone inhibitor 17-AAG attenuates Abeta-induced synaptic 
toxicity and memory impairment. J Neurosci, 34, 2464-70. 
CHENG, F., JIA, P., WANG, Q. & ZHAO, Z. 2014. Quantitative network mapping of the human kinome 
interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer 
therapy. Oncotarget, 5, 3697-710. 
CHEUNG, K. L., KHOR, T. O., HUANG, M. T. & KONG, A. N. 2010. Differential in vivo mechanism of 
chemoprevention of tumor formation in azoxymethane/dextran sodium sulfate mice by PEITC 
and DBM. Carcinogenesis, 31, 880-5. 
CHEUNG, K. L., KHOR, T. O., YU, S. & KONG, A. N. 2008. PEITC induces G1 cell cycle arrest on HT-
29 cells through the activation of p38 MAPK signaling pathway. AAPS J, 10, 277-81. 
CHIANG, W. C., CHING, T. T., LEE, H. C., MOUSIGIAN, C. & HSU, A. L. 2012. HSF-1 regulators DDL-
1/2 link insulin-like signaling to heat-shock responses and modulation of longevity. Cell, 148, 
322-34. 
CHIN, D., HUEBBE, P., PALLAUF, K. & RIMBACH, G. 2013. Neuroprotective properties of curcumin in 
Alzheimer's disease--merits and limitations. Curr Med Chem, 20, 3955-85. 
CHIN, M. P., REISMAN, S. A., BAKRIS, G. L., O'GRADY, M., LINDE, P. G., MCCULLOUGH, P. A., 
PACKHAM, D., VAZIRI, N. D., WARD, K. W., WARNOCK, D. G. & MEYER, C. J. 2014. 
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes 
mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol, 
39, 499-508. 
CHOI, H. S., LIN, Z., LI, B. S. & LIU, A. Y. 1990. Age-dependent decrease in the heat-inducible DNA 
sequence-specific binding activity in human diploid fibroblasts. J Biol Chem, 265, 18005-11. 
CHOI, Y., ASADA, S. & UESUGI, M. 2000. Divergent hTAFII31-binding motifs hidden in activation 
domains. J Biol Chem, 275, 15912-6. 
CHOO, Y. Y. & HAGEN, T. 2012. Mechanism of cullin3 E3 ubiquitin ligase dimerization. PLoS One, 7, 
e41350. 
CHOU, S. D., PRINCE, T., GONG, J. & CALDERWOOD, S. K. 2012. mTOR is essential for the 
proteotoxic stress response, HSF1 activation and heat shock protein synthesis. PLoS One, 7, 
e39679. 
CHOU, Y. C., CHANG, M. Y., WANG, M. J., YU, F. S., LIU, H. C., HARNOD, T., HUNG, C. H., LEE, H. 
T. & CHUNG, J. G. 2015. PEITC inhibits human brain glioblastoma GBM 8401 cell migration 
and invasion through the inhibition of uPA, Rho A, and Ras with inhibition of MMP-2, -7 and -9 
gene expression. Oncol Rep, 34, 2489-96. 
CHOWDHRY, S., ZHANG, Y., MCMAHON, M., SUTHERLAND, C., CUADRADO, A. & HAYES, J. D. 
2013. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of 
which can be modulated by GSK-3 activity. Oncogene, 32, 3765-81. 
CHRISTIANS, E., DAVIS, A. A., THOMAS, S. D. & BENJAMIN, I. J. 2000. Maternal effect of Hsf1 on 
reproductive success. Nature, 407, 693-4. 
CHU, B., ZHONG, R., SONCIN, F., STEVENSON, M. A. & CALDERWOOD, S. K. 1998. Transcriptional 
activity of heat shock factor 1 at 37 degrees C is repressed through phosphorylation on two 
distinct serine residues by glycogen synthase kinase 3 and protein kinases Calpha and Czeta. 
J Biol Chem, 273, 18640-6. 
CICERO, M. P., HUBL, S. T., HARRISON, C. J., LITTLEFIELD, O., HARDY, J. A. & NELSON, H. C. 
2001. The wing in yeast heat shock transcription factor (HSF) DNA-binding domain is required 
for full activity. Nucleic Acids Res, 29, 1715-23. 
CLEASBY, A., YON, J., DAY, P. J., RICHARDSON, C., TICKLE, I. J., WILLIAMS, P. A., CALLAHAN, 
J. F., CARR, R., CONCHA, N., KERNS, J. K., QI, H., SWEITZER, T., WARD, P. & DAVIES, T. 
G. 2014. Structure of the BTB domain of Keap1 and its interaction with the triterpenoid 
antagonist CDDO. PLoS One, 9, e98896. 
CLEREN, C., CALINGASAN, N. Y., CHEN, J. & BEAL, M. F. 2005. Celastrol protects against MPTP- 
and 3-nitropropionic acid-induced neurotoxicity. J Neurochem, 94, 995-1004. 
CLINICALTRIALS.GOV. Available: https://clinicaltrials.gov/ct2/results?term=rta+408&Search=Search 
[Accessed 18 May 2016 2016]. 
COHEN, P. 2009. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin 
Cell Biol, 21, 317-24. 
CONNOR, R. E., MARNETT, L. J. & LIEBLER, D. C. 2011. Protein-selective capture to analyze 
electrophile adduction of hsp90 by 4-hydroxynonenal. Chem. Res. Toxicol., 24, 1275-82. 
CONWAY, E. M., LIU, L., NOWAKOWSKI, B., STEINER-MOSONYI, M. & JACKMAN, R. W. 1994. Heat 
shock of vascular endothelial cells induces an up-regulatory transcriptional response of the 
thrombomodulin gene that is delayed in onset and does not attenuate. J Biol Chem, 269, 22804-
10. 
COPPLE, I. M., LISTER, A., OBENG, A. D., KITTERINGHAM, N. R., JENKINS, R. E., LAYFIELD, R., 
FOSTER, B. J., GOLDRING, C. E. & PARK, B. K. 2010. Physical and functional interaction of 
sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J Biol Chem, 285, 
16782-8. 
CORDOVA, C., GUTIERREZ, B., MARTINEZ-GARCIA, C., MARTIN, R., GALLEGO-MUNOZ, P., 
HERNANDEZ, M. & NIETO, M. L. 2014. Oleanolic acid controls allergic and inflammatory 
responses in experimental allergic conjunctivitis. PLoS One, 9, e91282. 
COSTA, S., REINA-COUTO, M., ALBINO-TEIXEIRA, A. & SOUSA, T. 2016. Statins and oxidative 
stress in chronic heart failure. Rev Port Cardiol, 35, 41-57. 
COTTO, J. J., KLINE, M. & MORIMOTO, R. I. 1996. Activation of heat shock factor 1 DNA binding 
precedes stress-induced serine phosphorylation. Evidence for a multistep pathway of 
regulation. J Biol Chem, 271, 3355-8. 
CRAIG, E. A., STEVENS, M. V., VAILLANCOURT, R. R. & CAMENISCH, T. D. 2008. MAP3Ks as 
central regulators of cell fate during development. Dev Dyn, 237, 3102-14. 
CUADRADO, A. & NEBREDA, A. R. 2010. Mechanisms and functions of p38 MAPK signalling. Biochem 
J, 429, 403-17. 
CUENDA, A. & ROUSSEAU, S. 2007. p38 MAP-kinases pathway regulation, function and role in human 
diseases. Biochim Biophys Acta, 1773, 1358-75. 
CURRIE, R. W. & KARMAZYN, M. 1990. Improved post-ischemic ventricular recovery in the absence 
of changes in energy metabolism in working rat hearts following heat-shock. J Mol Cell Cardiol, 
22, 631-6. 
CURRIE, R. W., KARMAZYN, M., KLOC, M. & MAILER, K. 1988. Heat-shock response is associated 
with enhanced postischemic ventricular recovery. Circ Res, 63, 543-9. 
CURRIE, R. W., TANGUAY, R. M. & KINGMA, J. G., JR. 1993. Heat-shock response and limitation of 
tissue necrosis during occlusion/reperfusion in rabbit hearts. Circulation, 87, 963-71. 
DAI, C., SANTAGATA, S., TANG, Z., SHI, J., CAO, J., KWON, H., BRONSON, R. T., WHITESELL, L. 
& LINDQUIST, S. 2012b. Loss of tumor suppressor NF1 activates HSF1 to promote 
carcinogenesis. The J Clin Invest, 122, 3742-54, 
DAI, C., WHITESELL, L., ROGERS, A. B. & LINDQUIST, S. 2007. Heat shock factor 1 is a powerful 
multifaceted modifier of carcinogenesis. Cell, 130, 1005-18. 
DARVESH, A. S., CARROLL, R. T., BISHAYEE, A., NOVOTNY, N. A., GELDENHUYS, W. J. & VAN 
DER SCHYF, C. J. 2012. Curcumin and neurodegenerative diseases: a perspective. Expert 
Opin Investig Drugs, 21, 1123-40. 
DAVIES, T. G., WIXTED, W. E., COYLE, J. E., GRIFFITHS-JONES, C., HEARN, K., MCMENAMIN, 
R., NORTON, D., RICH, S. J., RICHARDSON, C., SAXTY, G., WILLEMS, H. M., WOOLFORD, 
A. J., COTTOM, J. E., KOU, J. P., YONCHUK, J. G., FELDSER, H. G., SANCHEZ, Y., FOLEY, 
J. P., BOLOGNESE, B. J., LOGAN, G., PODOLIN, P. L., YAN, H., CALLAHAN, J. F., 
HEIGHTMAN, T. D. & KERNS, J. K. 2016. Monoacidic Inhibitors of the Kelch-like ECH-
Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-
Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery. J Med 
Chem, 59, 3991-4006. 
DAYALAN NAIDU, S., KOSTOV, R. V. & DINKOVA-KOSTOVA, A. T. 2015. Transcription factors Hsf1 
and Nrf2 engage in crosstalk for cytoprotection. Trends Pharmacol Sci, 36, 6-14. 
DAYALAN NAIDU, S., SUTHERLAND, C., ZHANG, Y., RISCO, A., DE LA VEGA, L., CAUNT, C. J., 
HASTIE, C. J., LAMONT, D. J., TORRENTE, L., CHOWDHRY, S., BENJAMIN, I. J., KEYSE, 
S. M., CUENDA, A. & DINKOVA-KOSTOVA, A. T. 2016. Heat Shock Factor 1 is a Substrate 
for p38 Mitogen-Activated Protein Kinases. Mol Cell Biol. (in press) 
DE WIT, R., VAN DER ZEE, J., VAN DER BURG, M. E., KRUIT, W. H., LOGMANS, A., VAN RHOON, 
G. C. & VERWEIJ, J. 1999. A phase I/II study of combined weekly systemic cisplatin and 
locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the 
uterine cervix. Br J Cancer, 80, 1387-91. 
DEACON, K. & BLANK, J. L. 1997. Characterization of the mitogen-activated protein kinase kinase 4 
(MKK4)/c-Jun NH2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 
and 3. MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo. J Biol 
Chem, 272, 14489-96. 
DEL BARCO BARRANTES, I., COYA, J. M., MAINA, F., ARTHUR, J. S. & NEBREDA, A. R. 2011. 
Genetic analysis of specific and redundant roles for p38alpha and p38beta MAPKs during 
mouse development. Proc Natl Acad Sci U S A, 108, 12764-9. 
DEL REINO, P., ALSINA-BEAUCHAMP, D., ESCOS, A., CEREZO-GUISADO, M. I., RISCO, A., 
APARICIO, N., ZUR, R., FERNANDEZ-ESTEVEZ, M., COLLANTES, E., MONTANS, J. & 
CUENDA, A. 2014. Pro-oncogenic role of alternative p38 mitogen-activated protein kinases 
p38gamma and p38delta, linking inflammation and cancer in colitis-associated colon cancer. 
Cancer Res, 74, 6150-60. 
DESAI, S., LIU, Z., YAO, J., PATEL, N., CHEN, J., WU, Y., AHN, E. E., FODSTAD, O. & TAN, M. 2013. 
Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional 
regulation of autophagy-related protein 7 (ATG7). J Biol Chem, 288, 9165-76. 
DHARMAPPA, K. K., KUMAR, R. V., NATARAJU, A., MOHAMED, R., SHIVAPRASAD, H. V. & 
VISHWANATH, B. S. 2009. Anti-inflammatory activity of oleanolic acid by inhibition of secretory 
phospholipase A2. Planta Med, 75, 211-5. 
DINKOVA-KOSTOVA, A. T. 2013. Chemoprotection against cancer by isothiocyanates: a focus on the 
animal models and the protective mechanisms. Top Curr Chem, 329, 179-201. 
DINKOVA-KOSTOVA, A. T., BAIRD, L., HOLMSTROM, K. M., MEYER, C. J. & ABRAMOV, A. Y. 2015. 
The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular 
bioenergetics. Biochem Soc Trans, 43, 602-10. 
DINKOVA-KOSTOVA, A. T., HOLTZCLAW, W. D., COLE, R. N., ITOH, K., WAKABAYASHI, N., 
KATOH, Y., YAMAMOTO, M. & TALALAY, P. 2002. Direct evidence that sulfhydryl groups of 
Keap1 are the sensors regulating induction of phase 2 enzymes that protect against 
carcinogens and oxidants. Proc Natl Acad Sci U S A, 99, 11908-13. 
DINKOVA-KOSTOVA, A. T. & KOSTOV, R. V. 2012. Glucosinolates and isothiocyanates in health and 
disease. Trends Mol Med, 18, 337-47. 
DINKOVA-KOSTOVA, A. T., MASSIAH, M. A., BOZAK, R. E., HICKS, R. J. & TALALAY, P. 2001. 
Potency of Michael reaction acceptors as inducers of enzymes that protect against 
carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci U S A, 
98, 3404-9. 
DONNELLY, T. J., SIEVERS, R. E., VISSERN, F. L., WELCH, W. J. & WOLFE, C. L. 1992. Heat shock 
protein induction in rat hearts. A role for improved myocardial salvage after ischemia and 
reperfusion? Circulation, 85, 769-78. 
DORION, S., LAMBERT, H. & LANDRY, J. 2002. Activation of the p38 signaling pathway by heat shock 
involves the dissociation of glutathione S-transferase Mu from Ask1. J Biol Chem, 277, 30792-
7. 
DUDA, D. M., BORG, L. A., SCOTT, D. C., HUNT, H. W., HAMMEL, M. & SCHULMAN, B. A. 2008. 
Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of 
conjugation. Cell, 134, 995-1006. 
DUNGU, J. N., ANDERSON, L. J., WHELAN, C. J. & HAWKINS, P. N. 2014. Cardiac transthyretin 
amyloidosis. Heart, 98, 1546-54. 
ELIA, G., POLLA, B., ROSSI, A. & SANTORO, M. G. 1999. Induction of ferritin and heat shock proteins 
by prostaglandin A1 in human monocytes. Evidence for transcriptional and post-transcriptional 
regulation. Eur J Biochem, 264, 736-45. 
ENGEL, F. B., SCHEBESTA, M., DUONG, M. T., LU, G., REN, S., MADWED, J. B., JIANG, H., WANG, 
Y. & KEATING, M. T. 2005. p38 MAP kinase inhibition enables proliferation of adult mammalian 
cardiomyocytes. Genes Dev, 19, 1175-87. 
ESCOS, A., RISCO, A., ALSINA-BEAUCHAMP, D. & CUENDA, A. 2016. p38gamma and p38delta 
Mitogen Activated Protein Kinases (MAPKs), New Stars in the MAPK Galaxy. Front Cell Dev 
Biol, 4, 31. 
FAHEY, J. W., ZALCMANN, A. T. & TALALAY, P. 2001. The chemical diversity and distribution of 
glucosinolates and isothiocyanates among plants. Phytochemistry, 56, 5-51. 
FANG, H., PENGAL, R. A., CAO, X., GANESAN, L. P., WEWERS, M. D., MARSH, C. B. & 
TRIDANDAPANI, S. 2004. Lipopolysaccharide-induced macrophage inflammatory response is 
regulated by SHIP. J Immunol, 173, 360-6. 
FARGNOLI, J., KUNISADA, T., FORNACE, A. J., JR., SCHNEIDER, E. L. & HOLBROOK, N. J. 1990. 
Decreased expression of heat shock protein 70 mRNA and protein after heat treatment in cells 
of aged rats. Proc Natl Acad Sci U S A, 87, 846-50. 
FARKAS, T., KUTSKOVA, Y. A. & ZIMARINO, V. 1998. Intramolecular repression of mouse heat shock 
factor 1. Mol Cell Biol, 18, 906-18. 
FAVATA, M. F., HORIUCHI, K. Y., MANOS, E. J., DAULERIO, A. J., STRADLEY, D. A., FEESER, W. 
S., VAN DYK, D. E., PITTS, W. J., EARL, R. A., HOBBS, F., COPELAND, R. A., MAGOLDA, 
R. L., SCHERLE, P. A. & TRZASKOS, J. M. 1998. Identification of a novel inhibitor of mitogen-
activated protein kinase kinase. J Biol Chem, 273, 18623-32. 
FELLNER, L. & STEFANOVA, N. 2013. The role of glia in alpha-synucleinopathies. Mol Neurobiol, 47, 
575-86. 
FENG, J., ZHANG, P., CHEN, X. & HE, G. 2011. PI3K and ERK/Nrf2 pathways are involved in oleanolic 
acid-induced heme oxygenase-1 expression in rat vascular smooth muscle cells. J Cell 
Biochem, 112, 1524-31. 
FENG, Y., HUANG, W., MENG, W., JEGGA, A. G., WANG, Y., CAI, W., KIM, H. W., PASHA, Z., WEN, 
Z., RAO, F., MODI, R. M., YU, X. & ASHRAF, M. 2014. Heat shock improves Sca-1+ stem cell 
survival and directs ischemic cardiomyocytes toward a prosurvival phenotype via exosomal 
transfer: a critical role for HSF1/miR-34a/HSP70 pathway. Stem Cells, 32, 462-72. 
FORSHEW, T., JOHNSON, C. A., KHALIQ, S., PASHA, S., WILLIS, C., ABBASI, R., TEE, L., SMITH, 
U., TREMBATH, R. C., MEHDI, S. Q., MOORE, A. T. & MAHER, E. R. 2005. Locus 
heterogeneity in autosomal recessive congenital cataracts: linkage to 9q and germline HSF4 
mutations. Hum Genet, 117, 452-9. 
FOURQUET, S., GUEROIS, R., BIARD, D. & TOLEDANO, M. B. 2010. Activation of NRF2 by 
nitrosative agents and H2O2 involves KEAP1 disulfide formation. J Biol Chem, 285, 8463-71. 
FU, Q., WANG, J., BOERMA, M., BERBEE, M., QIU, X., FINK, L. M. & HAUER-JENSEN, M. 2008. 
Involvement of heat shock factor 1 in statin-induced transcriptional upregulation of endothelial 
thrombomodulin. Circ Res, 103, 369-77. 
FUJIHARA, M., MUROI, M., TANAMOTO, K., SUZUKI, T., AZUMA, H. & IKEDA, H. 2003. Molecular 
mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the 
receptor complex. Pharmacol Ther, 100, 171-94. 
FUJIMOTO, M., HAYASHIDA, N., KATOH, T., OSHIMA, K., SHINKAWA, T., PRAKASAM, R., TAN, K., 
INOUYE, S., TAKII, R. & NAKAI, A. 2010. A novel mouse HSF3 has the potential to activate 
nonclassical heat-shock genes during heat shock. Mol Biol Cell, 21, 106-16. 
FUJIMOTO, M., IZU, H., SEKI, K., FUKUDA, K., NISHIDA, T., YAMADA, S., KATO, K., YONEMURA, 
S., INOUYE, S. & NAKAI, A. 2004. HSF4 is required for normal cell growth and differentiation 
during mouse lens development. EMBO J, 23, 4297-306. 
FUJIMOTO, M., OSHIMA, K., SHINKAWA, T., WANG, B. B., INOUYE, S., HAYASHIDA, N., TAKII, R. 
& NAKAI, A. 2008. Analysis of HSF4 binding regions reveals its necessity for gene regulation 
during development and heat shock response in mouse lenses. J Biol Chem, 283, 29961-70. 
FUKAGAWA, N. K. 1999. Aging: is oxidative stress a marker or is it causal? Proc Soc Exp Biol Med, 
222, 293-8. 
FUKUTOMI, T., TAKAGI, K., MIZUSHIMA, T., OHUCHI, N. & YAMAMOTO, M. 2014. Kinetic, 
thermodynamic, and structural characterizations of the association between Nrf2-DLGex 
degron and Keap1. Mol Cell Biol, 34, 832-46. 
GAN, N., WU, Y. C., BRUNET, M., GARRIDO, C., CHUNG, F. L., DAI, C. & MI, L. 2010. Sulforaphane 
activates heat shock response and enhances proteasome activity through up-regulation of 
Hsp27. J Biol Chem, 285, 35528-36. 
GARRIDO, C., SCHMITT, E., CANDE, C., VAHSEN, N., PARCELLIER, A. & KROEMER, G. 2003. 
HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle, 2, 579-84. 
GASCOIGNE, K. E. & TAYLOR, S. S. 2009. How do anti-mitotic drugs kill cancer cells? J Cell Sci, 122, 
2579-85. 
GEISLER, S., HOLMSTROM, K. M., TREIS, A., SKUJAT, D., WEBER, S. S., FIESEL, F. C., KAHLE, 
P. J. & SPRINGER, W. 2010. The PINK1/Parkin-mediated mitophagy is compromised by PD-
associated mutations. Autophagy, 6, 871-8. 
GEORGE, V. C., KUMAR, D. R., SURESH, P. K. & KUMAR, R. A. 2012. Apoptosis-induced cell death 
due to oleanolic acid in HaCaT keratinocyte cells--a proof-of-principle approach for 
chemopreventive drug development. Asian Pac J Cancer Prev, 13, 2015-20. 
GIBBS, A., SCHWARTZMAN, J., DENG, V. & ALUMKAL, J. 2009. Sulforaphane destabilizes the 
androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl 
Acad Sci U S A, 106, 16663-8. 
GOEDERT, M., CUENDA, A., CRAXTON, M., JAKES, R. & COHEN, P. 1997. Activation of the novel 
stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 
(MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J, 16, 
3563-71. 
GONZALEZ-TERAN, B., LOPEZ, J. A., RODRIGUEZ, E., LEIVA, L., MARTINEZ-MARTINEZ, S., 
BERNAL, J. A., JIMENEZ-BORREGUERO, L. J., REDONDO, J. M., VAZQUEZ, J. & SABIO, 
G. 2016a. p38gamma and delta promote heart hypertrophy by targeting the mTOR-inhibitory 
protein DEPTOR for degradation. Nat Commun, 7, 10477. 
GONZALEZ-TERAN, B., MATESANZ, N., NIKOLIC, I., VERDUGO, M. A., SREERAMKUMAR, V., 
HERNANDEZ-COSIDO, L., MORA, A., CRAINICIUC, G., SAIZ, M. L., BERNARDO, E., LEIVA-
VEGA, L., RODRIGUEZ, E., BONDIA, V., TORRES, J. L., PEREZ-SIEIRA, S., ORTEGA, L., 
CUENDA, A., SANCHEZ-MADRID, F., NOGUEIRAS, R., HIDALGO, A., MARCOS, M. & 
SABIO, G. 2016b. p38gamma and p38delta reprogram liver metabolism by modulating 
neutrophil infiltration. EMBO J, 35, 536-52. 
GOODSON, M. L., HONG, Y., ROGERS, R., MATUNIS, M. J., PARK-SARGE, O. K. & SARGE, K. D. 
2001. Sumo-1 modification regulates the DNA binding activity of heat shock transcription factor 
2, a promyelocytic leukemia nuclear body associated transcription factor. J Biol Chem, 276, 
18513-8. 
GORMAN, A. M., SZEGEZDI, E., QUIGNEY, D. J. & SAMALI, A. 2005. Hsp27 inhibits 6-
hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells. Biochem 
Biophys Res Commun, 327, 801-10. 
GREEN, R. A., MAYERS, J. R., WANG, S., LEWELLYN, L., DESAI, A., AUDHYA, A. & OEGEMA, K. 
2013. The midbody ring scaffolds the abscission machinery in the absence of midbody 
microtubules. J Cell Biol, 203, 505-20. 
GREENBLATT, M. B., SHIM, J. H., ZOU, W., SITARA, D., SCHWEITZER, M., HU, D., LOTINUN, S., 
SANO, Y., BARON, R., PARK, J. M., ARTHUR, S., XIE, M., SCHNEIDER, M. D., ZHAI, B., 
GYGI, S., DAVIS, R. & GLIMCHER, L. H. 2010. The p38 MAPK pathway is essential for 
skeletogenesis and bone homeostasis in mice. J Clin Invest, 120, 2457-73. 
GROVER, A., SHANDILYA, A., AGRAWAL, V., PRATIK, P., BHASME, D., BISARIA, V. S. & SUNDAR, 
D. 2011. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target 
elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics, 12 Suppl 1, 
S30. 
GUETTOUCHE, T., BOELLMANN, F., LANE, W. S. & VOELLMY, R. 2005. Analysis of phosphorylation 
of human heat shock factor 1 in cells experiencing a stress. BMC Biochem, 6, 4. 
GURGIS, F. M., ZIAZIARIS, W. & MUNOZ, L. 2014. Mitogen-activated protein kinase-activated protein 
kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and 
targeting. Mol Pharmacol, 85, 345-56. 
HAMILTON, K. L., MBAI, F. N., GUPTA, S. & KNOWLTON, A. A. 2004. Estrogen, heat shock proteins, 
and NFkappaB in human vascular endothelium. Arterioscler Thromb Vasc Biol, 24, 1628-33. 
HAN, J., LEE, J. D., BIBBS, L. & ULEVITCH, R. J. 1994. A MAP kinase targeted by endotoxin and 
hyperosmolarity in mammalian cells. Science, 265, 808-11. 
HAN, S., CHOI, J. R., SOON SHIN, K. & KANG, S. J. 2012. Resveratrol upregulated heat shock proteins 
and extended the survival of G93A-SOD1 mice. Brain Res, 1483, 112-7. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. Cell, 144, 646-74. 
HARTEVELT, M. M., BAVINCK, J. N., KOOTTE, A. M., VERMEER, B. J. & VANDENBROUCKE, J. P. 
1990. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation, 
49, 506-9. 
HASEGAWA, M., CUENDA, A., SPILLANTINI, M. G., THOMAS, G. M., BUEE-SCHERRER, V., 
COHEN, P. & GOEDERT, M. 1999. Stress-activated protein kinase-3 interacts with the PDZ 
domain of alpha1-syntrophin. A mechanism for specific substrate recognition. J Biol Chem, 
274, 12626-31. 
HASHIMOTO-TORII, K., TORII, M., FUJIMOTO, M., NAKAI, A., EL FATIMY, R., MEZGER, V., JU, M. 
J., ISHII, S., CHAO, S. H., BRENNAND, K. J., GAGE, F. H. & RAKIC, P. 2014. Roles of heat 
shock factor 1 in neuronal response to fetal environmental risks and its relevance to brain 
disorders. Neuron, 82, 560-72. 
HATCHER, H., PLANALP, R., CHO, J., TORTI, F. M. & TORTI, S. V. 2008. Curcumin: from ancient 
medicine to current clinical trials. Cell Mol Life Sci, 65, 1631-52. 
HAYES, J. D. & DINKOVA-KOSTOVA, A. T. 2014. The Nrf2 regulatory network provides an interface 
between redox and intermediary metabolism. Trends Biochem Sci, 39, 199-218. 
HE, S., LIMI, S., MCGREAL, R. S., XIE, Q., BRENNAN, L. A., KANTOROW, W. L., KOKAVEC, J., 
MAJUMDAR, R., HOU, H., JR., EDELMANN, W., LIU, W., ASHERY-PADAN, R., ZAVADIL, J., 
KANTOROW, M., SKOULTCHI, A. I., STOPKA, T. & CVEKL, A. 2016. Chromatin remodeling 
enzyme Snf2h regulates embryonic lens differentiation and denucleation. Development, 143, 
1937-47. 
HECTOR, A., GRIESE, M. & HARTL, D. 2014. Oxidative stress in cystic fibrosis lung disease: an early 
event, but worth targeting? Eur Respir J, 44, 17-9. 
HENSEN, S. M., HELDENS, L., VAN ENCKEVORT, C. M., VAN GENESEN, S. T., PRUIJN, G. J. & 
LUBSEN, N. H. 2013a. Activation of the antioxidant response in methionine deprived human 
cells results in an HSF1-independent increase in HSPA1A mRNA levels. Biochimie, 95, 1245-
51. 
HENSEN, S. M., HELDENS, L., VAN GENESEN, S. T., PRUIJN, G. J. & LUBSEN, N. H. 2013b. A 
delayed antioxidant response in heat-stressed cells expressing a non-DNA binding HSF1 
mutant. Cell Stress Chaperones, 18, 455-73. 
HETMAN, M., CAVANAUGH, J. E., KIMELMAN, D. & XIA, Z. 2000. Role of glycogen synthase kinase-
3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci, 20, 2567-74. 
HEYDARI, A. R., WU, B., TAKAHASHI, R., STRONG, R. & RICHARDSON, A. 1993. Expression of 
heat shock protein 70 is altered by age and diet at the level of transcription. Mol Cell Biol, 13, 
2909-18. 
HIERONYMUS, H., LAMB, J., ROSS, K. N., PENG, X. P., CLEMENT, C., RODINA, A., NIETO, M., DU, 
J., STEGMAIER, K., RAJ, S. M., MALONEY, K. N., CLARDY, J., HAHN, W. C., CHIOSIS, G. 
& GOLUB, T. R. 2006. Gene expression signature-based chemical genomic prediction 
identifies a novel class of HSP90 pathway modulators. Cancer Cell, 10, 321-30. 
HIETAKANGAS, V., AHLSKOG, J. K., JAKOBSSON, A. M., HELLESUO, M., SAHLBERG, N. M., 
HOLMBERG, C. I., MIKHAILOV, A., PALVIMO, J. J., PIRKKALA, L. & SISTONEN, L. 2003. 
Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of 
heat shock factor 1. Mol Cell Biol, 23, 2953-68. 
HIETAKANGAS, V., ANCKAR, J., BLOMSTER, H. A., FUJIMOTO, M., PALVIMO, J. J., NAKAI, A. & 
SISTONEN, L. 2006. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc 
Natl Acad Sci U S A, 103, 45-50. 
HILGARTH, R. S., HONG, Y., PARK-SARGE, O. K. & SARGE, K. D. 2003. Insights into the regulation 
of heat shock transcription factor 1 SUMO-1 modification. Biochem Biophys Res Commun, 303, 
196-200. 
HIROTSU, Y., KATSUOKA, F., FUNAYAMA, R., NAGASHIMA, T., NISHIDA, Y., NAKAYAMA, K., 
ENGEL, J. D. & YAMAMOTO, M. 2012. Nrf2-MafG heterodimers contribute globally to 
antioxidant and metabolic networks. Nucleic Acids Res, 40, 10228-39. 
HOLMBERG, C. I., HIETAKANGAS, V., MIKHAILOV, A., RANTANEN, J. O., KALLIO, M., 
MEINANDER, A., HELLMAN, J., MORRICE, N., MACKINTOSH, C., MORIMOTO, R. I., 
ERIKSSON, J. E. & SISTONEN, L. 2001. Phosphorylation of serine 230 promotes inducible 
transcriptional activity of heat shock factor 1. EMBO J, 20, 3800-10. 
HONDA, T., YOSHIZAWA, H., SUNDARARAJAN, C., DAVID, E., LAJOIE, M. J., FAVALORO, F. G., 
JR., JANOSIK, T., SU, X., HONDA, Y., ROEBUCK, B. D. & GRIBBLE, G. W. 2011. Tricyclic 
compounds containing nonenolizable cyano enones. A novel class of highly potent anti-
inflammatory and cytoprotective agents. J Med Chem, 54, 1762-78. 
HONG, Y., ROGERS, R., MATUNIS, M. J., MAYHEW, C. N., GOODSON, M. L., PARK-SARGE, O. K. 
& SARGE, K. D. 2001. Regulation of heat shock transcription factor 1 by stress-induced SUMO-
1 modification. J Biol Chem, 276, 40263-7. 
HONG, Y. H., UDDIN, M. H., JO, U., KIM, B., SONG, J., SUH, D. H., KIM, H. S. & SONG, Y. S. 2015. 
ROS Accumulation by PEITC Selectively Kills Ovarian Cancer Cells via UPR-Mediated 
Apoptosis. Front Oncol, 5, 167. 
HOSHINO, T., MURAO, N., NAMBA, T., TAKEHARA, M., ADACHI, H., KATSUNO, M., SOBUE, G., 
MATSUSHIMA, T., SUZUKI, T. & MIZUSHIMA, T. 2011. Suppression of Alzheimer's disease-
related phenotypes by expression of heat shock protein 70 in mice. J Neurosci, 31, 5225-34. 
HOWITZ, K. T., BITTERMAN, K. J., COHEN, H. Y., LAMMING, D. W., LAVU, S., WOOD, J. G., ZIPKIN, 
R. E., CHUNG, P., KISIELEWSKI, A., ZHANG, L. L., SCHERER, B. & SINCLAIR, D. A. 2003. 
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 
191-6. 
HSIEH, C. C., KURO-O, M., ROSENBLATT, K. P., BROBEY, R. & PAPACONSTANTINOU, J. 2010. 
The ASK1-Signalosome regulates p38 MAPK activity in response to levels of endogenous 
oxidative stress in the Klotho mouse models of aging. Aging (Albany NY), 2, 597-611. 
HU, C. K., COUGHLIN, M. & MITCHISON, T. J. 2012. Midbody assembly and its regulation during 
cytokinesis. Mol Biol Cell, 23, 1024-34. 
HU, L., MAGESH, S., CHEN, L., WANG, L., LEWIS, T. A., CHEN, Y., KHODIER, C., INOYAMA, D., 
BEAMER, L. J., EMGE, T. J., SHEN, J., KERRIGAN, J. E., KONG, A. N., DANDAPANI, S., 
PALMER, M., SCHREIBER, S. L. & MUNOZ, B. 2013. Discovery of a small-molecule inhibitor 
and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett, 23, 3039-
43. 
HU, R., XU, C., SHEN, G., JAIN, M. R., KHOR, T. O., GOPALKRISHNAN, A., LIN, W., REDDY, B., 
CHAN, J. Y. & KONG, A. N. 2006a. Gene expression profiles induced by cancer 
chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 
(-/-) mice. Cancer lett, 243, 170-92. 
HU, R., XU, C., SHEN, G., JAIN, M. R., KHOR, T. O., GOPALKRISHNAN, A., LIN, W., REDDY, B., 
CHAN, J. Y. & KONG, A. N. 2006b. Identification of Nrf2-regulated genes induced by 
chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life sci, 79, 1944-55. 
HU, Y. & MIVECHI, N. F. 2011. Promotion of heat shock factor Hsf1 degradation via adaptor protein 
filamin A-interacting protein 1-like (FILIP-1L). J Biol Chem, 286, 31397-408. 
HUBBARD, B. P. & SINCLAIR, D. A. 2014. Small molecule SIRT1 activators for the treatment of aging 
and age-related diseases. Trends Pharmacol Sci, 35, 146-54. 
HUBBARD, J., ERLICHMAN, C., TOFT, D. O., QIN, R., STENSGARD, B. A., FELTEN, S., TEN EYCK, 
C., BATZEL, G., IVY, S. P. & HALUSKA, P. Phase I study of 17-allylamino-17 
demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. 
Invest New Drugs, 29, 473-80. 
HUTTER, M. M., SIEVERS, R. E., BARBOSA, V. & WOLFE, C. L. 1994. Heat-shock protein induction 
in rat hearts. A direct correlation between the amount of heat-shock protein induced and the 
degree of myocardial protection. Circulation, 89, 355-60. 
ICHIJO, H., NISHIDA, E., IRIE, K., TEN DIJKE, P., SAITOH, M., MORIGUCHI, T., TAKAGI, M., 
MATSUMOTO, K., MIYAZONO, K. & GOTOH, Y. 1997. Induction of apoptosis by ASK1, a 
mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 275, 90-
4. 
ICHIMURA, Y., WAGURI, S., SOU, Y. S., KAGEYAMA, S., HASEGAWA, J., ISHIMURA, R., SAITO, 
T., YANG, Y., KOUNO, T., FUKUTOMI, T., HOSHII, T., HIRAO, A., TAKAGI, K., MIZUSHIMA, 
T., MOTOHASHI, H., LEE, M. S., YOSHIMORI, T., TANAKA, K., YAMAMOTO, M. & 
KOMATSU, M. 2013. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during 
selective autophagy. Mol Cell, 51, 618-31. 
INOUYE, S., KATSUKI, K., IZU, H., FUJIMOTO, M., SUGAHARA, K., YAMADA, S., SHINKAI, Y., OKA, 
Y., KATOH, Y. & NAKAI, A. 2003. Activation of heat shock genes is not necessary for protection 
by heat shock transcription factor 1 against cell death due to a single exposure to high 
temperatures. Mol Cell Biol, 23, 5882-95. 
ITOH, K., WAKABAYASHI, N., KATOH, Y., ISHII, T., IGARASHI, K., ENGEL, J. D. & YAMAMOTO, M. 
1999. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through 
binding to the amino-terminal Neh2 domain. Genes Dev, 13, 76-86. 
ITTNER, A., BLOCK, H., REICHEL, C. A., VARJOSALO, M., GEHART, H., SUMARA, G., GSTAIGER, 
M., KROMBACH, F., ZARBOCK, A. & RICCI, R. 2012. Regulation of PTEN activity by p38delta-
PKD1 signaling in neutrophils confers inflammatory responses in the lung. J Exp Med, 209, 
2229-46. 
JACOBS, A. T. & MARNETT, L. J. 2007. Heat shock factor 1 attenuates 4-Hydroxynonenal-mediated 
apoptosis: critical role for heat shock protein 70 induction and stabilization of Bcl-XL. J Biol 
Chem, 282, 33412-20. 
JACOBS, A. T. & MARNETT, L. J. 2010. Systems analysis of protein modification and cellular 
responses induced by electrophile stress. Acc Chem Res, 43, 673-83. 
JACOBY, E., TRESADERN, G., BEMBENEK, S., WROBLOWSKI, B., BUYCK, C., NEEFS, J. M., 
RASSOKHIN, D., PONCELET, A., HUNT, J. & VAN VLIJMEN, H. 2015. Extending kinome 
coverage by analysis of kinase inhibitor broad profiling data. Drug Discov Today, 20, 652-8. 
JAEGER, A. M., PEMBLE, C. W. T., SISTONEN, L. & THIELE, D. J. 2016. Structures of HSF2 reveal 
mechanisms for differential regulation of human heat-shock factors. Nat Struct Mol Biol, 23, 
147-54. 
JAIN, A., LAMARK, T., SJOTTEM, E., LARSEN, K. B., AWUH, J. A., OVERVATN, A., MCMAHON, M., 
HAYES, J. D. & JOHANSEN, T. 2010. p62/SQSTM1 is a target gene for transcription factor 
NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven 
gene transcription. J Biol Chem, 285, 22576-91. 
JANAKIRAM, N. B., INDRANIE, C., MALISETTY, S. V., JAGAN, P., STEELE, V. E. & RAO, C. V. 2008. 
Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats 
and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm Res, 25, 
2151-7. 
JENSEN, P., MOLLER, B. & HANSEN, S. 2000. Skin cancer in kidney and heart transplant recipients 
and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol, 42, 307. 
JESUS, J. A., LAGO, J. H., LAURENTI, M. D., YAMAMOTO, E. S. & PASSERO, L. F. 2015. 
Antimicrobial activity of oleanolic and ursolic acids: an update. Evid Based Complement 
Alternat Med, 2015, 620472. 
JHAVERI, K., TALDONE, T., MODI, S. & CHIOSIS, G. 2012. Advances in the clinical development of 
heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta, 1823, 742-55. 
JIANG, Y. Q., WANG, X. L., CAO, X. H., YE, Z. Y., LI, L. & CAI, W. Q. 2013. Increased heat shock 
transcription factor 1 in the cerebellum reverses the deficiency of Purkinje cells in Alzheimer's 
disease. Brain Res, 1519, 105-11. 
JIMENEZ-ARELLANES, A., LUNA-HERRERA, J., CORNEJO-GARRIDO, J., LOPEZ-GARCIA, S., 
CASTRO-MUSSOT, M. E., MECKES-FISCHER, M., MATA-ESPINOSA, D., MARQUINA, B., 
TORRES, J. & HERNANDEZ-PANDO, R. 2013. Ursolic and oleanolic acids as antimicrobial 
and immunomodulatory compounds for tuberculosis treatment. BMC Complement Altern Med, 
13, 258. 
JING, Y., LIU, W., CAO, H., ZHANG, D., YAO, X., ZHANG, S., XIA, H., LI, D., WANG, Y. C., YAN, J., 
HUI, L. & YING, H. 2015. Hepatic p38alpha regulates gluconeogenesis by suppressing AMPK. 
J Hepatol, 62, 1319-27. 
JIYAD, Z., OLSEN, C. M., BURKE, M. T., ISBEL, N. M. & GREEN, A. C. 2016. Azathioprine and Risk 
of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-analysis. Am J 
Transplant. (in press) 
JOHNSON, S. A. & HUNTER, T. 2005. Kinomics: methods for deciphering the kinome. Nat Methods, 
2, 17-25. 
JOLLY, C. & MORIMOTO, R. I. 2000. Role of the heat shock response and molecular chaperones in 
oncogenesis and cell death. J Natl Cancer Inst, 92, 1564-72. 
JOSEPH, J. A. & ROTH, G. S. 1992. Cholinergic systems in aging: the role of oxidative stress. Clin 
Neuropharmacol, 15 Suppl 1 Pt A, 508A-509A. 
JUTOORU, I., GUTHRIE, A. S., CHADALAPAKA, G., PATHI, S., KIM, K., BURGHARDT, R., JIN, U. H. 
& SAFE, S. 2014. Mechanism of action of phenethylisothiocyanate and other reactive oxygen 
species-inducing anticancer agents. Mol Cell Biol, 34, 2382-95. 
KALLIO, M., CHANG, Y., MANUEL, M., ALASTALO, T. P., RALLU, M., GITTON, Y., PIRKKALA, L., 
LOONES, M. T., PASLARU, L., LARNEY, S., HIARD, S., MORANGE, M., SISTONEN, L. & 
MEZGER, V. 2002. Brain abnormalities, defective meiotic chromosome synapsis and female 
subfertility in HSF2 null mice. EMBO J, 21, 2591-601. 
KALRA, S., KNATKO, E. V., ZHANG, Y., HONDA, T., YAMAMOTO, M. & DINKOVA-KOSTOVA, A. T. 
2012. Highly potent activation of Nrf2 by topical tricyclic bis(cyano enone): implications for 
protection against UV radiation during thiopurine therapy. Cancer Prev Res (Phila), 5, 973-81. 
KANG, M. I., KOBAYASHI, A., WAKABAYASHI, N., KIM, S. G. & YAMAMOTO, M. 2004. Scaffolding 
of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective 
phase 2 genes. Proc Natl Acad Sci U S A, 101, 2046-51. 
KANITKAR, M. & BHONDE, R. R. 2008. Curcumin treatment enhances islet recovery by induction of 
heat shock response proteins, Hsp70 and heme oxygenase-1, during cryopreservation. Life 
Sci, 82, 182-9. 
KANSANEN, E., JYRKKANEN, H. K., VOLGER, O. L., LEINONEN, H., KIVELA, A. M., HAKKINEN, S. 
K., WOODCOCK, S. R., SCHOPFER, F. J., HORREVOETS, A. J., YLA-HERTTUALA, S., 
FREEMAN, B. A. & LEVONEN, A. L. 2009. Nrf2-dependent and -independent responses to 
nitro-fatty acids in human endothelial cells: identification of heat shock response as the major 
pathway activated by nitro-oleic acid. J Biol Chem, 284, 33233-41. 
KARMAZYN, M., MAILER, K. & CURRIE, R. W. 1990. Acquisition and decay of heat-shock-enhanced 
postischemic ventricular recovery. Am J Physiol, 259, H424-31. 
KARRAN, P. 2006. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull, 
79-80, 153-70. 
KATO, K., ITO, H., KAMEI, K. & IWAMOTO, I. 1998. Stimulation of the stress-induced expression of 
stress proteins by curcumin in cultured cells and in rat tissues in vivo. Cell Stress Chaperones, 
3, 152-60. 
KAWAZOE, Y., TANABE, M., SASAI, N., NAGATA, K. & NAKAI, A. 1999. HSF3 is a major heat shock 
responsive factor duringchicken embryonic development. Eur J Biochem, 265, 688-97. 
KAZEMI-ESFARJANI, P. & BENZER, S. 2000. Genetic suppression of polyglutamine toxicity in 
Drosophila. Science, 287, 1837-40. 
KE, T., WANG, Q. K., JI, B., WANG, X., LIU, P., ZHANG, X., TANG, Z., REN, X. & LIU, M. 2006. Novel 
HSF4 mutation causes congenital total white cataract in a Chinese family. Am J Ophthalmol, 
142, 298-303. 
KENSLER, T. W., NG, D., CARMELLA, S. G., CHEN, M., JACOBSON, L. P., MUNOZ, A., EGNER, P. 
A., CHEN, J. G., QIAN, G. S., CHEN, T. Y., FAHEY, J. W., TALALAY, P., GROOPMAN, J. D., 
YUAN, J. M. & HECHT, S. S. 2012. Modulation of the metabolism of airborne pollutants by 
glucoraphanin-rich and sulforaphane-rich broccoli sprout beverages in Qidong, China. 
Carcinogenesis, 33, 101-7. 
KENSLER, T. W., WAKABAYASHI, N. & BISWAL, S. 2007. Cell survival responses to environmental 
stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol, 47, 89-116. 
KEREN, A. & BENGAL, E. 2010. Studying MAP Kinase pathways during early development of Xenopus 
laevis. Methods Mol Biol, 661, 409-20. 
KHAN, S. & HEIKKILA, J. J. 2011. Curcumin-induced inhibition of proteasomal activity, enhanced HSP 
accumulation and the acquisition of thermotolerance in Xenopus laevis A6 cells. Comp 
Biochem Physiol A Mol Integr Physiol, 158, 566-76. 
KHOR, T. O., CHEUNG, W. K., PRAWAN, A., REDDY, B. S. & KONG, A. N. 2008. Chemoprevention 
of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC). 
Mol Carcinog, 47, 321-5. 
KIAEI, M., KIPIANI, K., PETRI, S., CHEN, J., CALINGASAN, N. Y. & BEAL, M. F. 2005. Celastrol blocks 
neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. 
Neurodegener Dis, 2, 246-54. 
KIM, E., WANG, B., SASTRY, N., MASLIAH, E., NELSON, P. T., CAI, H. & LIAO, F. F. 2016. NEDD4-
mediated HSF1 degradation underlies alpha-synucleinopathy. Hum Mol Genet, 25, 211-22. 
KIM, G., MERIIN, A. B., GABAI, V. L., CHRISTIANS, E., BENJAMIN, I., WILSON, A., WOLOZIN, B. & 
SHERMAN, M. Y. 2012a. The heat shock transcription factor Hsf1 is downregulated in DNA 
damage-associated senescence, contributing to the maintenance of senescence phenotype. 
Aging Cell, 11, 617-27. 
KIM, K. A., LEE, J. S., PARK, H. J., KIM, J. W., KIM, C. J., SHIM, I. S., KIM, N. J., HAN, S. M. & LIM, 
S. 2004. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human 
liver microsomes. Life Sci, 74, 2769-79. 
KIM, K. H., JEONG, J. Y., SURH, Y. J. & KIM, K. W. 2010. Expression of stress-response ATF3 is 
mediated by Nrf2 in astrocytes. Nucleic acids Res, 38, 48-59. 
KIM, S. & SHAH, K. 2007. Dissecting yeast Hog1 MAP kinase pathway using a chemical genetic 
approach. FEBS Lett, 581, 1209-16. 
KIM, S. A., YOON, J. H. & AHN, S. G. 2012b. Heat shock factor 4a (HSF4a) represses HSF2 expression 
and HSF2-mediated transcriptional activity. J Cell Physiol, 227, 1-6. 
KIM, S. A., YOON, J. H., LEE, S. H. & AHN, S. G. 2005. Polo-like kinase 1 phosphorylates heat shock 
transcription factor 1 and mediates its nuclear translocation during heat stress. J Biol Chem, 
280, 12653-7. 
KIM, S. H., HONG, J. H. & LEE, Y. C. 2014. Oleanolic acid suppresses ovalbumin-induced airway 
inflammation and Th2-mediated allergic asthma by modulating the transcription factors T-bet, 
GATA-3, RORgammat and Foxp3 in asthmatic mice. Int Immunopharmacol, 18, 311-24. 
KLINE, M. P. & MORIMOTO, R. I. 1997. Repression of the heat shock factor 1 transcriptional activation 
domain is modulated by constitutive phosphorylation. Mol Cell Biol, 17, 2107-15. 
KNATKO, E. V., IBBOTSON, S. H., ZHANG, Y., HIGGINS, M., FAHEY, J. W., TALALAY, P., DAWE, 
R. S., FERGUSON, J., HUANG, J. T., CLARKE, R., ZHENG, S., SAITO, A., KALRA, S., 
BENEDICT, A. L., HONDA, T., PROBY, C. M. & DINKOVA-KOSTOVA, A. T. 2015. Nrf2 
Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice and Humans. Cancer 
Prev Res (Phila), 8, 475-86. 
KNOWLTON, A. A., KAPADIA, S., TORRE-AMIONE, G., DURAND, J. B., BIES, R., YOUNG, J. & 
MANN, D. L. 1998. Differential expression of heat shock proteins in normal and failing human 
hearts. J Mol Cell Cardiol, 30, 811-8. 
KNOWLTON, A. A. & KORZICK, D. H. 2014. Estrogen and the female heart. Mol Cell Endocrinol, 389, 
31-39 
KNOWLTON, A. A. & SUN, L. 2001. Heat-shock factor-1, steroid hormones, and regulation of heat-
shock protein expression in the heart. Am J Physiol Heart Circ Physiol, 280, H455-64. 
KOBAYASHI, A., KANG, M. I., OKAWA, H., OHTSUJI, M., ZENKE, Y., CHIBA, T., IGARASHI, K. & 
YAMAMOTO, M. 2004. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based 
E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol, 24, 7130-9. 
KOMATSU, M., KUROKAWA, H., WAGURI, S., TAGUCHI, K., KOBAYASHI, A., ICHIMURA, Y., SOU, 
Y. S., UENO, I., SAKAMOTO, A., TONG, K. I., KIM, M., NISHITO, Y., IEMURA, S., NATSUME, 
T., UENO, T., KOMINAMI, E., MOTOHASHI, H., TANAKA, K. & YAMAMOTO, M. 2010. The 
selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 
through inactivation of Keap1. Nat Cell Biol, 12, 213-23. 
KOMATSU, M., KUROKAWA, H., WAGURI, S., TAGUCHI, K., KOBAYASHI, A., ICHIMURA, Y., SOU, 
Y. S., UENO, I., SAKAMOTO, A., TONG, K. I., KIM, M., NISHITO, Y., IEMURA, S., NATSUME, 
T., UENO, T., KOMINAMI, E., MOTOHASHI, H., TANAKA, K. & YAMAMOTO, M. 2010b. The 
selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 
through inactivation of Keap1. Nature cell biology, 12, 213-23. 
KOMATSU, M., WAGURI, S., UENO, T., IWATA, J., MURATA, S., TANIDA, I., EZAKI, J., MIZUSHIMA, 
N., OHSUMI, Y., UCHIYAMA, Y., KOMINAMI, E., TANAKA, K. & CHIBA, T. 2005. Impairment 
of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol, 169, 425-
34. 
KONDO, N., KATSUNO, M., ADACHI, H., MINAMIYAMA, M., DOI, H., MATSUMOTO, S., MIYAZAKI, 
Y., IIDA, M., TOHNAI, G., NAKATSUJI, H., ISHIGAKI, S., FUJIOKA, Y., WATANABE, H., 
TANAKA, F., NAKAI, A. & SOBUE, G. 2013. Heat shock factor-1 influences pathological lesion 
distribution of polyglutamine-induced neurodegeneration. Nat Commun, 4, 1405. 
KOSTOV, R. V., KNATKO, E. V., MCLAUGHLIN, L. A., HENDERSON, C. J., ZHENG, S., HUANG, J. 
T., HONDA, T. & DINKOVA-KOSTOVA, A. T. 2015. Pharmacokinetics and pharmacodynamics 
of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a 
reversible covalent mode of action. Biochem Biophys Res Commun, 465, 402-7. 
KOURTIS, N., MOUBARAK, R. S., ARANDA-ORGILLES, B., LUI, K., AYDIN, I. T., TRIMARCHI, T., 
DARVISHIAN, F., SALVAGGIO, C., ZHONG, J., BHATT, K., CHEN, E. I., CELEBI, J. T., 
LAZARIS, C., TSIRIGOS, A., OSMAN, I., HERNANDO, E. & AIFANTIS, I. 2015. FBXW7 
modulates cellular stress response and metastatic potential through HSF1 post-translational 
modification. Nat Cell Biol, 17, 322-32. 
KUBO, M., LI, T. S., KURAZUMI, H., TAKEMOTO, Y., OHSHIMA, M., YAMAMOTO, Y., NISHIMOTO, 
A., MIKAMO, A., FUJIMOTO, M., NAKAI, A. & HAMANO, K. 2012. Heat shock factor 1 
contributes to ischemia-induced angiogenesis by regulating the mobilization and recruitment of 
bone marrow stem/progenitor cells. PLoS One, 7, e37934. 
KUMA, Y., SABIO, G., BAIN, J., SHPIRO, N., MARQUEZ, R. & CUENDA, A. 2005. BIRB796 inhibits 
all p38 MAPK isoforms in vitro and in vivo. J Biol Chem, 280, 19472-9. 
KWAK, M. K., RAMOS-GOMEZ, M., WAKABAYASHI, N. & KENSLER, T. W. 2004. Chemoprevention 
by 1,2-dithiole-3-thiones through induction of NQO1 and other phase 2 enzymes. Methods 
Enzymol, 382, 414-23. 
KWAK, Y. D., WANG, B., LI, J. J., WANG, R., DENG, Q., DIAO, S., CHEN, Y., XU, R., MASLIAH, E., 
XU, H., SUNG, J. J. & LIAO, F. F. 2012. Upregulation of the E3 ligase NEDD4-1 by oxidative 
stress degrades IGF-1 receptor protein in neurodegeneration. J Neurosci, 32, 10971-81. 
LABBADIA, J., CUNLIFFE, H., WEISS, A., KATSYUBA, E., SATHASIVAM, K., SEREDENINA, T., 
WOODMAN, B., MOUSSAOUI, S., FRENTZEL, S., LUTHI-CARTER, R., PAGANETTI, P. & 
BATES, G. P. 2011. Altered chromatin architecture underlies progressive impairment of the 
heat shock response in mouse models of Huntington disease. J Clin Invest, 121, 3306-19. 
LAO, C. D., RUFFIN, M. T. T., NORMOLLE, D., HEATH, D. D., MURRAY, S. I., BAILEY, J. M., BOGGS, 
M. E., CROWELL, J., ROCK, C. L. & BRENNER, D. E. 2006. Dose escalation of a curcuminoid 
formulation. BMC Complement Altern Med, 6, 10. 
LARA-GONZALEZ, P., WESTHORPE, F. G. & TAYLOR, S. S. 2012. The spindle assembly checkpoint. 
Curr Biol, 22, R966-80. 
LASSAR, A. B. 2009. The p38 MAPK family, a pushmi-pullyu of skeletal muscle differentiation. J Cell 
Biol, 187, 941-3. 
LAU, A., WANG, X. J., ZHAO, F., VILLENEUVE, N. F., WU, T., JIANG, T., SUN, Z., WHITE, E. & 
ZHANG, D. D. 2010. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: 
direct interaction between Keap1 and p62. Mol Cell Biol, 30, 3275-85. 
LAWSON, S. K., DOBRIKOVA, E. Y., SHVEYGERT, M. & GROMEIER, M. 2013. p38alpha mitogen-
activated protein kinase depletion and repression of signal transduction to translation 
machinery by miR-124 and -128 in neurons. Mol Cell Biol, 33, 127-35. 
LE MASSON, F., RAZAK, Z., KAIGO, M., AUDOUARD, C., CHARRY, C., COOKE, H., WESTWOOD, 
J. T. & CHRISTIANS, E. S. 2011. Identification of heat shock factor 1 molecular and cellular 
targets during embryonic and adult female meiosis. Mol Cell Biol, 31, 3410-23. 
LEE, J. C., LAYDON, J. T., MCDONNELL, P. C., GALLAGHER, T. F., KUMAR, S., GREEN, D., 
MCNULTY, D., BLUMENTHAL, M. J., HEYS, J. R., LANDVATTER, S. W. & ET AL. 1994. A 
protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372, 
739-46. 
LEE, J. C. & YOUNG, P. R. 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine 
signaling mechanisms. J Leukoc Biol, 59, 152-7. 
LEE, J. M., CALKINS, M. J., CHAN, K., KAN, Y. W. & JOHNSON, J. A. 2003. Identification of the NF-
E2-related factor-2-dependent genes conferring protection against oxidative stress in primary 
cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem, 278, 12029-38. 
LEE, M. J., NISHIO, H., AYAKI, H., YAMAMOTO, M. & SUMINO, K. 2002a. Upregulation of stress 
response mRNAs in COS-7 cells exposed to cadmium. Toxicology, 174, 109-17. 
LEE, S. J., PARK, S. Y., NA, J. G. & KIM, Y. J. 2002b. Osmolarity hypersensitivity of hog1 deleted 
mutants is suppressed by mutation in KSS1 in budding yeast Saccharomyces cerevisiae. 
FEMS Microbiol Lett, 209, 9-14. 
LEE, W. H., LOO, C. Y., BEBAWY, M., LUK, F., MASON, R. S. & ROHANIZADEH, R. 2013. Curcumin 
and its derivatives: their application in neuropharmacology and neuroscience in the 21st 
century. Curr Neuropharmacol, 11, 338-78. 
LEE, Y. J., KIM, E. H., LEE, J. S., JEOUNG, D., BAE, S., KWON, S. H. & LEE, Y. S. 2008a. HSF1 as 
a mitotic regulator: phosphorylation of HSF1 by Plk1 is essential for mitotic progression. Cancer 
Res, 68, 7550-60. 
LEE, Y. J., LEE, H. J., LEE, J. S., JEOUNG, D., KANG, C. M., BAE, S., LEE, S. J., KWON, S. H., 
KANG, D. & LEE, Y. S. 2008b. A novel function for HSF1-induced mitotic exit failure and 
genomic instability through direct interaction between HSF1 and Cdc20. Oncogene, 27, 2999-
3009. 
LESKO, E., GOZDZIK, J., KIJOWSKI, J., JENNER, B., WIECHA, O. & MAJKA, M. 2007. HSP90 
antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of 
rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs, 18, 
1173-81. 
LEVONEN, A. L., LANDAR, A., RAMACHANDRAN, A., CEASER, E. K., DICKINSON, D. A., ZANONI, 
G., MORROW, J. D. & DARLEY-USMAR, V. M. 2004. Cellular mechanisms of redox cell 
signalling: role of cysteine modification in controlling antioxidant defences in response to 
electrophilic lipid oxidation products. Biochem J, 378, 373-82. 
LI, S., MA, W., FEI, T., LOU, Q., ZHANG, Y., CUI, X., QIN, X., ZHANG, J., LIU, G., DONG, Z., MA, Y., 
SONG, Z. & HU, Y. 2014. Upregulation of heat shock factor 1 transcription activity is associated 
with hepatocellular carcinoma progression. Mol Med Rep, 10, 2313-21. 
LI, X., ZHANG, D., HANNINK, M. & BEAMER, L. J. 2004. Crystal structure of the Kelch domain of 
human Keap1. J Biol Chem, 279, 54750-8. 
LI, Y., ZHANG, T., SCHWARTZ, S. J. & SUN, D. 2011. Sulforaphane Potentiates the Efficacy of 17-
Allylamino 17-Demethoxygeldanamycin Against Pancreatic Cancer Through Enhanced 
Abrogation of Hsp90 Chaperone Function. Nutrition and cancer. 
LIBY, K., YORE, M. M., ROEBUCK, B. D., BAUMGARTNER, K. J., HONDA, T., SUNDARARAJAN, C., 
YOSHIZAWA, H., GRIBBLE, G. W., WILLIAMS, C. R., RISINGSONG, R., ROYCE, D. B., 
DINKOVA-KOSTOVA, A. T., STEPHENSON, K. K., EGNER, P. A., YATES, M. S., 
GROOPMAN, J. D., KENSLER, T. W. & SPORN, M. B. 2008. A novel acetylenic tricyclic bis-
(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver 
carcinogenesis induced by aflatoxin. Cancer Res, 68, 6727-33. 
LIN, C. H., TALLAKSEN-GREENE, S., CHIEN, W. M., CEARLEY, J. A., JACKSON, W. S., CROUSE, 
A. B., REN, S., LI, X. J., ALBIN, R. L. & DETLOFF, P. J. 2001. Neurological abnormalities in a 
knock-in mouse model of Huntington's disease. Hum Mol Genet, 10, 137-44. 
LIN, P. Y., SIMON, S. M., KOH, W. K., FOLORUNSO, O., UMBAUGH, C. S. & PIERCE, A. 2013. Heat 
shock factor 1 over-expression protects against exposure of hydrophobic residues on mutant 
SOD1 and early mortality in a mouse model of amyotrophic lateral sclerosis. Mol 
Neurodegener, 8, 43. 
LITTLEFIELD, O. & NELSON, H. C. 1999. A new use for the 'wing' of the 'winged' helix-turn-helix motif 
in the HSF-DNA cocrystal. Nat Struct Biol, 6, 464-70. 
LIU, A. Y., LIN, Z., CHOI, H. S., SORHAGE, F. & LI, B. 1989. Attenuated induction of heat shock gene 
expression in aging diploid fibroblasts. J Biol Chem, 264, 12037-45. 
LIU, A. Y., MATHUR, R., MEI, N., LANGHAMMER, C. G., BABIARZ, B. & FIRESTEIN, B. L. 2011. 
Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate 
transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J Biol Chem, 
286, 2785-94. 
LIU, C., LI, Y., ZUO, G., XU, W., GAO, H., YANG, Y., YAMAHARA, J., WANG, J. & LI, Y. 2013. 
Oleanolic Acid diminishes liquid fructose-induced Fatty liver in rats: role of modulation of 
hepatic sterol regulatory element-binding protein-1c-mediated expression of genes responsible 
for de novo Fatty Acid synthesis. Evid Based Complement Alternat Med, 2013, 1045-52. 
LIU, J. 1995. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol, 49, 57-68. 
LIU, J., LIU, Y. & KLAASSEN, C. D. 1995. Protective effect of oleanolic acid against chemical-induced 
acute necrotic liver injury in mice. Zhongguo Yao Li Xue Bao, 16, 97-102. 
LIU, P. C. & THIELE, D. J. 1999. Modulation of human heat shock factor trimerization by the linker 
domain. J Biol Chem, 274, 17219-25. 
LIU, X., WARD, K., XAVIER, C., JANN, J., CLARK, A. F., PANG, I. H. & WU, H. 2015. The novel 
triterpenoid RTA 408 protects human retinal pigment epithelial cells against HO-induced cell 
injury via NF-E2-related factor 2 (Nrf2) activation. Redox Biol, 8, 98-109. 
LO, S. C., LI, X., HENZL, M. T., BEAMER, L. J. & HANNINK, M. 2006. Structure of the Keap1:Nrf2 
interface provides mechanistic insight into Nrf2 signaling. EMBO J, 25, 3605-17. 
LOCKE, M. & TANGUAY, R. M. 1996. Diminished heat shock response in the aged myocardium. Cell 
Stress Chaperones, 1, 251-60. 
LOCKE, M., TANGUAY, R. M., KLABUNDE, R. E. & IANUZZO, C. D. 1995. Enhanced postischemic 
myocardial recovery following exercise induction of HSP 72. Am J Physiol, 269, H320-5. 
LU, H. & HALLSTROM, T. C. 2012. Sensitivity to TOP2 targeting chemotherapeutics is regulated by 
Oct1 and FILIP1L. PLoS One, 7, e42921. 
LU, L., HACKETT, S. F., MINCEY, A., LAI, H. & CAMPOCHIARO, P. A. 2006. Effects of different types 
of oxidative stress in RPE cells. J Cell Physiol, 206, 119-25. 
LU, M., KIM, H. E., LI, C. R., KIM, S., KWAK, I. J., LEE, Y. J., KIM, S. S., MOON, J. Y., KIM, C. H., KIM, 
D. K., KANG, H. S. & PARK, J. S. 2008. Two distinct disulfide bonds formed in human heat 
shock transcription factor 1 act in opposition to regulate its DNA binding activity. Biochemistry, 
47, 6007-15. 
LU, M., LEE, Y. J., PARK, S. M., KANG, H. S., KANG, S. W., KIM, S. & PARK, J. S. 2009. Aromatic-
participant interactions are essential for disulfide-bond-based trimerization in human heat shock 
transcription factor 1. Biochemistry, 48, 3795-7. 
LU, Y. F., LIU, J., WU, K. C. & KLAASSEN, C. D. 2014. Protection against phalloidin-induced liver injury 
by oleanolic acid involves Nrf2 activation and suppression of Oatp1b2. Toxicol Lett, 232, 326-
332. 
LU, Z. C. & WAN, F. H. 2008. Differential gene expression in whitefly (Bemisia tabaci) B-biotype females 
and males under heat-shock condition. Comp Biochem Physiol Part D Genomics Proteomics, 
3, 257-62. 
MABANDLA, M. V., NYOKA, M. & DANIELS, W. M. 2015. Early use of oleanolic acid provides protection 
against 6-hydroxydopamine induced dopamine neurodegeneration. Brain Res, 1622, 64-71. 
MAHALINGAIAH, P. K., PONNUSAMY, L. & SINGH, K. P. 2015. Chronic oxidative stress causes 
estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor 
alpha in MCF-7 breast cancer cells. Breast Cancer Res Treat, 153, 41-56. 
MAINES, M. D. & EWING, J. F. 1996. Stress response of the rat testis: in situ hydridization and 
immunohistochemical analysis of heme oxygenase-1 (HSP32) induction by hyperthermia. Biol 
Reprod, 54, 1070-9. 
MALHOTRA, D., PORTALES-CASAMAR, E., SINGH, A., SRIVASTAVA, S., ARENILLAS, D., HAPPEL, 
C., SHYR, C., WAKABAYASHI, N., KENSLER, T. W., WASSERMAN, W. W. & BISWAL, S. 
2010. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response 
through ChIP-Seq profiling and network analysis. Nucleic Acids Res, 38, 5718-34. 
MANGIARINI, L., SATHASIVAM, K., SELLER, M., COZENS, B., HARPER, A., HETHERINGTON, C., 
LAWTON, M., TROTTIER, Y., LEHRACH, H., DAVIES, S. W. & BATES, G. P. 1996. Exon 1 of 
the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological 
phenotype in transgenic mice. Cell, 87, 493-506. 
MANNA, P. R. & STOCCO, D. M. 2011. The role of specific mitogen-activated protein kinase signaling 
cascades in the regulation of steroidogenesis. J Signal Transduct, 2011, 821615. 
MARBER, M. S., MESTRIL, R., CHI, S. H., SAYEN, M. R., YELLON, D. M. & DILLMANN, W. H. 1995. 
Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases 
the resistance of the heart to ischemic injury. J Clin Invest, 95, 1446-56. 
MARCOTTE, D., ZENG, W., HUS, J. C., MCKENZIE, A., HESSION, C., JIN, P., BERGERON, C., 
LUGOVSKOY, A., ENYEDY, I., CUERVO, H., WANG, D., ATMANENE, C., ROECKLIN, D., 
VECCHI, M., VIVAT, V., KRAEMER, J., WINKLER, D., HONG, V., CHAO, J., LUKASHEV, M. 
& SILVIAN, L. 2013. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain 
through a non-covalent mechanism. Bioorg Med Chem, 21, 4011-9. 
MARTINEZ-RUIZ, A., VILLANUEVA, L., GONZALEZ DE ORDUNA, C., LOPEZ-FERRER, D., 
HIGUERAS, M. A., TARIN, C., RODRIGUEZ-CRESPO, I., VAZQUEZ, J. & LAMAS, S. 2005. 
S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide 
synthase regulatory activities. Proc Natl Acad Sci U S A, 102, 8525-30. 
MARUNOUCHI, T., ARAKI, M., MURATA, M., TAKAGI, N. & TANONAKA, K. 2013a. Possible 
involvement of HSP90-HSF1 multichaperone complex in impairment of HSP72 induction in the 
failing heart following myocardial infarction in rats. J Pharmacol Sci, 123, 336-46. 
MARUNOUCHI, T., MURATA, M., TAKAGI, N. & TANONAKA, K. 2013b. Possible involvement of 
phosphorylated heat-shock factor-1 in changes in heat shock protein 72 induction in the failing 
rat heart following myocardial infarction. Biol Pharm Bull, 36, 1332-40. 
MATTS, R. L., BRANDT, G. E., LU, Y., DIXIT, A., MOLLAPOUR, M., WANG, S., DONNELLY, A. C., 
NECKERS, L., VERKHIVKER, G. & BLAGG, B. S. 2011. A systematic protocol for the 
characterization of Hsp90 modulators. Bioorg Med Chem, 19, 684-92. 
MCCANN, H., STEVENS, C. H., CARTWRIGHT, H. & HALLIDAY, G. M. 2014. alpha-Synucleinopathy 
phenotypes. Parkinsonism Relat Disord, 20 Suppl 1, S62-7. 
MCMAHON, M., LAMONT, D. J., BEATTIE, K. A. & HAYES, J. D. 2010. Keap1 perceives stress via 
three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl 
Acad Sci U S A, 107, 18838-43. 
MCMAHON, M., THOMAS, N., ITOH, K., YAMAMOTO, M. & HAYES, J. D. 2004. Redox-regulated 
turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive 
Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem, 279, 31556-67. 
MCMAHON, M., THOMAS, N., ITOH, K., YAMAMOTO, M. & HAYES, J. D. 2006. Dimerization of 
substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" 
mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem, 281, 24756-
68. 
MEHLEN, P., HICKEY, E., WEBER, L. A. & ARRIGO, A. P. 1997. Large unphosphorylated aggregates 
as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione 
levels and generates a protection against TNFalpha in NIH-3T3-ras cells. Biochem Biophys 
Res Commun, 241, 187-92. 
MEHLEN, P., KRETZ-REMY, C., PREVILLE, X. & ARRIGO, A. P. 1996. Human hsp27, Drosophila 
hsp27 and human alphaB-crystallin expression-mediated increase in glutathione is essential 
for the protective activity of these proteins against TNFalpha-induced cell death. EMBO J, 15, 
2695-706. 
MEHLEN, P., PREVILLE, X., CHAREYRON, P., BRIOLAY, J., KLEMENZ, R. & ARRIGO, A. P. 1995. 
Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin 
confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected 
murine L929 fibroblasts. J Immunol, 154, 363-74. 
MEHLMAN, M. A. 1992. Dangerous and cancer-causing properties of products and chemicals in the oil 
refining and petrochemical industry. VIII. Health effects of motor fuels: carcinogenicity of 
gasoline--scientific update. Environ Res, 59, 238-49. 
MENDILLO, M. L., SANTAGATA, S., KOEVA, M., BELL, G. W., HU, R., TAMIMI, R. M., FRAENKEL, 
E., INCE, T. A., WHITESELL, L. & LINDQUIST, S. 2012. HSF1 Drives a Transcriptional 
Program Distinct from Heat Shock to Support Highly Malignant Human Cancers. Cell, 150, 549-
62. 
METCHAT, A., AKERFELT, M., BIERKAMP, C., DELSINNE, V., SISTONEN, L., ALEXANDRE, H. & 
CHRISTIANS, E. S. 2009. Mammalian heat shock factor 1 is essential for oocyte meiosis and 
directly regulates Hsp90alpha expression. J Biol Chem, 284, 9521-8. 
METZLER, B., ABIA, R., AHMAD, M., WERNIG, F., PACHINGER, O., HU, Y. & XU, Q. 2003. Activation 
of heat shock transcription factor 1 in atherosclerosis. Am J Pathol, 162, 1669-76. 
MITSUISHI, Y., TAGUCHI, K., KAWATANI, Y., SHIBATA, T., NUKIWA, T., ABURATANI, H., 
YAMAMOTO, M. & MOTOHASHI, H. 2012. Nrf2 redirects glucose and glutamine into anabolic 
pathways in metabolic reprogramming. Cancer Cell, 22, 66-79. 
MIZUMURA, K., TAKEDA, K., HASHIMOTO, S., HORIE, T. & ICHIJO, H. 2006. Identification of 
Op18/stathmin as a potential target of ASK1-p38 MAP kinase cascade. J Cell Physiol, 206, 
363-70. 
MOON, Y. J., BRAZEAU, D. A. & MORRIS, M. E. 2011. Dietary phenethyl isothiocyanate alters gene 
expression in human breast cancer cells. Evid Based Complement Alternat Med, 2011. 
MORIMOTO, R. I. 2011. The heat shock response: systems biology of proteotoxic stress in aging and 
disease. Cold Spring Harb Symp Quant Biol, 76, 91-9. 
MORLEY, J. F. & MORIMOTO, R. I. 2004. Regulation of longevity in Caenorhabditis elegans by heat 
shock factor and molecular chaperones. Mol Biol Cell, 15, 657-64. 
MOSSER, D. D., CARON, A. W., BOURGET, L., MERIIN, A. B., SHERMAN, M. Y., MORIMOTO, R. I. 
& MASSIE, B. 2000. The chaperone function of hsp70 is required for protection against stress-
induced apoptosis. Mol Cell Biol, 20, 7146-59. 
MUKUNDWA, A., LANGA, S. O., MUKARATIRWA, S. & MASOLA, B. 2016. In vivo effects of diabetes, 
insulin and oleanolic acid on enzymes of glycogen metabolism in the skin of streptozotocin-
induced diabetic male Sprague-Dawley rats. Biochem Biophys Res Commun, 471, 315-9. 
MUNTANE, J., PUIG-PARELLADA, P. & MITJAVILA, M. T. 1995. Iron metabolism and oxidative stress 
during acute and chronic phases of experimental inflammation: effect of iron-dextran and 
deferoxamine. J Lab Clin Med, 126, 435-43. 
MURSHID, A., CHOU, S. D., PRINCE, T., ZHANG, Y., BHARTI, A. & CALDERWOOD, S. K. 2010. 
Protein kinase A binds and activates heat shock factor 1. PLoS One, 5, e13830. 
MYZAK, M. C., DASHWOOD, W. M., ORNER, G. A., HO, E. & DASHWOOD, R. H. 2006a. 
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus 
mice. The FASEB J, 20, 506-8. 
MYZAK, M. C., HARDIN, K., WANG, R., DASHWOOD, R. H. & HO, E. 2006b. Sulforaphane inhibits 
histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. 
Carcinogenesis, 27, 811-9. 
MYZAK, M. C., KARPLUS, P. A., CHUNG, F. L. & DASHWOOD, R. H. 2004. A novel mechanism of 
chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res, 64, 5767-74. 
NACHAT, A., TUROFF-ORTMEYER, S., LIU, C. & MCCULLOCH, M. 2016. PEITC in End-Stage B-
Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP. 
Perm J, 20, 74-80. 
NAGAKURA, T., YASUDA, N., YAMAZAKI, K., IKUTA, H., YOSHIKAWA, S., ASANO, O. & TANAKA, 
I. 2001. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in 
dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun, 284, 501-6. 
NAKAI, A. & ISHIKAWA, T. 2000. A nuclear localization signal is essential for stress-induced dimer-to-
trimer transition of heat shock transcription factor 3. J Biol Chem, 275, 34665-71. 
NAKAI, A., KAWAZOE, Y., TANABE, M., NAGATA, K. & MORIMOTO, R. I. 1995. The DNA-binding 
properties of two heat shock factors, HSF1 and HSF3, are induced in the avian erythroblast 
cell line HD6. Mol Cell Biol, 15, 5268-78. 
NAKAI, A., SUZUKI, M. & TANABE, M. 2000. Arrest of spermatogenesis in mice expressing an active 
heat shock transcription factor 1. EMBO J, 19, 1545-54. 
NAKAI, A., TANABE, M., KAWAZOE, Y., INAZAWA, J., MORIMOTO, R. I. & NAGATA, K. 1997. HSF4, 
a new member of the human heat shock factor family which lacks properties of a transcriptional 
activator. Mol Cell Biol, 17, 469-81. 
NARENDRA, D., TANAKA, A., SUEN, D. F. & YOULE, R. J. 2008. Parkin is recruited selectively to 
impaired mitochondria and promotes their autophagy. J Cell Biol, 183, 795-803. 
NEEF, D. W., TURSKI, M. L. & THIELE, D. J. 2010. Modulation of heat shock transcription factor 1 as 
a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol, 
8, e1000291. 
NEWTON, E. M., KNAUF, U., GREEN, M. & KINGSTON, R. E. 1996. The regulatory domain of human 
heat shock factor 1 is sufficient to sense heat stress. Mol Cell Biol, 16, 839-46. 
NIMMANAPALLI, R., O'BRYAN, E. & BHALLA, K. 2001. Geldanamycin and its analogue 17-allylamino-
17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of 
Bcr-Abl-positive human leukemic blasts. Cancer Res, 61, 1799-804. 
NISHIZAWA, J., NAKAI, A., HIGASHI, T., TANABE, M., NOMOTO, S., MATSUDA, K., BAN, T. & 
NAGATA, K. 1996. Reperfusion causes significant activation of heat shock transcription factor 
1 in ischemic rat heart. Circulation, 94, 2185-92. 
NISHIZAWA, J., NAKAI, A., MATSUDA, K., KOMEDA, M., BAN, T. & NAGATA, K. 1999. Reactive 
oxygen species play an important role in the activation of heat shock factor 1 in ischemic-
reperfused heart. Circulation, 99, 934-41. 
NITTA, Y., ABE, K., AOKI, M., OHNO, I. & ISOYAMA, S. 1994. Diminished heat shock protein 70 mRNA 
induction in aged rat hearts after ischemia. Am J Physiol, 267, H1795-803. 
NOGALES, E., WOLF, S. G. & DOWNING, K. H. 1998. Structure of the alpha beta tubulin dimer by 
electron crystallography. Nature, 391, 199-203. 
OLSEN, J. V., BLAGOEV, B., GNAD, F., MACEK, B., KUMAR, C., MORTENSEN, P. & MANN, M. 2006. 
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell, 127, 
635-48. 
OSTLING, P., BJORK, J. K., ROOS-MATTJUS, P., MEZGER, V. & SISTONEN, L. 2007. Heat shock 
factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1. 
J Biol Chem, 282, 7077-86. 
PARIS, D., GANEY, N. J., LAPORTE, V., PATEL, N. S., BEAULIEU-ABDELAHAD, D., BACHMEIER, 
C., MARCH, A., AIT-GHEZALA, G. & MULLAN, M. J. 2010. Reduction of beta-amyloid 
pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J 
Neuroinflammation, 7, 17. 
PARKER, C. G., HUNT, J., DIENER, K., MCGINLEY, M., SORIANO, B., KEESLER, G. A., BRAY, J., 
YAO, Z., WANG, X. S., KOHNO, T. & LICHENSTEIN, H. S. 1998. Identification of stathmin as 
a novel substrate for p38 delta. Biochem Biophys Res Commun, 249, 791-6. 
PATEL, S. B., CAMERON, P. M., O'KEEFE, S. J., FRANTZ-WATTLEY, B., THOMPSON, J., O'NEILL, 
E. A., TENNIS, T., LIU, L., BECKER, J. W. & SCAPIN, G. 2009. The three-dimensional 
structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta 
compared with p38alpha. Acta Crystallogr D Biol Crystallogr, 65, 777-85. 
PENG, W., ZHANG, Y., ZHENG, M., CHENG, H., ZHU, W., CAO, C. M. & XIAO, R. P. 2010. 
Cardioprotection by CaMKII-deltaB is mediated by phosphorylation of heat shock factor 1 and 
subsequent expression of inducible heat shock protein 70. Circ Res, 106, 102-10. 
PENG, X., GUO, X., BORKAN, S. C., BHARTI, A., KURAMOCHI, Y., CALDERWOOD, S. & SAWYER, 
D. B. 2005. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP 
depletion in myocytes. J Biol Chem, 280, 13148-52. 
PEREZ, F. P., BOSE, D., MALONEY, B., NHO, K., SHAH, K. & LAHIRI, D. K. 2014. Late-onset 
Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the 
aging process. J Alzheimers Dis, 40, 1-17. 
PERISIC, O., XIAO, H. & LIS, J. T. 1989. Stable binding of Drosophila heat shock factor to head-to-
head and tail-to-tail repeats of a conserved 5 bp recognition unit. Cell, 59, 797-806. 
PERNG, M. D., CAIRNS, L., VAN DEN, I. P., PRESCOTT, A., HUTCHESON, A. M. & QUINLAN, R. A. 
1999. Intermediate filament interactions can be altered by HSP27 and alphaB-crystallin. J Cell 
Sci, 112 ( Pt 13), 2099-112. 
PETERANDERL, R. & NELSON, H. C. 1992. Trimerization of the heat shock transcription factor by a 
triple-stranded alpha-helical coiled-coil. Biochemistry, 31, 12272-6. 
PICKRELL, A. M. & YOULE, R. J. 2015. The roles of PINK1, parkin, and mitochondrial fidelity in 
Parkinson's disease. Neuron, 85, 257-73. 
PIERCE, A., PODLUTSKAYA, N., HALLORAN, J. J., HUSSONG, S. A., LIN, P. Y., BURBANK, R., 
HART, M. J. & GALVAN, V. 2013. Over-expression of heat shock factor 1 phenocopies the 
effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like 
deficits in mice modeling the disease. J Neurochem, 124, 880-93. 
PIETSCH, E. C., CHAN, J. Y., TORTI, F. M. & TORTI, S. V. 2003. Nrf2 mediates the induction of ferritin 
H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem, 278, 
2361-9. 
PLEDGIE-TRACY, A., SOBOLEWSKI, M. D. & DAVIDSON, N. E. 2007. Sulforaphane induces cell type-
specific apoptosis in human breast cancer cell lines. Mol Cancer Ther, 6, 1013-21. 
POSAS, F., WURGLER-MURPHY, S. M., MAEDA, T., WITTEN, E. A., THAI, T. C. & SAITO, H. 1996. 
Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the 
SLN1-YPD1-SSK1 "two-component" osmosensor. Cell, 86, 865-75. 
PRAKASAM, R., FUJIMOTO, M., TAKII, R., HAYASHIDA, N., TAKAKI, E., TAN, K., WU, F., INOUYE, 
S. & NAKAI, A. 2013. Chicken IL-6 is a heat-shock gene. FEBS Lett, 587, 3541-7. 
PRAPROTNIK, D., SMITH, M. A., RICHEY, P. L., VINTERS, H. V. & PERRY, G. 1996. Plasma 
membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of 
oxidative stress. Acta Neuropathol, 91, 1-5. 
PRESTERA, T., TALALAY, P., ALAM, J., AHN, Y. I., LEE, P. J. & CHOI, A. M. 1995. Parallel induction 
of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and 
antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol Med, 1, 827-
37. 
RABINDRAN, S. K., HAROUN, R. I., CLOS, J., WISNIEWSKI, J. & WU, C. 1993. Regulation of heat 
shock factor trimer formation: role of a conserved leucine zipper. Science, 259, 230-4. 
RACHAKONDA, G., XIONG, Y., SEKHAR, K. R., STAMER, S. L., LIEBLER, D. C. & FREEMAN, M. L. 
2008. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the 
ubiquitin ligase CUL3. Chem Res Toxicol, 21, 705-10. 
RAJASEKARAN, N. S., CONNELL, P., CHRISTIANS, E. S., YAN, L. J., TAYLOR, R. P., OROSZ, A., 
ZHANG, X. Q., STEVENSON, T. J., PESHOCK, R. M., LEOPOLD, J. A., BARRY, W. H., 
LOSCALZO, J., ODELBERG, S. J. & BENJAMIN, I. J. 2007. Human alpha B-crystallin mutation 
causes oxido-reductive stress and protein aggregation cardiomyopathy in mice. Cell, 130, 427-
39. 
RAJASEKARAN, N. S., FIRPO, M. A., MILASH, B. A., WEISS, R. B. & BENJAMIN, I. J. 2008. Global 
expression profiling identifies a novel biosignature for protein aggregation R120GCryAB 
cardiomyopathy in mice. Physiol Genomics, 35, 165-72. 
RAJASEKARAN, N. S., VARADHARAJ, S., KHANDERAO, G. D., DAVIDSON, C. J., KANNAN, S., 
FIRPO, M. A., ZWEIER, J. L. & BENJAMIN, I. J. 2011. Sustained activation of nuclear erythroid 
2-related factor 2/antioxidant response element signaling promotes reductive stress in the 
human mutant protein aggregation cardiomyopathy in mice. Antioxid Redox Signal, 14, 957-
71. 
RAYCHAUDHURI, S., LOEW, C., KORNER, R., PINKERT, S., THEIS, M., HAYER-HARTL, M., 
BUCHHOLZ, F. & HARTL, F. U. 2014. Interplay of acetyltransferase EP300 and the 
proteasome system in regulating heat shock transcription factor 1. Cell, 156, 975-85. 
REISMAN, S. A., ALEKSUNES, L. M. & KLAASSEN, C. D. 2009. Oleanolic acid activates Nrf2 and 
protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent 
processes. Biochem Pharmacol, 77, 1273-82. 
REISMAN, S. A., GOLDSBERRY, A. R., LEE, C. Y., O'GRADY, M. L., PROKSCH, J. W., WARD, K. W. 
& MEYER, C. J. 2015. Topical application of RTA 408 lotion activates Nrf2 in human skin and 
is well-tolerated by healthy human volunteers. BMC Dermatol, 15, 10. 
REISMAN, S. A., LEE, C. Y., MEYER, C. J., PROKSCH, J. W., SONIS, S. T. & WARD, K. W. 2014. 
Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced 
dermatitis. Radiat Res, 181, 512-20. 
REMY, G., RISCO, A. M., INESTA-VAQUERA, F. A., GONZALEZ-TERAN, B., SABIO, G., DAVIS, R. 
J. & CUENDA, A. 2010. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell 
Signal, 22, 660-7. 
RETZLAFF, M., STAHL, M., EBERL, H. C., LAGLEDER, S., BECK, J., KESSLER, H. & BUCHNER, J. 
2009. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep, 10, 1147-53. 
REYNOLDS, C. H., NEBREDA, A. R., GIBB, G. M., UTTON, M. A. & ANDERTON, B. H. 1997. 
Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem, 69, 191-8. 
RICHTER, K., HASLBECK, M. & BUCHNER, J. 2010. The heat shock response: life on the verge of 
death. Mol Cell, 40, 253-66. 
RITOSSA, F. 1996. Discovery of the heat shock response. Cell Stress Chaperones, 1, 97-8. 
RITOSSA, F. M. 1964. Experimental Activation of Specific Loci in Polytene Chromosomes of 
Drosophila. Exp Cell Res, 35, 601-7. 
RITOSSA, F. M. & VONBORSTEL, R. C. 1964. Chromosome Puffs in Drosophila Induced by 
Ribonuclease. Science, 145, 513-4. 
RODRIGUEZ-CARBALLO, E., GAMEZ, B. & VENTURA, F. 2016. p38 MAPK Signaling in Osteoblast 
Differentiation. Front Cell Dev Biol, 4, 40. 
ROSSI, A., CIAFRE, S., BALSAMO, M., PIERIMARCHI, P. & SANTORO, M. G. 2006. Targeting the 
heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy 
efficacy in cervical cancer. Cancer Res, 66, 7678-85. 
ROSSI, A., ELIA, G. & SANTORO, M. G. 1996. 2-Cyclopenten-1-one, a new inducer of heat shock 
protein 70 with antiviral activity. J Biol Chem, 271, 32192-6. 
ROY, S. M., GRUM-TOKARS, V. L., SCHAVOCKY, J. P., SAEED, F., STANISZEWSKI, A., TEICH, A. 
F., ARANCIO, O., BACHSTETTER, A. D., WEBSTER, S. J., VAN ELDIK, L. J., MINASOV, G., 
ANDERSON, W. F., PELLETIER, J. C. & WATTERSON, D. M. 2015. Targeting human central 
nervous system protein kinases: An isoform selective p38alphaMAPK inhibitor that attenuates 
disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci, 6, 666-80. 
SAHA, A. & DESHAIES, R. J. 2008. Multimodal activation of the ubiquitin ligase SCF by Nedd8 
conjugation. Mol Cell, 32, 21-31. 
SAITO, R., SUZUKI, T., HIRAMOTO, K., ASAMI, S., NAGANUMA, E., SUDA, H., ISO, T., YAMAMOTO, 
H., MORITA, M., BAIRD, L., FURUSAWA, Y., NEGISHI, T., ICHINOSE, M. & YAMAMOTO, M. 
2015. Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response. Mol 
Cell Biol, 36, 271-84. 
SAITO, T., ICHIMURA, Y., TAGUCHI, K., SUZUKI, T., MIZUSHIMA, T., TAKAGI, K., HIROSE, Y., 
NAGAHASHI, M., ISO, T., FUKUTOMI, T., OHISHI, M., ENDO, K., UEMURA, T., NISHITO, Y., 
OKUDA, S., OBATA, M., KOUNO, T., IMAMURA, R., TADA, Y., OBATA, R., YASUDA, D., 
TAKAHASHI, K., FUJIMURA, T., PI, J., LEE, M. S., UENO, T., OHE, T., MASHINO, T., WAKAI, 
T., KOJIMA, H., OKABE, T., NAGANO, T., MOTOHASHI, H., WAGURI, S., SOGA, T., 
YAMAMOTO, M., TANAKA, K. & KOMATSU, M. 2016. p62/Sqstm1 promotes malignancy of 
HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat 
Commun, 7, 12030. 
SAITOH, M., NISHITOH, H., FUJII, M., TAKEDA, K., TOBIUME, K., SAWADA, Y., KAWABATA, M., 
MIYAZONO, K. & ICHIJO, H. 1998. Mammalian thioredoxin is a direct inhibitor of apoptosis 
signal-regulating kinase (ASK) 1. EMBO J, 17, 2596-606. 
SANDQVIST, A., BJORK, J. K., AKERFELT, M., CHITIKOVA, Z., GRICHINE, A., VOURC'H, C., JOLLY, 
C., SALMINEN, T. A., NYMALM, Y. & SISTONEN, L. 2009. Heterotrimerization of heat-shock 
factors 1 and 2 provides a transcriptional switch in response to distinct stimuli. Mol Biol Cell, 
20, 1340-7. 
SANGLE, G. V., ZHAO, R., MIZUNO, T. M. & SHEN, G. X. 2010. Involvement of RAGE, NADPH 
oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 
and plasminogen activator inhibitor-1 in vascular endothelial cells. Endocrinology, 151, 4455-
66. 
SANTAGATA, S., HU, R., LIN, N. U., MENDILLO, M. L., COLLINS, L. C., HANKINSON, S. E., 
SCHNITT, S. J., WHITESELL, L., TAMIMI, R. M., LINDQUIST, S. & INCE, T. A. 2011. High 
levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast 
cancer. Proc Natl Acad Sci U S A, 108, 18378-83. 
SANTAGATA, S., MENDILLO, M. L., TANG, Y. C., SUBRAMANIAN, A., PERLEY, C. C., ROCHE, S. 
P., WONG, B., NARAYAN, R., KWON, H., KOEVA, M., AMON, A., GOLUB, T. R., PORCO, J. 
A., JR., WHITESELL, L. & LINDQUIST, S. 2013. Tight coordination of protein translation and 
HSF1 activation supports the anabolic malignant state. Science, 341, 1238303. 
SANTAGATA, S., XU, Y. M., WIJERATNE, E. M., KONTNIK, R., ROONEY, C., PERLEY, C. C., KWON, 
H., CLARDY, J., KESARI, S., WHITESELL, L., LINDQUIST, S. & GUNATILAKA, A. A. 2012. 
Using the heat-shock response to discover anticancer compounds that target protein 
homeostasis. ACS Chem Biol, 7, 340-9. 
SARGE, K. D., MURPHY, S. P. & MORIMOTO, R. I. 1993. Activation of heat shock gene transcription 
by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear 
localization and can occur in the absence of stress. Mol Cell Biol, 13, 1392-407. 
SARIKAS, A., HARTMANN, T. & PAN, Z. Q. 2011. The cullin protein family. Genome Biol, 12, 220. 
SARKAR, C., PAL, S., DAS, N. & DINDA, B. 2014. Ameliorative effects of oleanolic acid on fluoride 
induced metabolic and oxidative dysfunctions in rat brain: Experimental and biochemical 
studies. Food Chem Toxicol, 66, 224-36. 
SASAKI, H., SATO, H., KURIYAMA-MATSUMURA, K., SATO, K., MAEBARA, K., WANG, H., TAMBA, 
M., ITOH, K., YAMAMOTO, M. & BANNAI, S. 2002. Electrophile response element-mediated 
induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem, 277, 
44765-71. 
SATO, H., AMAGAI, K., SHIMIZUKAWA, R. & TAMAI, Y. 2009. Stable generation of serum- and feeder-
free embryonic stem cell-derived mice with full germline-competency by using a GSK3 specific 
inhibitor. Genesis, 47, 414-22. 
SATOH, T., REZAIE, T., SEKI, M., SUNICO, C. R., TABUCHI, T., KITAGAWA, T., YANAGITAI, M., 
SENZAKI, M., KOSEGAWA, C., TAIRA, H., MCKERCHER, S. R., HOFFMAN, J. K., ROTH, G. 
P. & LIPTON, S. A. 2011. Dual neuroprotective pathways of a pro-electrophilic compound via 
HSF-1-activated heat-shock proteins and Nrf2-activated phase 2 antioxidant response 
enzymes. J Neurochem. 
SAYDAM, N., STEINER, F., GEORGIEV, O. & SCHAFFNER, W. 2003. Heat and heavy metal stress 
synergize to mediate transcriptional hyperactivation by metal-responsive transcription factor 
MTF-1. J Biol Chem, 278, 31879-83. 
SCHEPERS, H., GEUGIEN, M., VAN DER TOORN, M., BRYANTSEV, A. L., KAMPINGA, H. H., 
EGGEN, B. J. & VELLENGA, E. 2005. HSP27 protects AML cells against VP-16-induced 
apoptosis through modulation of p38 and c-Jun. Exp Hematol, 33, 660-70. 
SCHINDLER, E. M., HINDES, A., GRIBBEN, E. L., BURNS, C. J., YIN, Y., LIN, M. H., OWEN, R. J., 
LONGMORE, G. D., KISSLING, G. E., ARTHUR, J. S. & EFIMOVA, T. 2009. p38delta Mitogen-
activated protein kinase is essential for skin tumor development in mice. Cancer Res, 69, 4648-
55. 
SCHUETZ, T. J., GALLO, G. J., SHELDON, L., TEMPST, P. & KINGSTON, R. E. 1991. Isolation of a 
cDNA for HSF2: evidence for two heat shock factor genes in humans. Proc Natl Acad Sci U S 
A, 88, 6911-5. 
SCHULTE, T. W., BLAGOSKLONNY, M. V., INGUI, C. & NECKERS, L. 1995. Disruption of the Raf-1-
Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. 
J Biol Chem, 270, 24585-8. 
SEO, H. R., CHUNG, D. Y., LEE, Y. J., LEE, D. H., KIM, J. I., BAE, S., CHUNG, H. Y., LEE, S. J., 
JEOUNG, D. & LEE, Y. S. 2006. Heat shock protein 25 or inducible heat shock protein 70 
activates heat shock factor 1: dephosphorylation on serine 307 through inhibition of ERK1/2 
phosphorylation. J Biol Chem, 281, 17220-7. 
SEO, M., LEE, Y. I., CHO, C. H., BAE, C. D., KIM, I. H. & JUHNN, Y. S. 2002. Bi-directional regulation 
of UV-induced activation of p38 kinase and c-Jun N-terminal kinase by G protein beta gamma-
subunits. J Biol Chem, 277, 24197-203. 
SEO, M. S., OH, S. Y., PARK, M. J., KIM, S. M., KIM, M. Y., HAN, S. I., PARK, H. G. & KANG, H. S. 
2005. Implication of reactive oxygen species, ERK1/2, and p38MAPK in sodium salicylate-
induced heat shock protein 72 expression in C6 glioma cells. Int J Mol Med, 16, 841-9. 
SHARMA, R., SHARMA, A., CHAUDHARY, P., PEARCE, V., VATSYAYAN, R., SINGH, S. V., 
AWASTHI, S. & AWASTHI, Y. C. 2010. Role of lipid peroxidation in cellular responses to D,L-
sulforaphane, a promising cancer chemopreventive agent. Biochemistry, 49, 3191-202. 
SHARROCKS, A. D., YANG, S. H. & GALANIS, A. 2000. Docking domains and substrate-specificity 
determination for MAP kinases. Trends Biochem Sci, 25, 448-53. 
SHEN, S. Q., ZHANG, Y., XIANG, J. J. & XIONG, C. L. 2007. Protective effect of curcumin against liver 
warm ischemia/reperfusion injury in rat model is associated with regulation of heat shock 
protein and antioxidant enzymes. World J Gastroenterol, 13, 1953-61. 
SHI, Y., MOSSER, D. D. & MORIMOTO, R. I. 1998. Molecular chaperones as HSF1-specific 
transcriptional repressors. Genes Dev, 12, 654-66. 
SHINKAWA, T., TAN, K., FUJIMOTO, M., HAYASHIDA, N., YAMAMOTO, K., TAKAKI, E., TAKII, R., 
PRAKASAM, R., INOUYE, S., MEZGER, V. & NAKAI, A. 2011. Heat shock factor 2 is required 
for maintaining proteostasis against febrile-range thermal stress and polyglutamine 
aggregation. Mol Biol Cell, 22, 3571-83. 
SIES, H. 2015. Oxidative stress: a concept in redox biology and medicine. Redox Biol, 4, 180-3. 
SINGH, A., HAPPEL, C., MANNA, S. K., ACQUAAH-MENSAH, G., CARRERERO, J., KUMAR, S., 
NASIPURI, P., KRAUSZ, K. W., WAKABAYASHI, N., DEWI, R., BOROS, L. G., GONZALEZ, 
F. J., GABRIELSON, E., WONG, K. K., GIRNUN, G. & BISWAL, S. 2013. Transcription factor 
NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest, 123, 2921-34. 
SINGH, G. B., SINGH, S., BANI, S., GUPTA, B. D. & BANERJEE, S. K. 1992. Anti-inflammatory activity 
of oleanolic acid in rats and mice. J Pharm Pharmacol, 44, 456-8. 
SMAOUI, N., BELTAIEF, O., BENHAMED, S., M'RAD, R., MAAZOUL, F., OUERTANI, A., 
CHAABOUNI, H. & HEJTMANCIK, J. F. 2004. A homozygous splice mutation in the HSF4 gene 
is associated with an autosomal recessive congenital cataract. Invest Ophthalmol Vis Sci, 45, 
2716-21. 
SMATHERS, R. L., GALLIGAN, J. J., STEWART, B. J. & PETERSEN, D. R. 2011. Overview of lipid 
peroxidation products and hepatic protein modification in alcoholic liver disease. Chem. Biol. 
Interact, 192, 107-12. 
SNYDER, G. H., CENNERAZZO, M. J., KARALIS, A. J. & FIELD, D. 1981. Electrostatic influence of 
local cysteine environments on disulfide exchange kinetics. Biochemistry, 20, 6509-19. 
SOGA, M., MATSUZAWA, A. & ICHIJO, H. 2012. Oxidative Stress-Induced Diseases via the ASK1 
Signaling Pathway. Int J Cell Biol, 2012, 439587. 
SONCIN, F., ZHANG, X., CHU, B., WANG, X., ASEA, A., ANN STEVENSON, M., SACKS, D. B. & 
CALDERWOOD, S. K. 2003. Transcriptional activity and DNA binding of heat shock factor-1 
involve phosphorylation on threonine 142 by CK2. Biochem Biophys Res Commun, 303, 700-
6. 
SORGER, P. K. & NELSON, H. C. 1989. Trimerization of a yeast transcriptional activator via a coiled-
coil motif. Cell, 59, 807-13. 
STRONACH, B. E. & PERRIMON, N. 1999. Stress signaling in Drosophila. Oncogene, 18, 6172-82. 
STUHLMEIER, K. M. 2000. Activation and regulation of Hsp32 and Hsp70. Eur J Biochem, 267, 1161-
7. 
SULLIVAN, E. K., WEIRICH, C. S., GUYON, J. R., SIF, S. & KINGSTON, R. E. 2001. Transcriptional 
activation domains of human heat shock factor 1 recruit human SWI/SNF. Mol Cell Biol, 21, 
5826-37. 
SUMARA, G., FORMENTINI, I., COLLINS, S., SUMARA, I., WINDAK, R., BODENMILLER, B., 
RAMRACHEYA, R., CAILLE, D., JIANG, H., PLATT, K. A., MEDA, P., AEBERSOLD, R., 
RORSMAN, P. & RICCI, R. 2009. Regulation of PKD by the MAPK p38delta in insulin secretion 
and glucose homeostasis. Cell, 136, 235-48. 
SURH, Y. J. & CHUN, K. S. 2007. Cancer chemopreventive effects of curcumin. Adv Exp Med Biol, 
595, 149-72. 
SUTHERLAND, C. 2011. What Are the bona fide GSK3 Substrates? Int J Alzheimers Dis, 2011, 
505607. 
SUZUKI, K., BOSE, P., LEONG-QUONG, R. Y., FUJITA, D. J. & RIABOWOL, K. 2010. REAP: A two 
minute cell fractionation method. BMC Res Notes, 3, 294. 
SUZUKI, K., MURTUZA, B., SAMMUT, I. A., LATIF, N., JAYAKUMAR, J., SMOLENSKI, R. T., 
KANEDA, Y., SAWA, Y., MATSUDA, H. & YACOUB, M. H. 2002. Heat shock protein 72 
enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion 
injury, associated with mitochondrial protection and apoptosis reduction. Circulation, 106, I270-
6. 
SUZUKI, T., MOTOHASHI, H. & YAMAMOTO, M. 2013. Toward clinical application of the Keap1-Nrf2 
pathway. Trends Pharmacol Sci, 34, 340-6. 
TAIPALE, M., KRYKBAEVA, I., KOEVA, M., KAYATEKIN, C., WESTOVER, K. D., KARRAS, G. I. & 
LINDQUIST, S. 2012. Quantitative analysis of HSP90-client interactions reveals principles of 
substrate recognition. Cell, 150, 987-1001. 
TAKAHASHI, I., EMI, Y., HASUDA, S., KAKEJI, Y., MAEHARA, Y. & SUGIMACHI, K. 2002a. Clinical 
application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. 
Surgery, 131, S78-84. 
TAKAHASHI, R., TOYODA, E., AOKI, Y., SUZUKI, K. T. & GOTO, S. 2002b. Paradoxical increase of 
heat-shock response with age in a substrain of F344 rats: comparison between F344/DuCrj 
and F344/Jcl. Mech Ageing Dev, 123, 1605-15. 
TAKAYA, K., SUZUKI, T., MOTOHASHI, H., ONODERA, K., SATOMI, S., KENSLER, T. W. & 
YAMAMOTO, M. 2012. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. 
Free Radic Biol Med, 53, 817-27. 
TAKII, R., INOUYE, S., FUJIMOTO, M., NAKAMURA, T., SHINKAWA, T., PRAKASAM, R., TAN, K., 
HAYASHIDA, N., ICHIKAWA, H., HAI, T. & NAKAI, A. 2010. Heat shock transcription factor 1 
inhibits expression of IL-6 through activating transcription factor 3. J Immunol, 184, 1041-8. 
TANG, Z., DAI, S., HE, Y., DOTY, R. A., SHULTZ, L. D., SAMPSON, S. B. & DAI, C. 2015. MEK guards 
proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1. Cell, 160, 729-
44. 
TANONAKA, K., TOGA, W., YOSHIDA, H. & TAKEO, S. 2003. Myocardial heat shock protein changes 
in the failing heart following coronary artery ligation. Heart Lung Circ, 12, 60-5. 
TEN HOVE, W., HOUBEN, L. A., RAAIJMAKERS, J. A., BRACKE, M. & KOENDERMAN, L. 2007. 
Differential regulation of TNFalpha and GM-CSF induced activation of P38 MAPK in neutrophils 
and eosinophils. Mol Immunol, 44, 2492-6. 
TER HAAR, E., PRABHAKAR, P., LIU, X. & LEPRE, C. 2007. Crystal structure of the p38 alpha-
MAPKAP kinase 2 heterodimer. J Biol Chem, 282, 9733-9. 
THIMMULAPPA, R. K., MAI, K. H., SRISUMA, S., KENSLER, T. W., YAMAMOTO, M. & BISWAL, S. 
2002. Identification of Nrf2-regulated genes induced by the chemopreventive agent 
sulforaphane by oligonucleotide microarray. Cancer Res, 62, 5196-203. 
THOMPSON, C. A. & BURCHAM, P. C. 2008. Genome-wide transcriptional responses to acrolein. 
Chem Res Toxicol, 21, 2245-56. 
TISSIERES, A., MITCHELL, H. K. & TRACY, U. M. 1974. Protein synthesis in salivary glands of 
Drosophila melanogaster: relation to chromosome puffs. J Mol Biol, 84, 389-98. 
TIWARI, S. K., AGARWAL, S., SETH, B., YADAV, A., NAIR, S., BHATNAGAR, P., KARMAKAR, M., 
KUMARI, M., CHAUHAN, L. K., PATEL, D. K., SRIVASTAVA, V., SINGH, D., GUPTA, S. K., 
TRIPATHI, A., CHATURVEDI, R. K. & GUPTA, K. C. 2014. Curcumin-loaded nanoparticles 
potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model 
via canonical Wnt/beta-catenin pathway. ACS Nano, 8, 76-103. 
TOBIUME, K., MATSUZAWA, A., TAKAHASHI, T., NISHITOH, H., MORITA, K., TAKEDA, K., 
MINOWA, O., MIYAZONO, K., NODA, T. & ICHIJO, H. 2001. ASK1 is required for sustained 
activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep, 2, 222-8. 
TONG, K. I., KATOH, Y., KUSUNOKI, H., ITOH, K., TANAKA, T. & YAMAMOTO, M. 2006. Keap1 
recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site 
molecular recognition model. Mol Cell Biol, 26, 2887-900. 
TONG, K. I., PADMANABHAN, B., KOBAYASHI, A., SHANG, C., HIROTSU, Y., YOKOYAMA, S. & 
YAMAMOTO, M. 2007. Different electrostatic potentials define ETGE and DLG motifs as hinge 
and latch in oxidative stress response. Mol Cell Biol, 27, 7511-21. 
TORMOS, A. M., ARDUINI, A., TALENS-VISCONTI, R., DEL BARCO BARRANTES, I., NEBREDA, A. 
R. & SASTRE, J. 2013. Liver-specific p38alpha deficiency causes reduced cell growth and 
cytokinesis failure during chronic biliary cirrhosis in mice. Hepatology, 57, 1950-61. 
TREMPOLEC, N., DAVE-COLL, N. & NEBREDA, A. R. 2013. SnapShot: p38 MAPK signaling. Cell, 
152, 656-656 e1. 
TRINKLEIN, N. D., MURRAY, J. I., HARTMAN, S. J., BOTSTEIN, D. & MYERS, R. M. 2004. The role 
of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock 
response. Mol Biol Cell, 15, 1254-61. 
TROST, S. U., OMENS, J. H., KARLON, W. J., MEYER, M., MESTRIL, R., COVELL, J. W. & 
DILLMANN, W. H. 1998. Protection against myocardial dysfunction after a brief ischemic period 
in transgenic mice expressing inducible heat shock protein 70. J Clin Invest, 101, 855-62. 
TROTT, A., WEST, J. D., KLAIC, L., WESTERHEIDE, S. D., SILVERMAN, R. B., MORIMOTO, R. I. & 
MORANO, K. A. 2008. Activation of heat shock and antioxidant responses by the natural 
product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell, 19, 1104-
12. 
TUSZYNSKI, J. A., CARPENTER, E. J., HUZIL, J. T., MALINSKI, W., LUCHKO, T. & LUDUENA, R. F. 
2006. The evolution of the structure of tubulin and its potential consequences for the role and 
function of microtubules in cells and embryos. Int J Dev Biol, 50, 341-58. 
UBERSAX, J. A. & FERRELL, J. E., JR. 2007. Mechanisms of specificity in protein phosphorylation. 
Nat Rev Mol Cell Biol, 8, 530-41. 
UCHIYAMA, T., ATSUTA, H., UTSUGI, T., OGURI, M., HASEGAWA, A., NAKAMURA, T., NAKAI, A., 
NAKATA, M., MARUYAMA, I., TOMURA, H., OKAJIMA, F., TOMONO, S., KAWAZU, S., 
NAGAI, R. & KURABAYASHI, M. 2007. HSF1 and constitutively active HSF1 improve vascular 
endothelial function (heat shock proteins improve vascular endothelial function). 
Atherosclerosis, 190, 321-9. 
VAN OOSTEN-HAWLE, P., PORTER, R. S. & MORIMOTO, R. I. 2013. Regulation of organismal 
proteostasis by transcellular chaperone signaling. Cell, 153, 1366-78. 
VASUDEVAN, S. A., SKOKO, J., WANG, K., BURLINGAME, S. M., PATEL, P. N., LAZO, J. S., 
NUCHTERN, J. G. & YANG, J. 2005. MKP-8, a novel MAPK phosphatase that inhibits p38 
kinase. Biochem Biophys Res Commun, 330, 511-8. 
VEDAM, K., NISHIJIMA, Y., DRUHAN, L. J., KHAN, M., MOLDOVAN, N. I., ZWEIER, J. L. & 
ILANGOVAN, G. 2010. Role of heat shock factor-1 activation in the doxorubicin-induced heart 
failure in mice. Am J Physiol Heart Circ Physiol, 298, H1832-41. 
VERMA, M., SHARMA, A., NAIDU, S., BHADRA, A. K., KUKRETI, R. & TANEJA, V. 2012. Curcumin 
prevents formation of polyglutamine aggregates by inhibiting Vps36, a component of the 
ESCRT-II complex. PLoS One, 7, e42923. 
VERMA, P., PFISTER, J. A., MALLICK, S. & D'MELLO, S. R. 2014. HSF1 protects neurons through a 
novel trimerization- and HSP-independent mechanism. J Neurosci, 34, 1599-612. 
VIHERVAARA, A., SERGELIUS, C., VASARA, J., BLOM, M. A., ELSING, A. N., ROOS-MATTJUS, P. 
& SISTONEN, L. 2013. Transcriptional response to stress in the dynamic chromatin 
environment of cycling and mitotic cells. Proc Natl Acad Sci U S A, 110, E3388-97. 
VILA, A., TALLMAN, K. A., JACOBS, A. T., LIEBLER, D. C., PORTER, N. A. & MARNETT, L. J. 2008. 
Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo 
biotinylation of azido and alkynyl derivatives. Chem Res Toxicol, 21, 432-44. 
WANG, G., YING, Z., JIN, X., TU, N., ZHANG, Y., PHILLIPS, M., MOSKOPHIDIS, D. & MIVECHI, N. 
F. 2004a. Essential requirement for both hsf1 and hsf2 transcriptional activity in 
spermatogenesis and male fertility. Genesis, 38, 66-80. 
WANG, H., LIU, K., GENG, M., GAO, P., WU, X., HAI, Y., LI, Y., LI, Y., LUO, L., HAYES, J. D., WANG, 
X. J. & TANG, X. 2013a. RXRalpha inhibits the NRF2-ARE signaling pathway through a direct 
interaction with the Neh7 domain of NRF2. Cancer Res, 73, 3097-108. 
WANG, H., YANG, H., SHIVALILA, C. S., DAWLATY, M. M., CHENG, A. W., ZHANG, F. & JAENISCH, 
R. 2013b. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-
mediated genome engineering. Cell, 153, 910-8. 
WANG, X., CHEN, Y., ABDELKADER, D., HASSAN, W., SUN, H. & LIU, J. 2015. Combination therapy 
with oleanolic acid and metformin as a synergistic treatment for diabetes. J Diabetes Res, 2015, 
973287. 
WANG, X., KHALEQUE, M. A., ZHAO, M. J., ZHONG, R., GAESTEL, M. & CALDERWOOD, S. K. 
2006. Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on serine 121, inhibits 
transcriptional activity and promotes HSP90 binding. J Biol Chem, 281, 782-91. 
WANG, X., YE, X. L., LIU, R., CHEN, H. L., BAI, H., LIANG, X., ZHANG, X. D., WANG, Z., LI, W. L. & 
HAI, C. X. 2010. Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP 
kinases. Chem Biol Interact, 184, 328-37. 
WANG, Y., GIBNEY, P. A., WEST, J. D. & MORANO, K. A. 2012. The yeast Hsp70 Ssa1 is a sensor 
for activation of the heat shock response by thiol-reactive compounds. Mol Biol Cell, 23, 3290-
8. 
WANG, Y., THERIAULT, J. R., HE, H., GONG, J. & CALDERWOOD, S. K. 2004b. Expression of a 
dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells. 
J Biol Chem, 279, 32651-9. 
WARRICK, J. M., CHAN, H. Y., GRAY-BOARD, G. L., CHAI, Y., PAULSON, H. L. & BONINI, N. M. 
1999. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the 
molecular chaperone HSP70. Nat Genet, 23, 425-8. 
WELCKER, M. & CLURMAN, B. E. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads 
of cell division, growth and differentiation. Nat Rev Cancer, 8, 83-93. 
WESTERHEIDE, S. D., ANCKAR, J., STEVENS, S. M., JR., SISTONEN, L. & MORIMOTO, R. I. 2009. 
Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science, 323, 
1063-6. 
WESTERHEIDE, S. D., BOSMAN, J. D., MBADUGHA, B. N., KAWAHARA, T. L., MATSUMOTO, G., 
KIM, S., GU, W., DEVLIN, J. P., SILVERMAN, R. B. & MORIMOTO, R. I. 2004a. Celastrols as 
inducers of the heat shock response and cytoprotection. J Biol Chem, 279, 56053-60. 
WESTERHEIDE, S. D., BOSMAN, J. D., MBADUGHA, B. N., KAWAHARA, T. L., MATSUMOTO, G., 
KIM, S., GU, W., DEVLIN, J. P., SILVERMAN, R. B. & MORIMOTO, R. I. 2004b. Celastrols as 
inducers of the heat shock response and cytoprotection. J Biol Chem, 279, 56053-60. 
WHITMARSH, A. J. & DAVIS, R. J. 2007. Role of mitogen-activated protein kinase kinase 4 in cancer. 
Oncogene, 26, 3172-84. 
WILD, A. C. & MULCAHY, R. T. 2000. Regulation of gamma-glutamylcysteine synthetase subunit gene 
expression: insights into transcriptional control of antioxidant defenses. Free Radical Res, 32, 
281-301. 
WILSON, K. P., FITZGIBBON, M. J., CARON, P. R., GRIFFITH, J. P., CHEN, W., MCCAFFREY, P. 
G., CHAMBERS, S. P. & SU, M. S. 1996. Crystal structure of p38 mitogen-activated protein 
kinase. J Biol Chem, 271, 27696-700. 
WINKEL, A. F., ENGEL, C. K., MARGERIE, D., KANNT, A., SZILLAT, H., GLOMBIK, H., KALLUS, C., 
RUF, S., GUSSREGEN, S., RIEDEL, J., HERLING, A. W., VON KNETHEN, A., WEIGERT, A., 
BRUNE, B. & SCHMOLL, D. 2015. Characterization of RA839, a Noncovalent Small Molecule 
Binder to Keap1 and Selective Activator of Nrf2 Signaling. J Biol Chem, 290, 28446-55. 
WINKLER, A., ARKIND, C., MATTISON, C. P., BURKHOLDER, A., KNOCHE, K. & OTA, I. 2002. Heat 
stress activates the yeast high-osmolarity glycerol mitogen-activated protein kinase pathway, 
and protein tyrosine phosphatases are essential under heat stress. Eukaryot Cell, 1, 163-73. 
WOODMAN, B., BUTLER, R., LANDLES, C., LUPTON, M. K., TSE, J., HOCKLY, E., MOFFITT, H., 
SATHASIVAM, K. & BATES, G. P. 2007. The Hdh(Q150/Q150) knock-in mouse model of HD 
and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain 
Res Bull, 72, 83-97. 
WU, J. H., MIAO, W., HU, L. G. & BATIST, G. 2010. Identification and characterization of novel Nrf2 
inducers designed to target the intervening region of Keap1. Chem Biol Drug Des, 75, 475-80. 
WU, K. C., CUI, J. Y. & KLAASSEN, C. D. 2011. Beneficial role of nrf2 in regulating NADPH generation 
and consumption. Toxicol Sci, 123, 590-600. 
WU, L., HU, C., HUANG, M., JIANG, M., LU, L. & TANG, J. 2013. Heat shock transcription factor 1 
attenuates TNFalpha-induced cardiomyocyte death through suppression of NFkappaB 
pathway. Gene, 527, 89-94. 
WU, L. X., XU, J. H., HUANG, X. W., ZHANG, K. Z., WEN, C. X. & CHEN, Y. Z. 2006. Down-regulation 
of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90. Acta 
Pharmacol Sin, 27, 694-9. 
WUST, P., HILDEBRANDT, B., SREENIVASA, G., RAU, B., GELLERMANN, J., RIESS, H., FELIX, R. 
& SCHLAG, P. M. 2002. Hyperthermia in combined treatment of cancer. Lancet Oncol, 3, 487-
97. 
XAVIER, I. J., MERCIER, P. A., MCLOUGHLIN, C. M., ALI, A., WOODGETT, J. R. & OVSENEK, N. 
2000. Glycogen synthase kinase 3beta negatively regulates both DNA-binding and 
transcriptional activities of heat shock factor 1. J Biol Chem, 275, 29147-52. 
XIA, W. & VOELLMY, R. 1997. Hyperphosphorylation of heat shock transcription factor 1 is correlated 
with transcriptional competence and slow dissociation of active factor trimers. J Biol Chem, 
272, 4094-102. 
XIAO, D., POWOLNY, A. A., MOURA, M. B., KELLEY, E. E., BOMMAREDDY, A., KIM, S. H., HAHM, 
E. R., NORMOLLE, D., VAN HOUTEN, B. & SINGH, S. V. 2010. Phenethyl isothiocyanate 
inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human 
prostate cancer cells. J Biol Chem, 285, 26558-69. 
XIAO, X., ZUO, X., DAVIS, A. A., MCMILLAN, D. R., CURRY, B. B., RICHARDSON, J. A. & BENJAMIN, 
I. J. 1999. HSF1 is required for extra-embryonic development, postnatal growth and protection 
during inflammatory responses in mice. EMBO J, 18, 5943-52. 
XIAO, Z., MI, L., CHUNG, F. L. & VEENSTRA, T. D. 2012. Proteomic analysis of covalent modifications 
of tubulins by isothiocyanates. J Nutr, 142, 1377S-81S. 
XIE, H. B., CAMMARATO, A., RAJASEKARAN, N. S., ZHANG, H., SUGGS, J. A., LIN, H. C., 
BERNSTEIN, S. I., BENJAMIN, I. J. & GOLIC, K. G. 2013. The NADPH metabolic network 
regulates human alphaB-crystallin cardiomyopathy and reductive stress in Drosophila 
melanogaster. PLoS Genet, 9, e1003544. 
XING, J., KORNHAUSER, J. M., XIA, Z., THIELE, E. A. & GREENBERG, M. E. 1998. Nerve growth 
factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase 
pathways to stimulate CREB serine 133 phosphorylation. Mol Cell Biol, 18, 1946-55. 
XU, D., ZALMAS, L. P. & LA THANGUE, N. B. 2008. A transcription cofactor required for the heat-
shock response. EMBO Rep, 9, 662-9. 
XU, Q., HU, Y., KLEINDIENST, R. & WICK, G. 1997. Nitric oxide induces heat-shock protein 70 
expression in vascular smooth muscle cells via activation of heat shock factor 1. J Clin Invest, 
100, 1089-97. 
XU, Y. M., HUANG, D. Y., CHIU, J. F. & LAU, A. T. 2012. Post-translational modification of human heat 
shock factors and their functions: a recent update by proteomic approach. J Proteome Res, 11, 
2625-34. 
YAN, L. J., CHRISTIANS, E. S., LIU, L., XIAO, X., SOHAL, R. S. & BENJAMIN, I. J. 2002. Mouse heat 
shock transcription factor 1 deficiency alters cardiac redox homeostasis and increases 
mitochondrial oxidative damage. EMBO J, 21, 5164-72. 
YANG, J., BRIDGES, K., CHEN, K. Y. & LIU, A. Y. 2008. Riluzole increases the amount of latent HSF1 
for an amplified heat shock response and cytoprotection. PLoS One, 3, e2864. 
YERBURY, J. J., GOWER, D., VANAGS, L., ROBERTS, K., LEE, J. A. & ECROYD, H. 2013. The small 
heat shock proteins alphaB-crystallin and Hsp27 suppress SOD1 aggregation in vitro. Cell 
Stress Chaperones, 18, 251-7. 
YIH, L. H., HSU, N. C., KUO, H. H. & WU, Y. C. 2012. Inhibition of the heat shock response by PI103 
enhances the cytotoxicity of arsenic trioxide. Toxicol Sci, 128, 126-36. 
YIN, N., QI, X., TSAI, S., LU, Y., BASIR, Z., OSHIMA, K., THOMAS, J. P., MYERS, C. R., STONER, 
G. & CHEN, G. 2016. p38gamma MAPK is required for inflammation-associated colon 
tumorigenesis. Oncogene, 35, 1039-48. 
YIN, P., KAWAMURA, T., HE, M., VANAJA, D. K. & YOUNG, C. Y. 2009. Phenethyl isothiocyanate 
induces cell cycle arrest and reduction of alpha- and beta-tubulin isotypes in human prostate 
cancer cells. Cell Biol Int, 33, 57-64. 
YOSHIMA, T., YURA, T. & YANAGI, H. 1998. Function of the C-terminal transactivation domain of 
human heat shock factor 2 is modulated by the adjacent negative regulatory segment. Nucleic 
Acids Res, 26, 2580-5. 
YOUNG, P. R. 2013. Perspective on the discovery and scientific impact of p38 MAP kinase. J Biomol 
Screen, 18, 1156-63. 
YU, Y., HAMZA, A., ZHANG, T., GU, M., ZOU, P., NEWMAN, B., LI, Y., GUNATILAKA, A. A., ZHAN, 
C. G. & SUN, D. 2010. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. 
Biochem Pharmacol, 79, 542-51. 
YUAN, J. M., MURPHY, S. E., STEPANOV, I., WANG, R., CARMELLA, S. G., NELSON, H. H., 
HATSUKAMI, D. & HECHT, S. S. 2016. 2-Phenethyl Isothiocyanate, Glutathione S-transferase 
M1 and T1 Polymorphisms, and Detoxification of Volatile Organic Carcinogens and Toxicants 
in Tobacco Smoke. Cancer Prev Res (Phila), 9, 598-606. 
ZARUBIN, T. & HAN, J. 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res, 15, 
11-8. 
ZARZOV, P., BOUCHERIE, H. & MANN, C. 1997. A yeast heat shock transcription factor (Hsf1) mutant 
is defective in both Hsc82/Hsp82 synthesis and spindle pole body duplication. J Cell Sci, 110 ( 
Pt 16), 1879-91. 
ZHANG, B., AU, Q., YOON, I. S., TREMBLAY, M. H., YIP, G., ZHOU, Y., BARBER, J. R. & NG, S. C. 
2009a. Identification of small-molecule HSF1 amplifiers by high content screening in protection 
of cells from stress induced injury. Biochem Biophys Res Commun, 390, 925-30. 
ZHANG, D. D. & HANNINK, M. 2003. Distinct cysteine residues in Keap1 are required for Keap1-
dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and 
oxidative stress. Mol Cell Biol, 23, 8137-51. 
ZHANG, D. D., LO, S. C., SUN, Z., HABIB, G. M., LIEBERMAN, M. W. & HANNINK, M. 2005. 
Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for 
degradation by a proteasome-independent pathway. J Biol Chem, 280, 30091-9. 
ZHANG, Q. & ZHANG, G. 2002. Activation and autophosphorylation of apoptosis signal-regulating 
kinase 1 (ASK1) following cerebral ischemia in rat hippocampus. Neurosci Lett, 329, 232-6. 
ZHANG, Q. S., MADDOCK, D. A., CHEN, J. P., HEO, S., CHIU, C., LAI, D., SOUZA, K., MEHTA, S. & 
WAN, Y. S. 2001. Cytokine-induced p38 activation feedback regulates the prolonged activation 
of AKT cell survival pathway initiated by reactive oxygen species in response to UV irradiation 
in human keratinocytes. Int J Oncol, 19, 1057-61. 
ZHANG, T., HAMZA, A., CAO, X., WANG, B., YU, S., ZHAN, C. G. & SUN, D. 2008. A novel Hsp90 
inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther, 7, 
162-70. 
ZHANG, T., LI, Y., YU, Y., ZOU, P., JIANG, Y. & SUN, D. 2009b. Characterization of celastrol to inhibit 
hsp90 and cdc37 interaction. J Biol Chem, 284, 35381-9. 
ZHANG, T., LIU, H., ZHU, C., BRIGGS, K., KANG, Y., FLEMING, J. A. & CURLEY, S. A. 2012. Silencing 
thioredoxin induces liver cancer cell senescence under hypoxia. Hepatol Res, 42, 706-13. 
ZHANG, X., JEFFS, G., REN, X., O'DONOVAN, P., MONTANER, B., PERRETT, C. M., KARRAN, P. 
& XU, Y. Z. 2007. Novel DNA lesions generated by the interaction between therapeutic 
thiopurines and UVA light. DNA Repair (Amst), 6, 344-54. 
ZHANG, Y., AHN, Y. H., BENJAMIN, I. J., HONDA, T., HICKS, R. J., CALABRESE, V., COLE, P. A. & 
DINKOVA-KOSTOVA, A. T. 2011. HSF1-dependent upregulation of Hsp70 by sulfhydryl-
reactive inducers of the KEAP1/NRF2/ARE pathway. Chem Biol, 18, 1355-61. 
ZHANG, Y., DAYALAN NAIDU, S., SAMARASINGHE, K., VAN HECKE, G. C., PHEELY, A., 
BORONINA, T. N., COLE, R. N., BENJAMIN, I. J., COLE, P. A., AHN, Y. H. & DINKOVA-
KOSTOVA, A. T. 2014. Sulphoxythiocarbamates modify cysteine residues in HSP90 causing 
degradation of client proteins and inhibition of cancer cell proliferation. Br J Cancer, 110, 71-
82. 
ZHANG, Y., WADE, K. L., PRESTERA, T. & TALALAY, P. 1996. Quantitative determination of 
isothiocyanates, dithiocarbamates, carbon disulfide, and related thiocarbonyl compounds by 
cyclocondensation with 1,2-benzenedithiol. Anal Biochem, 239, 160-7. 
ZHANG, Y. Q. & SARGE, K. D. 2007. Celastrol inhibits polyglutamine aggregation and toxicity though 
induction of the heat shock response. J Mol Med (Berl), 85, 1421-8. 
ZHAO, R., MA, X. & SHEN, G. X. 2008. Transcriptional regulation of plasminogen activator inhibitor-1 
in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell 
Biochem, 317, 197-204. 
ZHAO, R., MA, X., XIE, X. & SHEN, G. X. 2009. Involvement of NADPH oxidase in oxidized LDL-
induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular 
endothelial cells. Am J Physiol Endocrinol Metab, 297, E104-11. 
ZHAO, R., MOGHADASIAN, M. H. & SHEN, G. X. 2011. Involvement of NADPH oxidase in up-
regulation of plasminogen activator inhibitor-1 and heat shock factor-1 in mouse embryo 
fibroblasts induced by oxidized LDL and in apolipoprotein E-deficient mice. Free Radic Res, 
45, 1013-23. 
ZHAO, R. & SHEN, G. X. 2007. Involvement of heat shock factor-1 in glycated LDL-induced 
upregulation of plasminogen activator inhibitor-1 in vascular endothelial cells. Diabetes, 56, 
1436-44. 
ZHENG, C., LIN, Z., ZHAO, Z. J., YANG, Y., NIU, H. & SHEN, X. 2006. MAPK-activated protein kinase-
2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex 
consisting of p38, MK2, Akt, and Hsp27. J Biol Chem, 281, 37215-26. 
ZHENG, S., SANTOSH LAXMI, Y. R., DAVID, E., DINKOVA-KOSTOVA, A. T., SHIAVONI, K. H., REN, 
Y., ZHENG, Y., TREVINO, I., BUMEISTER, R., OJIMA, I., WIGLEY, W. C., BLISKA, J. B., 
MIERKE, D. F. & HONDA, T. 2012. Synthesis, chemical reactivity as Michael acceptors, and 
biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and 
cytoprotective agents. J Med Chem, 55, 4837-46. 
ZHU, B. T. & CONNEY, A. H. 1998. Functional role of estrogen metabolism in target cells: review and 
perspectives. Carcinogenesis, 19, 1-27. 
ZHU, X., ROTTKAMP, C. A., BOUX, H., TAKEDA, A., PERRY, G. & SMITH, M. A. 2000. Activation of 
p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in 
Alzheimer disease. J Neuropathol Exp Neurol, 59, 880-8. 
ZINGARELLI, B., HAKE, P. W., O'CONNOR, M., DENENBERG, A., WONG, H. R., KONG, S. & 
ARONOW, B. J. 2004. Differential regulation of activator protein-1 and heat shock factor-1 in 
myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am J 
Physiol Heart Circ Physiol, 286, H1408-15. 
ZIPPER, L. M. & MULCAHY, R. T. 2002. The Keap1 BTB/POZ dimerization function is required to 
sequester Nrf2 in cytoplasm. J Biol Chem, 277, 36544-52. 
ZOU, J., GUO, Y., GUETTOUCHE, T., SMITH, D. F. & VOELLMY, R. 1998. Repression of heat shock 
transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive 
complex with HSF1. Cell, 94, 471-80. 
ZOU, Y., LI, J., MA, H., JIANG, H., YUAN, J., GONG, H., LIANG, Y., GUAN, A., WU, J., LI, L., ZHOU, 
N., NIU, Y., SUN, A., NAKAI, A., WANG, P., TAKANO, H., KOMURO, I. & GE, J. 2011. Heat 
shock transcription factor 1 protects heart after pressure overload through promoting 
myocardial angiogenesis in male mice. J Mol Cell Cardiol, 51, 821-9. 
ZOU, Y., ZHU, W., SAKAMOTO, M., QIN, Y., AKAZAWA, H., TOKO, H., MIZUKAMI, M., TAKEDA, N., 
MINAMINO, T., TAKANO, H., NAGAI, T., NAKAI, A. & KOMURO, I. 2003. Heat shock 
transcription factor 1 protects cardiomyocytes from ischemia/reperfusion injury. Circulation, 
108, 3024-30. 
ZUR, R., GARCIA-IBANEZ, L., NUNEZ-BUIZA, A., APARICIO, N., LIAPPAS, G., ESCOS, A., RISCO, 
A., PAGE, A., SAIZ-LADERA, C., ALSINA-BEAUCHAMP, D., MONTANS, J., PARAMIO, J. M. 
& CUENDA, A. 2015. Combined deletion of p38gamma and p38delta reduces skin 
inflammation and protects from carcinogenesis. Oncotarget, 6, 12920-35. 
 
 
Vehicle 20 µM PEITC
Vehicle
10 µM Aloisine
5 µM Aloisine
5 µM BIRB0796
1 µM BIRB0796
Vehicle 10 µm Aloisine 5 µm Aloisine 5 µm BIRB0796 1 µm BIRB0796
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
N
or
m
al
is
ed
 m
ea
n 
flo
ur
es
ce
nc
e 
in
te
ns
ity
Vehicle 20 µM PEITC
A
B
APPENDIX FIGURE 5.1A
Appendix Fig. 5.1A. In-cell western kinase inhibitor screen. MCF7 cells (1 x 104) were seeded in each
well of a 96-well plate, and 16 h after seeding, the cells were pre-treated with either the vehicle (0.1%
DMSO) or the kinase inhibitors (Aloisine or BIRB0796) dissolved in conditioned media for 1 h. Subsequently,
the cells were treated with either the vehicle or 20 μM PEITC dissolved in conditioned media for a further 3 h
and fixed immediately after treatment. The cells were subjected to the in cell western technique. The fixed
cells were incubated with HSF1 pS326 primary antibody. Following primary antibody incubation, the cells
were incubated with secondary goat anti-rabbit IRDye 680 nm (LiCOR) antibody. Subsequently, the 96-well
plate was scanned and quantified using the LI-COR® Odyssey® Infrared Imaging system. The background
values were obtained from wells which contained cells that were not incubated with the primary antibody but
were only incubated with the secondary antibody.
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Appendix Fig. 5.1B. In-cell western kinase inhibitor screen. MCF7 cells (1 x 104) were seeded in each
well of a 96-well plate, and 16 h after seeding, the cells were pre-treated with either the vehicle (0.1%
DMSO) or the kinase inhibitors (CDK9-In or SB202190) dissolved in conditioned media for 1 h.
Subsequently, the cells were treated with either the vehicle or 20 μM PEITC dissolved in conditioned media
for a further 3 h and fixed immediately after treatment. The cells were subjected to the in cell western
technique. The fixed cells were incubated with HSF1 pS326 primary antibody. Following primary antibody
incubation, the cells were incubated with secondary goat anti-rabbit IRDye 680 nm (LiCOR) antibody.
Subsequently, the 96-well plate was scanned and quantified using the LI-COR® Odyssey® Infrared Imaging
system. The background values were obtained from wells which contained cells that were not incubated with
the primary antibody but were only incubated with the secondary antibody.
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APPENDIX FIGURE 5.1C
Appendix Fig. 5.1C. In-cell western kinase inhibitor screen. MCF7 cells (1 x 104) were seeded in each
well of a 96-well plate, and 16 h after seeding, the cells were pre-treated with either the vehicle (0.1%
DMSO) or the p38 kinase inhibitor ZM336372 dissolved in conditioned media for 1 h. Subsequently, the cells
were treated with either the vehicle or 20 μM PEITC dissolved in conditioned media for a further 3 h and
fixed immediately after treatment. The cells were subjected to the in cell western technique. The fixed cells
were incubated with HSF1 pS326 primary antibody. Following primary antibody incubation, the cells were
incubated with secondary goat anti-rabbit IRDye 680 nm (LiCOR) antibody. Subsequently, the 96-well plate
was scanned and quantified using the LI-COR® Odyssey® Infrared Imaging system. The background values
were obtained from wells which contained cells that were not incubated with the primary antibody but were
only incubated with the secondary antibody.
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APPENDIX FIGURE 5.2
Appendix Fig. 5.2. PEITC activates p38 and JNK1/2 MAPK. MDA-MB-231 cells (2.5 x 105
per well) growing in 6-well plates were treated with vehicle (0.1% acetonitrile) or PEITC for
either 24 h (A) or for the indicated periods of time (B) and 3 h (C). The levels of HSF1, pS326
HSF1 Hsp70, the p38 isoforms α, β, Ɣ, and δ, phosphorylated p38 (pp38), phosphorylated
p38α (pp38α), JNK1/2, and phosphorylated JNK1/2 (JNK1/2), were detected by western blot
analysis. Experiment performed by Dr. Ana Risco and Dr. Ana Cuenda.
